BUSINESS FORUM OvERvIEw
Transcription
BUSINESS FORUM OvERvIEw
FINAL PROGRAM 2013. 09. 11[Wed] ~ 13[Fri] KINTEX MANAGED BY PROGRAM BIO KOREA Organizing Committee Conference Business Forum Exhibition Pharm Fair Invest Fair Job Fair • Amino Acids • Biological Buffers • Chromatography Media • Column Cleaning Reagents • Lysing Agents • Minerals & Nutrients • pH Adjusters • Preservatives • Sugars • Surfactants improving improving lives In the hands of farmers, better seeds can help protect natural resources and promote biodiversity. Our rapidly growing population is putting limited resources — such as land, water and energy — under increased pressure. But with the right tools, farmers can conserve more for future generations. That’s improving agriculture. That’s improving lives. And that’s what Monsanto is all about. Pharma Confidence A formulation is only as good as the ingredients that comprise it. When creating your drug, improving patient welfare is your mission. Every molecule that goes into your product matters. By providing the right materials for every stage of drug development, from discovery to production, we help you formulate, manufacture and innovate with confidence. Learn more at www.avantormaterials.com/Pharmaceutical-Chemicals Avantor Performance Materials Int’l Inc. Korea Branch 8F, Wooduck Building, 832-2 Yeoksam-dong, Gangnamgu, Soeul, Korea Tel: +82 2-2052-0483 Fax: +82 2-571-5401 web: www.avantormaterials.com Trademarks are owned by Avantor Performance Materials, Inc. or its affiliates unless otherwise noted. ©2013 Avantor Performance Materials, Inc. Monsanto and Vine Design® is a registered trademark of Monsanto Technology LLC. ©2011 Monsanto Company. Visit us at BIO KOREA 2013 Booth C30 KINTEX Exhibition Center II Presentations in Room 307A: Controlling Raw Material Variation 9/11/13, 11:15 a.m. Improving Downstream Processing Performance 9/12/13, 11:15 a.m. C · O · N · T · E · N · T · S INTRO CONFERENCE BUSINESS FORUM EXHIBITION 008 Welcome Message 023 Conference Overview 059 Business Forum Overview 071 Exhibition Overview 009 모시는 글 024 Conference Program at a Glance 061 Floor Plan for Business Forum 072 Floor Plan for Exhibition 010 BIO KOREA 2013 Overview 026 Conference Track List 062 Presentation Schedule at a Glance 074 List of Exhibitor 013 BIO KOREA 2013 행사개요 029 Conference Plenary Speech 016 BIO KOREA 2013 Schedule at a Glance 030 Conference Program 065 Partnering Participation Status 019 BIO KOREA 2013 Floor Plan 055 Special Session Business/Technology/Int'l Country Partner Forum Job Fair SPECIAL EVENT 221 Job Fair Overview 237 The Entrepreneuship Boot Camp 2013 231 BIO KOREA 2013 Official Sponsors 223 Floor Plan for Job Fair Welcome Reception 232 BIO KOREA Shuttle Bus Service Bio-microphotography Exhibition BIO KOREA 2014 Poster Contest Welcome Message 모시는 글 It is our greatest pleasure to invite you to the largest Bio Event in Korea, the 8th BIO KOREA International Convention, with distinguished bio experts from all over the world. 세계적인 바이오 관련 전문 컨벤션으로 성장하고 있는 BIO KOREA가 올해로 8회째를 맞이하게 되었습니다. 전 세계 제약 · 바이오 산업은 고령화 의료보험 확대 등의 환경적 요인을 기반으로 전 세계적 경기침체에도 불구하고 관련 The global pharma · bio industry has been continuously growing with the rising of population aging and importance of healthcare, and its market size has reached 85 trillion and expanded to Asian and South American region in despite of the global economic crisis. Accordingly, Korean government has set the ultimate goal to become one of the top 7 leading bio nations by 2020 and been putting aggressive efforts to propel the Korean bio-industry by supporting R&D, funding, and any possible way. 시장은 아시아 및 중남미 지역으로 확대되어 지난 2012년 기준 약 800조원 규모로 성장 해 왔습니다. 이에 발맞춰 정부는 R&D 지원과 적극적인 보건산업 투자를 통해 글로벌 시장 속 대한민국의 위상을 높여 2020년 세계 7대 제약 바이오 강국으로 도약을 목표로 박차를 가하고 있습니다. 이러한 흐름과 변화 속에서 충청북도와 한국보건산업진흥원이 공동 주최하는 이번 BIO KOREA 2013은 미래 성장동력의 중추적인 역할로서의 보건산업이 앞으로 나아가야 할 방향을 제시할 훌륭한 나침반의 역할을 할 것이라 생각합니다. In the middle of this dramatic change, Chungbuk [Chungchoengbuk-do] and KHIDI [Korea Health Industry Development Institute] play pivotal roles to promote Korean bio-industry as the next future growth engine. BIO KOREA 2013 consists of conference, business forum, exhibition, and various bio-co-located events and visualizes the present and future of global bio world. It will be the most precious time and experience for the bio experts all over the world to learn the cutting edge information and attract many possible international business partners. 최신 국제 전문기술의 정보교류, 실질적인 비즈니스 창출을 위해 구성된 컨퍼런스, 비즈니스포럼, 전시회를 비롯하여 보건산업의 기술흐름을 파악할 수 있는 다양한 프로그램으로 구성된 BIO KOREA 2013은 세계 바이오 시장의 현황을 파악하고 미래를 예측할 수 있는 유익한 시간이 될 것 입니다. BIO KOREA 2013 개최를 통해 대한민국 제약 · 바이오 산업이 더욱 발전하기를 바라며, 참가하신 모든 분들께 행운이 함께 하시길 기원합니다. We sincerely hope that Korea bio industry will grow further through this meaningful event, and would like to take this opportunity to deliver our best wishes to all of you. Thank you. Yours sincerely Lee Si-Jong Ko Kyung-Hwa Governor of Chungcheongbuk-do & Co-Chairman BIO KOREA Organizing Committee President of Korea Health Industry Development Institute & Co-Chairman BIO KOREA Organizing Committee 008 이시종 고경화 충청북도 도지사 BIO KOREA 조직위원회 공동대표 한국보건산업진흥원 원장 BIO KOREA 조직위원회 공동대표 009 BIO KOREA 2013 Overview Main Program BIO INDUSTRY, the next generation growth engine for the future! Welcome to BIO KOREA 2013 International Convention at KINTEX. This 8th BIO KOREA, one of the most comprehensive bio technology events, will be held from September 11th to 13th. Conference D A T E September 11 (Wed) ~ 13 (Fri), 2013 V E N U E 3 ~ 4F, KINTEX Exhibition Center II companies and leading Korean research institutions. E xpected Participants Approximately, 3,500 experts from Bio industry, research institutes, academia, and interested individuals from all over the world. We greatly appreciate your interest in BIO KOREA 2013 and hope this event to be an enjoyable time for your Special Session BIO KOREA 2013 International Country Partner Forum, Osong International Bio Symposium, First started in 2006, annual BIO KOREA became the most influential and well known event in Asia, this event would provide a great opportunity for both domestic and foreign investors to meet fast growing Korean bio on sake. Pharmaceuticals specialized school seminar for the career development, Daekyung·Osong Title BIO KOREA 2013 International Convention Period September 11 (Wed) ~ 13 (Fri), 2013 Venue KINTEX Exhibition Center II Collaboration BIO Forum, Denmark Bio & Medtech Investment Seminar Business Forum D A T E September 11 (Wed) ~ 13 (Fri), 2013 V E N U E Hall 7, 8A, KINTEX Exhibition Center II (Business Forum Center) Program Conference, Business Forum, Exhibition, Pharm Fair, Invest Fair, Job Fair E xpected Participants Bio(Venture) Companies from Korea & Abroad, Bio-Clusters, Local Governments, Embassies, Investors, Research Institutes SUPPORTED BY PROGRAM 1:1 Partnering, Business / Technology Presentation, BIO KOREA 2013 nternational Country Organized by Chungcheongbuk-do, Korea Health Industry Development Institute Managed by BIO KOREA Organizing Committee Partner Forum Ministry of Health & Welfare Ministry of Trade, Industry and Energy Ministry of Food and Drug Safety Korean Intellectual Property Office Rural Development Administration GyongGi-Do Ministry of Health & Welfare Ministry of Health & Welfare Ministry of Trade, Industry and Energy Ministry of Trade, Industry and Energy Ministry of Food and Drug Safety Ministry of Food and Drug Safety Korean Intellectual Property Office Korean Intellectual Property Office Rural Development Administration Rural Development Administration GyongGi-Do GyongGi-Do Korea Research Institute of Bioscience & Biotechnology Korea Research Institute of Korea Research Institute of Bioscience & Biotechnology Bioscience & Biotechnology Korea Institute of Oriental Medicine Patent Information Promotion Center Korea Institute of Oriental Medicine Korea Institute of Oriental Medicine Patent Information Promotion Center Patent Information Promotion Center Osong Medical Innovation Foundation Kintex Osong Medical Innovation Foundation Osong Medical Innovation Foundation Kintex Kintex Korea Research Institute of Chemical Technology Korea Research Institute of Korea Research Institute of Chemical Technology Chemical Technology Daegu-Gyeongbuk Medical Innovation Foundation Daegu-Gyeongbuk Daegu-Gyeongbuk Medical Innovation Foundation Medical Innovation Foundation National Cancer Center National Cancer Center National Cancer Center Exhibition D A T E September 11 (Wed) ~ 13 (Fri), 2013 V E N U E Hall 7, 8A, KINTEX Exhibition Center II E xhibition Categories Pharmaceuticals & Drug Discovery, Medical devices & Lab Equipment, Food, Cosmetics, Bio Convergence, Law firm, Government organization, CMO, CRO, Consulting Services, Venture Capital, Academic Research Centers, Bio Product, Bio Process, Business Services, Clinical Trial, Bio IT, Bio Research, etc. Kroea Pharmaceutical Manufacturers Association Kroea Pharmaceutical Kroea Pharmaceutical Manufacturers Association Manufacturers Association Korea Medical Devices Industry Association Korea Medical Devices Korea Medical Devices Industry Association Industry Association 010 World Korean Medical Organization World Korean Medical WorldOrganization Korean Medical Organization Korea Drug Research Association Korea Biomedicine Industry Association Korea Drug Research Association Korea Drug Research Association Korea Biomedicine Industry Association Korea Biomedicine Industry Association Korean Hospital Association Korea Academy of Medical Science Korean Hospital Association Korean Hospital Association Korea Academy of Medical Science Korea Academy of Medical Science Korea International Medical Association Korea International Korea International Medical Association Medical Association Korea Phamaceutical Traders Association Korea Phamaceutical Traders Association Korea Phamaceutical Traders Association Korea Health Supplements Association Korea Health Supplements Korea Health Supplements Association Association Korea Food Industry Association Korea Cosmetic Association Korea Food Industry Association Korea Food Industry Association Korea Cosmetic Association Korea Cosmetic Association Korea Medical Devices Industrial Coop. Association Korea Medical Devices Korea Medical Devices Industrial Coop. Association Industrial Coop. Association Korea Research-based Pharm Industry Association Korea Research-based Pharm KoreaIndustry Research-based Pharm Association Industry Association Korea Medical Association Korea Biotechnology Industry Organization Korea Biotechnology Korea Biotechnology Industry Organization Industry Organization Osong Bio Promrtion Foundation Korea Medical Association Korea Medical Association Pharm Fair D A T E September 11 (Wed) ~ 13 (Fri), 2013 V E N U E 3 ~ 4F, KINTEX Exhibition Center II PROGRAM Pharma Korea 2020 Forum, PIN Conference, Invited Symposium by GPKOL, Global Night (Regional Networking Dinner), Signing Ceremony Osong Bio Promrtion Foundation Osong Bio Promrtion Foundation 011 BIO KOREA 2013 행사개요 INVEST FAIR 2013년 대한민국은 새 정부 출범과 함께 창의성과 융합을 앞세운 ‘창조경제’라는 새로운 패러다임을 맞이하였습니다. D A T E September 11 (Wed) ~ 13 (Fri), 2013 국내 보건산업도 이러한 변화에 발맞춰 창조경제의 중심에 서기 위한 도약을 준비하고 있으며, 정부 또한 국내 바이오 기업들이 V E N U E 4F & Hall 7, KINTEX Exhibition Center II 국내 시장을 넘어 세계로 나아가는 글로벌 기업으로 거듭날 수 있도록 지원하기 위해 다양한 방안을 모색하고 있습니다. PROGRAM HI Korea Investment Forum, Global Convergence Show-case 보건산업의 정책과 제도 개선, R&D 지원, 글로벌 제약산업 육성펀드 조성, 제약산업 육성 5개년 계획 등 정부의 적극적인 지원 속에 대한민국은 2020년, 7대 바이오 강국으로 거듭남을 준비하고 있습니다. Job Fair 이러한 시대의 흐름에 맞춰, 대한민국의 대표 바이오 컨벤션인 BIO KOREA는, 국내·외 제약·바이오산업의 전반을 아우르는 D A T E September 11 (Wed) ~ 12 (Thur), 2013 V E N U E Hall 8A, KINTEX Exhibition Center II E xpected Participants Recruiting Companies & Organizations from Bio Industry, and Job Seekers Special Program Opening Ceremony D A T E September 11 (Wed), 2013, 10:00 ~ 11:00 V E N U E Hall 6, KINTEX Exhibition Center II 보건산업의 허브로 거듭나기 위하여 다채로운 모습으로 제 8회 BIO KOREA를 2013년 개최하고자 합니다. 바이오산업의 활력을 불어넣는 실질적인 비즈니스의 장(場), 국제적 정보교류 및 기술거래의 장(場)으로서 그 역할을 훌륭히 수행해오고 있는 BIO KOREA 2013에서 바이오 산업의 현주소와 미래를 만나보시길 바랍니다. 기 간 2013년 9월 11일 (수) ~ 13일 (금), 3일간 장 소 KINTEX 제 2 전시장 주 최 충청북도, 한국보건산업진흥원 주 관 BIO KOREA 사무국 프로그램 컨퍼런스, 비즈니스포럼, 전시회, 팜페어, 인베스트 페어, 잡페어 후원기관 Welcome Reception D A T E September 11 (Wed), 2013, 18:00 ~ 20:30 V E N U E Outdoor Fountain Square, KINTEX Exhibition Center II E V E N T S Opening Performance, Welcoming remarks and Toast Co-located event • Bio-microphotography Exhibition D A T E September 11 (Wed) ~ 13(Fri), 2013 V E N U E Hall 8A, KINTEX Exhibition Center II • The Entrepreneurship Boot Camp 2013 D A T E September 10 (Tue), 2013, 10:00 ~ 17:00 V E N U E Conference Rm. 303, KINTEX Exhibition Center II Organized by KHIDI, ERA Consulting Group 012 013 주요 프로그램 안내 컨퍼런스 잡페어 일 시 2013년 9월 11일 (수) ~ 12일 (목), 2일간 10:00 ~ 17:00 소 KINTEX 제 2전시장 8A 홀 일 시 2013년 9월 11일 (수) ~ 13일 (금) 장 장 소 KINTEX 제 2전시장 3, 4층 컨퍼런스 룸 참가 대상 보건의료, 바이오 관련 학과 졸업예정자 및 신입/경력 구직자 참가 국내외 바이오산업 종사자, 연구기관, 학술단체 및 관심 있는 개인 등 국내외 약 3,500명 참가 기업 보건의료 및 바이오 산업 40개 우수기업 스페셜 세션 규모 B IO KOREA 2013 International Country Partner Forum, 오송 국제 바이오 심포지움, 제약산업특성화대학원 공동 국제 컨퍼런스, 대경·오송 바이오 공동 포럼, 한-덴마크 바이오 협력 세미나 스페셜 프로그램 안내 비즈니스 포럼 일 시 2013년 9월 11일 (수) ~ 13일 (금) 장 소 KINTEX 제 2전시장 7, 8A 홀 (Business Forum Center) 일 시 2013년 9월 11일 (수), 10:00 ~ 11:00 참가 바이오(벤처)기업, 제약기업, 클러스터, 지방자치단체, 각국 대사관, 투자기관, 연구기관 등 장 소 KINTEX 제 2전시장 6B 홀, 7 홀 앞 프 로 그 램 대상 개막행사 파트너링, 사업/연구 발표회, BIO KOREA 2013 International Country Partner Forum 전시회 환영만찬 일 시 2013년 9월 11일 (수) ~ 13일 (금) 장 소 KINTEX 제 2전시장 7, 8A 홀 전시 품목 의약품, 의료기기, 식품, 화장품, 융합 바이오, 컨설팅, 벤처캐피털, 대학 및 연구소, 병원, 로펌, 정부기관, 일 시 2013년 9월 11일 (수), 18:00 ~ 20:30 장 소 KINTEX 제 2전시장 앞 야외 분수 광장 프 로 그 램 식전공연, 환영사, 건배제의 등 CMO, CRO, Bio Process, Business Service, Clinical Trial, Bio IT, Bio Research 부대행사 팜페어 일 시 2013년 9월 11일 (수) ~ 13일 (금) 장 소 KINTEX 제 2전시장, 3, 4층 컨퍼런스 룸 프 로 그 램 일 시 2013년 9월 11일 (수) ~ 13일 (금) 장 소 KINTEX 제 2전시장 8A 홀 Pharma Korea 2020 Forum, PIN Conference, Invited Symposium by GPKOL, Global Night (Regional Networking Dinner), Signing Ceremony 인베스트 페어 일 시 2013년 9월 11일 (수) ~ 13일 (금) 장 소 KINTEX 제 2전시장 7홀 & 컨퍼런스 룸 4층 프 로 그 램 014 바이오 현미경 사진 The Entrepreneurship Boot Camp 2013 일 시 2013년 9월 10일 (화), 10:00 ~ 17:00 장 소 KINTEX 제 2전시장 컨퍼런스 룸 303호 주 관 한국보건산업진흥원, ERA Consulting Group HI Korea Investment Forum, 융복합 창조기술 Show Case 015 BIO KOREA 2013 Schedule at a Glance September 10 (Tue) September 12 (Thur) Program Registration Boot Camp, Conference & Business Forum, Exhibition The Entrepreneurship The Entrepreneurship Boot Camp 2013 Boot Camp 2013 : De Risking Your Globalisation Strategies -for Korean Life Science Companies VenueTime Program Registration Conference & Business Forum, Exhibition, Job Fair Program VenueTime Lobby 2F 09:00~18:00 Registration Conference & Business Forum, Exhibition, Job Fair Lobby 2F 09:00~18:00 Rm. 303 10:00~17:00 Conference u-Health Rm. 301 09:30~18:00 Translational Research Rm. 302 09:30~17:30 Medicinal Bio-convergence and Mouse Phenotype Analysis Rm. 303 09:30~11:30 Technology Licensing Rm. 303 13:00~17:15 09:00~18:00 Pharma & Biotech Intellectual Property Rm. 304 09:30~17:30 10:00~11:00 Finance - HI KOREA Investment Forum (Free Admission) Rm. 401, 402 10:00~17:00 Business Forum 1:1 Partnering Hall 8A 10:00~18:00 10:30~18:00 Hall 7 & 8A 10:00~18:00 September 11 (Wed) VenueTime Lobby 2F Opening Ceremony Plenary Speech Hall 6B Exhibition Opening Ceremony Hall 7 Conference Vaccine Rm. 301 13:00~16:50 Medicinal Bio-convergence and Mouse Phenotype Analysis Rm. 302 13:00~17:30 Beauty Rm. 303 13:00~17:30 Business / Technology Presentation Hall 7 (Open stage I) BIO KOREA 2013 International Country Partner Forum Medical Device Rm. 304 13:00~16:10 Exhibition Exhibition Pharm Fair CONFERENCE - PIN (Pharmerging Innovative Networking) Conference (Free Admission) Rm. 403, 404 09:00~18:00 Global Night - Reginal Networking Dinner (Invited Only) Rm. 406, 407 18:00~20:30 Job Fair Consulting for Candidates (Resume, Interview, and Image Making etc.) Hall 8A (Job Fair Zone) 10:00~17:00 Special Lecture : “Consilience: The Unity of Knowledge “ 11:00~12:00 Hall 8A Jae Chun Choe, Professor, Ewha Womans University (Open stage 2) Pharmaceutical Specialized Graduate School Conference 14:10~16:00 : Pharmaceutical Education & Career Development Business Forum 1:1 Partnering Hall 8A 10:00~18:00 (Business Forum Center) Business/Technology Presentation Exhibition Exhibition Pharm Fair FORUM - Phrama Korea 2020 Forum Job Fair Consulting for Candidates (Resume, Interview, and Image Making etc.) Special Lecture : “Future Social Mega-Trends And Future Jobs” Hall 8A 14:00~15:00 Young Sook Park, Chair, Millennium Project Korea (Open stage 2) Healthcare Industry Job Presentation 15:30~17:00 Special Session London Health Forum (Free Admission) 14:00~17:30 Co-located Events Welcome Reception Export Marketign Conference for Medical Device Rm.308 15:00~18:00 BIO KOREA 2014 Poster Contest Hall 8A 10:00~18:00 Bio-microphotography Exhibition Hall 8A 10:00~18:00 016 Hall 7 (Open stage I) 13:00~18:00 Hall 7 & 8A 10:00~18:00 Hall 6B 13:30~18:30 Hall 8A (Job Fair Zone) 10:00~17:00 Rm. 405 Outdoor fountaion Square 18:00~20:30 Co-located Events Denmark Bio & Medtech Investment Seminar Rm. 308 09:00~18:00 Rm. 406, 407 09:00~16:00 10:00~18:00 IP Technology Seminar BIO KOREA 2013 Poster Contest Hall 8A Bio-microphotography Exhibition Hall 8A 10:00~18:00 017 BIO KOREA 2013 Floor Plan September 13 (Fri) Program Registration Conference & Business Forum, Exhibition VenueTime Lobby 2F Biotech Crops Rm. 301 10:00~17:30 Therapeutic Antibodies Rm. 302 10:00~17:30 Stem Cell Rm. 303 13:00~18:00 Finance - HI KOREA Investment Forum (Free Admission) Rm. 401, 402 09:30~16:00 Business Forum 1:1 Partnering Hall 8A 10:00~18:00 Business/Technology Presentation Hall 8A (Open stage I) BIO KOREA 2013 International Country Partner Forum Exhibition Exhibition Room 401~407 402 407 Conference Special Session 406 403 405 404 10:30~18:00 Room 301~304, 307~308 10:00~17:00 Pharm Fair SYMPOSIUM (Invited Symposium by GPKOL) Rm. 303, 304 09:00~12:30 MOU SIGNING CEREMONY Rm. 403, 404 10:00~12:30 Rm. 406, 407 09:00~18:00 Co-located Events IP Technology Seminar 401 09:00~18:00 Hall 7 & 8A 4F BIO KOREA 2013 Poster Contest Hall 8A 10:00~18:00 Bio-microphotography Exhibition Hall 8A 10:00~17:00 3F Conference 301 308 307 302 The Entrepreneurship Boot Camp 2013 Special Session Room 305 306 303 305 304 BIO KOREA Secretariat (Conference) Room 306 Speaker's Registration Preview Room 1F Hall 6 6 Opening Ceremony 2F 10 7 Hall 7, 8A Exhibition 8A 9 8B 018 Business Forum Job Fair Registration Desk (2F Lobby) 019 MEMO Conference Overview Conference Overview Conference Program at a Glance Conference Track List Plenary Speech Conference Program 020 Conference Overview The key strategic industry of Korea in the 21st Century! Covering a diverse range of applications and areas such as pharmaceuticals, biomedicines, medical services, food, agriculture, energy, chemical and environment, the Bio industry has become the future growth engine, fueled by the growth of Information Technology (IT) and Nano Technology (NT). BIO KOREA 2013 Conference will be a place to discuss and acquire the cutting edge knowledge on various topics including Vaccines, Therapeutic Antibodies, Biotech Crops, Stem Cell, Bio-convergence, u-Health and so on to firmly secure the global competitiveness. DATE: September 11 (Wed) ~ 13 (Fri), 2013 Venue: 3~4F, KINTEX Exhibition Center II MAY 28 ~ 30, 2014 / KINTEX Brand New Start in MAY! Expected No. of Participants: Approximately, 3,500 experts from Bio industry, research institutes, academia, and interested individuals from all over the world. Official Languages: English, Korean 023 Conference Program at a Glance Paid Admission DATE Conference Room 3, 4 F, KINTEX Exhibition Center II Rm. 301 Rm. 302 Sep. 12 (Thur) Conference Room 3, 4 F, KINTEX Exhibition Center II Rm. 303 Track 5. Medicinal Bio-convergence and Mouse Phenotype Analysis (S1) In Vivo-mimic 3D Cell Culture System Track 12. Beauty (S1) Convergence & Fundamental Technology for Cosmetics - Technology Application for Cosmetics - Screening, Evaluation & Formulation 13:00~15:00 13:00~15:00 13:00~15:00 (S2) Regulatory Issues on Vaccine (S2) Mouse Models for the Novel Drug Development (S2) Functional & Fermented Cosmetics Functional & Fermented Cosmetic Ingredient through Fermentation Technology Rm. 402 Rm. 403 Rm. 404 Track 8. Medical Device (S1) Medical Device Industry as a Driving Force for National Growth: Strategies for Medical Device R&D in Korea and Japan 13:00~15:05 (S2) Medical Equipment Industry as a Driving Force for National Growth: (Eastern Asia) National Strategies for Development of Medical Equipment 15:30~16:10 15:30~16:50 15:30~17:30 15:30~17:30 Track 6. u-Health (S1) Health Big Data as a National Asset-Pitfalls and Challenge on Public Health Data Sharing Track 7. Translational Research (S1) Translational Research - Concept and practice of TR Track 5. Medicinal Bio-convergence and Mouse Phenotype Analysis (S3) Mouse Phenogenomics for Drug Development 09:30~11:00 09:30~11:30 09:30~11:00 10:00~11:20 10:20~11:40 (S2) Consumer-centered Personal Health Records and Health Data Platforms – From Personal Health Records to Big Data (S2) Translational Research - Translation from Animal Model to Human Track 10. Technology Licensing (S1) Strategy and Support for Steps to Promote the Commercialization from Early Stage Innovations 13:00~15:00 (S2) Recent Trends of Court Decision and Presecution/ Examination Practice Regarding Pharmaceutical Patent 13:00~14:30 (S2) Company IR (Public Company) (S2)Technology Transfer Organization's Experiences and Cases of Increasing Value (S3) Major Antitrust Issues on Pharmaceutical Industry 13:00~14:30 13:00~15:00 (S3) PHR and Big Data-Use of Data and Management of Personal Health Record in the Medical Environment (S3) Clinical Application of Novel Targeted Agents Based on Genomics - Personalized Medicine 14:45~16:15 15:30~17:30 Track 9. Pharma & Biotech Track 11. Finance -HI Track 11. Finance -HI Intellectual Property KOREA Investment Forum KOREA Investment Forum (S1) FDA ANDA Approval (S1) Korea Bio Pharma Fund Partnering Procedure and Patent Sources & Investment Trends Infringement Case Study in 2013 Partnering Track 13. PIN (Pharmerging Innovative Networking) Conference (S1) China · ASEAN Session 10:15~11:15 (S2) Latin America Session 11:15~12:15 (S3) Russia ∙ Kazakhstan Session 13:45~14:45 (S4) Eastern Europe Session 13:00~17:30 14:45~15:30 (S5) Middle East Session 15:40~16:40 15:15~17:15 (S6) Special Session (IO Procurement and PCI/S Membership Application) 16:40~17:20 14:45~15:45 (S4) Global Strategy for Intellectual Property Licensing 16:00~17:30 16:30~18:00 Track 3. Bio Crops (S1) Understanding Climate Changes and Adapting Future Agricultural Production 024 Rm. 401 10:00-17:00 Track 1. Vaccine (S1) Vaccine R&D (S4) The Current Status of Smart Health Care Sep. 13 (Thur) Rm. 304 The Entrepreneurship Boot Camp 2013 Sep. 10 (Tue) Sep. 11 (Wed) Free Admission Track 2 Therapeutic Antibodies (S1) Therapeutic Antibodies Track 4. Stem Cell (S1) Tissue Specific Mesenchymal Stem Cells and Their Clinical Application Track 11. Finance - HI Track 11. Finance - HI KOREA Investment Forum KOREA Investment Forum (S3) Korea Bio Pharma Fund Partnering Sources & Investment Trends in 2013 10:00~11:50 10:00~11:50 10:10~11:40 13:00~14:00 (S2) Managing Food Sustainability in a Climate Constrained World via Technical Advances 13:30~14:50 (S2) Innovative Application of Anitbodies (S2) Tissue Engineering Using Biomaterials and Stem Cells (S4) Company IR (Private Company) 13:30~15:00 14:30~15:30 13:20~16:00 (S3) Development and Commercialization of Biotech Crops (S3) Antibodies and Beyond (S3) Clinical Application of Tissue Specific Stem Cells 15:30~17:30 15:30~17:30 16:00~18:00 Partnering 025 Conference Track List 01 Vaccine 06 u-Health : Vaccine R&D and Regulatory Issues : u-Health Convergence Session 1 Vaccine R&D Session 1 Health Big Data as a National Asset Session 2Regulatory Issues on Vaccine Session 2Consumer-centered Personal Health Records and Health Data Platforms Session 3 PHR and Big Data Session 4 The Current Status of Smart Health Care 02 Therapeutic Antibodies : Therapeutic Antibodies Session 1 Therapeutic Antibodies Session 2Innovative Application of Antibodies Session3 07 Translational Research : Navigating Biomedical Discovery towards Clinical Practice Session 1 Translational Research - Concept and Practice of TR 03 Biotech Crops Session 2 Translational Research - Translation from Animal Model to Human : Key Solutions for Climate Changes and Sustainable Agriculture Session 1 Understanding Climate Changes and Adapting Future Agricultural Production Session 3Clinical Application of Novel Targeted Agents Based on Genomics – Personalized Medicine Session 2Managing Food Sustainability in a Climate Constrained World via Technical Advances Session 3Development and Commercialization of Biotech Crops Antibodies and Beyond 04 Stem Cell : Current Development of Stem Cell Therapy and Tissue Regeneration Session 1 Tissue Specific Mesenchymal Stem Cells and Their Clinical Application Session 2Tissue Engineering Using Biomaterials and Stem Cells Session 3 Clinical Application of Tissue Specific Stem Cells 05 Medicinal Bio-convergence and Mouse Phenotype Analysis 08 Medical Device : Creative Economy and Medical Device Industry Session 1 Medical Device Industry as a Driving Force for National Growth Session 2Medical Equipment Industry as a Driving Force for National Growth 09 Pharma & Biotech Intellectual Property : Top Legal Issues on Pharmaceutical Industry - Intellectual Property and Antitrust Session 1 FDA ANDA Approval Procedure and Patent Infringement Case Study Session 2Recent Trends of Court Decision and Presecution/Examination Practice Regarding Pharmaceutical Patent : Convergence Model System and Its Phenotype Analysis for Efficient Drug Discovery Session 1 In Vivo-mimic 3D Cell Culture System Session 2Mouse Models for the Novel Drug Development Session 3 Major Antitrust Issues on Pharmaceutical Industry Session 3 Mouse Phenogenomics for Drug Development Session 4 Global Strategy for Intellectual Property Licensing 026 027 Plenary Speech 10 Technology Licensing : Sustainable Value Chain in Technology Licensing from Bench to Market Session 1Strategy and Support for Steps to Promote the Commercialization from Early Stage Innovations Session 2Technology Transfer Organization's Experiences and Cases of Increasing Value Innovative Biomedical Futures for Korea This talk presents forecasts for biomedical futures that offer the most promise for Korea to take a lead role in science and industry. A new understanding of health and disease will emerge at the periphery of JONATHAN PECK 11 Finance IAF (Institute for Alternative Futures), President today’s biological thought so that technologies that are conceived of today become everyday means for improving health around the world. Biology will advance through new theory that provokes research into healing, : HI Korea Invest Forum 2013 Session 1 Korea Bio Pharma Fund Sources & Global Investment Trends in 2013 consciousness and modalities of care that improve wellbeing in ways that Session 2 Company IR (Public Company) are highly valuable to societies and communities yet often less costly than Session 3 Cross-border VC and PE Fund Investment Opportunities and Strategies current modalities. Along with new theory we can see remarkable tools Session 4 Company IR (Private Company) emerging as nanotechnology enables atomic and molecular advances guided by the knowledge revolution that combines man and machine in 12 Beauty : Recent Developments in Cosmetic R&D for Making a New Leap Forward Session 1Convergence & Fundamental Technology for Cosmetics - Technology Application for Cosmetics - Screening, Evaluation & Formulation Session 2Functional & Fermented Cosmetics - Functional & Fermented Cosmetic Ingredient through Fermentation Technology new ways. Korea has natural advantages for leading a new value proposition for success rather than following the well-worn medical path that only leads to more unaffordable disease treatments which will be harder to sell as markets and governments get smarter. D A T E September 11 (Wed), 2013 10:20~11:00 V E N U E Hall 6B, KINTEX Exhibition Center II 13 PIN (Pharmerging Innovative Networking) Conference Session 1 China · ASEAN Session Session 2 Latin America Session Session 3 Russia · Kazakhstan Session Session 4 Eastern Europe Session Session 5 Middle East Session Session 6 Special Session (IO Procurement and PCI/S Membership Application) 028 029 Conference Program Sponsored by IVI Session 2. Vaccine Regulatory Issues Track 01. Vaccine : Vaccine R&D and Regulatory Issues Sep. 11(Wed), 13:00~16:50 Historically, vaccines have been reduced, eliminated and eradicated infectious diseases, therefore continuing efforts are being made in the research & development in vaccines. Now, vaccines are expanding target disease categories and improving technologies; cancer, chronic diseases, therapeutics and personalized or specialized and so on. This vaccine track symposium will give an overview of vaccine research and development (R & D) with new approaches and diseases. In addition to the R & D, regulatory affairs will be discussed what is being revised and updated in regards to registering and approving vaccines. This track will be of particular interest to participants from research, academia, pharmaceutical and bio-venture company, government authorities. Session 1. Vaccine R&D 15:30~16:50 This second session will share knowledge and experiences of regulatory affairs of vaccines and serve as a linkage to the first session. During this session, speakers will present general and specific issues of regulatory affairs, regulatory requirements, preparing dossiers to national authorities and review procedures and other related issues. Therefore, this session will provide and be understood changes or revisions of regulatory affairs to the participants who are interested in vaccines. Session Chair Soon Ae Kim, Research Scientist, Translational Research Division, International Vaccine Institute (IVI) 15:30~16:10 Regulatory Aspects of Vaccine Development Stephen W Cook, Vice President, Vaccine Global Regulatory, Head of International Region (EMAP / Japan / WHO) 16:10~16:50 Current Status of Approval Process and Policy Direction for Vaccine in Korea SeungHwa Hong, Director, Korea Food and Drug Administration, Biologics Division 13:00~15:00 This first session will give some perspectives including outcomes and opportunities of vaccine research and development (R & D) with new approaches and target disease. Topics will be provided on vaccine research and development for prevention of co-infection with virus and bacteria, current outcomes and perspectives about new technological approaches such as DNA vaccine, and new vaccine R & D. This session will provide understanding trends of new approaches and challenges in vaccine R & D. Session Chair Thomas F. Wierzba, Deputy Director General, International Vaccine Institute, Development and Delivery 13:00~13:40 Adenovirus Vector-induced Innate-adaptive Protective Immunity duo Against Viral and Bacterial Infections De-Chu Christopher Tang, Korean Brain Pool Program Scientist, International Vaccine Institute, Laboratory Science Division 13:40~14:20 Synthetic DNA Vaccines for Difficult Targets David B. Weiner, Professor, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine 14:20~15:00 Development of and Target Product Profile Considerations for Human CMV Vaccines Paul Kilgore, Associate Professor, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University 030 031 Session 2. Innovative Application of Antibodies Track 02. Therapeutic Antibodies : Therapeutic Antibodies Sep. 13(Fri), 10:10~17:30 Therapeutic antibodies, the main-stream format of drug developments, take up 37% of total biological drug in developing process and 20% of biological drugs waiting for FDA approval. According to estimation by Global Industry Analysts, therapeutic antibody market will reach 200 billion dollars by 2013. Currently there are 33 therapeutic antibodies in use and it is estimated there will be 55 therapeutic antibodies in market by 2018. Since demand for therapeutic antibodies are increasing constantly, multi-national pharmaceutical companies and Korean pharmaceutical companies are working actively to develop novel therapeutic antibody drugs. Through this track, we will look into current research focus and status of scientists in antibody developments. New applications using therapeutic antibodies and second generation antibodies will also be discussed. Session 1. Therapeutic Antibodies 10:10~11:40 Therapeutic antibodies are new paradigms for drug development. Technologies regarding development of therapeutic antibodies are rapidly. Through this session, top-tier scientists working in active field of therapeutic antibody drug development will present their research focus and results. Session Chair JunHo Chung, Professor, Seoul National University, Department of Biochemistry and Molecular Biology 10:10~10:40 Probing Affinity and Fine-Specificity of TCR Multimers and a TCR-like Antibody with PeptideHLA Libraries Gijsbert Grotenbreg, Assistant professor, National University of Singapore, Microbiology 10:40~11:10 Bispecific Antibodies Co-targeting HER2 and IGF-IR for Cancer Treatment Mei-Yun, Assistant professor, Hong Kong University, Microbiology Li Ka Shing Faculty of Medicine 11:10~11:40 Development of Therapeutic Antibodies Against Human C5 Dong Jo Kim, Team Leader(Senior Manager), Celltrion, Biotech R&D Institute 032 13:30~15:00 Various application and modification of antibodies to enhance affinity and specificity are being tried actively. We will be able to take a peak into up-to-date therapeutic antibody modification researches through this session. Session Chair Yong-Sung Kim, Professor, Ajou University, Applied Chemistry and Biological Engineering 13:30~14:00 Humanized Mouse Technology for Drug Development Jianzhu Chen, Professor, Massachusetts Institute of Technology, Koch Institute for Integrative Cancer Research 14:00~14:30 C omputational Design and Characterization of Artificial Selenoenzyme Based on Antibody Scaffold Quan Luo, Assistant Professor, Jilin University, Department of Chemistry 14:30~15:00 Platform Technology for Next Generation Antibody Therapeutics Byeong Doo Song, President, Scripps Korea Antibody Institute, Division of Research Program Session 3. Antibodies and Beyond 15:30~17:30 Many innovative approaches using antibodies were suggested recently. Scaffolds or aptamers with characters similar to antibodies are being actively developed. This session will concentrate on new views and formats of antibodies and therapeutics molecules. Session Chair Byeong Doo Song, President, Scripps Korea Antibody Institute, Division of Research Program 15:30~16:10 Platform Technology for the Next Generation Therapeutic Antibody Targeting Solid Tumors Yong-Sung Kim, Professor, Ajou University, Applied Chemistry and Biological Engineering 16:10~16:50 Biomedical Applications of a Novel Class of High-affinity Peptides (Aptides) Sangyong Jon, Professor, KAIST, Department of Biological Sciences 16:50~17:30 Non-antibody Scaffold for Developing Therapeutic Agents Hak-Sung Kim, Professor, KAIST, Department of Biological Sciences 033 Sponsored by Rural Development Administration, Monsanto Korea Inc., ILSI Korea Session 2. Managing Food Sustainability in a Climate Constrained World via Technical Advances 13:30~14:50 Track 03. Biotech Crops : Key Solutions or Climate Changes and Sustainable Agriculture Sep. 13(Fri), 10:00~17:20 Climate changes, often unusual and extreme in nature, have been growingly observed around the world, threatening sustainable food production and subsequently having impacts on global and national food security. Global grain prices have been fluctuated significantly in part due to the instability in grain supply regulating from global warming and climate change. It is of utmost importance to address this issues, which has driven many research to overcome these increasing challenges especially via technical advances. Therefore, these scientific sessions are planned to review the current status of climate changes from the perspectives of food production and economic aspects; to highlight key technical advances such as agriculture modeling and/or developing abiotic stress resistant biotech crops such as drought tolerant as one way to stabilize food supply against climate change; and to evaluate biotech crops as a mean to resolve instability of food supply from climate change in terms of benefits and/or limits. Session 1. Understanding Climate Changes and Adapting Future Agricultural Production 10:00~11:50 Climate changes have been growingly observed around the world, threatening sustainable food production. Demand for food crops continuously increases due to the increase in global population and changes in diet patterns from income growth. This session is planned to review the current status of climate changes from the perspectives of food production and economic aspects, which in turn help develop adaptation models and/or national policies to address the issues. Session Chair Kyu Hang Kyung, Professor, Sejong University, Food Science 10:00~10:30 Overview on Climate Change Adaptation in Agricultural Production Young Han Kwon, Director General, Korea Environment Institute, Korea Adaptation center for Climate Change 10:30~11:10 Impacts of Climate Change on Food Security and Livelihoods and Policy Responses Mark Rosegrant, Director, International Food Policy Research Institute(IFPRI) 11:10~11:50 Assessing Options for Adapting Agriculture and Food Systems to Climate Change James Jones, Distinguished Professor, University of Florida, Florida Climate Institute 034 This session is planned to introduce the trends in research, global and local, on technical advances and modeling for adaptation to climate changes from the perspectives of sustainable agricultural production. Also discussed will be what the research gaps would be for improved sustainable agriculture. Session Chair Ki Hwan Park, Professor, Chung-ang University, Food Science and Technology 13:30~14:10 Managing Future Crop Productivity under Changing Climate in Korea - Focusing on Rice Genetic Improvement for Heat Tolerance Hee Jong Koh, Director, Seoul National University, Plant Molecular Breeding Center 14:10~14:50 Increasing Sustainable Agriculture Productivity through Agricultural Technology Generation Jerry Hjelle, President, International Life Science Institute Session 3. Development and Commercialization of Biotech Crops 15:20~17:20 In this session, there will be interesting presentations about the current status of developing and commercialized Biotech crops, especially against climate changes. The session will provide global and local cases to evaluate biotech crops as a mean to resolve instability of food supply from climate change in terms of benefits and/or limits. Session Chair Yang Do Choi, Professor, Seoul National University, Department Agricultural Biotechnology 15:20~15:40 Current Status of GM Crop Development in Korea Soo Chul Park, Director, National Center for GM Crops, Rural Development Administration 15:40~16:10 Development of Biotech Crops against Climate Changes in Korea Yeon Hee Lee, Chief, National Academy of Agricultural Science, RDA, Agricultural Biotechnology 16:10~16:40 Introduction of Monsanto Pipeline for the Sustainable Yield from Climate Change Min Sang Lee, Regulatory Affairs Manager, Monsanto Korea, Regulatory Affairs 16:40~17:20 Q&A/General Discussion 035 Session 2. Tissue Engineering Using Biomaterials and Stem Cells Track 04. Stem Cell : Current Development of Stem Cell Therapy and Tissue Regeneration Sep. 13(Fri), 13:00~18:00 It is widely recognized that stem cells are present in a variety of tissues in the human body. Typical examples are bone marrow, fat, muscle, and cardiac tissue. The major research fields encompass stem cell isolation, purification, large expansion, specific lineage differentiation, and clinical applications. Although stem cells are a very promising tool in disease treatment and tissue regeneration, it is still unclear about the efficacy of stem therapy. One of the main issue is that the majority of transplanted cells fails to survive at the target site and thus engraft rate of transplanted cells is extremely low. Therefore a plausible solution using tissue engineering approach is to combine stem cells with biomaterials. This track introduces current development of stem cell therapy and tissue engineering, specifically 1) Tissue specific mesenchymal stem cells and their clinical application, 2) Tissue engineering using biomaterials and stem cells and 3) Clinical application of tissue specific stem cells. Session 1. Tissue Specific Mesenchymal Stem Cells and Their Clinical Application 13:00~14:00 It is widely recognized that stem cells are present in a variety of tissues in the human body. Typical examples are bone marrow, fat, muscle, and cardiac tissue. The major research fields encompass stem cell isolation, purification, large expansion, specific lineage differentiation, and clinical applications. Specifically bone marrow or adipose-derived stem cells are commercialized and many cases of clinical trials are underway worldwide. In this session, studies using tissue specific adult stem cells will be introduced and some related issues are discussed. Session Chair Gun-il Im, Professor, Dongguk University Ilsan Hospital, Orthopaedics 13:00~13:30Innate Differentiation Propensity of Tissue-Resident Stem Cells & Its Application for Regenerative Strategy Young-il Yang, Professor, Paik Institute for Clinical Research, Inje University, School of Medicine, Pathology 13:30~14:00 Regenerating Articular Cartilage - the Challenge of Creating the Stable Chondrocyte Phenotype Brian Johnstone, Professor, Oregon Health and Science University, Orthopaedics and Rehabilitation 14:15~15:15 Although stem cells are a very promising tool in disease treatment and tissue regeneration, it is still unclear about the efficacy of stem therapy. One of the main issue is that the majority of transplanted cells fails to survive at the target site and thus engraft rate of transplanted cells is extremely low. Therefore a new option using tissue engineering approach is to combine stem cells with biomaterials. In this session, some approaches utilizing biomaterials to manipulate stem cells is introduced and relevant issues, including clincical implications and commercialization will be discussed. Session Chair Jin Ho Lee, Professor, Hannam University, Dept. of Advanced Materials 14:15~14:45 Biofunctional Materials for Tissue Engineering Applications Heungsoo Shin, Associate Professor, Hanyang University, Bioengineering 14:45~15:15 Stem Cell Commitments in 3D ECM-hydrogels Nathaniel S. Hwang, Assistant Professor, Seoul National University, School of Chemical and Biological Engineering Session 3. Clinical Application of Tissue Specific Stem Cells 15:30~17:30 Stem cells residing in diverse tissues in our body are highly valuable resources in regenerative medicine. It is believed that stem cells derived from a target tissue can be more potent in therapeutic effect for the same target regeneration. Therefore this session overviews the recent development of clincial applications of specific tissue-derived stem cells and trend of stem cell-based gene therapy. Especially some barriers in developing stem cell therapy and possible technical and clinical solutions will be discussed. Session Chair Shin-Yoon Kim, Professor, Orthopedic Surgery, Kyungpook National University, College of Medicine 15:30~16:00 Tonsil-derived Mesenchymal Stromal Cells: Successful Banking & Clinical Application Hae Sang Park, Clinical Assistant Professor, Otorhinolaryngology - Head & Neck Surgery, Ewha Womans University Mokdong Hospital 16:00~16:30 Neural Stem Cells and Translational Research Kook In Park, Professor, Yonsei University College of Medicine, Pediatrics 16:30~17:00 More Insights into Mesenchymal Stem Cells as Therapeutics Ki Chul Hwang, Professor, Yonsei University Collage of Medicine, Severance Biomedical Institute 17:00~17:30 Umbilical Cord Blood Therapy Potentiated with Erythropoietin for Children with Cerebral Palsy MinYoung Kim, Professor, CHA University, Rehabilitation Medicine 036 037 Sponsored by IMPC / KMPC Session 2. Mouse Models for the Novel Drug Development Track 05. Medicinal Bio-convergence and Mouse Phenotype Analysis : Convergence Model System and Its Phenotype Analysis for Efficient Drug Discovery Sep. 11(Wed), 13:00~17:30 / Sep. 12(Thur), 09:30~11:30 Despite the constant increase in R&D investment for new drug discovery, the investment return is getting lower in the pharmaceutical industry. This is a crisis not only to the industry itself but also to human health and welfare. The difficulty mainly results from the high failure rate and long term R&D periods involved in drug discovery. In order to overcome this crisis, NT, IT convergence & multi-omics data integration being presented as an alternative technology innovation. In this track, experts from various discipline will share their knowledge about 3D cell culture systems, mouse model development and systematic mouse phenotype analysis in drug discovery. Session 1. In Vivo-mimic 3D Cell Culture System High failure rate in clinical trials of the drug development process is a major burden in respect of cost and time. Animal disease models used in the preclinical trials have limitations in recapitulating human disease because they are different in the pathological processes in various aspects. To improve those limitations of disease model, in this session, we discuss how to generate proper mouse models and analyze them efficiently. Session Chair Sunghoon Kim, Professor, Seoul National University, College of Medicine 15:30~16:10 Mouse Models for the Novel Drug Development Ho Jun Seol, Associate professor, Sungkyunkwan University School of Medicine, Samsung Medical Center 16:10~16:50In Vivo Fluorescence Cellular Imaging of Animal Model for Human Disease by Intravital Microscopy Pilhan Kim, Professor, KAIST, Graduate School of Nanoscience and Technology 16:50~17:30 DNA Damage Pathway in Cancer, Aging, and Development Ho Lee, Senior Scientist, National Cancer Center, Biomolecular Function Research Branch Session 3. Mouse Phenogenomics for Drug Development 13:00~15:00 Recently, Drug development takes increased money, but the number of approved drug is decreased. This situation is caused by the gap between basic research and clinical trials. Basic scientists usually use cell line for their convenience, but there are many different cellular response between conventional cell culture system and in vivo system. To solve this gap, in vivo-mimic 3 dimensional cell culture being presented as an alternative platform. In this session, experts from various discipline will share their thechnologu and knowledge to narrow the gap in drug development. 15:30~17:30 09:30~11:00 13:00~13:40 3D Culture of Blood Vessels; Perfusable Blood Vessels on a Chip Noo Li Jeon, Professor, Seoul National University, School of Mechanical and Aerospace Engineering The laboratory mouse as a model of human disease has proved to be a powerful tool for drug development, with dozens of the top selling medicines generated in part through the application of a mouse model. However, There are still many challenges ahead to maximize the value of the mouse as a model, particularly for drug development. These involve limited understanding of phenotype of mouse in genotypic, systemic and systematic level. To overcome this, we need phenogenomic approach, which is the functional annotation of human genome by the phenotype assessment of mutant mice. Systematic phenotype assessments in mutant mouse allow us to find new function of human gene leading to development of new drugs. In this session we will discuss how genotype-phenotype analysis and high throughput screens in the mouse are being used in translational research and where they can help advance the drug discovery process. 13:40~14:20 High-Throughout, Microarray-Based Platforms for Predictive 3D Cell-based Screening Bosung Ku, Principal Engineer, Samsung Electro-Mechanics 14:20~15:00 In vitro 3D Heterotypic Cell Culture Assay Seok Chung, Associate Professor, Korea University, School of Mechanical Engineering 09:30~10:00 International Mouse Phenotyping Consortium: Defining Gene Function Using KO mice Mark Moore, Executive Director, IMPC Session Chair Sunghoon Kim, Professor, Seoul National University, College of Medicine Session Chair Je Kyung Seong, Professor, Seoul National University, Veterinary Medicine Han Woong Lee, Professor, Yonsei University, Biochemistry 10:00~10:30 Mouse Metabolic and Sensory Phenotyping in Korea Mouse Phenotype Consortium (KMPC) Je Kyung Seong, Professor, Seoul National University, Veterinary Medicine 10:30~11:00 Knockout Mice Created by TALEN-mediated Gene Targeting Han Woong Lee, Professor, Yonsei University, Biochemistry 038 039 Session 3. PHR and Big Data-Use of Data and Management of Personal Health Record in the Medical Session 2. Environment 14:45~16:15 Track 06. u-Health : u-Health Convergence Sep. 12(Thur), 09:30~18:00 There have been many of attempts to enhance the quality of human life with the great store of information in the 21st century. The continuously growing amount of information has turned in to the 'Big Data' and it has been resulted in outstanding progress in many of health fields such as PHR, disease prevention, and quality health service, and accordingly, the international stand of Korean health industry in the global world has been escalated. These sessions will review and discuss about the current status and prosperity of u-Health, emerged from the convergence of IT and BT. Session 1. Health Big Data as a National Asset - Pitfalls and Challenge on Public Health Data Sharing 09:30~11:00 In the era of “Big Data”, the government is responsible for utilizing the medical data in treating disease and providing optimal health environment to the public. The policies in deploying the health and medical data in the advanced countries would be discussed and review what are the concern and legal and administrative measures regarding the governmental use of medical data. Moreover, it will cover the convergence of u-Health and information technology as a health information. Session Chair Seung Hoon Lee, Director, National Cancer Center, Office of Public Relations and Collaboration 09:30~10:00Health Data Utilization in Public Organizations, and Ict, Creative Economy in Fast Growing Information Society Young Sung Lee, Professor, Chungbuk National University, Department of Health Informatics and Management/College of Medicine 10:00~10:30 Use of Public Data and Protection of Privacy in Healthcare Hyoung Wook Park, Assistant Professor, Dankook University Medical College, Department of Social Medicine 10:30~11:00 Telemedicine Based on T(-ele) Shirt Gi-Soo Chung, Korea Institute of Industrial Technology Session 2. Consumer-centered Personal Health Records and Health Data Platforms - From Personal Health Records to Big Data 13:00~14:30 As consumers are becoming more empowered by information and technology, it is starting to consolidate health data siloed in various healthcare organizations into personal health records. The cost of personal health devices is constantly decreasing and the development of mobile health apps is spurring with the penetration of smartphones. Now, consumers need a health data platform to aggregate and manage diverse data regarding one's health, including genetic information. Cloud-based health data platforms can fulfill these needs, turning personal health records into big data with genotypic and phenotypic information of numerous individuals. In this session, the speakers will introduce the concept of a consumercentered personal health record, and explain how a health data platform can create an ecosystem. The speakers will also share some characteristics of Korean consumers through the case of a personal health record system in Korea. Session Chair 13:00~13:30 13:30~14:00 14:00~14:30 040 Suk Hwa Kim, Professor, Seoul National University Hospital Plastic Surgery The What and Why of a Consumer-centered Personal Health Record Suk Hwa Kim, Professor, Seoul National University Hospital Plastic Surgery An Open Health Data Platform and Its Ecosystem James G. Boram Kim, Researcher, Seoul National University, College of Medicine My Chart in My Hand: Hospital Tethered Mobile Health Record Application Soo Yong Shin, Research Assistant Professor, Asan Medical Center, Biomedical Informatics Environment can be provided in more convenient and efficient, as m-Health and u-Health through smart IT fusion are provided medical services recently, personal health records has become a hot topic in the medical field studies the application of technology to take advantage of big data that has been investigated. By integration analysis of data to generate knowledge and verifying, use of big data in the medical environment in the future, in order to provide medical services according to the patient that the physician can make a medical accurate and it is predicted that would be an important analytical tool. In this session, you can be utilized how they are managed future, we will try and check at the moment, personal health records of these attempts to provide a forum for active exchange. Session Chair Il Kon Kim, Professor, Kyungpook National University, School of Computer and Science 14:45~15:15 Overview of Global PHR Platform and Big Data Jeong-Whun Kim, Associate Professor, Seoul National University Bundang Hospital, Otorhinolaryngology 15:15~15:45 Clinical Data Warehouse System for Personalized Care Guideline Development In Young Choi, Assistant Professor, The Catholic University of Korea, Graduate School of Health Management and Policy 15:45~16:15 Big Data Business Model Jung Kim, CEO, DBdiscover Session 4. The Current Status of Smart Health Care 16:30~18:00 A report published by GSMA(GSM Association) and PricewaterhouseCoopers predicted that mHealth could save over 1 million lives in Sub-Saharan Africa over the next five years and help cut healthcare costs in OECD countries by over 400 billion USD in 2017. In this session, three topics of smart healthcare using smart devices for mHealth will be discussed, those are, Hospital information system for smart healthcare, Trend of ICT for smart healthcare, and Mobile emergency care on board. Session Chair Tae Soo Lee, Professor, Chungbuk National University, College of Medicine 16:30~17:00 Seamless Healthcare Model : Connecting Patients and Professionals for Better Care Hye-Jeong Jeong, Research Professor, Yonsei University 17:00~17:30 The Evolution Path of Smart Mobile Health and Case Studies Seungsu Baek, Director, Health Connect Co.Ltd, Healthcare Business Development Division 17:30~18:00 Mobile Emergence Care in Ambulance Dong Keun Jung, Professor, Dong-A University, College of Medicine, Department of Medical Engineering 041 Session 2. Translational Research - Translation from Animal Model to Human Track 07. Translational Research : Navigating Biomedical Discovery towards Clinical Practices Sep. 12(Thur), 09:30~17:30 The core goal of translational research in medicine is to develop the products solving medically unmet needs (T1) and to verify the feasibility of research products to medicine (T2). T1 translational research can be achieved by integrative and cooperative studies performed by the associative specialists in basic, clinical, and industrial sectors and T2 translational research is for the improvement of people's health status. Translational research has recently become a focus of concern because of growing awareness of a widening gap between advances in basic science and the practical application of that knowledge. One manifestation of this gap is the lack of growth of new drug approvals despite a more than 10-fold increase in spending by the pharmaceutical and biotechnology industries over the past 40 years. One of factors contributing to this R&D productivity crisis is the difficulty of crossing the valley of death: the gulf between finding a promising new agent and demonstrating its safety and efficacy in humans. In this session, scientific requirements and developmental strategies required to cross the valley of death, thus leading to the successful clinical investigation of anti-cancer drugs, will be presented. Session Chair The scope of translational research is not restricted to a certain stage of technology relevant level (TRL) of healthcare R&D. It requires holistic approaches to resolve medically unmet needs and to maximize the efficiency and productivity of R&D. 13:00~15:00 J ang-Seong Kim, Principal Scientist, Korea Research Institute of Bioscience and Biotechnology Research Center for Integrated Cellulomics 13:00~13:40 Targeting Tumor Microenvironment for Pancreatic Cancer Treatment Sang Seok Koh, Principal Investigator, Korea Research Institute of Bioscience and Biotechnology Immunotherapy Research Center 13:40~14:20 Inhibition of Tumor Progression by a Novel Anti-cancer Therapeutic antibody Targeting VEGF and Dll4 Weon-Kyoo You, Principal Research Scientist, Hanwha Chemical, Biologics R&D Center 14:20~15:00 Fulfilling the Promise of Drug Discovery and Development: Role of PK/PD and Biomarkers in Early Decision Sang Hoon Lee, VP and Co-founder, PharmAbcine, Management Session 1. Translational Research - Concept and Practice of TR 09:30~11:30 Session 3. Clinical Application of Novel Targeted Agents Based on Genomics - Personalized Medicine 15:30~17:30 Many scientific discoveries from genetic and molecular biological laboratories had not been successfully linked to the medical use such as prevention, diagnosis, and therapeutic treatment of disease. The concept of translational research has been emerged to solve this problem. Translational research can effectively promote the clinical application of R&D outcomes from basic science to valuable medical products. Session Chair Byung Soo Kim, Director, KHIDI, Department of Translational Research 09:30~10:00 Bench to Bedside – Drug Discovery & Development in Singapore Louise Sarup, Head of Business Development & Licensing, A*STAR 10:00~10:30 Mechanism of Action of Novel Insulin Sensitizers Patrick R. Griffin, Professor and Chair, The Scripps Research Institute, Scripps Florida, Molecular Therapeutics 10:30~11:00 The Role of New Drug Development Center of DGMIF : Promotion of Translational Research Seong Heon Kim, Director of Medicinal Chemistry, DGMIF, New Drug Development Center 11:00~11:30 The Conceptual Debate of Translational Research uk Kwan Kim, Director, Science & Technology Policy Institute (STEPI), Division for Industrial Innovation S Research 042 With tremendous progress of biotechnology and genomics, molecular targeted agents are the mainstream of the new drugs in cancer treatment resulting in improving clinical outcome. However, still there are many problems exist including the proper assay for target identification, drug resistance from tumor heterogeneity, and different drug toxicity profiles from cytotoxic agents with ethnic differences. Hence the effort for personalized therapy based on the patients’ and tumor characteristics for maximizing antitumor effect and minimizing drug toxicity is necessary. We need the development of proper biomarker assay, biomarker driven clinical trials, especially multinational trials. In this session, we will discuss the current status of personalized medicine in cancer and proper strategy to overcome the limitations in development of novel molecular targeted agents through multinational trials. Session Chair Hyun Cheol Chung, Professor, Yonsei Cancer Center, Yonsei University College of Medicine, Yonsei University Health System, Division of Medical Oncology 15:30~16:10 Global Development on Monoclonal Antibody Biosimilar Ho Ung Kim, Department Leader, Celltrion Inc. Clinical Planning, Clinical Statistics, Medical Affairs 16:10~16:50 Challenges in Multinational Trials Atsushi Ohtsu, Professor, National Cancer Center Hospital East 16:50~17:30 Development of Novel Anticancer Drugs from Whole Genome Sequencing Yeul Hong Kim, Professor, Korea University, Oncology-Hematology 043 Sponsored by The Korean Society of Medical & Biological Engineering, Korean Society of Biomaterials, The Korean Society of Mechanical Engineering, The Institute of Electronics Engineers of Korea Session 2. M edical Equipment Industry as a Driving Force for National Growth Session 2. : (Eastern Asia) National Strategies for Development of Medical Equipment15:30~16:10 Track 08. Medical Device : Creative Economy and Medical Device Industry Sep. 11(Wed), 13:00~16:10 The track will discuss the issues regrading medical device R&D and industrization. The medical device industry will encourage the creative economy and contribute to the future growth engines of Korea. Session 1. Medical Device Industry as a Driving Force for National Growth Session 2. : Strategies for Medical device R&D in Korea and Japan Medical equipment industry is a capital-technology dependent industry, with a long expense retrieval period due to a long development period before production (3~5 years). Continued investments are crucial due to high initial expenses, small market, and short product lifespan. Another obstacle is the different regulations between different countries, which hinders international trade. Numerous specialized, small-to-middle sized companies dominate the department-based research market, while the market for relatively expensive parts and products are controlled by larger companies. We invite experts from across the societies to discuss the policies suggested by the government to promote R&D support, regulation and registration, and balanced market growth. Session Chair 13:00~15:05 The medical equipment industry is a part of public health industry, aiming to improve the quality of human lives through combined efforts of the medical field and various fields of engineering. The production of medical equipments require cooperation of various fields of science such as clinical studies and engineering, including but not limited to electrical, electronic, mechanical, material, and optical technology. Furthermore, government regulations must be maintained on the medical equipment industry as it directly impacts and is influenced by the overall health and wellness of the patients. Therefore, the government encourages development, production and clinical trials while regulating safety, sales, efficacy, and ensuring the ownerships of intellectual properties. We invite experts to discuss future strategies for development of medical equipments, optimization, and fusion and application of various fields of engineering. We also invite experts to discuss government-involved development of medical equipments in Korea and Japan. Session Chair Zang-Hee Cho, Professor, Gachon University, Neuroscience Research Institute 13:00~13:02 Opening Adress Kyung Sun, Professor, Korea University 13:02~13:05 Congratulatory Adress Dae-Kyung Kim, Chair, NSTC, Expert Councilon Life Science and Welfare 13:05~13:35 Action Plan of Promotion of Medical Device Innovation in Japan Yoshiyuki Taenaka, Director, National Cerebral and Cardiovascular Center, Research and Development Initiative Center Panel Kui Won Choi, Director, Korea Institute of Science and Technology, Biomedical Research Institute Panel Discussion oung Huh, Program Director, Korea Evaluation Institute of Industrial Technology, Emerging Industry PD Y Group Mi Na Ha, Director, Korea Health Industry Development Institute, Department of Infrastructure Development un-jong Cha, Division Director, Division of Electrical Engineering, Information Science, and Convergence E Research, Directorate for Basic Research in Science and Engineering, National Research Foundation of Korea Hee Chan Kim, Professor, Seoul National University, Department of Biomedical Engineering, College of Medicine Ki Dong Park, Professor, Ajou University, Molecular Science and Technology Doo Yong Lee, Professor, KAIST, Mechanical Engineering Chang-Hyun Oh, Professor, Korea University, Department of Electronics and Information Engineering Hee Byoung Park, Director, Korea Medical Devices Industrial Cooperative Association Tae-Geon Kang, Director, Korea Medical Devices Industry Association, Industry Development Department 13:35~14:05 National R&D Strategies of Medical Devices Bong Soo Kim, Director, Ministry of Science, ICT and Future Planning, Expert Council on Life Science and Welfare 14:05~14:20 Role and Responsibility of Biomedical Engineer for the Development of Domestic Medical Device Industry Hee Chan Kim, Professor, Seoul National University, Department of Biomedical Engineering, College of Medicine 14:20~14:35 Recent Advances in Biomaterials-based Medical Devices Ki Dong Park, Professor, Ajou University, Molecular Science and Technology 14:35~14:50 Toward Open Innovation in the Medical Devices Industry Doo Yong Lee, Professor, KAIST, Mechanical Engineering 14:50~15:05 Present and Future of Research and Development of Medical Electronic Systems Chang-HyunOh, Professor, Korea University, Department of Electronics and Information Engineering 044 045 Session 2. Recent Trends of Court Decision and Presecution/Examination Practice Regarding Session 2. Pharmaceutical Patent 13:00~14:30 Track 09. Pharma & Biotech Intellectual Property : Top Legal Issues in Pharmaceutical Industry - Intellectual Property and Antitrust Sep. 12 (Thur), 10:00~17:30 The pharmaceutical industry can sustain its growth through protecting intellectual property rights of research and development in the field. First, we should know how they are protected. It is important to understand what protections foreign and domestic courts grant to intellectual property rights in the pharmaceutical field, and what recent trends are in presecution/examination process. Also, we should understand the limits of protection. Understanding the proper scope of rights through knowing recent regulation trends is necessary. Lastly, we should take a look at the exercise of intellectual property rights through licensing. This section will take a look at recent court decisions involving pharmaceutical patents in Republic of Korea and the United States. Court decisions about probability of obtaining a patent grant (in particular, the recent Supreme Court’s Myriad decision) or ones regarding interpretations of patent claims are essential for requesting protection through patent in future. Also, the section will examine trends of presecution/examination practices by Korean Intellectual Property Office and U.S. Patent and Trade Office, thereby having time to find out a desirable way to apply for a patent. Session Chair Junghi Park, Partner, BAE, KIM & LEE LLC 13:00~13:30 The Analysis of Korean Court Cases in the Area of Pharmaceuticals for Recent 3 Years So Young Ahn, Patent Attorney, Dr. Ahn International Patent Law Office, Patent 13:30~14:00 Recent Trends on Patent Applications and Examination Practices in the Field of Pharmaceuticals in Korea Yong Kim, Patent Examiner, Korean Intellectual Property Office, Pharmaceutical Exmination Division Session 1. FDA ANDA Approval Procedure and Patent Infringement Case Study 10:00~11:20 Some of issues that arise in ANDA patent litigation are common to patent litigation in general, many more, however, derive uniquely from the Hatch-Waxman Act and the regulations associated with FDA approval of a patented or generic pharmaceutical drug. Combining the elements successfully requires considerable expertise. This session details the process at the intersection between the statutory and regulatory scheme governing approval of pharmaceutical drugs and U.S. patent law in the context of ANDA patent litigation. Specific emphasis is placed on presenting the issues, the strategies, and the tactics from the perspective of both branded and generic pharmaceutical companies. For the pharmaceutical companies, the federal courts and other governing bodies (the arbiters in this litigation), and even the consumers, the work represents an insiders’ guide to the process as a means of offering understanding and perspective. Session Chair 14:00~14:30 The Future of Biotech Patents after Recent U.S. Supreme Court Decisions Judith Kim, Partner, Sterne Kessler Goldstein & Fox, Bio Session 3. Major Antitrust Issues in Pharmaceutical Industry 14:45~15:45 Recently, the Fair Trade Commission is tightening regulations on unfair trades in the pharmaceutical field. The Fair Trade Commission particularly notified Guidelines for Fair Trades in the Pharmaceutical Field. This section will examine why the guideline is enacted and what it is about, and furthermore take a look at major fair trade issues in the field. Session Chair Eric Eui-Kwon Kim, Attorney at law, Dong-A Pharmaceutical, Legal Affairs Team 14:45~15:15 EU Competition Law Enforcement in the Pharmaceutical Industry Hee-Eun Kim, Attorney, Covington & Burling LLP, Brussels Office 15:15~15:45 The Trend of Antitrust Law Enforcement in the Pharmaceutical Sector Il Kang, Partner, BAE, KIM & LEE LLC, Antitrust Team Kyung Ae Yoon, Patent Attorney, Yul Chon LLC, IP group 10:00~10:40 FDA ANDA Approval Procedure and Patent Infringement Case Study Heajin Jung, Attorne, Heajin Jung Law Firm, LLC 10:40~11:20 Hatch-Waxman Practice: Practical Considerations and Strategies Ari Zytcer, Attorney-at-Law, Vorys, Sater, Seymour and Pease, Pharma/Biotech Patent Group Session 4. Global Strategy for Intellectual Property Licensing 16:00~17:00 IP Licensing is an important opportunity for domestic pharmaceutical firms to make profits. The first step is to secure a strong patent for licensing. Due diligence, an investigation conducted during licensing process with foreign businesses, should be thoroughly prepared as well. Licensing negotiation strategy is also necessary. This session will examine major issues one should know for IP licensing. Session Chair Chiho Choi, Director, Management Planning, KAIST 16:00~16:30 Pitfalls in Pharmaceutical Licensing Chiho Choi, Director, Management Planning, KAIST 16:30~17:00 IP Due Diligence in Pharma/Biotech Out-licensing Mihsun Koh, Patent Attorney, Vorys, Sater, Seymour and Pease LLP, Pharma/Biotech Patent Group 17:00~17:30 Intercultural Challenges for Asian Companies in Partnerring with European Companies Sebastian Fernandez, Founder, Atenea Management Services 046 047 Sponsored by MSD Session 2. T echnology Transfer Organization's Experiences and Cases of Increasing Value Track 10. Technology Licensing : Sustainable Value Chain in Technology Licensing from Bench to Market Sep. 12 (Thur), 13:00~17:15 The ecosystem of bio technology & pharmaceutical value chain include inventors (academic and research institutes), technology transfer organization, and companies in need. It is critical to oversee the organic structure and each component and the strategy to add value. These sessions will discuss the ideal approach for a successful technology licensing and transfer. 15:15~17:15 Among the key components of successful technology transfer are competency and experiences of Technology Transfer Organization (TTO). Experienced TTOs are significantly involved beyond the initial technology transfer. From experiences of recognized institutions, an insight can be learned for what can be done for next steps for enhancing the capacities of Korean TTOs. Session Chair Jangyoung Lee, Medi-post, Business Development 15:15~15:45 From Research to Commercialization – The Technion Experience Benjamin Soffer, CEO, Technion Technology Transfer 15:45~16:15 Commercialization of University's Technology & Role of Techno Holding Company Moon Kyu Lee, Director, Sogang University Holdings, Headquarters 16:15~16:45 External Opportunity in Asia : Key Considerations in Early Stage Collaboration, Big Pharma Perspectives Yuan-Hua Ding, Senior Director, Pfizer, Worldwide R&D 16:45~17:15 K ey Considerations for Early Stage Collaboration, Korea Bioventure perspectives, Stories of PharmAbcine Development Strategies and Partnership Jin-SanYoo, CEO, PharmAbcine Session 1. Strategy and Support for Steps to Promote the Commercializationfrom Early Stage Session 2. Innovations 13:00 ~ 15:00 Despite the overall increase of R&D budgets, the whole pharmaceutical industry has faced the challange of decreased productivity. Development and commercialization of early-stage innovations are exposed to high risks of failures at various stages. From the experiences of global organizations, we would learn the know-how and strategies for overcoming hurdles and successful commercialization of innovative medicinal products. Session Chair Dongho Lee, CEO, Korea Drug Development Fund Pleanary Speaker Partnering for Innovation; Merck's Strategy and Experiences in Early Stage Alliance 13:00~13:30Greg Wiederrecht, Vice President, Merck Research Laboratories, WWL&A/ESA 13:30~14:00 Sigapore's Biomedical Industry : The Role of A*STAR Benjamin Seet, Executive Director, Agency for Science, Technology and Research, Biomedical Research Council 14:00~14:30 Israel’s Incubator Program Ofer Fohrer, Commercial Attaché, Embassy of Israel 14:30~15:00 A Strategy for Biotechnology Transfer and Commercialization Hyun Mo Yang, Director, TechnoValue, MoT Department 048 049 Special Sponsor: Ministry of Health & Welfare Session 3. Cross-border VC anc PE Fund Investment Opportunities and Strategies Track 11. Finance : HI Korea Invest Forum 2013 Sep. 13. (Fri) 10:00~11:50 Sep. 12 (Thur) 10:00~17:00 / Sep. 13 (Fri) 09:30~16:00 Bio Korea 2013 will host the Bio Invest Forum Sessions, featuring presentations and panel discussions to help identify and understand Korean Pharma PE & biotech VC fund sources and investment opportunities. Participants include global and local venture capitalists, investment bankers, government representatives and company executives who are looking for cross-border strategic and financial alliances and network opportunities. Session Chair Ike Whan Lee, Person CEO of Alopax Bio-Consulting, Inc. 10:00 - 10:20An Investment Banker’s View on the Future Growth for Biotech and Pharma, and the Areas of Greatest Opportunity for Korean Companies Billy Cho, Vice President of Citi Group, Hongkong 10:20 - 10:40 Israel’s Life Science Industry Guy Shinar, Venture Partner of YozmaGroup 10:40 - 11:00 Global B2B to Eong-term Outperform Ji-Hyun Kim, Analyst of Kiwoom Securities Co., Ltd Session 1. Korea Bio Pharma Fund Sources & Investment Trends in 2013 Session Chair Sep. 12. (Thur) 10:20~11:40 11:20 - 11:40The Biotechnology Capital Raising Environment Globally and in Asia Pacific - Outlook and Recent Developments Vijay Karwal, Managing Director of Head of Industrials, Consumer & Healthcare Asia Pacific, CIMB Investment Bank 11:40~11:50 Break Dong-Su Jeong, Attorneys at Law YULCHON Panel 10:20 - 10:40 Investment Overview on Korea Bio/Pharma Companies Youn-hoon Joo, Health Industry Leader of Samil/PwC Advisory Korea Panel Discussion 11:50~12:30 B. Christopher Kim, Partner, Oxford Bioscience Partners (Moderator) 10:40 - 11:00Introducing KoFC Fund for Strengthening the Competitiveness of Korean Pharmaceutical Industry Jin-Woo Park, Manager of Korea Finance Corporation Caleb Winder, Director, Excel Venture Management Timothy E. Sullivan, Head of Life Science, RBS Citizen Patrick Keenan, Director and Chief Counsel, Nomoda Capital Innovations 11:00 - 11:20 InterVest Global Pharmaceutical Fund 2013 Myung-Kee Kim, Executive Managing Director of InterVest Co., Ltd. Billy Cho, Vice President, Citi Group 11:20 - 11:40 Global Bio-Pharma Investment Trends and Strategy Hongbo Lu, Executive Director of OrbiMed Advisors LLC Session 2. Company IR (Public Company) Sep. 12. (Thur) 13:00~17:00 13:00~17:00 Participating Companies LegoChem, Cristal genomics, Hanmi pharmaceuticals and etc. (Total 8 companies) 050 Session 4. Company IR (Private Company) Sep. 13. (Fri) 13:20~16:00 13:20~16:00 Participating Companies PharmAbcine, Corestem, ChunLab and etc. (Total 8 companies) 051 Session 2. Functional & Fermented Cosmetics - Functional & Fermented Cosmetic Ingredient through Session 2. Fermentation Technology 15:30~17:30 Track 12. Beauty : Recent Developments in Cosmetic R&D for Making a New Leap Forward Sep. 11 (Wed), 13:00~17:30 Cosmetics industry that fits well to realize creative economy has a good potential to become a Nation’s future growth engine. Cosmetics industry of most advanced countries are well developed. It needs innovative and creative convergence technology and also is significantly influenced by cultural factors. Developments of various platform technologies and leading edge innovative technologies are necessary in cosmetic R&D. NCR has provided supports for the cosmetic R&D in order to transform domestic cosmetics industry into export oriented industry. Fermentation technology, a key process for the production of valuable bioactive compounds, plays an important role in the cosmetics industry recently. Due to its natural process and skin effective products, many companies are developing fermentation-based ingredient production. Pitera from SK-II is an example of fermentation-based ingredients. This session provides recent research and developing trends from cosmetics industry. Session Chair Wan Goo Cho, Professor, Jeonju University, College of Alternative Medicine 15:30~16:00 Patent Map of Functional & Fermented Cosmetic Ingredient Hyang-Bok Lee, Research Professor, Inha University, Biological Engineering, College of Engineering 16:00~16:30 Skin Effects of Hydrolysed Ginseng Saponins Produced by the Enzymatic Hydrolysis of Ginseng Saponins Myeong Hun Yeom, Amorepacific Corporation R&D Center, Hanbang Application Research Team / Skin Research Institute 16:30~17:00 Fermentation Technology and Cosmetic Ingredients Seung-jin Hwang, Senior Researcher, Fermentation & Oriental Herb Team, Skinomics Research Center, LG Household & Health Care Research Park Session 1. Convergence & Fundamental Technology for Cosmetics - Technology Application for Session 2. Cosmetics - Screening, Evaluation & Formulation 13:00~15:00 17:00~17:30 About Development Natural Cosmetics through Fermentation Technology and Its Insights Dong-Il Jang, CEO, COTDE Co., Ltd Cosmetics industry is a convergence industry that requires innovative convergence technology consisting of diverse disciplinary science and technology fields, which are cell engineering, biotechnology, surface chemistry, natural product research, fermentation technology, nano technology, human sensibility ergonomics, mechanical engineering, information technology, etc. Especially in recent years, it is becoming important to develop platform technologies such as high throughput screening, efficacy & safety evaluation, formulation technology for enhancing delivery or sensory properties. In this session, the recent progress of some of the NCR projects in this area will be presented. Session Chair Ih-Seop Chang, CTO, Bioland, Ochang Factory 13:00~13:30 Effects of melanosomal P protein on the melanin production and melanosome maturation in Melan-A cell Eun-Ki Kim, Professor, Inha University, Biological Engineering 13:30~14:00 Development of Systems Skin Toxicology-based Alternative Methods for the Advancement of Animal Welfare Ai-Young Lee, Professor, Dongguk University Graduate School of Medicine, Department of Dermatology 14:00~14:30 Methods/Guidelines for Evaluating Skin and Lip Moisturization Biedermann Kim, Senior Director, Franchise Medical Lead, Pfizer Consumer Healthcare R&D, Personal Care and Respiratory 14:30~15:00 Providing Functionalities to Polysaccharides Jonghwi Lee, Professor, Chung-Ang University, Chemical Engineering and Materials Science 052 053 Special Session Track 13. PIN (Pharmerging Innovative Networking) Conference Sep.12 (Thu) 10:00-17:20 • London Health Forum • Denmark Bio&Medtech Investment Seminar • Osong International Bio Symposium The conference this year reflected pharmaceutical companies' regional-based needs. As a result, the conference will cover more comprehensive topics in depth such as, procurement of pharmaceutical products, marketing strategies, and regulatory affairs. 10:15~11:15 Session 1 11:15~12:15 Session 2 Latin America Session 13:45∼14:45 Session 3 Russia · Kazakhstan Session 14:45~15:30 Session 4 Eastern Europe Session 15:40~16:40 Session 5 Middle East Session 16:40~17:20 Session 6 Special Session (IO Procurement and PCI/S Membership Application) 054 • Daekyung·Osong Collaboration BIO Forum China · ASEAN Session 055 MEMO BUSINESS FORUM Overview Business Forum Overview Floor Plan for Business Forum Presentation Schedule at a Glance Business / Technology / Int'l Country Partner Forum Partnering Participation Status 056 Business Forum Overview Bio industry! The next generation growth engine for the future! The global Bio industry has had an average annual growth of 10% for the past 20 years. The number of biorelated businesses has increased by about 7 times, multiplying the overall value of bio-industry and playing a pivotal role in global economic growth. Bio industry is directly related to many challenges of humanity in fields such as medicine, agriculture and environment. Widely considered as a high-value added industry of the future, bio industry is expected to receive increased government funding, resulting in its diversification and further growth. Bio industry will aid in a virtuous circle of economic growth and technology advancements. BIO KOREA 2013 Business Forum is the place to discover the latest trends of bio-technology for the future grow of your company. Hundreds of companies will showcase their advanced technology at BIO KOREA 2013. Bio-companies armed with superior products and technologies will attend business presentations and exchange information at partnering meetings, building strategic business relationships through 1 on 1 meeting and collaborating on MAY 28 ~ 30, 2014 / KINTEX Brand New Start in MAY! multi-scale projects. BIO KOREA 2013 Business Forum celebrates its eighth anniversary. The Business Forum, consisting of partnering and Business / Technology presentation, will serve as a venue where corporations with advanced technologies can meet with research institutions and other bio business leaders to share knowledge and to encourage further innovation in the bio-industry. 058 059 Floor Plan for Business Forum Partnering Partnering provides an opportunity to meet with potential business and technology partners to discuss mutual interests through pre-scheduled one-on-one meetings. D A T E V E N U E Partnering Time Sep. 11 (Wed) ~ 13 (Fri), 2013 Hall 7, 8A, KINTEX Exhibition Center II (Business Forum Center) 30min. • Find a potential business partner through online pre-matching System • Effective meeting schedule management through the pre-scheduling system • Independent offline meeting at on-site booth Business / Technology Presentation Preview Room Pharm Fair Zone BIO KOREA 2013 Business Presentation is the place to meet domestic and international frontrunners who have new products, technologies, business strategies and projects. D A T E V E N U E Partnering Time Partnering Zone Business Forum Center Sep. 11 (Wed) ~ 13 (Fri), 2013 Hall 7, 8A, KINTEX Exhibition Center II (Open stage 1) 30min. (Including Q&A) • Discover potential investors via advanced technology and business strategy presentation • Exchange the latest cutting edge technology and information • The critical opportunity to benchmark successful business strategy International Country Partner Forum International Country Partner Forum is for the global biotechnology industry leaders to enhance international awareness and competitiveness. D A T E V E N U E Sep. 12 (Thur) ~ 13 (Fri), 2013 Hall 7, 8A, KINTEX Exhibition Center II (Open stage 1) Global Data, Frost&Sullivan's Presentation The presentation is mainly focus on the bio-pharmaceutical, M&A, APAC Market Trend, and Licensing. 060 Cafeteria Sponsor Zone Partnering Center Internet Lounge Info-Desk Global Data, Global Life Science Trends and Opportunities Trends in Deals-Healthcare Market Asia-Pacific Region, Dr. Vikas Bedi Asia Pacific Market Outlook, Mr. Joshua Owide Biotech Market Research Report Global Life Science Trends and Opportunities, Mrs. Geeta Dhanoa 061 Business / Technology Presentation & International Country Partner Forum Schedule at a Glance Biz Tech Company Time Country Name September 11 (Wed), Open Stage I Company Time Country Name United States 13:00~13:30 of America Eli Lilly and Company 13:30~14:00 September 12 (Thu), Open Stage I ICPE Presentation Presentation Title India Global Data Trends in Deals-Healthcare Market Asia-Pacific Region 10:30~12:00United Global Data Asia Pacific Market Outlook Kingdom Presentation Presentation Title Open Innovation at Eli Lilly 13:00~13:05 India Association of Biotechnology Introduction to the India Session Led Enterprises Republic Aprilbio Co. of Korea Republic of Korea Kolon Life 14:00~14:30 Science Utilization of Safa Technology for Developing a Long-Acting Human Growth Hormone by Extending Serum Half-Life 13:07~13:17 Biotechnology Industry Research Assistance Council Catalysing the Growth of an Innovation Driven Biotech Enterprise Tissuegene-C (Tg-C) a Cell-Mediated Gene Therapy for Osteoarthritis Cold Chain Solution for Bio-Industry Centre for Cellular and Molecular Platforms C-CAMP: An Enabler of Cutting Edge Life Science Research in India 14:30~15:00 13:19~13:29 13:31~13:41 Arjuna Natural Extracts 13:43~13:53 India 13:55~14:05 Aaranya Biosciences Private Limited 14:07~14:17 Indian Council of Agricultural Research 14:19~14:29 Criyagen Agri & Biotech 14:29~14:30 Association of Biotechnology Summary and Conclusion Led Enterprises 15:00~15:30 Republic of Korea 15:30~16:00 Tnt Express Center for Nutraceutical and Introduction of Next-Generation BioGreen21 Project Pharmaceutical & Cnpm Materials Seoul Metropolitan Seoul Magok R&D Industrial Complex Ir Government Wips Co., Ltd 16:00~16:30 India 16:30~16:45 16:45~17:00 India 17:00~17:15 17:15~17:30 17:30~18:00 062 Republic of Korea Association of Biotechnology Led Enterprises Department of Biotechnology Methodologies for Establishing Patent Strategies in the Field of Biology and Best Practices India's African Pharmaceutical Safari - An Able Strategy for Developing Markets Biotechnology in India. Opportunities, Challenges and the Roadmap Ahead BiracCatalysing The Growth of an Innovation Driven Biotech Enterprise Indian Council of Agricultural Research Harnessing Agricultural Innovation Automatic Identification of N-Linked Glycopeptides in Kbsi (Korea Basic Biosimilar Pharmaceuticals: Glycoprotein Analysis (Gpa) Science Institute) System 14:30~15:30 Denmark 15:30~16:30China BCM-95 - The Bio-Available Curcumin Biosimilars & Biobetters Outsourcing Models, Opportunities and Challenges in India Translational Health Science & THSTI, CDSA and Clinical Research in India Technology Institute DTU Harnessing Agricultural Innovation Agriculturally Important Microbes (Aims) for Nutrition and Biotic S tress Management in Crop Plants The Danish Farm to Fork Approach and Food Security Technologies from Novozymes to Enable Development of Novozyme Biobetters and Biosuperiors PKUCare Health Industrial Park Shenogen Pharma Group United StatesKbi 16:30~17:00 of America Biopharma, Inc. Republic 17:00~17:30 BIOTOXTECH Republic of Korea of Korea 17:30~18:00 SCAS-BTT Bioanalysis Promoting Investment in Beijing, China Shenogen Pharma Group CMC Strategies for Therapeutic Antibody Development Innovative Engine for Oncology Drug Discovery Unique Translational Model in CVMD Research 063 Partnering Participation Status 2013 Partnering Participating Company List September 13 (Fri), Open Stage I Company Time Country Name 10:30~11:10 Malaysia Frost & Sullivan Presentation Presentation Title Global Life Science Trends and Opportunities The Market Information of Spain : Strategies for the Novel Drug Licensing in-and-out for Korean Pharmaceuticals 11:15~12:15 Spain Pharmaphenix Introduction of PARCDEL'ALBA (Barcelona Synchrotron Park) 13:00~13:10 13:10~13:20 13:20~13:30 United 13:30~13:40 Arab 13:40~13:50 Emirates Oncopharma Urban Pharmacy Propharma Planet Pharmacy AMMC(Iraq) 13:50~14:00 Pharmastore 14:00~14:10 Al-Hayat 14:10~14:20 Life Pharma 14:30~15:00 Republic National Culture of Korea Collection for Pathogens Republic of Korea Kbsi (Korea Basic 15:00~15:30 Science Institute) 15:30~16:00Switzerland 16:00~16:30 Republic Of Korea Republic of Korea 16:30~17:00 064 Introduction of Products and Services of Pharmaphenix Debiopharm International S.A. Korea Institute of Oriental Medicine Introduction of U.A.E Companies A Bukwang Pharmaceutical Co.,Ltd Aaranya Biosciences Private Limited ACTUS Biotechnologies C Ahn-gook pharmaceutical Center for Nutraceutical and Pharmaceutical Materials AJU IB INVESTMENT Center for Nutraceutical and Pharmaceutical Materials Al-Hayat Center for Nutraceutical and Pharmaceutical Materials ALK Abelló Center for Nutraceutical and Pharmaceutical Materials Ampliqon A/S Centre for Cellular and Molecular Platforms AMRI Changzhou Siyao Pharm. AMRI Chong Kun Dang AMRI Chong Kun Dang Amway Korea Chong Kun Dang AngioLab, Inc. Chong Kun Dang (Out-licensing) APEXEL CO.,LTD Chong Kun Dang Pharmaceutical Corp. AprilBio Co. Chuncheon Bioindustry Foundation Arjuna Natural Extracts Ltd CLINICAL QA & WRITING Asan Medical Center Clinigene International Limited Association of Biotechnology Led Enterprises CMC Biologics A/S atenea Management Services Criyagen Agri & Biotech Pvt Ltd Cure Medical Supplies B Introduction to National Culture for Pathogens (Nccp) in Korea A Novel Innovative Technology for Protein-Protein Interaction in Live Cells Debiopharm Group™- We Develop for Patients Preventive and Treatment Medicine for Diabetic Complications World’s First Allogeneic Stem Cell Drug From Cord Blood and MediPost Co., Ltd. The Path To Successful Commercialization Beijing JiaLin Pharmaceutical Company D Beijing Tide Pharmaceutical Co.,Ltd. Daewon Pharm Beijing Tide Pharmaceutical Co.,Ltd Daewoong Pharmaceutical Lifescience Research Insti BINEX Daewoong Pharmaceuticals Co. Ltd BINEX Daeyeon Chemicals Co.,Ltd BioModics Dako Bioneer A/S Darae law & IP Firm Bionutrigen Co.,Ltd. Debiopharm International S.A. Bio-Synectics, Inc. DELPHI GENETICS Biotechnology Industry Reserach Assistance Council DeltaTech-Korea Ltd BIOTOXTECH Department of Biotechnology Boehringer Ingelheim Dong Wha Pharm Boryung Pharmaceutical Co.,Ltd. Dong-A ST Boryung Pharmaceutical Co.,Ltd. DTU - Technical University of Denmark 065 E ImmuneMed, Inc. KOREA UNIVERSITY MEDICAL CENTER P Ecron Acunova Indian Council of Agricultural Research KOREA UNIVERSITY MEDICAL CENTER PCI Biotech Ecron Acunova A/S INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KRIBB PCL, Inc. Efficient Pharma Management Corp. AJOU UNIV KRIBB Peptron Eli Lilly and Company Industry-University Cooperation Foundation HYU KWANGDONG PHARMACETUICAL CO.,LTD PHARMA STORES ERA Consulting Group Intelligent Pharma EternoGen Pharmaphenix L Pharmaphenix S.L. Eubiologics Co.,Ltd. J Leiden Bio Science Park Pharmatory Ltd. EyeGene, Inc. JEIL Pharmaceutical Co.,Ltd. LG Life Sciences Pharmatory Ltd. F JUNGJIN INT'L IP LAW FIRM LG Life Sciences Planet Pharmacies F.Hoffmann-La Roche Ltd, Roche Pharma Japan JW Pharmaceutical Corp. LIFEPHARMA PRA Lonza Propharma Medcal Supplies Fermentec FIC at University of Ulsan K Fit.Life Inc KBI Biopharma, Inc. M S KBSI(Korea Basic Science Institute) Meabco A/S Samyang Biopharmaceuticals Corp. G KBSI(Korea Basic Science Institute) MEDIPOST Co.,Ltd. Samyang Biopharmaceuticals Corporation GCB KCRN Research MetaBio, Inc. sanofi aventis Gill Jennings & Every LLP KCRN Research MicroDigital Sathguru Inc. GNU Office of Academy & industry Collaboration Kem-En-Tec Diagnostics MorphoSys AG SCAS-BTT Bioanalysis Green Cross KEOSYS Medical Imaging MSD (Merck Sharp Dohme Corp) SEOBONG Bio Bestech Co.,Ltd. Green Cross KHIDI(Korea Health Industry Development Institute) MSD (Merck Sharp Dohme Corp.) Seoul Metropolitan Government Green Cross Corporation K-MAC GVK BIOSCIENCES PRIVATE LIMITED KOLMAR KOREA N Seoul Pharma Co.,Ltd. Seoul Pharma Co.,Ltd. Kolon Life Science Nairoukh Pharma SEOUL PHARMA.CO.LTD H Korea Biomedicine Industry Association National Culture Collection for Pathogens Servier Han Wha Pharma Co.,Ltd. Korea Drug Development Fund National OncoVenture Shandong Hongjitang Medicine Group Hanmi Pharmaceuticals Korea Institute of Oriental Medicine National OncoVenture Shandong Pallet Environmental Engineering Company Hanmi Pharmaceuticals Korea Institute of Oriental Medicine Nippon Boehringer Ingelheim (Bio Manufacture Div) Shandong Pepway Medicine Company Hanmi Pharmaceuticals Korea Intellectual Properties Strategy Institute Novo Nordisk Shandong Qidu Pharmaceutical Co.,Ltd KOREA UNIVERSITY MEDICAL CENTER Novozymes Biopharma A/S Shenogen Pharma Group I KOREA UNIVERSITY MEDICAL CENTER ILDONG Pharm. Co.,Ltd. (Biologics) KOREA UNIVERSITY MEDICAL CENTER O SK Biopharmaceuticals ILDONG Pharm. Co.. LTD KOREA UNIVERSITY MEDICAL CENTER OliPass Corporation SK Biopharmaceuticals ILDONG PHARMACEUTICAL Co.,Ltd. KOREA UNIVERSITY MEDICAL CENTER OliPass Corporation SK Chemicals Co. Ltd. ILDONG PHARMACEUTICAL Co.,Ltd. KOREA UNIVERSITY MEDICAL CENTER ONCOPHARMA MIDDLE EAST Stemgent | Asterand IL-YANG PHARMACEUTICAL Co.,Ltd. KOREA UNIVERSITY MEDICAL CENTER ORTHO-LINK IL-YANG PHARMACEUTICAL Co.,Ltd. KOREA UNIVERSITY MEDICAL CENTER 066 Sinensis Life Sciences BV 067 T TAEJOON PHARM.Co.,Ltd The Catholic University of Korea Industry-Academic The Catholic University of Korea Industry-Academic The Catholic University of Korea Industry-Academic Tracer Pharma Translational Health Science & Technology Institute U UTR Investment & Research Group V ViroMed Co.,Ltd. Vivagen Co.,Ltd W WIPS Co.,Ltd WON INTERNATIONAL PATENT & LAW FIRM *Companies above completed registration before September 3 before September 3, 2013 068 Exhibition Overview Exhibition Overview Floor Plan for Exhibition List of Exhibitor Exhibition Overview Exhibition Overview BIO KOREA 2013 Exhibition expects to host 300 companies and 20,000 visitors from all over the world. This event will be an outstanding exhibition of an international lever embracing every field of the bio industry. D A T E September 11 (Wed) ~ 13 (Fri), 2013 V E N U E Hall 7 & 8A, KINTEX Exhibition Center II Exhibition Categories Pharmaceutics Bio-Technology Hospital Governments Food Lab Equipment Cosmetics Medical Device Consulting Service Logistics Venture Capital Chemicals Policy Academic Research Clinical Trial MAY 28 ~ 30, 2014 / KINTEX Brand New Start in MAY! EXHIBITION ZONE Country Pavilion / Innovative Pharmaceuticals Zone / NET·GH Zone / Convergence Zone / Special Zone / Business Forum Zone / Job Fair Zone / Bio Industry Zone, etc Exhibition & On-Site Registration Hours Dates Exhibition Hour On-site Registration Sep.11 (Wed) 10:00 ~ 18:00 09:00 ~ 18:00 Sep.12 (Thur) 10:00 ~ 18:00 09:00 ~ 18:00 Sep.13 (Fri) 10:00 ~ 17:00 09:00 ~ 16:00 071 Floor Plan for Exhibition KINTEX Hall 7 & 8A Open Stage I Preview Room PR Lounge & Food Court C48 C43 A40 B46 A36 B45 C45 C40 B40 D47 D43 D42 A34 A33 E46 D45 D40 E45 A24 E40 F47 F42 F45 F41 F40 G47 G42 H47 H42 I47 I42 J47 J42 G40 H40 I40 J40 B38 B37 B33 C33 D38 D33 E38 E34 F39 F34 G39 E33 F38 F33 G38 E37 E32 B36 B35 B30 C30 D30 E36 E31 Business Forum Center BIO Job Fair Cafeteria Convergence Technology Exhibition Korea Innovative Pharmaceutical Company A31 A30 E47 E42 D46 D41 A35 G33 K30 G37 G32 G35 G30 E35 E30 A21 A20 A15 L39 L34 M39 M34 N39 N34 L38 L33 M38 M33 N38 N33 Sponsor Zone L37 L32 F30 A23 A22 Partnering Zone Pharm Fair Zone L36 L31 N36 N31 L35 L30 N35 N30 Partnering Center Info-Desk B25 B22 B24 B21 G22 C23 C20 D20 E20 F20 G24 G20 H22 H23 H20 L22 I20 J20 K20 B23 B20 M25 M22 L24 L21 M24 L23 L20 M23 M20 N25 N23 O25 O22 N20 O23 O20 P25 P22 Q22 R25 R22 P24 P21 Q23 Q21 R23 R21 P20 A14 A13 B13 C13 A10 A 072 O18 O13 D10 A12 A11 Internet Lounge B10 C10 B C E10 F10 G10 H10 I10 J10 K10 P13 N10 O10 P11 P10 E F G H I J K R20 Q19 Q14 R19 R14 Q18 Q13 R18 R13 L10 M10 D Q20 L M N O P Q15 Q10 R15 R10 Q R Bio-micro photography Exhibition BIO KOREA 2014 Poster Contest S Open Stage II T U 073 List of Exhibitor N38 Aaranya Biosciences Pvt. Ltd. D43 AccugenHealthcare Inc. (주)아큐젠헬스케어 E10 AG SKIN LAB Co., Ltd. 에이지스킨랩(주) L30 AL HAYAT PHARMACEUTICALS L10 ALK Abello 에이엘케이 아벨로 A31 Allbalance Inc. 주식회사 올 발란스 L10 Ampliqon A/S 엠플리콘 D46 Antibody and Receptor Therapeutics Co. (주)에이앤알쎄라퓨틱스 A22 AnyGen Co., Ltd. 애니젠(주) R18 APEXEL Co., Ltd. 에이펙셀(주) M33 Arjuna Natural Extracts Ltd E20 Asan Medical Center 서울아산병원 M39 Association of Biotechnology Led Enterprises R22 AT LAB Co., Ltd. (주)에이티랩 Q10 BioCore Co., Ltd. 바이오코아(주) N20 BioHealth Innovation (BHI) 바이오헬스이노베이션 L37 BioMed Central C10 Bio-Med Connect Center(BMCC) 삼성서울병원 바이오-의료커넥트센터 A40 Biomedical IT Convergence Center IT의료융합기술사업단 E10 Biometrix Technology Inc. (주)바이오메트릭스테크놀로지 L10 BioModics ApS 바이오메딕스 L10Bioneer 바이오니어 R14 Biorhythm Co., Ltd. (주)바이오리듬 D45 Bionutrigen Co., Ltd. (주)바이오뉴트리젠 N39 Biotech Industry Research Assistance Council (BIRAC) R25 Biotechnology Industrialization Center 생물자원산업화센터(주) A21 Biotoxtech Co., Ltd. 바이오톡스텍 N34 Center for Cellular and Molecular Platforms (CCAMP) D47 DAEJEON TECHNOPARK (재)대전테크노파크 E10 Chuncheon Bioindustry Foundation (재)춘천바이오산업진흥원 E36 Daewon Pharm.Co., Ltd. 대원제약 E40 Chungbuk National University Department of Industrial Parmacy 충북대학교 제약산업특성화대학원 G37 Daewoong Pharmaceutical Co., Ltd. 대웅제약 Q21 CHUNGBUK NATIONAL UNIVERSITY TLO 충북대학교 산학협력단 P20 Chungcheong Institute for Regional Program Evaluation 충청지역 의약바이오기업 클러스터 G10Chungcheongbuk-do 충청북도 E10 ChungDo Pharm. Co. Ltd. (주)청도제약 P25 Chungnam technopark Bio Center (재)충남테크노파크 바이오센터 L10 CMC Biologics 씨엠시 바이올로직스 B40CnS (주)씨엔에스 K30 Convergence Technology Exhibition (KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE) 융복합 기술전시관(한국보건산업진흥원) L10 Copenhagen Capacity 코펜하겐 캐퍼시티 Q14 CoSeedBioPharm Co., Ltd. (주)코씨드바이오팜 Q15 DAEYON CHEMICALS Co., Ltd. 대연화학(주) P24 DAIN NATURAL Co., Ltd. (주)다인내추럴 L10Dako 다코 D40Dbio.Inc (주)대덕바이오 G47 Darae Law & IP firm 특허법인다래 M34 DEPARTMENT OF BIOTECHNOLOGY (Government of India) E40 Department of Industrial Pharmaceutical Science, School of Pharmacy, SungKyunKwan University 성균관대학교 약학대학 제약산업학과 G30 DONG WHA PHARM 동화약품 A10 Dongguk Medical Device Innovation Center 동국대학교 의료기기 개발촉진 센터 L32 Dubai International Pharmaceuticals and Technologies Conference and Exhibition 두바이 제약 및 제약기기 전시회 & 컨퍼런스 O20 Covance Laboratories Korea Ltd. 코반스래버래토리 코리아(주) L10 Ecron Acunova A/S 에크론 아쿠노바 L20 British Embassy Seoul / UK Trade & Investment 주한영국대사관 R23 CRH(Converging Research Headquarter) for Bio- Pharmaceuticals 바이오제약사업본부 L22 Embassy of Canada 주한캐나다대사관 D20 Avison Biomedical Research 연세의료원(에비슨의생명연구센터) G35 Boryung Pharmaceutical Co., Ltd. 보령제약 주식회사 M38 Criyagen Agri & Biotech Pvt. Ltd. F39 BCWORLD PHARM. Co., Ltd. (주)비씨월드제약 H42 Cactus Communications Korea Ltd G39 BINEX Co., Ltd. D20 Cancer Hospital / GAP2014 연세의료원(암병원/GAP2014) C45 ATMI LifeSciences 에이티엠아이 R15 BKT Co., Ltd. C30 Avantor Performance Materials, Inc. 아반토 퍼포먼스 머티리얼즈 인터내셔널 인크, 한국지점 (주)바이넥스 (주)부강테크 (주)캑터스 커뮤니케이션즈 코리아 E42 Bio Convergence, Inc. K30 CARIMA CO LTD (주)바이오컨버전스 K30 Bio-Age Inc. 074 (주)바이오에이지 (주)캐리마 E30 Chong Kun Dang Pharmaceutical Corp. K10 (주)종근당 N30 CRYO DIFFUSION 크리오 디푸젼 G32 DAE HWA PHARMACEUTICAL Co., Ltd. 대화제약 주식회사 O25 DAE YOUNG FOODS CO, LTD. 대영식품(주) G40 Daegu-Gyeongbuk Medical Innovation Foundation 대구경북첨단의료산업진흥재단 L24 Embassy of Poland Trade & Investment Promotion Section 주한 폴란드대사관 무역/투자 진흥부 L21 Embassy of the Kingdom of the Netherlands 주한네덜란드 대사관 A35Encopharm 엔코팜 B25 EU Gateway Programme Korea Office EU 게이트웨이 프로그램 사무국 B36 Eubiologics Co., Ltd. 유바이오로직스 075 E10 Farming association corp. BBKO 영농조합법인 비비코 F42IIAMHUB E33 JW PHARMACEUTICAL JW중외제약 K30 KOREA UNITED PHARM. INC. 한국유나이티드제약(주) B10Fermentec 퍼멘텍 G33 ILDONG PHARMACEUTICAL Co., Ltd. 일동제약 주식회사 K30 JW PHARMACEUTICAL JW중외제약 O10 Korea University Medical Center 고려대학교 의료원 K30 Fit.Life Inc. 휘트닷라이프 F45 IL-YANG PHARMACEUTICAL. Co., Ltd. 일양약품 (주) M22 KBI BIOPHARMA E35 Kwangdong Pharmaceutical Co., Ltd. 광동제약 Q20 Foundation of Research and Business, Chungnam National University 충남대학교 산학협력단 A12 Incheon Free Economic Zone 인천광역시 경제자유구역청 E10 Gangneoung Science Industry Foundation Marine Bio Industry Support Center 강릉과학산업진흥원 R25GinSeng (주)진생 D41 GL Biotech Inc. (주)지엘바이오테크 J10 Green Cross Corporation 녹십자 R19 Green-Growth Silkworm-Industry Regional Innovation System 충북대학교 녹색성장 누에산업 RIS사업단 L36 GVK Biosciences Private Limited F10 Gyeonggi Institute of Science & Technology Promotion 재단법인 경기과학기술진흥원 E31 HANDOK Inc. (주)한독 (주)이암허브 L10 Kem-En-Tec Diagnostics 캠엔택 다이그노스틱스 (주)경방 B37 Kyongshin Scientific Co. Ltd 경신과학(주) A30K-MAC 케이맥(주) O18 KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL 경북대학교병원 E37 KOLMAR KOREA Co., Ltd. 한국콜마(주) I20, LG Life Sciences F33LG생명과학 B45 Korea Basic Science Institute 한국기초과학지원연구원 K30 Legochem Biosciences, Inc. 레고켐 바이오사이언스 H22 KITECH(Korea Institute of Industrial Technology) 한국생산기술연구원 N25 Marken Ltd 마켄 M24 International Pharmaceutical Federation (FIP) A33 KOMA BIOTECH 고마바이오텍(주) F41 Markpro co. E10 International Scientific Standards 인터내셔널 사이언티픽 스탠다드 I10 N20 Maryland Bio Park 메릴랜드 바이오 파크 K30 IntroMedic Co., Ltd. E45 Medical Korea 2014(Korea Health Industry Development Institute) 메디컬코리아 2014 (한국보건산업진흥원) E10 ImmuneMed, Inc. (주)이뮨메드 A13 Industry-academic Cooperation Foundation, Keimyung University 계명대학교 산학협력단 C10 Samsung Medical Center, Institute Refractory Cancer Research 삼성서울병원 난치암연구 사업단 (주)인트로메딕 C43 IWOO scientific coporation (주)이우 과학교역 R21 JBK Natural medicine Institute 제이비케이자연의학연구소 O10 Health Industry TLO Council (KOREA HEALTH INDUSTRY DEVELOPMENT INSTITUTE) 보건의료 TLO협의체관(한국보건산업진흥원) B20~ Jecheon Korean Medicine Bio Promotion B22Foundation 제천한방바이오재단 L35 HIMEDIA LABORATORIES PVT. T.D R25 HMAX Inc 농업회사법인(주)에이치맥스 F20 Jeonnam BioPharmaceutical Research Center (JBRC) 전남생물산업진흥원 생물의약연구원 L23 Embassy of Hungary 주한 헝가리 대사관 N20 JG Business Link International 제이지 비지니스 링크 인터네셔널 P21 HV BIO C23 JID Corporation Co., Ltd. (주)제이아이디코퍼레이션 N20 Johns Hopkins University 존스 합킨스 대학교 Korea Drug Development Fund 범부처신약개발사업단 A14 Korea Biomedicine Industry Association 한국바이오의약품협회 J20 Korea Institute of Oriental Medicine 한국한의학연구원 G20 Korea Institute of Toxicology 안전성평가연구소 R25 Korea licorice farming association corporation 한국감초영농조합법인 E46 Korea International Medical Association 사단법인 한국국제의료협회 D10 Korea National Enterprise for Clinical Trials 국가임상시험사업단 I42 KOREA PHARM 2014 제4회 국제의약품전 H40 HYUNDAI Micro Co., Ltd. 현대마이크로 (주) G42 JUNGJIN INT'L IP LAW FIRM 정진국제특허법률사무소 C13 Korea Research Institute of Bioscience and Biotechnology 한국생명공학연구원 F34 HYUNDAIPHARM. Co., Ltd. 현대약품(주) E10 JW CreaGene Inc. JW크레아젠 F20 Korea Testing & Research Institute 한국화학융합시험연구원 076 B20 Kyeong Bang Co., Ltd. N35 KEOSYS Medical Imaging Q22 Industry-Academic Cooperation Foundation JEJU NATIONAL UNIVERSITY 제주대학교 산학협력단 G38 HANLIM PHARM Co., Ltd. 한림제약(주) F20 Hwasun County Vaccine Industry District (Regional Specialized Development District) 화순백신산업특구 (지역특화발전특구) M25 KCRN Research, LLC (주)마크프로 M20 MedClaris Inc. (주)메드클래리스 L10 MEABCO A/S 미압코 E10 MEDIAN Diagnostics Inc. (주)메디안 디노스틱 B46 Medical Writing 메디컬라이팅 B21 Mediogen Co., Ltd. 주식회사 메디오젠 N10 Merck Ltd. Korea 머크 주식회사 A24 META BIOMED 메타바이오메드 J42 MetaBio, Inc. 메타바이오 주식회사 C48 MicroDigital Co., Ltd. 마이크로디지탈 N23 State of Missouri 미국 미주리 주정부 사무소 P22 MODNSKIN Inc. (주)모든스킨 077 N20 Montgomery County 몽고메리 카운티 L38 Pharmaphenix S.L. 파마페닉스 E38 SK Chemicals 에스케이케미칼 K30 Unhwa Co. ,Ltd. B35 MPI Research 엠피아이 리서치 P11 PIPC (Patent Information Promotion Center) 한국특허정보원 특허정보진흥센터 R13 SNC-Lavalin Korea 에스엔씨라발린코리아 N20 University of Maryland School of Medicine 메릴랜드 약학 대학 Q18 NANOSCOPE SYSTEMS, INC. 나노스코프시스템즈(주) N36 Piramal Healthcare Ltd. Q23 Song Am Trading Corp. 송암교역 B23 VGX International, Inc. 브이지엑스인터내셔널(주) O13 National Cancer Center 국립암센터 L31 Propharma Medical Supplies B24 Soon Chun Hyang Lab-based Industry Cooperation 순천향대학교 LINC사업단 G22 Vivagen Co., Ltd. R10 SPIRAXSARCO KOREA 한국스파이렉스사코(주) H47 WONWOO SYSTEMS Co., Ltd. F38 ST Pharm.Co., Ltd. 에스티팜(주) G24 WORLD COURIER KOREA.,LTD. 월드쿠리어 코리아 K30 REGENPRIME Co., Ltd. 리젠프라임(주) N23 Missouri Trade & Investment Office - South Korea 미국 미주리 주정부 사무소 F40 WIPS Co., Ltd. 주식회사 윕스 E10 Regeron, Inc. L39 Strex, Inc. I47 A15 Natural Bio-Materials Inc. (주)엔비엠 H10 NET/GH CERTIFICATION (Korea Health Industry Development Institute) NET.GH 인증관(한국보건산업진흥원) K30NEOFECT 네오펙트 A11 NFEC (National Research Facilities & Equipment Center) 국가연구시설장비진흥센터 E47 Noanix Corporation (주)노아닉스 K30NOUSCO 누스코 C20NOVAPRO.,Ltd (주)노바프로 L10 NOVO Nordisk 노보노디스트 M23 PRA International K30 ProteomeTech Inc. (주)프로테옴텍 R20 Puretech P&T Co., Ltd. (주)퓨어테크피앤티 (주)리제론 I40 REP. OF NEW BRUNSWICK SCIENTIFIC CO., INC (주)한국 엔비에스 R25 REXGENE BIOTECH Co., Ltd. (주)렉스진바이오텍 C10 Samsung Medical Center (Clinical Trial Center) 삼성서울병원(임상시험센터) A34 Rev-Med, Inc (주)레보메드 L10 Novozymes Biopharma DK A/S 노보자임 바이오파마 M10 SEDIA(Sabah Economic Development and Investment Authority 사바 경제개발 투자청 A23 NTS Co., Ltd. 엔티에스 주식회사 P13 Samwoo S&T 삼우에스앤티 R25 OUR HOME A20 SCAS-BTT Bioanalysis (주)아워홈 (주)스카스비티티바이오애널리시스 O22 OLYMPUS KOREA Co., Ltd. 올림푸스한국(주) Q13 sellus Co., Ltd. 주식회사 셀루스 B30 Orient Bio Inc. 주식회사 오리엔트바이오 D30 SEOUL METROPOLITAN GOVERNMENT 서울특별시 마곡사업추진단 K30 PANAGENE, Inc. 주식회사 파나진 B13 Seoulin Bioscience J47 PCL, Inc. 피씨엘(주) D20 Severance Hospital Gene Bank 연세의료원(세브란스유전자은행) L34 Pharma Line Inc 파마라인(주) D20 Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases(SIRIC) 연세의료원 (세브란스 뇌심혈관질환융합연구사업단) N31 Pharma Stores LLC K30Pharmabcine 078 (주)파멥신 (주)서린바이오사이언스 E32, SHIN POONG PHARM F47 신풍제약(주) N20 State of Maryland Business Office-Korea 메릴랜드주 한국무역통상부 Q19 Synex Consulting Ltd. 사이넥스 C40 TAEJIN ENG Co., Ltd. (주)태진이엔지 E34 Taejoon Pharmaceutical Co., Ltd. 태준제약 L33 Taiwan Bio Industry Organization (BioTaiwan 2014) (주)운화 (주)비바젠 (주)원우시스템즈 WON INTERNATIONAL PATENT & LAW FIRM 원 국제특허법률사무소 B22Yakchoin 약초인 D33 Yonsei Medical Device Development & Promotion Center 연세대학교 의료기기개발촉진센터 D20 Yonsei University Health System 연세의료원 (특허출원 및 기술사업화/연구중심병원) D38 Yonsei University Wonju Severance Hospital 연세대학교 원주세브란스병원 C33 TEPIK (Transgovernmental Enterprise for Pandemic K20 Young Sciences, Inc. Influenza in Korea) (주)영사이언스 신종인플루엔자 범 부처 사업단 O23 YUJIN HITECH Co., Ltd. L10 Technical University of Denmark 유진하이텍(주) 덴마크공과대학 B33ZETACORPORATION H23 testo Korea Ltd. 주식회사 제타 테스토코리아 J40 (주)FMS-KOREA L10 The Embassy of Denmark (주)에프엠에스코리아 주한 덴마크 대사관 D42 (주)K-Greenbio The National Project for Personalized Genomic (주)케이그린바이오 Medicine R25 (재)충북테크노파크 바이오센터 제천감초산업육성사업단 차세대 맞춤의료 유전체 사업단 K30 BioInfra Inc. H20 TNT Express 티엔티 익스프레스 L10 Tracer Pharma 트레이서 파마 (주)바이오인프라 K30 Boryung Pharmaceutical Co., Ltd. 보령제약 주식회사 N33 Translational Health Science and Technology Insitute (THSTI) K30 U&I CORPORATION 유앤아이(주) 079 N38 D43 Aaranya Biosciences Pvt. Ltd. CEO ADD TEL FAX E-MAIL URL E Savithiri Shivakumar R eg office:4-1-216/154,G-1,Karthikeya Nagar, Nacharam, Hyderabad, India, Pin:500076. 917207855908 914027151506 [email protected] www.aaranyabiosciences.com X H I B I T S Participant E10 L30 AccugenHealthcare Inc. AG SKIN LAB Co., Ltd. (주)아큐젠헬스케어 에이지스킨랩(주) CEO ADD TEL FAX E-MAIL URL E Mi Jin Sohn 손미진 #302, Daejeon Bioventure Town 461-8, Jeonmindong, Yuseong-gu, Daejeon, 305-811, Korea 82-42-364-5001 82-42-367-3030 [email protected] http://www.accugen.co.kr X H I B I T S Surearly Self Test Devices 및 바이오의약품 분석 서비스 CEO ADD TEL FAX E-MAIL URL E AL HAYAT PHARMACEUTICALS Sunyoung, Lee 이선영 #101, 641-6, Saimdang-ro, Gangneung-si, Gangwondo, Korea 82-33.70.7545.2525 82-33.655.9673 [email protected] http://cosmeticsoem.co.kr X H I B I T S Functional Basic Cosmetics & Mask Pack CEO ADD TEL FAX E-MAIL URL E Youngseo Park 박영서 3F, Dongam Building, 1485-14, Seocho-Dong, Seocho-Gu, Seoul, 137-876, Korea 82-2-587-9923 82-2-587-9924 [email protected] http://www.allbalance.co.kr X H I B I T S Laboratory instruments & Salvislab Cleaners 기초화장품 & 마스크팩 I N T R O D U C T I O N I N T R O D U C T I O N Provide research activities to both small and large -본 제품은 BT 및 IT 기술 융합에 의해 개발된 현장검사용 체외진단 분석기기로 바이오센서를 내장한 ready-to-use 형과 바이오센서 molecules include medicinal chemistry, assay development 를 교체할 수 있는 교체형의 두 가지 형태의 제품으로 개발되었음. & screening, ADMET, physicochemical profiling, disease models and safety. -당사는 항체 개발, 면역분석법 확립 및 밸리데이션, 면역원성 분석 과 같은 바이오의약품의 분석 서비스를 수행하고 있음. I I N T R O D U C T I O N N T R O D U C T I O N Allbalance Inc. is a company specializing in handling all aspects of high-end measuring devices, laboratories & industrial related equipment. Cosmetics | Quasi-Drug | Personal Care OEM. ODM Company A SUCCESSFUL GLOBAL BUSINESS PARTNER, One stop full *We provide expert services and solutions to optimize installations, ensure operational efficiencies and support personalized service to maintain prime condition of all of equipment we handle. Not only from Brand plan, Design, Production, Quality *With extensive on-site field experiences we ensure best management but to distribution consulting. possible representation of your product to the end-user customers. [Major Business] *At Allbalance we pride ourselves in providing only the OEM Apply your brand and design best products to industry clients. ODM Inquire us development of your products. OGM Original Global Management 안녕하십니까. 분석기기 전문업체 올발란스 입니다. 당사는 매틀러토 OBM Original Brand Manufacturing 레도, 밀레, 안톤파, 샐비스랩의 공식 대리점으로 국내 유수의 제약, We can produce an only one product for you. *It is possible to produce a Private Brand with a single product. *It is possible to produce any products around the world whatever you want. *It is possible to produce popular products of ME TOO. *Supplying seperate formulas of skin care in bulk. *Supplying seperate formulas of make up in bulk. 화학, 식품, R&D 분야로의 많은 기술적 경험을 가지고 있습니다. 또 한 GLP, GMP, HACCP 및 USP등의 다양한 규정 하에서 요구되는 실험 장비와 관련된 문제점으 다양한 노하우와 최선의 서비스로 카 운셀링 합니다. 변함없는 고객 여러분의 신뢰와 사랑을 바탕으로 최 고의 제품과 서비스로 보답하겠습니다. 감사합니다. 피부생리활성에 근거한 기능성화장품만을 공급함으로써 피부친화주 의를 실현하고 아울러 피부에대한 깊은 관심과 이해를 바탕으로 끊 임없는 연구발전을 거듭하여 궁극적으로 이상적인 피부를 이루어 나 간다는 에이지스킨랩만의 방법론적이자 철학을 의미하며 전 세계인 의 피부와 더불어 존재하는 에이지스킨랩은 피부를 지키는 사명을 다 하면서 세계로 뻗어가는 글로벌 회사로 성장할 것입니다. 080 081 L10 A31 L10 D46 ALK Abello Allbalance Inc. Ampliqon A/S Antibody and Receptor Therapeutics 에이엘케이 아벨로 주식회사 올 발란스 엠플리콘 에이앤알쎄라퓨틱스 CEO ADD TEL FAX E-MAIL URL Jens Bager Bøge Allé 6-8 DK-2970 Hørsholm Denmark 45-4574-7576 45-4574-8690 [email protected] www.alk-abello.com CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O Youngseo Park 박영서 3F, Dongam Building, 1485-14, Seocho-Dong, Seocho-Gu, Seoul, 137-876, Korea 82-2-587-9923 82-2-587-9924 [email protected] http://www.allbalance.co.kr N 알레르기 원인의 독특한 치료법인 면역제 치료법 부문에서 세계적 인 리더이며 연구중심의 회사입니다. 우리 회사는 매년 약 20%의 수 익을 새로운 면역제 및 치료법을 개발 연구에 투자하고 있습니다. WHO에 의해 알레르기의 원인을 치료하는 유일한 방법으로 인정된 다양한 알레르기 치료제를 생산합니다. ADD TEL FAX E-MAIL URL X H I B I T S 전자저울 및 초자세척기 Laboratory instruments & Salvislab Cleaners N T R O D U C T I O N Allbalance Inc. is a company specializing in handling all aspects of high-end measuring devices, laboratories & industrial related equipment. *We provide expert services and solutions to optimize installations, ensure operational efficiencies and support to maintain prime condition of all of equipment we handle. *With extensive on-site field experiences we ensure best possible representation of your product to the end-user customers. *At Allbalance we pride ourselves in providing only the best products to industry clients. 안녕하십니까. 분석기기 전문업체 올발란스 입니다. 당사는 매틀러토 레도, 밀레, 안톤파, 샐비스랩의 공식 대리점으로 국내 유수의 제약, 화학, 식품, R&D 분야로의 많은 기술적 경험을 가지고 있습니다. 또 한 GLP, GMP, HACCP 및 USP등의 다양한 규정 하에서 요구되는 실험 장비와 관련된 문제점으 다양한 노하우와 최선의 서비스로 카 운셀링 합니다. 변함없는 고객 여러분의 신뢰와 사랑을 바탕으로 최 고의 제품과 서비스로 보답하겠습니다. 감사합니다. Helle Nørgaard Thestrup Stenhuggervej 22 DK-5230 Odense M Denmark 45-7020-1169 45-7020-1179 [email protected] www.ampliqon.com URL ADD TEL FAX E-MAIL URL I E I 082 CEO N T R O D U C T I O Kyoung mi Sung 성경미 Suite 1104, E&C Venture Dream Tower 6-Cha, 19729, Guro-Dong, Guro-Gu, Seoul, 152-719, Korea 82-2-801-9300 82-2-801-9330 [email protected] http://www.antibodyreceptor.com N 효소 제조회사로 2002년 설립되어, 화학시약으로 구성된 상품 들을 포함하여 생산품을 확장하였으며, 현재 1000여 개의 다양한 시약 들 을 생산하고 있습니다. 또한 고품질의 DNA중합효소 와 다양한 PCR 효소를 생산하며, 전세계적으로 병원과 연구기관, 생명과학 산업을 위한 시약들을 생산 및 공급합니다. I N T R O D U C T I O N 1.ANRT is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases. Our mission is to develop a first-in-class and best-in-class mAb for those target diseases. 2.Mammalian cell expression offers the most comprehensive post-translational modifications and is ideally suited for expression of antibodies and proteins where posttranslational modifications are vital. ANRT uses a range of mammalian cell types and optimization techniques to enable expression and scale up of recombinant protein production to suit your research needs. 1.ANRT은 암과 염증성 질환과 같은 인간의 질병의 치료를 위한 혁 신적인 검색 기술과 우수한 인적 자원을 이용하여 치료용 완전 인간항체(단클론 항체)를 개발하는 전문 생명 공학 회사입니다. 우리는 목표는 그 대상 질환에 대해 first-in-class 과 best-inclass의 항체를 개발 하는 것입니다. 2.단백질의 경우 ‘번역 후 수식 (posttranslational modification)’ 양 상이 치료 효능, 체내 안정성 및 면역 부작용 등에 중요한 영향을 미친다는 사실이 알려지면서, 생산량 (quantity) 보다 원형 단백 질과 동일하거나 그 이상의 품질 (quality)을 지닌 단백질을 생산 할 수 있는 기술의 개발이 중요해지고 있습니다. 따라서 ANRT는 E.coli 가 아닌 동물세포 (HEK 293, CHO) 에서 발현 및 정제하여 의약품 원료 수준의 정제 과정을 거쳐 최고 품질의 단백질을 생 산하고 있습니다. 083 A22 R18 M33 AnyGen Co., Ltd. Apexel Co., Ltd. 애니젠(주) 에이펙셀(주) CEO ADD TEL FAX E-MAIL URL Kim jae il 김재일 R m. 303, head Quarter Jeonnam Nano Bio Research Center San 109, Samtae-ri, nam-myun, Jangseong-gun 82-61-395-1180 82-61-395-1184 [email protected] http://anygen.com CEO ADD TEL FAX E-MAIL URL X H I B I T N T R O D U C T I O Cheong- Ja, Kim 김청자 24-1 Daejeon-Ri, Songra-Myeon, Buk-Gu, Pohang, Gyeongbuk Korea 82-54-262-4922~3 82-54-262-0896 [email protected] http://www.apexel.kr X H I B I T S Nano 3D Mill (dry type). Nano Calcium, Mulberry Leaves Nano powder, Mushroom Nano powder, Chitosan Nano powder. N 나노분쇄기 (그림), 나노칼슘, 뽕잎나노분말, 차가버섯 나노분말, 키토 산나노 분말, 각종 나노분말. Anygen was founded in may 2000, as a laboratory venture company at gwangju institute of science & Technology(Gist) and has been working in the field of peptide APIs devellopment and manufacturing for the past ten years. We manufacture high-quality custom made peptides by applying our thorough product managing system(ISO 9001, 14001) in the synthesis and purification of peptides, and we supply the peptides demanded by customers by applying costume-made synthesis and purifications according to the level of difficulty in the synthesis and types of modification. I N T R O D U C T I O N Apexel Co., Ltd. has specialized in R&D and production of nano powder in any sizes of any materials under any conditions, without dispersant. The nano powder specially from l000 to 1 nano by topdown method is made by our own equipment"Fworld-best and world-first Nano 3D Mill (dry type). We have been supplying excellent nano materials to many companies, research institutes and universities, sometimes co-working with them for R&D and manufacturing new 펩타이드 전문기업 애니젠은 2000년 5월 광주과학기술원 내 실험실 materials. 벤처로 창업하여 지난 10여년 동안 펩타이드 원료개발 및 대량생산 We have continuously contributed to our customers to lead 분야에 주력하고 있습니다. the business in their areas by our best nano technology 애니젠(주)은 펩타이드합성 및 정제에 대한 엄격한 제품관리 시스템 을 도입하여 고품질의 주문자 펩타이드를 제작하고 있으며, 합성의 난이도와 modification의 종류에 따른 맞춤식 합성, 정제법을 적용 함으로서 주문자가 원하는 펩타이드를 신속하게 제공하고 있습니다. 에이펙셀 (주)는 대부분의 물질을 어떠한 조건에서도 분산제 없이 다 양한 입도분포의 나노크기로 제조할 수 있는 능력을 갖추고, 나노분 말제조 및 융합과 나노신소재의 R&D를 수행하는 세계에서 하나뿐인 업체입니다. 특히 1 나노에서 1000나노까지를 top-down 방식에 의해 당사에 서 자체 개발한 장비 (세계최고, 세계유일)Nano 3D Mill (건식)로 생산하고 있습니다. 당사는 많은 기업, 연구기관, 대학에 나노분말과 물질을 공급하고 있 으며, 때로는 신물질개발과 생산에 협업합니다. 084 Asan Medical Center 서울아산병원 S Peptide APIs, Custom peptide, Cosmetic peptide I Arjuna Natural Extracts Ltd CEO ADD TEL FAX E-MAIL URL Mr. P. J. Kunjachan P.B.No:126, Bank Road, Alwaye - 683 101, Kerala, INDIA 91 484 4080400 91 484 2622612 [email protected] http://www.arjunanatural.com CEO ADD TEL FAX E-MAIL URL E E E E20 E X H I B I T Seong-Wook Park 박성욱 #88, Olympic-ro 43 gil, Songpa-gu, Seoul 82-1688-7575 82-2-3010-4182 [email protected] http://amc.seoul.kr X H I B I T S S -Introduction of Asan Medical Center and its research activities -S uccessful technology transfer, joint research and investment promotion I N T R O D U C T I O N -Introduction of Asan Medical Center and its research activities Arjuna Natural Extracts Ltd (ANEL) is a leading manufacturer of Natural health food ingredients & Botanical extracts -S uccessful technology transfer, joint research and investment promotion used in Dietary supplement Industry. Started in 1989, we are an ISO 22000:2005 and GMP certified company. Our facilities are FDA registered and products are Koshered, -서울아산병원의 연구활동 소개 Halal certified and our R&D facility is approved as In-House -국, 내외 제약사와 기술이전 및 전략적 제휴 상담 R&D lab by Govt. of India. Manufacturers of N T R O D U C T I O N •Advanced botanical extracts (clinically documented & I patented) Asan Medical Center, a government designated Research•Standardized Herbal & Spice Extracts driven Hospital, was established in 1989 and has made •Omega–3 oil –Vegetable source every effort to invest in research and clinical excellence. •Omga-3 oil & powder – Marine source With an unwavering spirit of “caring for life and sharing •Essential Oils with those in need and pain, ” AMC has also attempted to Key Products – BCM -95 fulfill its responsibility to society. AMC, the proven leader in •W ORLD'S Largest selling BIO-AVAILBLE TURMERIC patient care is now presenting the exclusive quality in R&D EXTRACT – BCM-95 competence as a world class Research-driven Hospital. •7 patents worldwide and there are 10 patents pending •H ave published animal & human studies; Studies 올해 연구중심병원으로 선정된 서울아산병원은 1989년 개원한 이래 are done in India, USA, Australia, Hong Kong, Italy, 끊임없는 연구개발과 임상진료에 대한 아낌없는 투자로 세계적 수준 의 의료성과를 달성해왔으며 ‘생명존중의 정신’과 이웃의 아픔을 함 Singapore and UK. •Enhanced oral bioavailability of curcumin in the blood 께하는 ‘나눔 정신’을 실천함으로써 존경 받는 병원으로 사회적 책임 up to 7 to 10 times that of curcumin 95% ; retention of 을 다해오고 있습니다. 이제 진료를 바탕으로 축적된 지식을 첨단 보 건의료의 연구개발과 사업화를 통하여 HT 산업발전을 이끌어가는 curcumin in blood even at 8 hours 세계적 수준의 연구중심병원으로의 성장을 기대합니다. Other major products •Garcinia extract •Boswellia extract •Green coffee bean extract •Pomegranate extract •Amla extract Food & Ag 085 M39 R22 Association of Biotechnology Led Enterprises CEO ADD TEL FAX E-MAIL URL E Dr. P.M. Murali No 123/C 16th Main Road, 5th Cross, 4th Block, Koramangala, Bangalore, 560034 India 91 11 23731127 91 11 23731127 [email protected] www.ableindi.org X H I B I T S C45 AT LAB Co., Ltd. ATMI LifeSciences (주)에이티랩 에이티엠아이 CEO ADD TEL FAX E-MAIL URL E Youngtaek, Kim 김영택 #5-105, 89, Seoho-ro, Gwonseon-gu, Suwon-si, Gyeonggi-do, 441-853 KOREA 82-31-292-8960 82-31-292-8962 [email protected] http://www.atlabco.com X H I B I T S ABLE is a national forum that represents the Indian Cosmetic ingredient Biotechnology Sector. ABLE has over 270 members representing all verticals of the sector like agribiotech, bio- 화장품 원료 pharma, industrial biotech and bioinformatics. I N T R O D U C T I O N AT LAB mainly develops functional cosmetic ingredient and specialized in encapsulation technology. With a slogan “Happy life, providing humanity health and beauty”, we promise that we will provide customers best product quality and service. 저희 회사는 불안정한 기능성 물질을 안정화하는 독자적인 기술을 보유하고 있고, 이러한 기술을 접목하여 화장품 원료를 주력으로 개 발하는 업체입니다. 인류에 아름다움과 건강함을 제공하여 삶을 이롭게 한다는 경영이념 아래, 저희 모든 임직원은 고객에게 최상의 품질과 서비스를 제공해 드릴 것을 약속합니다. 은 무균적으로 액체나 파우더를 이송, 저장 할 수 있도록 만든 1회용 액체백이나 파우더백, 바이오 믹싱 시스템에서 사용되는 1회용 무균 CEO 정강진 ADD 46-904 2F 198-32 Bora-dong Giheung-gu Yongin4 si Gyeonggi-do, Korea 82-31-217-3671 82-31-217-2673 [email protected] http://www.Atmi-lifesciences.com TEL FAX E-MAIL URL E X H I B I T 믹서백, 세포배앙공정에서 사용되는 1회용 바이오리액터백 등을 제 조하는데 사용되고 있습니다. 또한 1회용 고착 세포 및 바이러스 배 양 시스템 및 1회용 줄기 세포 배양 시스템은 생산하고 있습니다. 이 외에도 ATMI LifeScience는 모든 멸균 과정에서 쓰일 수 있는 1회 용 타이백 멸균백, 메디컬 백, 정전기 방지 백 등의 제품도 제조하고 있습니다. S Single-use Tyvek Sterilization Bag & Antistatic Bag Single-use Liquid & Powder Transfer Bag Single-use Mixing System (PadMixer, LevMixer, MagMixer, WandMixer, JetMixer) Single-use Paddle-Stirred Bioreactor Single-use Adherent cell & Virus Culture System Single-use Stem cell Culture System 1회용 타이백 멸균백 및 정전기 방지백 1회용 액체백 및 파우더백 1회용 무균믹서 (패드믹서, 레브믹서, 마그네틱믹서, 완드믹서, 제트 믹서) 1회용 패들 교반 바이오리액터 1회용 고착세포 및 바이러스 배양 시스템 1회용 줄기세포 배양 시스템 I N T R O D U C T I O N Headquartered in Danbury, Connecticut, ATMI was founded in 1986. Now a global company, ATMI has a total of twelve locations and over 800 employees. ATMI has three manufacturing locations in USA and Belgium. ATMI is a leading supplier of materials, materials packaging and materials delivery systems for semiconductor, flat panel display and life science manufacturers. Core competencies include rapid process development, high performance materials, packaging solutions, single-use, and disposable material technologies. The company operates under two divisions- Semiconductor and LifeSciences. ATMI는 반도체 및 바이오 공정과 관련된 고 청정 제품이나 설비를 생산하는 다국적 기업입니다. 특히, ATMI LifeScience는 모든 바이 오 공정에 사용할 수 있도록 ISO class 5의 고청정 조건에서 블로우 압출기로 TK8이라는 필름을 자체 생산하고 있습니다. 이 TK8 필름 086 087 C30 D20 F39 G39 Avantor Performance Materials, Inc. Avison Biomedical Research BCWORLD PHARM. Co., Ltd. BINEX Co., Ltd. 아반토 퍼포먼스 머티리얼즈 인터내셔널 인크, 한국지점 연세의료원 (에비슨의생명연구센터) (주)비씨월드제약 (주)바이넥스 CEO ADD TEL FAX E-MAIL URL Robert John Ferguson 8th Fl, Wooduck building, 832-2, Yeoksam-dong, Gangnam-gu, Seoul, Korea. 135-750 82-2-2052-0483 82-2-571-5401 [email protected] http://avantormaterials.com CEO ADD TEL FAX E-MAIL E X H I B I T S Excipients, chromatography resins and processing chemicals for Biotech & pharmaceutical developments. URL I N Sue Goo Rhee 이서구 50 Yonsei-ro Seodaemun-gu, Seoul 120-752, Korea Yonsei University, College of Medicine Yonsei Biomedical Research Institute Avison Biomedical Research Center (ABMRC) 82-2-2228-0610~0613 82-2-2227-8129 [email protected] http://medicine.yonsei.ac.kr/research/study_ center T R O D U C T I O N Avison Biomedical Research Center (ABMRC) was opened in April 2013. The primary goal of ABMRC lies in being a facilitator of research collaboration between clinical and basic medical research departments, and in the advancement of medical research through our state of I N T R O D U C T I O N the art infrastructure and immense biomedical research AvantorTM Performance Materials is a global specialty activities. We expect ABMRC to serve as the foundation chemical business with a well developed reputation for for the acceleration and industriali -zation of the field of its high standard of quality products in four demanding biomedical research. markets, Biotechnology/ Pharmaceuticals, Electronics, Laboratory Research and Diagnostic. Specially with our Biotechnology/pharmaceuticals products, we bring quality to every stage of product development so you can formulate, manufacture and innovate with confidence. CEO ADD TEL FAX E-MAIL URL E Steve Hong 홍성한 Gyung Building, 78, Gaepo-ro, 22-gil, Gangnamgu, Seoul, 135-961. Korea 82-2-2182-0488 82-2-574-5064 [email protected] http://www.bcwp.co.kr X H I B I T S Sinraci inj. / Mepem inj. Etc. ADD TEL FAX E-MAIL URL E Myoung Ho Jeong 정명호 7-48, Songdo-Dong, Yeonsu-Gu, Incheon, Korea 406-840 82- 32 - 850 - 3114 82- 32 - 850 - 3299 [email protected] http://www.bi-nex.com X H I B I T S Biologics, Biosimilar, CDMO, Small molecule, ophthalmic solution 실라신 주사 / 메펨 주 등 바이오의약품과 합성의약품에 개발과 생산에 필요한 각종 부형제, 크 로마토그래피 레진 그리고 각종 프로세싱 화합물. 아반토 퍼포먼스 머터리얼은 전 세계적으로 바이오텍, 제약, 전자 그 리고 실험실연구와 진단 분야에서 우수한 기준과 품질에 맞추어져 개발된 전문화된 화학물 회사입니다. 특히 바이오텍, 제약분야에서는 검증된 기술을 통해 여러분의 합성, 생산 그리고 개발단계에 검증된 품질의 제품을 제공합니다. CEO I I N T R O D U C T I O N BCWORLD PHARM is a R&D driven pharmaceutical company that has been committed to developing innovative formulations and only-one products. It strives to provide quality generics as well as value-added novel formulation products through cutting-edge technology including immediate/controlled release as well as fastdissolving DDS, combined formulation, gastro-retentive system and depot formulation. Recently BCWORLD PHARM not only has been certified as Korea Innovative Pharmaceutical Company (KIPC) by Korea Ministry of Health & Welfare but also designated as Advanced Technology Center (ATC) by Korea Ministry of Knowledge Economy. Also, the construction of EUGMP/ cGMP facility is expected to be finished by March 2014. 주│비씨월드제약은 ' Bio . Chemical R & D 중심의 Global Standard 제약기업'을 지향하며 제제연구 분야에 있어서는 국 내 최고 수준의 R&D 중심 제약회사입니다. 판교 소재의 Global Research Institute (GRI)는 우수한 제제 및 합성기술을 바탕으로 DDS (약물전달시스템) 및 신약후보물질 개발과 다수의 국책 과제를 진행하고 있습니다. 최근에는 혁신형 제약기업과 우수기술센터로 선 정되었고, 2014년 3월에는 EUGMP/cGMP 공장을 신축할 예정입 니다. N T R O D U C T I O N As the only biologics CDMO in Korea, BINEX plays the key role in solving the manufacturing bottleneck of the biopharmaceutical industry with its hands-on experience with blockbuster biologics and a top-notch biomanufacturing facility in compliance with the US and EU-GMP regulations. BINEX has been able to acquire the commercialization right for a few biosimilars of blockbuster biologic products from business partners in return of providing a reliable and high quality CDMO services for their products. Binex is equipped with various ophthalmic products, which covers all the major ophthalmic solution sectors. As well as with its recently renovated facility in compliance with cGMP/BGMP standards, BINEX has accumulated the experience and know-how over 20 years, and it is able to offer the high quality and superior cost competitiveness to partners. We are looking for opportunities to license out, exporting and commercialize our products all over the world with domestic and global partners. cGMP & EU-GMP에 부합하는 바이오 의약품 One-stop CMO 서 비스 제공이 가능한 바이넥스는 다양한 경험을 통해 노하우와 track records를 축적하였고 고객사들과 전략적 제휴를 통해 특정 지역 내 바이오 의약품의 상용화 권리를 확보하였다. 또한 점안제 사업에 전문성을 갖추고 있는 바이넥스는 최근 부산 합 성 의약품 생산 공장을 cGMP/BGMP 기준으로 리모델링하여 보다 높은 수준의 수탁사업을 파트너들에게 제공하게 되었다. 국내외 협력을 통해 바이오의약품 및 점안제의 license out, 수출, 상용화를 위한 파트너사를 찾고 있다. 088 089 E42 K30 Q10 N20 Bio Convergence, Inc. Bio-Age Inc. BioCore Co., Ltd. BioHealth Innovation (BHI) (주)바이오컨버전스 (주)바이오에이지 바이오코아(주) 바이오헬스이노베이션 CEO ADD TEL FAX E-MAIL URL Kenny Kim 김경원 313., IL-Shin B/D, Ogumro 13 gil 7 songpa-gu, seoul Korea 82-2-2243-9488 82-2-3391-2342 biocinf@ hanmail.net http://www.GBSkr.com CEO ADD TEL FAX E-MAIL URL Youn Jae Chun 윤재춘 5 F Bldg. Samsung-Dong, Gangnam-Gu, Seoul 135-881, Korea 82-2-550-8940 82-2-550-8941 [email protected] http://www.istech21.com CEO ADD TEL FAX E-MAIL URL Hyung-Sik Choie 최형식 6 0 - 2 1 I T M i r a e To w e r 8 F, G a s a n - d o n g , Geumcheon-gu, Seoul, Korea 82-2-2205-9900 82-2-790-3929 [email protected] http://www.bio-core.com CEO ADD TEL FAX E-MAIL URL E E X H I B I T NanoAnalytics TisXell Bioshake TSE Scientifica S E X H I B I T S SALT: Statistical analysis software for clinical and medical data 나노언알라이틱스 티셀, 바이오쉐이크 티에스이 사이언티피카 SALT: 임상 자료 통계 분석 전문 소프트웨어 I N T R O D U C T I O N Bio-Age Inc. (previously ISTECH Inc.) is a biotech company based on the bioinformatics and medical informatics technology in Korea. Bio-Age Inc. focuses on developing and providing many kinds of analysis softwares and system such as SALT (clinical data analysis software), GenPlex (gene expression data analysis software), SNPAnalyzer (SNP data analysis software), LABIS (electronic laboratory note) and BioAge-Smart Care (biological age prediction system). (주)바이오에이지 (구 이즈텍)은 생명정보공학 기술을 바탕으로 한 바 이오 전문 기업입니다. 현재 급속도로 발전하고 있는 인간 유전체 분 석 기술을 이용하여 다양한 연구 프로젝트를 성공적으로 수행해오고 있으며, 축적된 연구 성과를 바탕으로 생명정보공학, 임상, 의료 분 야에 특화된 시스템 및 데이터 분석 프로그램을 개발하여 제품화 하 E X H I B I T Richard Bendis 22 Baltimore Road, Rockville, MD 20850 1-301-637-6439 1-301-476-4531 rbendisig.com http://www.biohealthinnovation.org X H I B I T S S ‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland Temperature Controlled Packaging / Cold Chain Solutions / 2020’ Strategic Plan Introduction Regulatory Compliance Packaging 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, I N T R O D U C T I O N Johns Hopkins University, University of Maryland School Intelsius began operations in 1998, when we developed of Medicine, Montgomery County, University of Maryland a unique packaging solution for the transportation of BioPark, BioHealth Innovation 총 7개 업체 함께 참여 samples suspected of containing BSE (Bovine Spongiform Encephalitis or “Mad Cow Disease”). Within a year, N T R O D U C T I O N Intelsius became the first UN-certified BSE sample shipper I in the world. The company soon went global, becoming Biohealth Innovation will connect market relevant research widely recognized as one of the market leaders of sample assets to apporopriate fundind, management and markets transport and temperature-complinat packaging solution. to facilitate the development of commercially viable bio health products and companies. 영국에 본사를 두고 있는 패키징 전문 글로벌 기업인 인텔시어스는 온도조절 패키징을 이용한 Cold Chain Solutions을 전 세계 40여 개국에 제공하고 있으며, 국제운송규정에 적합한 UN인증 제품들을 공급하고 있습니다. 또한 PCM (상변화물질)과 VIP (진공단열재) 재 료를 이용한 하이엔드급의 포장재를 공급하여 온도에 민감한 의약품, 생물학적제제 및 각종 샘플 등의 안전 운송에 기여하고 있습니다. BioHealth Innovation은 메릴랜드주 내의 제약사, 연구소, 투자기 업, 마케팅 기업이 연합해서 설립한 기업으로 메릴랜드나 미국 또는 해외기업 중에서 연구.시험과정을 거친 결과물 중에서 가치가 있는 과제를 상업화에 필요한 자금투자부터 마케팅 까지의 과정을 지원해 주는 프로그램을 시행하는 업무를 진행한다. 고 있습니다. 현재 개발되어 상용화된 제품으로는 SALT, GenPlex, SNPAnalyzer, LABIS, BioAge-Smart Care 등이 있습니다. 090 091 L37 C10 BioMed Central CEO ADD TEL FAX E-MAIL URL Matthew Cockerill 7th floor, W&H Building, 367-13, Seogyo-dong, Mapo-gu, Seoul, Korea 82-2-3142-9660 82-2-3142-5768 [email protected] http://www.biomedcentral.com A40 Bio-Med Connect Center (BMCC) Biomedical IT Convergence Center Biometrix Technology Inc. 삼성서울병원 바이오-의료커넥트센터 IT의료융합기술사업단 (주)바이오메트릭스테크놀로지 CEO ADD TEL FAX E-MAIL URL X H I B I T S Publishing I N T R O D U C T I O N BioMed Central is an STM (Science, Technology and Medicine) publisher which has pioneered the open access publishing model and is at the cutting edge of ensuring that the results of scientific research are made openly available throughout the international community. Our portfolio of over 250 journals includes a combination of broad titles and specialist journals across all areas of biology, medicine and chemistry; 146 of the journals we publish now have an Impact Factor. Sa Ik Bang 방사익 81, Irwon-Ro, Gangnam-Gu, Seoul, 135-710, Korea 82-2-2148-7149 82-2-3410-0036 [email protected] http://www.bmcc.or.kr CEO ADD TEL FAX E-MAIL URL E E E10 X H I B I T Sang Hee Kim 김상희 (730-916) R304 General Business Support Center 350-27 Gumidaero, Gumi, Gyeongbuk, Korea 82-54-464-3211~2 82-54-464-3213 [email protected] http://bitc.geri.re.kr CEO ADD TEL FAX E-MAIL URL Kim Taisun 김태선 #2-2 Bioventure Plaza 198-60 Hupyong-dong, Chuncheon-si. Gangwon-do, 200-160, Korea 82-33-258-6097 82-33-258-6099 [email protected] http://www.bmtchip.com S Consulting, Education and Connect Services on BioMedical Industry 바이오-의료제품의 컨설팅, 교육, 커넥트 서비스 E X H I B I T S E X H I B I T S Introduction of National Infrastructure Construction Plan HPV 6G DNA kit for Parts & Materials of Medical Equipment HPV Genotyping 9G membrane kit MTB DR-RIF 9G membrane kit 전자의료기기 부품소재 산업화 기반구축사업 소개자료 I N T R O D U C T I O N Bio-Med Connect Center, BMCC, was established in 2009 to lay the infrastructure to facilitate systematic translational research between Industry-University-Institute and Hospital for successful market entry of biomedical products reflecting the needs of final consumers. BMCC has an advisory board composed of specialists and professionals from various fields including basic science, patents, licensing, laws, regulations and management to provide high-quality services in consulting, education and connecting for the long-term success of biomedical companies. BMCC는 바이오·의료 제품의 성공적인 시장 진입과 경쟁력 제고 를 목표로 산업통상자원부 사업의 일환으로서 2009년 설립되었으 며, 의료기관과 산·학·연간의 양방향 네트워크를 통해서 체계적인 중개연구를 수행할 수 있는 인프라 구축에 노력하고 있습니다. 또한, 전문 의료진을 주축으로 기초과학, 특허, 인허가, 법률, 비즈니 스와 관련된 다양한 분야의 전문가들을 자문위원으로 모시고 바이 오·의료산업 관련 기업에게 컨설팅, 교육, 비즈니스 커넥션 등을 지 원하여 국내 바이오 산업의 발전을 도모하고자 합니다. I I N T R O D U C T I O N The mission of the Biomedical IT Convergence Center in Gumi is to enhance the global competitiveness of topnotch biomedical device equipment industry in Korea. The center plays an important role in the national infrastructure construction project for the parts & material of medical IT convergence equipment and has received funding of $130 million for 5 years by the Ministry of Trade, Industry & Energy, Gyeongsangbukdo Province and Gumi city from 2011. It helps to establish the Commercialization R&DB Center to vitalize biomedical industry and the Industrial Complex for medical equipment in Gumi that will be the hub city of a world’s leading industrial cluster for Medical IT Parts and Materials convergence industry in Korea. N T R O D U C T I O N Biometrix Technology INC. (BTM) are committed to development of methods for diagnosis of various diseases, including cancer and viral or bacterial infections, by further developing our innovative 9G chips technology which has proven to yield unparalleled levels of sensitivity and specificity in DNA chips. (주)바이오메트릭스 테크놀로지 (BMT)는 민감도 및 특이도가 최고수 준인 9G DNAChip 기술을 개발하여 이를 다양한 암 및 바이러스성 감염질환을 조기검진할 수 있는 올리고유전자 칩과 지노타이핑 키트 들을 개발하고 판매하는 바이오칩 전문기업입니다. IT의료융합기술사업단은 디스플레이, 모바일 및 반도체 부품소재산 업에서 세계적인 경쟁력을 확보하고 있는 구미국가산업단지 내 전자 의료기기 부품소재 산업화 기반을 조성하여, 글로벌 의료클러스터 및 생산단지로 육성하고자 산업통상자원부, 경상북도 및 구미시의 지원 으로 (총 사업비: 1213.5억) 5년간 전자의료기기 부품소재 산업화 기반구축사업을 진행하고 있습니다. 이를 통해 전자의료기기 기술개 발 5대 육성분야에 대한 연구수행을 통해 의료기기 산업단지를 후방 지원할 수 있는 전자의료기기 부품소재 의료 클러스터의 역할을 담 당할 것입니다. 092 093 L10 L10 R14 BioModics ApS Bioneer Biorhythm Co., Ltd. 바이오메딕스 바이오니어 (주)바이오리듬 CEO ADD TEL E-MAIL URL Peter Thomsen Gregersensvej 7, 1 DK-2630 Høje Tåstrup Denmark 45-6166-6619 [email protected] www.biomodics.com CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O Peter Thomsen Kogle Allé 2 DK-2970 Hørsholm Denmark 45-4516-0444 45-4516-0455 [email protected] www.bioneer.dk CEO ADD TEL FAX E-MAIL N 실리콘 기반 의료기기들을 위해 Hypermatrix 기술을 이용하여 혁 신적인 솔루션을 개발하는 회사입니다. 폴리머(polymer) 의료기기 에 적용된 이산화탄소 공정기술특허를 기반으로 의료기기들을 생산 하며, 임플란트, 카데터, 스텐츠 등에 적용 가능한 다양한 솔루션을 개발하며 실리콘 기반 의료기기 및 바이오필름 등을 생산합니다. I N T R O D U C T I O N 북쪽 코펜하겐 25km지점에 본사를 두고 25년 이상 제약, 생명공학 회사 및 제약회사들에게 개선된 약물 개발 프로세스의 개발, 생산성 증진을 목표로 한 기기의 개발, 기술개발 그리고 단백질 생산 및 관 련된 상품 제공하는 회사입니다. 또한, 다양한 치료전략의 개발을 위 한 컨설팅 및 협업을 지원 합니다. URL E Yong-Hyun JUNG 정용현 # 101, Chungbuktechnopark Biocenter, 6864, Yangcheongri, Ochangeup, Cheongwongun, Chungbuk, South Korea 82-70-8777-0707 82-31-216-7719 [email protected] www.biorhythm.kr X H I B I T 트를 정부산하 기관과 충남북 지역사회 협력 하에 각 대학교 공동연 구 지원과 함께 수행하며 바이오 생명공학분야의 글로벌프로젝트화 에 온 심혈을 기울이고 있다. 요구르트유산균이 우유나 당류에 배양 한 제품인 반면 김치유산균은 김치파쇄액에 단일 또는 다종의 유산 균 우점종을 배양시킨 순식물성 유산균으로 3단계 코팅 특허등록 공 법을 이용하여 생산하고 있다. 본 제품을 섭취 후 짧은 시간 내에 숙 변제거나 쾌변 및 황금색변과 같은 속효능 반응을 감지할 수 있는 제 품이다. 활용분야는 건강기능식품, 의약품, 화장품, 바이오제품, 동물 의약 품에 응용 적용할 수 있으며, 건강산업에 있어서 상당한 고부가 가치성의 상품이다. S 마이크로캡슐화 김치유산균 Super Kimchi lactobacillus I N T R O D U C T I O N * This is made by cultivating a variety of lactobacillus fermentans, which grows in a Korean indigenous food, Kimchi, and coating three times with casein protein and kelp powder, so the lactic acid bacteria in Kimchi can reach intestines and grow and breed, allowing to intake both nutrition and lactic acid bacteria in kimchi. (Tip) Taking the daily amount of lactic acid bacteria recommended in this product has a same effect of taking 1kg of kimchi. 1.Substance form : yellowish brown kimchi powder in which 1g of powder has 10 billion LAB (the number of LAB and the size of a particle are optional) 2.Dosage : 1~2 times/day (1~2capsule/1time :1~2g), probiotics:10billions /g 3. Intake method : intake with water * Effect : intestinal comfort in normal and regular motion without fecal incontinence after continuing intake, immunity improvement, probiotic effect. This invention helps to improve immune system against SARS, avian influenza or virus. 수 천년동안 우리의 선조들의 얼과 숨결이 깃들어 있는 김치 속에 들 어있는 “김치유산균”은 온 인류에게 건강상품으로서 영원하리라 확 신한다. 또한 동결건조 김치의 유용한 성분의섭취를 통한 인체내 흡 수는 물론 김치유산균이 위산, 답즙산에 살아 남아 소장과 대장에서 그 기능을 최대로 발휘할 수 있도록 하였다. 김치관련 다양한 프로젝 094 095 D45 N39 Bionutrigen Co., Ltd. Biotech Industry Research Assistance Council (BIRAC) (주)바이오뉴트리젠 CEO ADD TEL FAX E-MAIL URL R25 BOK SONG HAE 복성해 BVC #207 KRIBB, 52 Eoeun-dong, Yuseong-ku, Daejeon, S. Korea 82-42-861-0637 82-42-861-0639 [email protected] http://www.bionutrigen.com CEO ADD TEL FAX E-MAIL URL Dr. Renu Swarup, MD A-254, 3rd Floor, Bhisham Pitamah Marg, Defence Colony, New Delhi – 110 024 India 91-47744500 91-47744511 [email protected] http://www.birac.nic.in A21 Biotechnology Industrialization Center Biotoxtech Co., Ltd. 생물자원산업화센터(주) 바이오톡스텍 CEO ADD TEL FAX E-MAIL URL Yeon-Sil Lee 이연실 # B-806, Gwangmyeong SK Technopark, Sohadong, Gwangmyeng-si, Gyeonggi-do, Rep. of Korea 82-2-2083-3024 82-2-2083-3026 [email protected] http:// CEO ADD TEL FAX E-MAIL URL E X H I B I T S I N T R O D U C T I O N JBB20 (Liver Health Food Ingredient), Slim&Slim (Slimming Govt. of India Enterprise Food Ingredient) JBB20 (간 건강소재), Slim&Slim (항비만소재) I N T R O D U C I T I O N Bionutrigen Co,.Ltd. was established in 1999 to develop the new natural edible food grade materials without toxicity and side effects for maintaining slimming body line, skin beauty, good liver health, heart health and metabolism. Bionutrigen's business-goal is to develop nontoxic health food ingredients and products from vegetables & fruits for maintaining healthy levels of body fat, cholesterol, LDL, triglyceride, blood sugar and to support fat control, heart health, liver health, lovely body line, skin beauty. Our new products Slim&SlimPWH™ and JBB20™ are helpful for achieving the above goals. (주)바이오뉴트리젠은 비만증, 간질환, 당뇨병 등을 포함하는 다양한 성인병의 예방에 탁월한 건강식품, 음료, 식품첨가제 및 미용식품 소 재 개발과 더불어 독성과 부작용이 없는 의약품 원료개발을 위한 천 연 신소재 개발을 주요 목표로 하고 있다. 현재 비만증, 간질환 및 아 름다운 피부 및 몸매관리에 유용한 Slim&Slim과 JBB20을 개발하는 데 성공하여 E.U, 미국, 중국, 러시아, 일본 등 전 세계에 마케팅을 시 작하여 활발한 성과를 이루고 있다. 096 N T R O D U C T I O N Biotechnology Industry Research Assistance Council (BIRAC) is a Section 25 ‘Not-for-Profit Company’ of Government of India, that is registered under Indian Companies Act 1956, and has been set up as Department of Biotechnology’s interface agency, which serves as a single window for the emerging biotech industries. BIRAC is guided by an Independent Board of Directors comprising senior professionals, academicians, policy makers and industrialists. As a Government of India enterprise, it endeavours to bring professionalism, transparency and efficiency into its functioning while providing support to catalyze the transformation of the emerging Indian bioeconomy. I N T R O D U C T I O Jong-Koo Kang 강종구 O chang Scientific Industrial Complex, 686-2 Yangcheong-ri, Ochang-eup, Cheongwon-gun, Chungcheongbuk-do, 363-883, Korea 82-43-210-7777 82-43-210-7778 [email protected] http://www.biotoxtech.com N X H I B I T S BIC focuses on theintergrated preventive medicine E Industrialization and R&D which is based on IP (Intellectual •N on-Clinical Field: Toxicity study/ Efficacy study/ Property), TK (Traditional Knowledge) and Bio-Resources of Histopathology and clinical pathology study Technical Valuation. •Analysis field: PK/TK, ADME, RI •New compound discovery field •Consulting drug development •의약품/식품/화장품/세포치료제/화학물질/농약/의료기기 등에 관 한 안전성 시험 수행 •PK/TK, ADME, RI 분석업무 •유효성시험 및 물질 Screening •임상병리 및 조직병리 업무수탁 •비임상시험에 관한 Consulting 및 대관업무 I N T R O D U C T I O N Biotoxtech is a life science company and a Contract Research Organization (CRO) that primarily conducts compliance studies for product safety. Headquartered in Ochang, Korea, Biotoxtech owns and operates a 146, 300sq.ft. Facility, With 10 years of industry experience, Biotoxtech conducts compliance safety testing and research following Good Laboratory Practices (GLP). The safety studies performed in support of OECD, United States FDA, Japanese MHLW, and other international regulatory compliance for products developed from biotech, chemical, agrochemical and pharmaceutical industries. The safety services include complete range of toxicology, acute, sub-chronic, and chronic toxicity, reproductive toxicity, genotoxicology, ecotoxicology, carcinogenicity, pharmacokinetics (PK), toxicokinetics (TK), bioavailability, ADME, analysis and synthesis, Efficacy Evaluation, Histopathology & Hematology. 097 R15 L20 BKT Co., Ltd. (주)부강테크 CEO ADD TEL FAX E-MAIL URL E Il Ho Jung 정일호 4 F, Allnations Bldg, 789-6, Yeoksam-Dong, Gangnam-Gu, Seoul, Korea 82-2-3453-5221 82-2-556-2205 [email protected] http://www.bkt21.com X H I B I T S FMX (Anti-Fouling Membrane System) FMX 막오염 저감형 분리막 시스템 I N T R O D U C T I O N • 회사소개 During the initial period of BKT established, BKT aimed niche market of advanced wastewater treatment in livestock. As an environmental company, BKT provide the optimum process of advanced sewage treatment process, special membrane filtration system (FMX) and anaerobic digestate process across the business sector. Based on accumulated technologies in environmental field, FMX technologies (membrane filtration) application is expands to various sectors, and BKT also carries forward bio industry field. By starting supply FMX into CJ amino acid manufacturing process, it expands business with Production separation (Bulk filtration), has strong points in high density culture filtration of downstream process and Diafiltration sector. Additionally, bio-industrial sector has great expectation on vigorous business, through proceeding bulk separation process in animal medical supplies manufacturing process and filtration/concentration process in amino acid manufacturing process etc. Furthermore, BKT as a leader in environmental green tech companies, at the same time positioned high density membrane market leader in bio-industries to become best membrane technology holding company. • 제품소개 FMX is the most advanced membrane filtration system that overcomes technological limitation and maximizes 098 treatment efficiency of high solid, high density and high viscosity application which conventional membrane system cannot handle. FMX is able to applied pollutant filtrate/ separation process with accuracy and ease of operation in various industries such as environmental industrial process, bio-manufacturing process, and chemical plant etc. Conventional membrane system has ability of advantage in raw material recovery/concentration, energy reduction and reuse of byproducts. Though there were serious problems of fouling resistance. Especially, characteristic of high density and high viscosity substance were inappropriate for the process and may require frequent cleaning issue or economic loss of membrane replacement plus constraint of maintenance. FMX was developed to overcome of obstacles such as fouling that conventional membrane filtration system couldn’t handle. By applying vortex generator in FMX, it prevents membrane fouling and lead to high density and high viscosity treatment application in various industries. FMX may effective in separation of micro-organism in biosector and product separation (bulk filtration), filtration and diafiltration of high density cultivate process. FMX gives a more than twice of high concentrate results from the existing membrane separation process and increases substance recovery rate. Plus, it has expectation of energy cost saving and reduces production period efficiency through post-treatment load factor from decreasing inflow rate of DF water during the general diafiltration process. FMX quality and durability has been approved worldwidely through acquired of CE (EU certification system) and ISO (ISO 9001/14001) certification based on the FMX technical skills. Through technical performance assessment, FMX is applied in domestic various industries such as biotech and environment , biopharmaceutical (animal drug), biofood (amino acid) and chemistry process etc., currently. British Embassy Seoul / UK Trade & Investment 주한영국대사관 -납세 및 관련 법규에 대한 상세한 안내 3. 주요 인맥 소개 및 연결 -해당 산업 전문가 네트워크 연결: 인센티브 전문가, R&D전문가, 사업계획 고문, 연구기관 등의 비지니스 네트워크 형성 CEO ADD TEL FAX E-MAIL URL Scott Wightman (Ambassador) . 영국 내 사업 부지 선정 British Embassy Seoul, Sejong-daero 19-gil 24, 4 해당 사업에 적절한 지역 및 사업부지 선정 지원 Jung-gu, Seoul 100-120 Republic of Korea 설립과 운영에 필요한 컨설팅 제공 82-2-3210-5612 . 글로벌 기업으로의 도약 5 82-2-3210-5637 -IMF가 인정한 유럽 및 세계시장으로 진출할 수 있는 게이트웨이 [email protected] 저희 투자팀은 위의 모든 사항들이 원할하게 진행되도록 진출 이 전 http://www.ukti.gov.uk 부터 진출 이 후 관리까지 전면 지원해드립니다. 제공되는 모든 서비 스는 무료/ 대외비입니다. E X H I B I T S Government 정부기관 I N T R O D U C T I O N UK Trade & Investment (UKTI) works with UK-based businesses to ensure their success in international markets, and encourage the best overseas companies to look to the UK as their global partner of choice. UKTI has professional advisers both within the UK and across more than 100 international markets. UKTI has a customer commitment to helping its UK and international customers by providing a range of services, to a high standard and improve customer service by listening to customer feedback. We also have a co-ordination role across government to establish a more systematic approach to relationships with companies which are the most economically significant investors and exporters. 영국무역투자청은 영국과 해외기업 간의 무역 및 투자사업을 지원하 는 기관입니다. UKTI 서울 투자팀은 한국 기업이 영국으로 진출할 수 있도록 도와드립니다. 영국내 투자 및 사업 기회를 찾아드리고 현 지에서 비지니스가 성장하도록 모든 과정에서 적극적으로 지원하고 있습니다. 영국 진출을 위한 투자팀의 지원사항 1. 영국시장 안내 -영국의 시장 동향을 바탕으로 사업성을 파악 -자금조달, 비자, 기업등록, 재정협조 정책, 생산품 분야, 법인세, 현지 직원채용 등에 대한 정보 제공 및 지원 2. 영국정부에 관한 정보 제공 -해당 정부 부처와 협회, 지방자치 기관 등에 한국기업 소개 099 G35 H42 D20 K30 Boryung Pharmaceutical Co., Ltd. Cactus Communications Korea Ltd Cancer Hospital / GAP2014 CARIMA CO LTD 보령제약 주식회사 (주)캑터스 커뮤니케이션즈 코리아 연세의료원 (암병원/GAP2014) 캐리마 CEO ADD TEL FAX E-MAIL URL E Tae Hong Choi 최태홍 (110-750) Boryung Bldg, #66-21, Wonnam-dong, Chongro-Ku, Seoul, Korea 82-2-708-8168 82-2-708-8439 [email protected] http://www.boryung.co.kr X H I B I T S Kanarb (Anti-hypertensive drug) N T R O D U ADD TEL FAX E-MAIL URL E Shriram Poonja 121-706, Renaissance Tower # 1701 Mallijae-Ro 14, Mapo-Gu, Seoul, Korea 82-2-538-3177 82-2-703-3177 [email protected] www.editage.co.kr X H I B I T C T I O N Boryung Pharmaceutical Company (here after Boryung) founded in 1963 based on company's ideology, "coexistance and co-prosperity" has led Korean pharmaceutical industry concentrating its utmost efforts on the development of new drugs. Boryung makes an effort to strengthen the product pipelines in the specialty areas such as cardiovascular drugs, antineoplastics drugs and antibiotics/antiviral. Boryung devote itself to achieving aspiration of the company which is "Dedicating to the health of Mankind" and becoming a global innovative pharmaceutical company. Boryung Pharmaceutical has developed Kanarb, an antihypertensive drug that has been approved by the KFDA as the 15th new drug, and also it is 8th new ARB drug in the world. Boryung is in the process of exporting Kanarb to 13 countries in South America, BRICs, southeast Asia, the U.S., and Europe. N T R O D U C T I O N Editage provides entire service for the overall areas in Journal Publication like Translation, English Editing & Journal Publication Support. We have provided Editing Services for around 214, 000 papers in 112 countries all over the world. We also have the business area in English Education, especially in Writing and provide total solution to the Market. 에디티지는 한.영 번역에서부터 영문교정 및 저널투고서비스에 이르 기까지 영문 학술논문 투고에 있어 전반적인 서비스를 제공하고 있 습니다. 전 세계 약 112개국 214, 000건의 영문교정 실적을 보유하고 있으 1963년 창립된 보령제약은 ‘삶의 질’을 높이는 우수한 의약품을 계 며, 그 밖에 맞춤형 영어교육사업 영역 또한 보유하고 있어 영문학술 속적으로 발매해왔으며 지속적인 혁신을 통해 궁극의 목적인 ‘인류 건강에 공헌’을 영속적으로 실천하는 기업이다. 특히, 심혈관계 질환 과 항암 분야에 파이프라인을 집중하고 있다. 카나브 정은 세계 8번 째 ARB 신약이자, KFDA로부터 15번째로 승인 받은ARB 계열 항 고혈압제 신약으로 중남미 13개국과의 수출 계약을 비롯해BRICs 및 중동아시아, 미국, 유럽 등 전세계적으로 수출을 진행하고 있다. 100 ADD TEL FAX E-MAIL URL I 영문교정 저널투고지원 영문논문 작성법 교육 및 워크숍 한.영 번역 I CEO S English-Language Editing Publication Support Training and Workshops Translation 카나브, 원료의약품 I CEO 논문에 관한 토탈솔루션을 제공하고 있습니다. N Sung Hoon Noh 노성훈 Cancer Hospital, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-752, Korea 82-2-2228-8000 82-2-362-9973 [email protected] h ttp://sev.iseverance.com/cancer/centerintro/ cancer_hospital/cancer_hospital_intro/ http://www.gap2014.org T R O D U C T I O N The Yonsei Cancer Center was established by the Yonsei University Health System as the first Korean cancer center in 1969 and has played an important role in Korea’ cancer research and treatment through collaborating with the Cancer Research Institute. The New Yonsei Cancer Hospital, which will newly reopen in 2014, will mark a new era in cancer treatment with comprehensive cancer care, prevention and research. The most acclaimed cancer center in the world, MD Anderson manages the multi-national, multi-organization GAP program – Global Academic Programs, and organizes the annual GAP conference, which is the very place to share research experience and strengthen the sister institute network. The next GAP conference will be held in May in Seoul, Korea. The conference will be co-hosted by the Yonsei Cancer Center, one of the sister institutes of MD Anderson, in conjunction with Korean Cancer Association. As the 1st GAP conference held in Asia, GAP 2014 represents the advancing status of Korean cancer research. We are sure GAP 2014 will be an excellent opportunity to share experience and bolster the ties of the research network with international colleagues. CEO ADD TEL FAX E-MAIL URL E Byungkeuk, Lee 이병극 157-862 264-26 Yeomchang-dong Gangseogu, Seoul 82-2-3663-8877 82-2-3283-4466 [email protected] http://www.carima.co.kr X H I B I T S 3D Printer Master Plus I N T R O D U C T I O N Carima has been involved in optical engineering for over years with research and development for decades, big investment, Master Plus(3D Printer) came out with our own optical technology and specific skills 저희 업체에 대해 간략히 소개드리면 캐리마는 1983년 사진현상기 사업으로 출발해 30년간 광학기기 전문기업으로 입지를 다져왔으며 수십년의 연구개발과 수백억원의 거액을 투자, 캐리마의 디지털 광학 기술과 노하우를 총동원해 마스터 플러스(3D 프린터)를 개발해 내었 습니다. -연세암센터는 1969년 한국 최초로 된 후 연세암연구소와 함께 중 개-임상연구를 긴밀히 협력하며 국내 암연구와 진료를 선도하여 왔습니다. 2014년 암병원 신축을 맞이하여 포괄적 암 진료, 예방, 연구에 이르는 새로운 개념의 최고 암 진료 경험을 추구하는 최고 의 암센터로 재도약 할 것입니다. -세계 최고의 암센터인 MD 앤더슨 암센터는 세계 유수의 암병원들 과 자매결연을 맺고 매년 성과를 교류하고 네트워크를 발전시키는 국제학술대회인 GAP (Global Academic Programs)을 개최해 왔습니다.. 2014년 5월 연세암센터와 대한암학회는, 아시아 최초 로 GAP 2014를 공동주관하여 개최합니다. 학술적 성과를 교류하 고 국제 연구자들과 협력하는 훌륭한 기회가 될 것입니다. 101 K10, E30 N34 가, 시판되고 있으며, 이러한 성공적인 신약개발 경험을 바탕으로 Chong Kun Dang Pharmaceutical Corp. thiazolidinedion 유래의 당뇨병 치료제인 CKD-501 (상품명: 듀 (주)종근당 비에)이 2013년 식약처로부터 허가를 획득하고, 2014년 발매 예 정이다. Tubulin 저해기전 항암제인 CKD-516 및 HDAC 저해기 Kim Jung Woo 김정우 CEO 전 항암제 CKD-581이 임상1상 진행 중에 있으며, 2009년 미국 368, 3-ga, Chungjeong-ro, Seodaemun-gu, Seoul ADD Zafgen에 기술수출된 고도비만 치료제 CKD-732는 해외에서 임 120-756, Korea 상 2상을 진행하고 있다. 최근에는 바이오사업에 집중 투자하여 바 82-2-2194-0300 TEL 이오시밀러와 백신을 개발하고 있으며, 네스프 바이오시밀러 CKD82-2-2194-0369 FAX 11101과 자궁경부암 예방백신 CKD-12201이 임상 1상을 진행중 E-MAIL [email protected] 에 있다. http://www.ckdpharm.com URL E X H I B I T S CKD-501, CKD-732, CKD-828, CKD-841, CKD-11101, CKD-12201 Center for Cellular and Molecular Platforms (CCAMP) CEO ADD TEL FAX E-MAIL URL E N T R O D U C T I O N Chong Kun Dang Pharmaceutical Corp. (CKD Pharm.), based in Seoul, Korea, is a fully integrated pharmaceutical company manufacturing both active pharmaceutical ingredients and finished products. We have experiences over half century in manufacturing products through fermentation and synthetic technologies and continuously strive to develop new drugs. Furthermore, We are trying to investigate new drugs through drug discovery and delivery platform technologies in the post-genomic era. In 2012, our revenue was $419million and CKD invested about $46 million in R&D activities. CamtobellⓇ was launched in 2004, as the first CKD new drug developed by own technology. Based upon this successful experience, DuvieⓇ which is a thiazolidinedion derivative for type 2 diabetes has been approved by MFDS. Phase I clinical trials for CKD-516 (Tubulin inhibitor & VDA) and CKD-581 (Pan-HDAC inhibitor for cancer) are ongoing currently. In addition, CKD-732 (Fumagillin derivative) developed by CKD has been licensed to Zafgen and is in Phase II clinical trials for the treatment of morbid obesity in Australia. As biologics, both CKD-11101 (biosimilar) and CKD-12201 (HPV vaccine) are in Phase I clinical trials. (주)종근당은 원료, 완제의약품을 제조, 판매하는 제약기업으로 지난 반세기 동안 발효 및 합성기술에 의한 제품생산에 많은 경험과 노하 우를 축적해왔다. 4, 612억원 (2012년)매출 규모의 종근당은 축적 된 기술을 바탕으로 신약개발을 위해 꾸준히 노력하고 있으며 2012 년에는 연구개발비로 약 505억원을 투자하였다. 2004년 자체연구를 통해 개발된 캄토벨은 국내에서 항암제로 허 102 Prof. Ramaswamy S NCBS-TIFR, GKVK Post, Bellary Road, Bangalore 560065, India 91-80-6718-5100 91-80-2363-6662 [email protected] www.ccamp.res.in X H I B I T S N T R Chuncheon Bioindustry Foundation (재)춘천바이오산업진흥원 CEO ADD TEL FAX E-MAIL URL E Lee Si-woo 이시우 2 00-161 Hupyong-dong 198-53, Chuncheon, Gangwon, Korea 82-33-258-6165 82-33-258-6170 [email protected] http://www.cbf.or.kr X H I B I T S Health functional food, Food ingredient, Food additives, Drug medicin Standard booth I I E10 O D U C T I O N C-CAMP is a Department of Biotechnology(Govt. Of India) initiative, with a mandate of enabling successful bioscience research and entrepreneurship. 기능성 식품, 소재, 첨가물, 화장품, 의약품 등 I N T R O D U C T I O N Chuncheon Bioindustry Foundation (CBF) is a non-profit organization established in January, 2003, aims to promote the growth of bio-venture companies by collecting and solving various problems of the biotech companies. CBF helps to exchange information, support technological development and activate the exchange of knowledge and experiences of management and industrialization in biotech field. CBF also provides systematic support for business start-up, technology/development, marketing and manufacturing with a well-organized excellent infrastructure. Through this effort, CBF intends to strengthen the international competitiveness of the national bio-venture industries and economy, and will contribute to develop Gangwon regional industry by fostering bio-industry as a national core strategic industry in the 21 st century. 춘천 Bioindustry 재단 (CBF)는 2003년에 설립된 비영리 단체입니 다 생명 공학 기업의 다양한 문제들을 수집하고 해결함으로써 바이 오 벤처 기업의 성장을 촉진하는 것을 목표로 하고 있습니다. CBF는 정보를 교환 및 기술 개발을 지원하고, 지식과 생명 공학 분야의 관 리 및 산업화의 경험 교류를 활성화하는데 도움이 됩니다. 또한, 훌륭 한 인프라와 기술 개발, 마케팅 및 제조에 대한 체계적인 지원을 제 공합니다. 이러한 노력을 통해 CBF는 국내 바이오 벤처 산업과 경제의 국제 경 쟁력을 강화하고, 21 세기 국가 핵심 전략 산업으로 바이오 산업을 육성하여 강원 지역 산업 발전에 기여할 것입니다. 103 E40 Q21 P20 G10 Chungbuk National University Department of CHUNGBUK NATIONAL UNIVERSITY TLO 충북대학교 산학협력단 Industrial Parmacy Chungcheong Institute for Regional Program Evaluation 충북대학교 제약산업특성화대학원 충청지역 의약바이오기업 클러스터 CEO ADD TEL FAX E-MAIL URL CEO Jin Tae Hong 52 Naesudong-ro, Cheongju Chungbuk 361-763 82-43-261-2800 82-43-268-2732 [email protected] http://pharm.chungbuk.ac.kr ADD TEL FAX E-MAIL URL Shin Eung-Soo 신응수 (361-763) Chungbuk National Univ., Gaesin-dong, Heungdeok-gu, Cheongju-si, Chungbuk, Korea 82-043-261-3872 82-043-261-3499 [email protected] http://sanhak.chungbuk.ac.kr CEO ADD TEL FAX E-MAIL URL E X H I B I T S E X H I B I T • Perform National Research & Development •Perform Joint Research & Development with Business • Register 150 Case Patents of Bio Technology PR content for department of industrial pharmacy 대학원 안내 및 홍보물 N T R O D U C T I O 충청북도 Lee Si-Jong 이시종 8 2sangdang-ro, Sangdang-gu, Cheongju-si, Chungcheongbuk-do, Korea 82-43-220-4623 82-43-220-4619 http://www.cb21.net CEO Lee kyung mi 이경미 803 8F Deadeok Tech Biz Center, 386-2 Doryongdong, Yuseong-gu, Daejeon, 305-340, Korea 82-42-934-8651 82-42-934-8368 [email protected] http://chungcheong.irpe.or.kr S ADD TEL FAX URL E X H I B I T S 충청북도 바이오산업 현황 및 육성시책 등 E X H I B I T S medicine and medical supplies I N T R O D U C T I O N 지방자치단체 의약품 I Chungcheongbuk-do N -to educate and train students to become leading opinion leaders in the area of Pharmaceutical R&D, Regulation, and Pharmaceutical management of technologies. -to contribute to the advancement of the pharmaceutical sciences based on multidisciplinary knowledge through outreach and public service. I N T R O D U C T I O N 충청지역사업평가원은 충청지역의 강소기업육성을 목표로 광역경제 권선도육성사업 등을 운영하고 있으며 바이오 분야 중 의약바이오 선도산업 지원을 통한 지속성장형 의약바이오 산업 성장동력 창출을 목표로 생물의약품, 합성의약품, 소재, 동물의약품 분야의 기업들을 지원 하고 있습니다. -제약기업의 R&D관리, 인허가, 기술경영 등 사업화에 있어 핵심역 할을 담당할 석박사급 전문 인력 및 기업에서 혁신리더로 성장할 수 있는 중간 관리자 양성 -글로벌 신약 개발 능력의 혁신성을 높이기 위한 산업체의 인재수 요에 부응하기 위해 약학•의학•경영•법학 등 다학제간 융합지 식을 갖춘 석박사급 전문인재 양성 104 105 E10 P25 L10 B40 ChungDo Pharm. Co. Ltd. Chungnam Technopark Bio Center CMC Biologics CnS (주)청도제약 (재)충남테크노파크 바이오센터 씨엠시 바이올로직스 (주)씨엔에스 CEO ADD TEL FAX E-MAIL URL Kim Sung-Jin 김성진 202 Hi-Tech Venture Town, 198-53 Hupuyeongdong, Chuncheon, Gangwon-do 200-160, Korea 82-10-2840 4002 82-303-0950 5878 [email protected] http://www.ichungdo.com CEO ADD TEL FAX E-MAIL URL Jang Woncheol 장원철 Daehangno 121, Nonsan-si, Chungnam 82-41-980-5461 82-41-735-5629 [email protected] http://ctp.or.kr/ http://cnasc.or.kr CEO ADD TEL FAX E-MAIL URL I E X H I B I T S 1. Urine test strip & reader 2. Diet-Test Strip 3. Blood Glucose Monitoring System I N T R O D U C E X H I B I T S Biomaterials 바이오소재 (동물약품, 건강기능성식품, 화장품 외) T I O N I N T R O D U C T I O N N Claes Glassell Vandtaarnsvej 83B DK-2860 Soeborg Denmark 45-7020-9470 45-7020-9476 [email protected] www.cmcbio.com T R O D U C T I O CEO ADD TEL FAX E-MAIL URL N E Ji-sun, Im 임지순 3, Daewharo178, Daedeok-ge.Daejeon, korea 82-42-670-8054 82-42-633-8056 [email protected] http://www.biocns.com X H I B I 2001 년 코펜하겐에 설립된 이후, 생물학적 생산시설인 ICOS Lab, Pilot - fermenter, S, M, B Biologics를 2007년에 시애틀, 워싱턴에, 2012년에는 버클리, 캘 리포니아에 XOMA를 설비하였고 지금은 400명의 직원들과 함께 N T R O D U C T 세계 주도적인 CMO가 되었습니다. 임상 전 연구, 임상시험 그리고 I 시장생산을 위한 단백질 기반 치료법의 cGMP 제조를 위한 custom Microbial fermentation, culture apparatus service를 전문으로 합니다. T I S O N Since 1991, we have exported urine test strip & reader, Diet Chungnam Techno Park Bio Center was established by the test strip and Blood glucose monitoring system in the world Ministry of Knowledge and Economy. We are a regional market center specializing in animal resources. CTP Bio-Center shall create the 21st.Century“Mecca” of industrial support 1991년 이래 소변검사지 및 분석기, 다이어트검사지, 혈당기를 세계 for agri-businesses related to livestock feed, food and 시장에 수출하고 있는 진단제품 전문기업. meat processing by networking and co-operation with industries, universities, R&D centers and governmental agencies. We conduct to research to support animal related companies & institutes, by networking and clustering so that domestic animal industries will become stronger and more competitive internationally as well as increasing the economic power of Chungnam province. 한국 바이오산업의 메카 (재)충남테크노파크 바이오센터는 충남지역 의 바이오관련 기술개발, 마케팅, 시제품 개발 등 각종 사업화 지원을 통해 그린바이오 중심의 우수기업 육성을 추진하고 있습니다. 바이오 센터에서는 동물약품, 건강기능성식품, 화장품, 사료첨가제분야 등에 대한 지원기업인 다인네추럴, HvBio, 모든스킨, 하이드로비티 등 6 개 기업의 제품을 출품하였습니다. 106 107 K30 L10 Convergence Technology Exhibition (Korea Health Industry Development Institute) 융복합 기술전시관 (한국보건산업진흥원) ADD TEL FAX E-MAIL URL E Covance Laboratories Korea Ltd. 코펜하겐 캐퍼시티 (주)코씨드바이오팜 코반스래버래토리 코리아(주) CEO H I B I T S Creative convergence and advanced HT product and service (HI Korea Invest Fair 2013) 보건산업 창조적 융복합 기술 및 제품 N Claus Lønborg Nørregade 7B DK-1165 Copenhagen K Denmark 45-3322-0222 [email protected] www.copcap.com T R O 하겐에 자리를 잡고자하는 모든 회사들이 비지니스기회를 획득할 수 있도록 한다. 모든 외국회사들에게 서비스는 열려있으며, 무료이 다. 제공하는 서비스의 항목으로 는 시장개요, 산업지식, 신생기업 관련 서비스, 땅 및 재산과 관련된 리서치, 파트너 및 매칭시스템을 포함해 코펜하겐에 대한 비지니스케이스를 만드는 데에도 도움을 준다. CEO ADD TEL FAX E-MAIL URL Choi Ok Gyu 최옥규 38, Wolgok-Gil, Gangnae-Myeon, CheongwonGun, Chungbuk, 363-792, South Korea<#103, 3rd building of Business Incubation Center> 82-43-274-9097 82--43-274-9098 [email protected] http://www.coseed.co.kr D U C T I O N Advanced HT Showcase; displays and promotes the advanced HT products and services and provides consultation and media interview to foster investment in HT industry. 국내 보건산업 기업의 기술투자 및 파트너쉽 기회 제공을 위해 개최 되는 ‘HI Korea Invest Fair’와 연계하여 우수기술 전시, 홍보, 기술 정보교류, 미디어 인터뷰, 투자상담 및 기술 포스터전시 등을 운영. CEO ADD TEL FAX E-MAIL URL E E X H I B I T Joe Kim 김용균 2F, Songnam BD, #1358-6, Seocho-dong, Seochogu, Seoul 137-862 Korea 82-2-503-0780 82-2-503-0515 [email protected] http://www.covance.com X H I B I T S S Non-clinical study, CMO/CMC service, Biotech service, BioCosmetic ingredients - Snail secretion Filtrate, Cosmetic analysis, Regulatory services for US & EU, Phase I clinics, preservative, Schizandra chinensis Fruit Extract, Forsythia Global Clinical studies. suspensa Fruit Extract. Chemical/Biologics의 비임상 시험과 US IND, EU EMEA filing 화장품 원료-달팽이점액여과물, 화장품 방부제, 오미자추출물, 연교 service, Covance 자체 Clinic에서의 Phase I study를 수행하고 있습니다. 추출물,버섯콜라겐 (HI Korea Invest Fair 연계) I CoSeedBioPharm Co., Ltd. KO Kyung-hwa 고경화 1 87 Osongsaengmyeong2 (i)-ro, Osong-Eup, TEL Cheongwon-gun, Chungcheongbukdo 363-951, E-MAIL URL KOREA 82-43-713-8273 82-43-713-8908 I N T R O D U C T I O N [email protected] 투자증진, 비지니스시장확보 및 클러스터성장을 위해 설립된 덴마 http://www.khidi.or.kr 크케피탈(Danish Capital)지역의 기관이다. 비영리기구로써 코펜 X O20 Copenhagen Capacity ADD CEO Q14 I N T R O D U C T I O N Established in April 2006 -Certified ISO9001(Quality Management System) and ISO14000 (environmental management system) - Business certified as INNO-BIZ - We've been producing 500 Oriental herb extracts. -We have 18 patents about cosmetic materials including natural substances as main ingredient. -We have the efficacy and safety evaluation system and capacity to develop new cosmetic materials. -We are scheduled to move into Osong High-Tech Medical Integrated Complex. (4630m2 -2013.11) 또한 CMC (Radio-synthesis, CMO업무포함), Phase II & III 그리 고 Phase IV에 이르기까지 신약 개발과 관련한 거의 모든 써비스를 제공하고 있습니다. I N T R O D U C T I O N Covance is one of the world’s largest and most comprehensive drug development services companies with more than 10, 000 employees in 60 countries. Through its nonclinical, clinical and commercialization services, Covance has helped pharmaceutical and biotech companies develop one-third of all prescription medicines in the market today. 1940년 미국에서 설립되었으며, CMC, 독성시험 및 임상시험 대행 - 2006년 4월 법인설립 - 화장품 원료 개발 및 생산기업. - ISO9001(품질경영시스템), ISO14000(환경경영시스템) 획득 - INNO-BIZ 인증기업. - 150여 품목의 한방추출물 소재 보유. -천연물질의주요성분을 함유하는 화장료 조성물에 관한 특허등록 18건. - 자체 소재개발 및 평가시스템 구축. - 오송첨단의료복합단지 연구소입주 확정(4630m2) 108 업체입니다. 미국, 영국, 프랑스, 독일에 독성쎈터를 운영하고 있으 며, 영국에 Radio labeling synthesis, 프랑스에 Chemical CMO, 독일에 영장류 쎈터를 운영하고 있습니다. Phase I 을위해 미국 에 ( 하와이포함) 10여개 Covance clinic과 스위스/영국에도 Covance clinic을 운영하고 있습니다. 또한 전세계 60여개국에 지사를 운영하고 있으며, 약 1만여명의 직 원이 일하고 있습니다. 명실상부한 가장 큰 global CRO중 하나이 며, 전년도 매출은 2조5천억원을 기록하고 계속 성장하고 있습니다. Compound search부터 CMC, 독성시험, IND-filing service, Phase I, II, III, IV까지 one-stop-service를 지향하고 있습니다. 109 R23 M38 CRH (Converging Research Headquarter) for Bio-Pharmaceuticals 바이오제약사업본부 CEO ADD TEL FAX E-MAIL URL Criyagen Agri & Biotech Pvt. Ltd. CEO Kim Jung-hoe 김정회 Rm905, Main Building, Kaist ICC, 119, Munji-ro, Yuseong-gu, Daejeon 82-42-350-8414 82-42-350-8410 [email protected] http://bph.kaist.ac.kr ADD TEL FAX E-MAIL URL X H I B I T S Panels, brochures I N T R O D U C T I O Dr. Basavaraj Girennavar Lab 210, IABT, University of Agricultural Sciences, Dharwad-580005,Karnataka,India 91-9741414048 91-8362446616 [email protected] http://www.criyagen.com N T R O D U C T I O N Criyagen Agri & Biotech Private Limited, Bangalore, India is working in the field of Research and development of new generation biofertilisers, Micro nutrients, plant growth promoters and hormones. G32 CRYO DIFFUSION DAE HWA PHARMACEUTICAL Co., Ltd. 크리오 디푸젼 대화제약 주식회사 CEO ADD TEL FAX E-MAIL URL Phiippe Doinel 49 rue de Verdun, 27690 Lery France 33 2 32 59 62 25 33 2 32 59 00 65 [email protected] vwww.cryodiffusion.com CEO ADD TEL FAX E-MAIL URL I I E N30 N T R O D U C T I O Han-Koo, Lee 이한구 495, Hanu-ro, Hoengseong-eup, Hoengseonggun, Gangwon-do, Korea 82-2-6716-1071~3 82-2-588-3111 [email protected] http://www.dhpharm.co.kr N X H I With more than 50 years of experience Cryo Diffusion has E developed the most complete range of cryogenic products Plasters, Cataplasma, Patch. etc. B I T S 50년 이상의 경험을 바탕으로 Cryo Diffusion는 가장 완벽한 극저 첩부제, 카타플라스마, 패취제 등 온 제품들을 개발했다. N The Converging Research Haedquarter for BioPharmaceuticals located at KAIST ICC in Daejeon carries out the Converging Reserch Project for Bio-Pharmaceuticals with the three Converging Research Centers such as Bio-molecular process Engineering, BiopharmaceuticalsTailored DDS, and CTC based Cancer Prognosis and Diagnosis. The headquarter was selected in 2009 as a part of New Technology Convergence-gype Growth Engine Program (government program) with an aim to promote converging researches in the BT sector. 대전 카이스트 문지캠퍼스에 위치한 바이오제약사업본부는 교과부 신기술융합형성장동력사업의 일환으로 2009 선정되어 우리본부가 관리하는 3개의 융합연구단이 (‘분자생물공정 융합연구단’, 바이오의 약품 맞춤형 약물 전달시스템 융합연구단’, ‘혈중 암세포 암예후 진단 융합연구단’) 바이오제약분야의 융합 연구를 수행하고 있습니다. I N T R O D U C T I O N DAEHWA has been steadily endeavoring to meet your expectation to have a healthful life and escape from a hazard of disease. We supply the best quality pharmaceutical products to the people who earnestly need them, and realize the dignity of human life through our research and development. “Nothing is more precious and valuable than life.” is our permanent spirit and goal. DAEHWA Pharmaceutical Co., Ltd. was established in 1984 and with the completion of the c-GMP facilities in 2009, we are striving to produce high quality pharmaceutical products from“ Raw Material” to “Finished Products”. 1984년 1월 19일 대화제약 (주)를 설립하여 현재까지 의약품을 제 조 판매하는 중견기업으로 강원도 횡성공장 및 향남공장에서 정제, 경질캡슐제, 연질캡슐제, 연고제, 주사제, 플라스타 (파스) 등 150여 품목의 제품을 생산 판매하고 있습니다. 꾸준한 R&D 투자를 통해 경구용 항암제 (DHP107)의 성공적인 임 상시험 완료와 약물전달시스템 (DDS) 기술을 활용한 전문의약품용 패치형 제품을 비롯한 고부가가치 신제품 개발에 역량을 집중하고 있습니다. “생명력의 극대화, 인간다움의 추구, 긍지와 베품”이라는 사훈과 기 업이념을 실천하고, 주주중시의 경영과 함께 좋은 의약품 개발에 최 선을 다하며 미래 가치를 향상시키는 기업입니다. 110 111 O25 G40 DAE YOUNG FOODS CO, LTD. Daegu-Gyeongbuk Medical Innovation Foundation 대영식품(주) CEO ADD TEL FAX E-MAIL URL D47 Jong Rok, Lee 이종록 32 Geum gu 4Gil, Bo eun-eup, Bo eun-gun, Chung cheng buk-do, South Korea 82-2-409-6900 82-2-409-6300 [email protected] http://www.daeyoungfoods.co.kr 대구경북첨단의료산업진흥재단 CEO ADD TEL E-MAIL URL DAEJEON TECHNOPARK Daewon Pharm.Co., Ltd. (재)대전테크노파크 대원제약 CEO You Seung Kim 김유승 701-310, 88, Dongnae-ro, Dong-gu, Daegu, Korea 82-53-790-5114v53-790-5189 [email protected] http://dgmif.re.kr http://medivalley.re.kr ADD TEL FAX E-MAIL URL E E X H I B I T S E X H I B I T S Chewing Gum Items (sugarless and functional), Promotion exhibition Compressed Candies (Breath Freshener) 대구경북첨단의료산업진흥재단 및 대구경북첨단의료복합단지 홍보 자료 츄잉껌류 및 캔디류 I N T R O D U C T I O N I N T R O D U C T I O N 1984년 8월 설립된 대영식품 (주)은 꾸준한 발전을 거듭하여 현재 ※Contribution to Korean medical industry by fostering 충청북도 보은군에 위치한 제1, 2, 3공장 (2013년 4월 준공) 및 연구 Medivalley as a global medical R&D hub. Medivalley 개발실에서 껌류, 초콜릿가공품, 캔디류를 생산하여 할인점, 편의점, is a medical cluster that is being created as a way of 특수유통에 NB제품 및 PB제품으로 공급 하고 있으며, 수출을 통하여 developing new, high-tech medicines and medical 해외시장에서도 제품의 품질을 인정받고 있는 강소 기업입니다. equipment. 좋은 환경에서 안전한 제품이 생산된다는 신념아래 ISO9001 및 HACCP (2011년 8월) 인증을 획득하였으며, 자체 냉장 창고를 운영 하여 보다 신선한 제품을 위한 품질관리에 최선을 다하고 있습니다. 특히 최근에는 바이오테크닉을 결합한 여러가지 형태의 기능성 제품 개발에 박차를 가하고 있으며, 자사 브랜드인 "SWEETORY"를 통한 국내 및 해외시장 개척에 더욱 정진하고 있습니다. 현재 대영식품 (주) Main Category인 Gum류 시장 규모는 2003 년이후 자일리톨껌 위주의 기능성 제품 운영으로 2, 300억-2, 400 억 수준의 매출을 유지하고 있으며, 자사는 철저한 시장 세분화 전 략으로 이마트 PL제품과 코스트코코리아등 국내 주요 Channel 및 Account에 판매중에 있으며, 국내 유일 일본 껌시장 개척을 통해 연 간 100억이상의 껌 매출을 달성 (저스코, 무지등)하고 있습니다. 자사의 주력 제품군인 껌류에서는 아직 트랜드 변화 및 컨셉 차별화 포인트가 지지 부진하여, 자사가 기획하고 2009년 런칭한 "이마트 졸 음깨는껌" 출시로 기능성 시장의 리딩 구현이 가능하다고 봅니다. 또한 2011년 "이마트 천연치클껌" 과, 2012년 껌의 Long -Lasting 및 츄잉성 강화 제품 (진라임스타일, 아로마틱스타일)을 국내 시장 및 수출 시장에 런칭하여 매출 증가에 기여 하고 있습니다. 이번 "바이오 코리아 2013"에 기능성 CONCEPT을 응용한 츄잉껌 6 종 (졸음깨는껌, 화이트닝, OUR VITA, 니코프리, 에너지업, 후레쉬 브레스)과 기능성 TABLET 7종 (OUR VITA VITAMINE-A, B, C, D, E, 칼슘, 루테인)을 출품하여, 기능성 소재의 제형 변화에 대한 고객의 소구 정도 및 건강기능식품군으로의 확대성을 통한 신성장 동력을 창 출할 기회로 보고 있습니다. 112 ※대구경북첨단의료복합단지 (Medivalley)는 국가 주도의 프로젝 트로 신약과 의료기기 산업을 전략적으로 육성하기 위해 조성되는 첨단의료산업 클러스터입니다. DGMIF (대구경북첨단의료산업진흥재단)은 Medivalley의 성공 적 조성 및 발전을 위해 설립된 연구지원기관입니다. E36 Park Jun-byeong 박준병 305-811 대전시 유성구 유성대로 1662 82-42-930-2880 82-42-930-2889 [email protected] http://www.daejeontp.or.kr/english/index.php X H I B I T CEO ADD TEL FAX E-MAIL URL S I N Baek, Seung Ho/ Baek, Seung Ryel 백승호, 백승열 386, Cheonhodaero, Sungdong-gu, Seoul, Korea 82-2-2204-6926 82-2-498-9151 [email protected] http://www.daewonpharm.com/en T R O D U C T I O N Completed product and base material GMP medicine and Since the establishment in 1958 with a founding idea of medical supplies sample and PR (public relations) catalog “realization of human health”, Daewon Pharm. Co., Ltd. etc. has made the best efforts for human health and happiness through manufacturing and providing specialized 완제 및 원료 GMP 의약품 샘플 및 홍보 카달로그 등 medicines. We produce reliable and safe medicines by securing world-class manufacturing facilities and superior R&D capabilities. With its first export to Vietnam in I N T R O D U C T I O N 1994, Daewon Pharm. Co., Ltd. has made eye-opening Nano and bio businesses by establishing infrastructure and achievements of exports. Now, we export out products clusters in the functional nano materials and bio industries. to 35 countries including major Asian countries such as The bio and nano industries are supported through joint China, Latin America, Middle East, CIS, and Africa. Daewon Pharm. Co., Ltd. is exporting about 50 products and is R&D, education/training and business networking. expanding its export volume with products such as Pelubi 나노소재 및 바이오산업의 인프라와 클러스터 구축을 통해 나노 및 tablet, a new chemical entity, and Oramin Capsule, multi바이오 관련기업을 지원하는 기관입니다. 공동연구개발, 교육훈련, vitamin supplement with Korean Ginseng. 기업 간의 네트워크 등을 주도함으로써 바이오나노산업의 거점이 되 겠습니다. 대원제약은 1958년 ‘인류건강의 실현’이라는 창업이념을 바탕으로 설립되어 창업초기부터 현재까지 전문치료제만을 생산, 공급함으로 써 인류의 건강과 행복을 위해 최선을 다해 온 기업입니다. 세계적인 수준의 생산시설과 우수한 R&D 역량을 보유하고 있으며, 현재 아시 아 주요국가와 중남미, 중동, CIS, 아프리카 등 약 35개국에 의약품 을 수출하고 있습니다. 대원제약은 순환기계, 호흡기계 등 모든 치료 영역에 사용할 수 있는 전문치료제를 생산하고 있습니다. 113 G37 Q15 P24 L10 Daewoong Pharmaceutical Co., Ltd. DAEYON CHEMICALS Co., Ltd. DAIN NATURAL Co., Ltd. Dako 대웅제약 대연화학(주) (주)다인내추럴 다코 CEO ADD TEL FAX E-MAIL URL Lee Jong Wook 이종욱 135-715, 163-3 Samsung-dong, Kangnam-gu, Seoul, Korea 82-2-550-8533 82-550-8660 [email protected] http://www.daewoong.com/ CEO 김연두 CEO ADD 69 Jersey Avenue, New Brunswick, NJ 089017 3605 USA 82-31-702-8734 82-2-3482-8761 [email protected] http://www.spectrumchemical.com ADD TEL FAX E-MAIL URL TEL FAX E-MAIL URL Hwang Incheol 황인철 130-33, Gasong-ro, Pungse-myeon, Dongnam-gu, Cheonan-si, Chungcheongnam-do, 330-913 82-2-3436-1589 82-2-421-1599 [email protected] http://www.momejon.co.kr CEO ADD TEL FAX E-MAIL URL I E X H I B I T S Chemical: URSA, Albis, Luphere, Olostar Biological: Easyef, Caretropin, Nabota E X H I B I T S Bio Chemical USP/NF, EP, BP, JP Pharmaceutical reagent HPLC / GC solvents Bio Chemical Chemical: 우루사, 알비스, 루피어, 올로스타 등 Biological: 이지에프, 케어트로핀, 나보타 등 N T R O D U C T I O I N T R O D U C H I B I T S N T R O D U C T I O N 1966년에 덴마크 의사인 Niels Harboe가 설립하였으며, 그는 임 상활용을 위한 항체의 표준화에 선구적 역할을 했습니다. 그 이래로, Dako는 체외 진단 산업의 병리학 부문에서 선구적 역할을 하며 글 health functional food 로벌 기업으로 성장해왔으며 본부를 덴마크에 두고 미국에도 진출하 였고 시약과 기기, 소프트웨어들은 100군데 이상의 시장에서 팔리고 있습니다. I N Established in 1945, Daewoong Pharmaceuticals is a leading pharmaceutical company in South Korea, which maintains the No. 1 position in prescription drug market domestically and also has a steady presence in East Asia, as a result of our strong marketing and sales division. With $1.3 billion USD group revenue, and over 2, 000 employees, we have built a strong internal core competency for new drug development and cultivated valuable collaborations, not only regionally, but also globally. Aiming to become a global healthcare company, Daewoong has broadened international operations by strategically establishing branch offices throughout Asia and the United States, and research centers in China and India, besides Korea. X 건강기능성식품 외 USP/NF, EP, BP, JP 약전용 시약, HPLC / GC 고순도 용제 I E Lars Holmqvist Produktionsvej 42 DK-2600 Glostrup Denmark 45-4485-9500 45-4485-9595 [email protected] www.dako.com T I O N Spectrum manufactures and distributes 15, 000 fine chemical products and 2, 000 USP/NF, BP, EP, JP, FCC grade products. The California and New Jersey plants are also FDA registered drug establishments and operate under current Good Manufacturing Practices (cGMP). 1971년 미국 캘리포니아 주에 설립되었으며 15, 000여 종의 정밀 화학 제품과 2, 000여 종의 USP/NF, BP, EP, JP, FCC grade 제품 은 제약, 식품 업체의 개발, 생산에 널리 사용되고 있습니다. N T R O D U C T I O N DAIN NATURAL Co., Ltd. performs health food research, distribution, manufacturing. Business: New functional food discovery, analysis and efficacy evaluation DAIN NATURAL Co., Ltd. was exhibiting products (The Root’s omega-3; ginseng oil-containing, Ginkgo onion juice; omega-3 containing) (주)다인내추럴은 건강기능식품 연구, 유통, 제조 등 건강기능식품 전 반적인 분야에 걸쳐 활발한 활동을 하고 있는 업체로 새로운 식품소 제를 탐색, 분석, 효능평가 하는 등의 노하우를 보유하고 있어 건강기 능식품 시장에서 차별성 있는 기술과 제품 개발에 매진하고 있습니다. (주)다인내추럴에서는 인삼오일이 함유된 뿌리담은 오메가-3와 오메 가-3가 함유된 은행잎 담은 양파즙 제품을 출품하였습니다. cGMP 요구에 부합되며 미국 FDA와 ISO9001:2008 인증 통과 제 품은 고객이 원하는 최상의 품질을 유지하고 있습니다. 대웅제약은 국내 상위 제약사 중 하나로 영업력과 마케팅력을 바탕 으로 처방 시장에서는 1위를 차지하고 있습니다. 중국, 베트남, 필리 핀, 태국, 인도네시아 등의 아시아 국가에서 해외 지사를 운영 중이 며, 그 외의 많은 국가와도 케미컬, 바이오 의약품, 의료기기 등을 가 지고 해외 사업을 활발히 하고 있습니다. 114 115 D40 G47 무재선충)을 방제하기 위한 약제의 개발을 진행하고 있으며, 현재 중 국 황산지역에서 최종 필드 테스트를 진행중입니다. 두번째로, 탈모를 방지하고, 발모를 유발하는 신규 물질을 개발중입 Dbio.Inc (주)대덕바이오 CEO ADD TEL FAX E-MAIL URL Sung Chang-Keun 성창근 #411, Agriculture B&B Center, Chungnam National University, Gung-dong, Yusung-gu, Daejeon, Korea 82-42-821-6722 82-42-822-2287 [email protected] http://www.dbio.co.kr 니다. 현재 개발된 신규물질 (Grd301)은 인삼으로부터 발견한 물질 로서, 기존 발모제보다 그 성능과, 안정성이 우수합니다. 현재 임상시 험 중이며, 대한민국 내에서는 Hair Tonic과 Hair Shampoo의 형 태로 제품을 출시하였습니다. 세번째로는, 양파, 마늘, 멜론 등 박류 식물의 뿌리에 기생하는 뿌리 혹선충 방제약제의 개발입니다. 이는 천연물로부터 추출해낸 물질을 주원료로 생산되며, 뿌리혹선충을 방제하고 토양의 지질을 개선하여 작물 생산성을 친환경적 (화학농약이 아님)으로 증대시킵니다. M34 Darae Law & IP firm 특허법인다래 CEO ADD TEL FAX E-MAIL URL X H I B I T S Functional Food Functional Rice Hair Shampoo & Tonic N T O D U C T I O N DBIO, Inc. is a Bio-venture company established in 2, 000. Our company is founded by Chungnam National University professors. We are searching and marketing the new bio materials through the unique R&D model. Twenty researchers are the mainly focusing three different topics. Firstly, how to protect pine tree from the pandemic pine wilt disease in Asia and Europe. This technology is now field testing in the Mt. Whang of China. Secondly, how to activate the epidermal hair follicle cell for bald peoples? Identified compounds (Grd301) are now in the stage of preclinical phase, also in the market as a hair tonic. Thirdly, root nematode could be easily controlled in onions, pepper, garlic farming. This company is now very success in marketing with this cash cow products. We are now very much interested in introducing to international markets. 주식회사 대덕바이오는 2000년에 설립한 국립충남대학교 교수창업 바이오-벤처기업입니다. 당사는 특별한 연구개발모델을 통해 신슈 바이오소재를 끊임없이 탐 색하고, 개발하고 있습니다. 20여명의 전문연구원들이 각기 다른 3 가지 주제를 가지고 연구를 수행중입니다. 첫째로, 아시아와 유럽에 걸쳐 널리 발병중인 소나무시들음병 (소나 116 H I B I T CEO ADD TEL FAX E-MAIL N T R O E X H I B I T S M 34 I D Dr. K. Vijay Raghavan Ministry of Science & Technology, Block 2, 7th floor, CGO Complex Lodhi Road, New Delhi 110003, India 91-11-24365972 91-11-24362884 [email protected] http://www.dbtindia.nic.in S Daraelaw Brochure Introduction of BT technology I R X 다래 회사 소개 기술이전 대상 기술 홍보자료 건강보조식품 기능성 쌀 기타 화장품 I Seung-Moon Park 박승문 1 35-080 10th, KIPS, 647-9 Yeoksam-Dong, Gangnam-Gu, Seoul 82-2-3475-7701 82-2-3475-7778 [email protected] http://www.daraelaw.co.kr/ URL E E DEPARTMENT OF BIOTECHNOLOGY (Government of India) U C T I O N Darae is the 1st IP specialized firm in korea. We strategically approach every issue with a consideration of not only short term consequence, but also contractual, regulatory and any potential risks. Every matter is thoroughly handled by an integrated team of attorneys, technical advisers and supporting staffs. The final review of documents by partners and senior associates ensure our clients succeed. Comprehensive one-stop service: A complete service from filing of application to resolving of disputes in relation to IP Rights of our clients. The industry and medial recongnize DARAE’s excellence in the area of IP. Best IP law firm by chamber & partners (Asia), 2008, 2009, 2010, 2012. 다래는 특허법원 판사 출신 변호사, 특허심판원 심판관 출신 변리사 중 심으로 설립되었으며, 2008~2012년 5년 연속으로 Chambers Asia 에서 국내 최고의 지적의 지적재산권 전문 로펌으로 선정되었습니다. 사업범위는 특허출원 부터 R&D 기획단계에서의 특허전략, 특허맵, 선행기술조사, 대학 기업 보유특허평가 및 자산실사, 등의 IP 컨설팅, 기술사업화 및 마케팅 활동 뿐아니라 지적재산권의 법률 분쟁해결 까지 지적재산권 관련한 전부분야를 포함하고 있습니다. N T R O D U C T I O N The Department of Biotechnology (DBT), under the Ministry of Science and Technology was established in 1986 to give a new impetus to the development of the field of modern biology and biotechnology in India. The department has made significant achievements in the growth and application of biotechnology in the broad areas of agriculture, health care, animal sciences, environment, and industry. The department has more than 14 autonomous institutes. The impact of the biotechnology related developments in agriculture, health care, environment and industry, has already been visible and the efforts are now culminating into products and processes. More than 5000 research publications, 4000 post-doctoral students, several technologies transferred to industries and patents filed including US patents. Department of Biotechnology (DBT) has been interacting with more than 5, 000 scientists per year in order to utilise the existing expertise of the universities and other national laboratories. Necessary guidelines for transgenic plants, recombinant vaccines and drugs have also been evolved. ※ space included, within 150 characters 특히, BT 분야는 미래창조부의 R&D 우수성과물을 대상으로 기술사 업화 과제를 진행하여 성공적인 성과를 도출한 경험을 보유하고 있 습니다. 117 E40 G30 Department of Industrial Pharmaceutical Science, School of Pharmacy, SungKyunKwan University ADD TEL FAX E-MAIL URL E X H I Dongguk Medical Device Innovation Center 동화약품 동국대학교 의료기기 개발촉진 센터 ADD Eui-Kyung Lee 2066 Seobu-ro, Jangan-gu, Suwon, Gyeonggi-do 440-746, Korea 82-31-299-7786 82-31-292-8800 [email protected] http://pharmind.skku.edu/index.asp B I T S Video contents and PR leaflet for graduate school of industrial pharmaceutical science at SungKyunKwan University L32 DONG WHA PHARM CEO 성균관대학교 제약산업학과 CEO A10 TEL FAX E-MAIL URL Je Hwa Park 박제화 5 Soonwha-dong, Joong-gu, Seoul Korea 82-2-2021-9300 82-2-778-2336 [email protected] http://dong-wha.co.kr Kim Sung Min 김성민 425 Industry & Academy Collaboration Foundation Dongguk Univ. 814 -9 Siksa-dong, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea 82-31 961 5605 82-31 961 5610 www.dmicweb.or.kr CEO ADD TEL FAX URL E X H I B I T I 자보플록사신, 까스활명수 N T R O D U C T I 두바이 제약 및 제약기기 전시회 & 컨퍼런스 CEO ADD TEL FAX E-MAIL URL Abdul Salam Al Madani #504, 503 Nonhyun-ro Gangnam-gu Seoul Korea 82-2-6000-4718 82-2-6499-1027 [email protected] http://www.duphat.ae S Zabofloxacin, Gas Whal Myung Su-Q I Dubai International Pharmaceuticals and Technologies Conference and Exhibition O N Established as the first Korean pharmaceutical company in 1897, Dong Wha remained committed to bringing 성균관대학교 제약산업특성화대학원 소개 동영상 및 홍보 리플렛 happiness to customers and employees with its management focucing on happiness of people. R&D Pipeline I N T R O D U C T I O N Quinolones Antibiotics Zabofloxacin (DW224) - Phase III The graduate school of industrial pharmaceutical science at Diabetic Nephropathy DW1029 - Phase II SKKU was established by Ministry of Health and Welfare’s support to accelerate new drug development and global 동화약품은 1897년 대한민국 최초 제약기업으로 설립된 이래 인간 expansion of domestic pharmaceutical companies in 2012. 행복 경영을 통하여 고객 및 직원 모두의 행복을 추구하여 왔습니다. The graduate school has been focusing on educating and 연구소는 1973년 설립되어 까스활명수, 후시딘연고, 판콜 등 많은 training the elite who can lead the” age” of pharmaceutics. 신제품을 개발하였으며, 2010년 현재의 최첨단 연구소를 경기도 용 To achieve this, multidisciplinary(pharmacy, medicine, 인에 신축, 이전해 연구 기반을 한 차원 높이고, 신약과 신제품 연구 technology, business and law) convergent curriculum 에 매진하고 있다. 세계 최초 방사성 간암 치료제 '밀리칸주' 의 신약 for convergent education of 3 tracks(Regulatory affairs, 개발을 성공하였으며, 현재는 퀴놀론항균제 (DW224), 당뇨병성 신 Pharmacoeconomics and Management of pharmaceutical 증 치료제 (DW1029)의 개발을 통해 세계적으로 인정 받을 수 있는 technology) based on practices according to sciences and 동화의 두번째, 세번째 신약이 탄생 될 수 있도록 최선의 노력을 다 regulations has been developed and operated. N T R O D U C T I O N E X H I B I T The Dongguk University Medical Device Innovation Center DUPHAT 2014 uses a web-based project management system called ‘I-Portal’ and seeks to discover growth tools for the medical 중동 유일의 제약 및 제약기기 전문전시회 DUPHAT 소개 device industry, such as surgical instruments, electronic devices, communication network based U-health devices I N T R O D U C T I and medical materials. S O N DUPHAT – Dubai International Pharmaceuticals and Technologies Conference and Exhibition has evolved to be one of the most important annual pharmaceutical event (Surgical Instruments), 전기전자 의료기기 (Electronic devices), since its inception in 1995.The event is held under the 네트워크 통신망을 기반으로 하는 유헬스 의료기기 ( U-health patronage of H.H. Sheikh Hamdan Bin Rashid Al Maktoum, devices), 의료용 재료 (medical materials) 등 미래 의료기기 산업 Deputy Ruler of Dubai, Minister of Finance, UAE and 의 성장 동력 아이템을 발굴하기 위해 노력하고 있습니다.). President of Dubai Health Authority 동국대학교 의료기기 개발촉진센터는 ‘I-Portal’이라는 웹기반의 프 로젝트 관리 시스템을 갖추고, 수술에 사용하는 전문 시술용 기구 중동의 최대 제약 및 제약기기 전문전시회 DUPHAT에 많은 한국기 업들의 관심과 성원 부탁드립니다. 하고 있습니다. 성균관대학교 제약산업특성화대학원은 국내 제약기업의 신약 개발 및 글로벌 진출을 촉진하기 위해 2012년에 보건복지부 지원으로 설 립되었다. 제약산업 핵심인력 양성을 위해 의약품인허가/경제성평 가/제약기술경영 등 3개 트랙의 이론/실무 융합형 교육을 위해 다학 제적(약학, 의학, 공학, 경영학 등) 교육 커리큘럼을 개발하여 운영하 고 있다 118 119 L10 L22 L24 Ecron Acunova A/S Embassy of Canada 에크론 아쿠노바 주한캐나다대사관 CEO ADD TEL FAX E-MAIL URL Klaus D. Wiedey Agern Allé 13 DK-2970 Hørsholm Denmark 45-4516-8800 45-4516-8801 [email protected] www.ecronacunova.com ADD TEL FAX E-MAIL URL 1, Jeongdong-gil(Jeong-dong), Jung-gu, Seoul 2 100-120 Korea 82-2-3783-6000 82-2-3783-6147 [email protected] www.korea.gc.ca L21 Embassy of Poland Trade & Investment Promotion Section N T R O D U C T I O N 국제적인 임상시험수탁기관(CRO)이며, 덴마크, 스칸디나비아, 서유 럽뿐만 아니라 동유럽에도 그 지점을 보유하고 있으며 아시아에 국 가 및 미국에도 진출하였습니다. Phase I에서 Phase III, BA/BE와 PK/PD연구뿐만 아니라 임상연구에 구체적이고 다양한 경험을 토 대로 Scandinavian 대학시설과 다른 대형 병원들과 다양한 공동연 구를 하고 있습니다. 주한네덜란드 대사관 주한 폴란드대사관 무역/투자 진흥부 CEO ADD TEL FAX E-MAIL I Embassy of the Kingdom of the Netherlands URL CEO Mr. Karol Peczak D ongkyung B/d 4th F, #604, Hannam-dong, Yongsan-gu, Seoul 82-2-3785-2471~2 82-2-797-0853 [email protected] http://seoul.trade.gov.pl ADD TEL FAX E-MAIL URL E E X H I B I T S Information Paul Menkveld 10F Jeongdong Bldg., 15-5 Jeong-dong, Jung-gu, Seoul, 100-784 82-2-311-8600 82-2-311-8650 [email protected] http://southkorea.nlembassy.org/ X H I B I T S General introduction to Dutch life sciences, one of the Netherlands’ 10 top sectors, including Leiden Bio Science Park 정보 네덜란드의 생명과학 분야 선두주자인 라이덴 바이오 산업 단지를 비롯한 바이오 산업 전반에 대한 소개 I N T R O D U C T I O N Our main mission is to strengthen business relations between Poland and Korea. You can contact us if you look for the best investment destination and reliable suppliers. We offer the following information. -T he information on the market and industry (the information on Polish economy and each industry, fairs/ expositions -Opportunity of the investment in Poland -Business climate in Poland (regulations related to foreign companies, privatization of the state-owned company, taxation, labor market etc.) -Contact points of producers, distribution companies, associations in Poland. -C ontact points of Special Economic Zone (SEZ), technology and industrial park etc. I N T R O D U C T I O N Embassy of the Kingdom of the Netherlands makes an effort to strengthen business relations and promote cooperation in science and technology between Korea and the Netherlands. We have free service of providing from general information to customized consultation for the companies who are interested in extending their business to the Netherlands. For research organizations and universities, we hold a joint seminar and help to arrange meetings for R&D matchmaking. We try to connect our projects with the 9 top sectors designated by the Dutch government and life life-sciences are one of them. Leiden Bio Science Park is to be the focus of the exhibition. Leiden Bio Science Park is the leading life sciences cluster in the Netherlands and ranks among the top five most 주한 폴란드대사관 무역/투자 진흥부의 주요 업무는 양국의 비즈니 successful science parks in Europe. It is fully dedicated to 스 관계를 강화하는 것입니다. 최고의 투자처를 찾고 계시거나 신뢰 biomedical life sciences and offers opportunities for both 할 수 있는 공급업체를 찾고 계신다면 저희에게 연락을 주시기 바랍 start-ups and established companies. 니다. 저희는 다음과 같은 분야와 관계된 정보를 제공하고 있습니다. -시장 및 산업정보 (폴란드 경제 및 각 산업분야에 관한 정보, 폴란 드 전시회 및 박람회 정보) -폴란드 투자기회 (투자 인센티브 시스템 등) -폴란드 비즈니스 환경 (외국인 비즈니스와 관련된 법률, 공기업의 민영화, 세법, 노동시장 등) 주한 네덜란드 대사관은 한국과 네덜란드 양국 간 비즈니스 관계를 강화하고, 과학기술 분야의 협력을 증진시키기 위해 노력하고 있습니 다. 특히 네덜란드 정부가 지정한 9개의 Top sector에 역량을 집중 하고 있는데, 생명과학도 그 중 하나입니다. 이번 전시는 유럽 지역에 서 가장 성공적인 5대 첨단 과학 단지 중 하나로 손꼽히는 라이덴 바 이오 산업단지를 중심으로 구성됩니다. -폴란드 제조업체, 유통업체 및 협회 등의 연락처 -특별경제구역 (SEZ), 기술 및 산업 파크 기타 폴란드 기관 연락처 120 121 A35 B25 B36 E10 Encopharm EU Gateway Programme Korea Office Eubiologics Co., Ltd. Farming association corp. BBKO 엔코팜 EU 게이트웨이 프로그램 사무국 유바이오로직스 영농조합법인 비비코 CEO ADD TEL FAX E-MAIL URL KIM KYUNG SOO 김경수 7 3-28, Singok2-dong, Daeheung Bldg 2nd F1 Uijeongbu-si, Gyeonggi-do, Korea 82-2-566-5772~3 82-2-555-0752 [email protected] http://www.encopharm.net CEO ADD TEL FAX E-MAIL URL Mr. Taesung Kim 김태성 (135-090) 5F., Trade Tower, World Trade Center, Samsung-dong, Gangnam-gu, Seoul, Korea 82-2-6000-5208 82-2-6000-6702 [email protected] http://www.eu-gateway.kr CEO ADD TEL FAX E-MAIL URL Baik Yeong Ok 백영옥 200-160 BioVenture Plaza 3rd Floor 3-2, 3-3 56 Soyangang-ro, ChunCheon-si, Gangwon-do, Korea 82-33-258-6131 82-33-258-6135 [email protected] http://eubiologics.com/ CEO ADD TEL FAX E-MAIL URL E X H I B I T S Translation Services Company for Bioindustries 바이오 산업 번역교정 전문회사 I N T R O D U C T I O N ENCO-PHARM is a translation company specialized for bio and technological industries. The quality of ENCO-PHARM’s translation service for clinical trial-related documents has recently been recognized. We have signed contracts for translation services with 200 institutions, including worldclass CROs such as Quintiles, CMIC Korea Co., Ltd., LG Life Sciences Ltd., Donga ST, Daewoong Pharmaceutical Co., Ltd., and Pharmabcine. ENCO-PHARM has been signing contracts with leading institutions in Korea for the past five years, thanks to the support from a number of our clients, which has helped us accumulate a rich experience in translating different types of documents in a wide variety of specialized fields. When you need consulting for translation services in the bio and technological industries, please let ENCO-PHARM help you. All the members of ENCO-PHARM will always do our best to improve our services. Thank you. E X H I B I T S The 2014 Exhibition promoting business cooperation between EU and Korean companies, will take place at the COEX InterContinental Hotel Harmony Ballroom on 11 and 12 March. Through the Programme, Korean visitors may expect to get followings: •Make new contacts and strengthen the relationships with EU companies •I d e n t i f y p o t e n t i a l s u p p l i e r s , s u b c o n t r a c t o r s , representatives, importers and distributors •Discover current & future trends in the EU markets 2014년 3월 11일 (화)~12 (수) 코엑스 인터컨티넨탈 호텔 하모 니볼룸에서 개최되는 ‘2014 헬스케어/의료기술 전시상담회 (2014 Healthcare & Medical Technologies)’는 기술적, 재정적으로 그 적합성을 검증 받은 EU기업들의 우수한 제품과 기술을 국내 관련 기 업들에게 소개하고 일대일 비즈니스 상담을 진행합니다. 주요 전시분 야는 유럽 재활의학/건강관련기기, 임상/검사용기기, 진찰/진단용기 기, 의료용품, 의료정보시스템, 치과관련기기, 병원설비 등 입니다. I N T R O D U C T I O I N T R O D U C T I O Ryu Jea-Young 유재영 2 26 Ocean Bio Center, Gangneung Science Developmentt Foundation, 641-22Saimdang-ro, Gangrneung-si Gangwon-Do 82-33-643-0226 82-33-648-0226 [email protected] http://bbko.kr N EuBiologics Co., Ltd. is a biopharmaceutical company supplying a wide range of CRMO (Contract Research and Manufacturing Organization) services for biopharmaceuticals and safe and effective vaccines with the goal of improving global public health. We provide customized CRMO services in accordance with clients’ project stages including cell line development, manufacturing process development, GMP production and validation as well as regulatory support. (주)유바이오로직스는 바이오의약 제품개발과 관련해 세포주 제 작, 제조공정 및 분석법의 개발과 밸리데이션, 비임상 및 임상시험 용 제품의 GMP 수탁생산 등에 대한 통합적인 서비스 (CRMO, Contract Research and Manufacturing Organization)를 제공 하는 바이오 벤처기업이입니다. 유바이오로직스의 CRMO서비스를 활용하면 다음 6가지의 효과를 기대할 수 있습니다. 시설투자 절감, 다수의 임상개발과제 진행시의 비용 절감, 개발업무 E X H I B I T S Leached Tea 오죽잎차 I N T R O D U C T I O N organic ojuk tea produced in ojukheon of f Gangneung, a pristine area. Non-caffeine organic tea made with clean baby leaves 청정 강원 강릉 지역의 오죽헌 주변에서 자생, 재배하는 오죽잎으로 차를 제조하는 회사로 2011년 창업하여 잎차 이외에 같은 재료로 분말, 환, 엑기스 등을 제품화. 전국 최초로 오죽잎의 제품화에 성공. 집중을 통한 연구생산성 향상, 선진 GMP 운영 및 실사에 대한 부담 경감, 시장출시 기간의 단축, 상업화 및 시장예측 실패에 따르는 위험 최소화. N Launched in Korea in 2009, the EU Gateway Programme is funded and managed by the European Union. The 저희 엔코팜은 바이오기술 산업분야의 특화된 번역전문회사이며, 최 Programme provides support for small and medium-sized 근 임상시험 번역의 우수한 품질을 인정받아 세계적인 CRO인 퀸 EU companies with advanced products and technologies to 타일즈, (주)시믹코리아, LG생명과학, 동아ST, 대웅제약, (주)파멥신 develop business partnerships with Korean companies. 등 200개 기관과 약정을 맺고 번역서비스를 진행하고 있습니다. 지 난 5년동안 많은 고객들의 도움으로 국내유수의 기관들과 약정을 맺 EU 게이트웨이 프로그램 (EU Gateway Programme)은 유럽연합 어왔으며, 그로 인해 다양한 수많은 특수분야 문서등 을 번역해왔습 (The European Union)의 예산으로 운영되는 비즈니스 협력 프로 니다. 바이오 및 기술산업의 전반적인 번역과 관련하여 상의하실 사 그램으로, 국내 헬스케어 및 의료기술분야 기업과의 비즈니스 관계를 항이 있으시면 엔코팜을 찾아주시기 바랍니다. 앞으로 저희 EncoPharm의 직원들과 더불어, 최선을 다하는 모습과 늘 향상되는 모습 을 보여드리겠습니다. 감사합니다. 개척하고 발전시키고자 하는 EU기업 지원을 목적으로 합니다. 122 123 B10 K30 Q20 Fermentec Fit.Life Inc. 퍼멘텍 (주)휘트닷라이프 CEO ADD TEL FAX E-MAIL URL Lee, Heung Yong 이흥용 1108-13, Namchon-ri, Oksan-myeon, Cheongwon -gun, Chungcheonbuk-do, Korea 82-43-231-3500 82-43-218-6073 [email protected] http://www.fermentec.co.kr/eng CEO ADD TEL FAX E-MAIL URL E X H I Fermenter, Bio- reactor B I T Yoosuk Jung 정유석 F 4 0 5 , R & D B C e n t e r, 1 0 5 G w a n g g y o - ro , Yeongtong-gu, Suwon, Gyeonggi-do, Korea, 443766 82-31-888-5144 82-31-888-5145 [email protected] http://www.fitdotlife.com R25 Foundation of Research and Business, Chungnam National University Gangneung Science Industry Foundation Marine Bio Industry Support Center 충남대학교산학협력단 (재)강릉과학산업진흥원 해양바이오사업단 Dongil, Seo 서동일 (305-764) 대전광역시 유성구 대학로 99 충남대학교 산 CEO ADD ADD 학연연구본부 TEL FAX E-MAIL URL 82-42-821-7173 82-42-821-8710 [email protected] http://tlo.cnu.ac.kr/ TEL FAX E-MAIL URL S E X H I B I T S Fitmeter (Physical Activity Monitor) E X H I B I T E I N T R O X H I B I T S Marine Bio Products, Functional Foods 휘트미터(활동량측정기) I Chung Sang Key 정상기 Gangneung Science Industry Park, Saimdang-ro 641-22, Gangneung-city, Gangwon Province, 210340, Republic of Korea 82-33-650-3352 82-33-648-2162 [email protected] http:// www.gsif.or.kr S 시제품, 판넬 등 발효기, 미생물 반응기, 배양기 D U C T I O N We provide technology-intensive devices and services conducive to promotion of health with pleasure, pursue long-term mutual interests for all the parties concerned and establish the corporate culture for encouraging experts and creating synergy systematically. Our main product is a physical activity monitor(Fitmeter) which is world's best accuracy level and support exercise program of American College of Sports Medicine the world's first. (주)휘트닷라이프는 사람들이 즐겁게 건강을 증진시킬 수 있는데 도움 이 되는 기술집약적 제품과 서비스를 제공하고, 모든 관계인들의 장기 적 상호 이익을 추구하며, 전문가들이 자신의 장점을 키우고 활용하면 서 조직적으로 시너지를 일으킬 수 있는 기업문화를 확립합니다. 우리의 주요 제품은 활동량 측정기인 휘트미터로 임상검증된 세계 최고 수준의 정확성을 지녔으며, 활동량 측정기 중에서는 세계 최초 로 미국스포츠의학협회(ACSM)의 질환별 운동 프로그램을 연동했습 니다. 124 CEO N T R O D U C T I O N 해양바이오 기능성 제품 패혈증 예방 및 치료용 약학 조성물 방광압 진단 키트 기술 I N T R O D U C T I O N Gangneung Science Industry was established in 2007 sponsored by the Ministry of Knowledge Economy, Ministry of Education, Science & Technology, the Gangwon province and Gangneung city Major Businesses - Attract promising companies located in other regions - Post-BI (Business Incubator) / TBI (Technological Business Incubating) projects - Joint R&D and technology transfer projects - Information exchange projects, business matching / exchange programs. -Education & Training Project / Business Support Project -Management and support service -Build-up&develop Gangneung Science Industry complex 강릉과학산업진흥원 해양바이오사업단은 강원영동권 해양바이오 제 품 개발 및 고부가가치 창출 시스템을 구축하고 해양바이오기업체의 단기적 고도기술 접목 및 상품화를 위한 장비 구축 296종 355대를 구축하고 해양바이오지원센터, 벤처공장, 산업단지를 연결하는 기업 지원 선순환적 체제를 구축하고 있다. 특히 현장애로 기술지도 및 시 제품 공동연구개발을 통한 제품 품질 강화와 혁신체제 및 네트워크 구축으로 지역경제 활성화에 일익을 담당하고 있다. 125 R25 D41 J10 R19 GinSeng GL Biotech Inc. Green Cross Corporation (주)진생 (주)지엘바이오테크 녹십자 CEO ADD TEL FAX E-MAIL URL Hong youg gi 홍용기 BI Center 110, 599 Daewon Univ. Sinwol-dong, Jecheon-si, Chungvuk, Korea 82-43-652-7350 82-43-653-7350 [email protected] http://gscodes.com CEO ADD TEL FAX E-MAIL URL E X H I B I T Kim Won-Dae 김원대 N 506 Industry-Academy Cooperation Center, Pai-Chai University #1337, Gwapyung-dong, Yuseong-gu Daejeon, Korea 82-42-671-4455 82-42-671-4457 [email protected] http://www.glbt.co.kr S ADD TEL FAX E-MAIL URL X H Apply sweet herb syrup, Tea for a strong man, Tea for beautiful women Healthfood, cosmetics I B I T S 건강보조식품, 화장품 Il-Sup Huh 허일섭 303 Bojeong-dong, Giheung-gu, Yongin, 446-770, Korea 82-31-260-9527 82-31-260-9408 [email protected] http://www.greencross.com X H I B I T N T R O D U C T I O N I N T R O D U C T I O ADD TEL FAX E-MAIL Soo Han Kwon 권수한 5 2 Naesoodong-ro Heungduk-gu Cheongju, Chungbuk 361-763, South Korea 82-43-261- 3666 82-43-263-3664 [email protected] www.nueris.or.kr X H I B I T S Green Cross Corporation is displaying the R&D pipeline E with the explanation of representative late stage products. Mulberry&Mulberry Leaf Mask Pack, Cosmetics, Health Functional Food 녹십자는 R&D 파이프라인 및 주요 글로벌 프로젝트의 포트폴리오를 뽕잎/오디 마스크팩, 화장품, 건강기능성식품 N we are researching herbal materials and developed products with industry-academic cooperation which are domestic Universities, research institutes, government agency and domestic individual enterprises for several years. we have Arthritis Health food, Atopic cosmetics, 황기젤리, 남다른차, She 비밀스런차, 발라먹는조청, 천년숨결 진홍삼 pimple trouble care cosmetics, Feminine hygiene cosmetics. (주)진생은 자연의 생명력을 담아 맛과 전통을 계승하는 먹거리를 만 들자는 사명으로 식품사업에 진출하였습니다. 고객의 소중한 건강을 위해 바이오 기술분야를 향한 끊임없는 연구를 통해 한국적 가치와 건강한 자연의 맛을 담은 제품들로 국민들이 안심하고 먹을 수 있는 건강한 먹거리를 만들어 갈것입니다. 천연물을 연구하는 바이오기업으로 한국에너지기술연구원, 중소기업 청, 한밭대학교, 충북대학교, 서원대학고, 대전 테크노파크, 다움코스 텍, 대화약품 등과의 산학연 연구를 통해 개발되었습니다. PCT 국제 특허 출원, ISO9001인증, 미국 FDA 등록 등을 완료하였습니다. 자 사의 제품으로는 퇴행성 관절염, 골다공증 등 관절 질환 보조 식품, 아토피성 피부 개선용 화장품, 여드름 피부 개선용 화장품, 여성 청결 또는 생리통 완화제를 개발하였습니다. 126 CEO S 전시하고 있습니다 I 충북대학교 녹색성장 누에산업 RIS사업단 URL E E 한방조청, 한방차, 한방젤리 CEO Green-Growth Silkworm-Industry Regional Innovation System I N T R O D U C T I O N Green Cross Corporation (GCC) is one of the leading pharmaceutical companies in Korea which made approximately $682 Million in revenue for the 2012 sales year. Since its establishment in 1967, GCC has pioneered in the field of biopharmaceuticals including vaccines, plasma-derivatives, recombinant proteins and therapeutic antibodies. I N T R O D U C T I O N 충북대학교 녹색성장 누에산업 RIS사업단은 누에산업관련 제품을 먹 을거리, 입을거리, 바를거리로 나누어 누에와 뽕을 활용한 누에산업 을 신성장 바이오산업으로 육성하기 위해 기술개발을 통한 지역기업 의 애로기술 및 품질고도화 지원, 마케팅 활성화 등을 수행 1967년 창립 이래 녹십자는 국내 생명공학산업을 선도해 온 대표적 인 연구개발 중심기업으로 백신, 혈액제제, 재조합 단백질 및 항체 등 바이오 의약품 분야에서 국제적인 생명공학 전문기업이다. 세계 세 번째 B형간염백신 및 세계 최초 유행성출혈열백신을 개발하였으며 최근에는 유전자재조합 A형 혈우병 치료제와 신종플루 백신을 잇따 라 개발하는 등 차별화된 노하우와 경쟁력을 확보하고 있다. 127 L36 F10 GVK Biosciences Private Limited CEO ADD TEL FAX E-MAIL URL E31 Gyeonggi Institute of Science & Technology Promotion Mr. Manni Kantipudi Plot No. 28 A, IDA Nacharam, Hyderabad- 500076. India [email protected] http://www.gvkbio.com 재단법인 경기과학기술진흥원 CEO ADD TEL FAX E-MAIL URL E X H I B I T S CRO I I N T R O D U C T I O N GVK BIO is a global Contract Research Organization (CRO) and a preferred partner of choice to over 267 global Lifescience, Cosmetic, Electronic and Fine chemical manufacturers, and research institutions. Our discovery services consist of Chemistry, Analytical, Biology, Informatics, and Custom Synthesis and Manufacturing (KFDA, USFDA, EDQM, PMDA, cGMP approved); the development services include Clinical research, Clinical pharmacology and Process R&D. N T R O D U C T I O N The GSTEP is committed to the advancement of the regional industries and economic development through research and promotion of science and industrial technologies. Our Key functions : 1.Establish and operate research and supporting facilities 2.Support the development of science and industrial technologies 3.Develop and support medical, bio and pharmaceutical industries 4.Conduct S&T policy research and develop policy implementation strategy 5.Build R&D project feedback system including performance assessment and evaluation 6.Promotion cooperation and exchanges in science and industrial technologies and provide relevant information 설립목적 : 과학 및 산업분야 기술에 관한 연구와 진흥을 통하여 지 역 산업의 고도화와 경제발전에 기여 주요기능 1. 연구 및 지원시설의 설치 운영 2. 과학 및 산업분야 기술개발 지원 3. 의료, 바이오, 제약산업 육성 및 지원 4. 과학기술정책 연구 및 추진전략 수집 5. 연구개발사업 성과분석, 평가 등 환류시스템 구축 6. 과학, 산업기술에 관한 협력, 교류, 정보지원 한 비전을 선포했으며, 현재 서울 역삼동 본사, 10개 지방사무소, 충 북 음성 공장에 750여명의 임직원이 근무하고 있습니다. 주요 전문의약품으로는 ▲당뇨병치료제 아마릴, 아마릴M, 아마릴멕 스, 가브스 ▲고혈압치료제 테베텐, 트리테이스, 트리아핀 ▲폐동맥 (주)한독 Young-Jin KIM, Churl-Joon KIM 김영진, 김철준 132 Teheran-ro Gangnam-gu Seoul 135-755 Korea 고혈압치료제 트라클리어 ▲전립선치료제 자트랄XL ▲폐질환치료 82-2-527-5114 제 닥사스, 온브리즈 ▲백신 아다셀, 뉴모 23 등이 있으며, 일반의약 82-2-527-5001 품으로는 소화제 훼스탈, 금연보조제 니코스탑, 여드름치료제 클리어 http://www.handok.co.kr/english/ CEO Park Chung-Taek 박정택 G wanggyo-ro 147, Yengtong-gu, Suwon, Gyeonggi-do 443, 270, Korea 82-31-888-6893 82-31-888-6899 [email protected] http://www.gstep.re.kr 고 ‘대한민국을 대표하는 혁신적인 글로벌 헬스케어 기업’이 되기 위 HANDOK Inc. ADD TEL FAX URL 틴 등이 있습니다. 또한 ▲진단검사의학분야의 의료기기와 시약 ▲ E X H I B I T S Company, R&D Introduction 기업 및 연구개발 소개 I N T R O D U C T I O N Handok is committed to innovation on many levels and its business has grown both through strategic partnerships with other companies as well as innovative research. Handok was founded in1954 and has been listed on the Korea Stock Exchange since 1976. The company has never recorded a deficit year since establishment. Handok grew as a joint venture with Hoechst/Aventis/ Sanofi from 1964 to 2012. Handok has also established strategic collaborations in several areas with multiple multinational pharmaceutical companies. In 2013, Handok changed its company name from Handok Pharmaceutical Co., Ltd to Handok Inc. and declared its vision to become Korea’s leading global total healthcare company. We are working to bring new products to Korea through partnerships, internal R&D, and state-ofthe art manufacturing with a global standard compliance program. Handok’s businesses mainly focus on prescription drugs along with consumer health care products, medical devices and In Vitro Diagnostics business, food supplements and medical nutrition. Handok’s flagship products include Amaryl and Amaryl M (antidiabetics), Teveten (antihypertensives), Tritace (CV protectives) and Xatral XL (BPH). Also Handok’s representative OTC products include Festal, Nicostop, and Allegra D. 건강기능식품 네이처셋 (NatureSet) ▲메디컬 뉴트리션 (Medical Nutrition: 특수의료용도식품) 사업을 하고 있습니다. 한독은 당뇨 복합치료제 아마릴 엠과 아마릴 멕스를 개량신약으로 개발하여 국내에 출시했으며, 세계로 수출하고 있습니다. 또한, 혁신 신약, 바이오 의약품, 개량신약, 의료기기 등 적극적인 연구개발 활동 을 전개하고 있습니다. 한독 음성공장은 국내는 물론 WHO, FDA 의 GMP 기준에 맞게 설 계•건설되어 KGMP, cGMP의 엄격한 품질관리 기준을 준수하고 있으며, 첨단 자동화 설비와 검증된 공정관리를 통해 국내 유수 기업 에 우수 의약품을 공급하고 있습니다. 한독은 1954년 설립 이후 훽스트, 아벤티스, 사노피 등 세계적 제약 회사들과의 협력을 통해 우리나라 제약산업의 선진화에 기여해 왔으 며, 윤리경영을 바탕으로 지속적인 혁신을 통해 대한민국 제약회사로 성장하고 있습니다. 2013년 한독약품에서 한독으로 사명을 변경하 128 129 G38 O10 HANLIM PHARM Co., Ltd. Health industry TLO council (Korea Health Industry Development Institute) 한림제약(주) CEO ADD TEL FAX E-MAIL URL JAE YOON KIM 김재윤 1656-10, Seocho-Dong, Seocho-Gu, Seoul, Korea 82-2-3489-6000 82-2-3489-6101 [email protected] http://www.hanlim.com 보건의료 TLO협의체관 (한국보건산업진흥원) CEO ADD TEL FAX E X H I B I T S DAGES CAP. LODIEN TAB. HYALURON EYE DROPS. NASATIVE NASAL SPRAY N T R O E-MAIL URL R25 HIMEDIA LABORATORIES PVT. T.D 농업회사법인(주)에이치맥스 CEO KO Kyung-hwa 고경화 1 87 Osongsaengmyeong2 (i)-ro, Osong-Eup, Cheongwon-gun, Chungcheongbukdo 363-951, KOREA 82-43-713-8273 82-43-713-8908 [email protected] http://www.khidi.or.kr HMAX Inc ADD TEL FAX E-MAIL URL E Mr. V.M. Warke A-516, Swastik Disha Business Park, LBS Marg, Mumbai 400 086, India 91-22-61471919 91-22-61471920 [email protected] http://www.himedialabs.com X H I B I T S Chemicals, Foods, Environment, Microbiological Products E D U C T I O X H I B I T S Health industry TLO council Technology Exhibition TLO : Technology licensing Office 다제스캡슐, 로디엔정, 히아루론점안액, 나자티브나잘 스프레이 I L35 N ‘보건의료 TLO 협의체’ 기술전시 TLO : Technology licensing Office As one of the leading companies in Korea, HANLIM N T R O D U C T I O N specializes in R&D and manufacturing of API/BPIs, I pharmaceutical product and has an experience in exporting KHIDI (Korea Health Industry Development Institute), as a range of products to China, the USA, Nigeria etc. the sole organization provides supports for the health industry, has inaugurated ‘Health Industry TLO Council’ in 한림제약은 한국의 선도 기업으로서, 제약분야의 기술개발, 원료 및 May, 2013. The TLO Council organizes the show case to 완제 제조를 전문으로 하고 있으며, 중국, 미국, 나이지리아 등에 다 promote the advanced technology and products of Korea 양한 의약품 수출 경험을 보유하고 있다. Health Industry at BIO KOREA 2013 exhibition. 한국보건산업진흥원은 국내유일의 보건산업 육성기관으로 2013년 5월에 보건산업의 기술사업화 활성화를 위한 ‘보건의료 TLO협의체’ 를 발족을 하여, 이번 ‘BIO KOREA 2013’ 전시회에서 협의체 기관 및 기술의 우수성을 알리고 글로벌 경쟁력을 강화하기 위한 기술전 시, 홍보관 운영. I N T R O D U C T I O N Manufacturer and exporter of microbiological products, dehydrated culture media, raw materials i.e. peptones, tryptone, yeast extract, agar agar powder for the fermentation and bulk drug manufacturing industries, tissue culture media for production of vaccine, biochemicals, laboratory chemicals, vegetable peptones, vegetable extracts, vegetable hydrolysates and infusion. We offer a full range of vegetable peptones from plant proteins which are free from BSE/TSE. Vegetable peptones can replace animal origin peptones in microbiological culture media, fermentation and food industry. Our company is a ISO, CE Mark, WHO-GMP certified company. We are exporting our products to over 127 countries around the world. CEO ADD TEL FAX E-MAIL URL E Chan-Ho Lee 이찬호 Zip 350-290, 992 WangAm-dong, Jecheon City, ChungBuk, KOREA 82-43-642-7890 82-43-642-7891 [email protected] http://www.teaterra.co.kr X H I B I T S Fermented Licorice TEA-TOX Korean RED GINSENG with Fermented Licorice. Oriental Herbal Tea Value Class 4 Set (No worries Tea, Body Line helper Tea, Clean Blood Red Tea, Body Defence Tea) Herbal Teas 6 Set (Feeling much lighter FENNEL TEA, Young & full of life PEPPERMINT TEA, Comforting CAMOMILE TEA, Black tea in South Africa ROOIBOS TEA, for ladies HERBAL TEA, for men HERBAL TEA) 발효감초 티톡스차 발효감초 홍삼차 한방 침출차 밸류클래스 4종세트 (걱정제로차, 맵시라인차, 깨끗한차, 보디가드차) 허브차 6종세트 (가벼워지는 펜넬티, 생기발랄 페퍼민트티, 편안한 캐모마일티, 남아공의 홍차 루이보스티, 여성 허브티, 남성 허브티) I N T R O D U C T I O N HMAX (Brand Name:TeaTerra) supplies almost 100 various kinds of natural and organic whole Korean herbs (treated whole herbs, fermented herbal raw herbs, infusion teas and traditional Korea teas) and other products since 2004. Our products are made to focus on gender-specific, symptomspecific and seasonal teas. All products made by HMAX (Tea Terra) meet the following principles and standards. 저희 HMAX (브랜드명:티테라)는 2004년에 설립되었으며 약 100 여 가지의 다양한 종류의 자연그대로의 유기농 한국 허브를 공급하 고 있습니다. 자연상태의 허브와 발효허브, 그리고 이런 허브와 약재를 함께 우려 낸 차 그리고 한국 전통 차 모두를 취급합니다. 저희 제품들은 특정 성별과, 특정 증상에 초점을 맞추어 만들어 지고 있으며 계절의 특성에도 맞게 만들어집니다. HMAX (티테라)의 모 든 제품들은 원칙과 기준에 맞춰 제작됩니다. 130 131 L23 P21 Hungary F20 HV BIO Hwasun County Vaccine Industry District (Regional Specialized Development District) 헝가리 CEO ADD TEL FAX URL Tibor Baloghdi (140-809) 58 Jangmunro, Yongsan-gu, Seoul 82-2-793-7883 82-2-792-2126 [email protected] Oh Hong Guen 오홍근 #410, CTP BIOCENTER Daehangno 121, Nonsan-si, Chungnam 83 63-851-7061 83-63-850-7558 http:// huvet.koreasme.com CEO ADD TEL FAX URL H20 화순백신산업특구 (지역특화발전특구) CEO ADD TEL E-MAIL URL E X H I B I T S Feed additive, CRO R&D 사료첨가제, 전임상실험 I N T R D U C T I O N HV bio continues to make efforts on study and develop constantly for harmonizing world with human and animal. As our corporate ideal is respect human and animals, we try to become advanced, contributed company for social welfare which will meet such thinking: 1. increasedtechnology 2. future-oriented 3. mutual-communion between human and animals 4. environment-friendly. HV bio has released various feed additives made with natural calcium and will place on fulfillment of environment-friendly animal husbandry by improving level of immunity of numbers of disease like AI, as well as increasing productive capacity of rural households. HV bio는 사람과 동물의 조화로운 세상을 열기 위해서 지속적인 연 구·개발을 수행해나가고 있습니다. 인간과 동물을 존중하는 기업이 념으로 발전하는 기업, 사회에 헌신하는 기업이 되도록 노력하고 있 으며 1. 기술발전적인 사고 2. 미래지향적인 사고 3. 인간과 동물과의 상호교감 사고 4. 친환경적인 사고 이 4가지를 사훈을 삼고 있습니 다. HV bio는 많은 연구개발 실적을 토대로 천연칼슘을 소재로 한 각 종 동물용사료첨가제를 출시하고 있으며 농가의 생산성 향상, 조류독 감 예방등 각종 질병에 대한 면역력을 증진시켜 친환경축산을 실현 시킬수 있는 토대를 만들어 드리겠습니다. 132 현대마이크로(주) CEO Hong I Sik 홍이식 Donghungil 23 Hwasun-eup, Hwasun County, South JeollaProvince 519-805, Korea 82-61-374-0001 [email protected] h ttp://www.hwasun.go.kr/2011/en/county/01/ index03.php http://sezone.smba.go.kr ADD TEL FAX E-MAIL URL E Young-taek, Kim 김영택 4th Floor, Hyobong B/D 223 Ipjeong-Dong, JungKu, Seoul, South Korea 82-2-2273-8490~2 82-2-2273-8493 [email protected] http://hdmicro.co.kr X H I B I T S Plasticware of bio-Industry for laboratory, Syringe/ Membrane Filter, Filter Paper, Biocontainer Assemblies, Facilities and Main Business Area of Hwasun County Cartridge Filter etc. Vaccine District Lab용 플라스틱웨어, 시린지필터, 멤브레인필터, 여과지, 멸균바이오 E O HYUNDAI Micro Co., Ltd. X H I B I T S 2012년 우수연구특구로 지정된 화순 백신특구에 입주해있는 전남 백, 카트리지필터 등 생물산업진흥원 생물의약연구원과 한국화학융합시험연구원 헬스케 어연구소, 녹십자 백신공장, 전남대학교병원 등의 우수 연구기관 I N T R O D U C T I O N Hwasun County Vaccine Industry District has been established in 2010, to develop Vaccine Research and Development, Preclinical and Clinical Trial, and manufacturing Service in one place. In Hwasun Vaccine District, there are JBF Biopharmaceutical Research Center, KTR Healthcare Canter, Greencross Vaccine Factory and Jeonnam University Hospital. 화순백신특구는 2010년 전남 화순군 화순읍등 2개 읍면에 면적 985,860m2 규모로 생물의약일반산업단지와 전남대병원을 중심으 로 지역특화발전특구로 지정되었습니다. 특구지정을 통해 바이오 클 러스터와 메디컬 클러스터를 조성하여 백신 산업화와 생물의약품 완 제라인을 전남생물산업진흥원 생물의약연구원에 구축하고, 생물의약 품의 전임상을 담당할 한국화학융합시험연구원의 헬스케어연구소, 임상을 담당할 전남대학교병원, 그리고 백신을 제품화하는 녹십자백 신공장 등을 구축하였습니다. I N T R O D U C T I O N We, HYUNDAI Micro have provided Syringe filters and Plastic ware such as cell culture dish, petri dish and conical tube which are necessarily used in bio industry field to domestic and abroad markets. These products are manufactured in our own plants. Also, we have imported cartridge filters and various filters in order to close to the customers. We will be a company which can give customers more trusts with competitive bio products. 당사는 바이오산업 분야에서 필수적으로 사용되고 있는 페트리디쉬, 코니칼 튜브 셀컬쳐디쉬 등의 플라스틱웨어 제품들과 시린지필터를 직접 제조, 생산하여 국내외에 공급해드리고 있습니다. 또한 카트리 지필터를 비롯하여 각종 필터 제품들도 수입하여 고객사께 다가가고 있습니다. 더욱 경쟁력 있는 바이오산업 관련 제품으로 신뢰받는 귀 사의 파트너가 되겠습니다. 133 F34 F40 G33 F45 HYUNDAIPHARM. Co., Ltd. IIAMHUB ILDONG PHARMACEUTICAL Co., Ltd. IL-YANG PHARMACEUTICAL. Co., Ltd. 현대약품(주) (주)이암허브 일동제약 주식회사 일양약품(주) CEO ADD TEL FAX E-MAIL URL Yoon chang hyun 윤창현 204-4, Nonhyeon-Dong, Gangnam-Gu, Seoul, Korea 82-2-2600-3848 82-2-2693-7628 [email protected] http://www.hyundaipharm.co.kr CEO ADD TEL FAX E-MAIL URL E X H I B I T Kyoyoung Ku 구교영 140-872 5F, 51-1, Hangangno 2ga, Yongsan-gu, Seoul, Korea 82-2-792-2398 82-2-792-2396 [email protected] http://www.iiam.co.kr S X H I B I T S Technology Valuation PantrosIP 마이녹실, 버물리, 나또밸런스, 루핑 ADD TEL FAX E-MAIL URL JUNG CHI LEE 이정치 137-733 2, Baumoero 27-gil, Seocho, Seoul, Korea 82-2-526-3114 82-2-526-3031 [email protected] http://www.ildong.com X H I B I T N T R O D U C T I O N Hyundai Pharm, established in 1965, has been selected as one of innovative pharmaceutical companies and ATC (Advanced Technology Center) based on 3 R&D centers focusing on developing new drugs. Hyundai Pharm also signed on Technology Transfer Agreement with about 40 local companies in Korea. There are about 170 products distributing by Hyundai Pharm such as OTC products (MoolPas, Bumooly, Minoxyl and so on) and ETC products (CV, Respiratory, OBGY, CNS and so on). Hyundai Pharm has been transferred its technology to the global market like Europe and it was based on its R&D for IMDs. I N I T R O D U C T I O N PantrosIP’s solution significantly improves R&D and IP processes providing for ample cost savings potential and improved technological position. Solutions include private corporate portfolio management, industry analysis, competitive patent intelligence, and unparalleled patent informatics. 기술가치평가 : 경제성 분석 및 기술가치평가의 다년간의 경험과 체 계적이고 표준화된 모델을 기반으로 신뢰성 있고 객관적인 근거를 제시하는 가치평가를 수행합니다. PantrosIP : 대량 특허의 포트폴리오 관리, 등급평가를 통한 특허 자 현대약품 (1965년 창립)은 3곳의 연구소를 기반으로 신약개발에 주력 을 하여 혁신형 제약기업 및 ATC (우수기술연구센터)에 선정되었음. 국내 40여개사와 제제기술 계약을 체결함. 일반의약품 (물파스, 버물리, 탈모치료제 마이녹실 등)과 전문의약품 산의 효율적 관리, 거래 대상 특허의 재무적 가치평가를 통해 라이센 싱 전략수립, 특허분쟁 대응 근거 마련 등 전략적 의사결정을 지원하 는 솔루션입니다. TEL FAX E-MAIL E Anticancer product, Probiotics, APIs, CMO business N T R O D U C Dong Yeon, Kim 김동연 110, Hagalro, Giheung-gu, Yong-in-si, Gyunggiido, Korea 82-2-570-3700~7 82-2-570-3708~9 [email protected] http://www.ilyang.co.kr X H I B I T S Supect (Radotinib), Noltec (Ilaprazole), Vaccine, ETC/OTC, Health Functional Food, Drinks 항암제, 유산균 제품, 원료의약품, CMO사업 PantrosIP ADD S 기술가치평가 I CEO URL E E Minoxyl, Bumooly, Natto Balance, Ruping CEO T I O N ILDONG PHARMACEUTICAL Co., Ltd. has been contributing to healthier and happier lives since 1941. We are developing creative and outstanding finished products and APIs utilizing all knowledge and know-how available. Especially, we have constructed dedicated Anti-cancer building and Cephalosporins building in 2010 which are high-end production system pursuing for global market. 일동제약은 1941년 창립 후 인류의 건강과 행복에 기여하는 기업으 로 성장해왔다. 올해 출시 50주년인 아로나민과 대표 품목인 비오비 타 등 OTC 제품이 소비자들에게 잘 알려져 있으며, 큐란, 후루마린 등의 전문 의약품들도 의약사들에게 유명한 제품이다. 완제공장인 안 성공장과 원료공장인 청주공장에서 최고품질의 제품이 생산되고 있 으며, 특히 항암제, 세파 항생제 생산능력은 국내 최대이다. 슈펙트, 놀텍, 백신, OTC/ETC의약품, 건강기능식품, 드링크 등 I N T R O D U C T I O N Global leader in R&D of new chemicals and biological products Since 1946, based on the company's slogan 'Respect humanity', 'Promote human's health' and 'improve welfare', IL-Yang Pharmaceutical has dedicated to people’s health by manufacturing superior medicines. With the start of 'NOLTEC (Ilaprazole)', so-called future generation's antiulcer medicine, we are developing 'SUPECT (Radotinib)', a super leukemia cure and expanding into the field of vaccination business and BIO medication. IL-Yang has been advancing into a top-ranking pharmaceutical company in the world through its R&D capabilities with development of new chemical entities and innovative biological products. 신약 개발의 글로벌 리더 일양약품 (고혈압, 호흡기, 산부인과, 정신계 약물, 외과 등) 170 여 제품을 판 매함. 1946년 창업이래 “인간존중의 사명을 갖고 인류의 건강과 복지를 위하여 정성을 다한다” 라는 기업이념 속에 한국제약산업의 발전사 Unmet needs가 충족된 개량신약에 대한 연구를 통해 해외유럽 기 와 그 맥을 함께해왔습니다. 차세대 항궤양제로 불리우는 국산 14호 신약 “NOLTEC”, 차세대 슈퍼 백혈병 치료제 “SUPECT”, 백신사업 및 새로운 성장 동력인 BIO 혁신신약 개발 능력 확대를 기점으로 일 양약품은 글로벌 신약기업으로의 명성을 점차 확대 해 나가고 있습 니다. 술수출을 하고 있음. 134 135 A12 Q22 Incheon Free Economic Zone Industry-Academic Cooperation Foundation JEJU NATIONAL UNIVERSITY 인천광역시 경제자유구역청 CEO ADD TEL FAX E-MAIL URL E Lee Jong Cheol 이종철 G-Tower, 175 Art Center-daero, Yeonsu-gu, Incheon 406-840, Korea 82-32-453-7363 82-32-453-7389 [email protected] http://www.ifez.go.kr X H I B E10 I T S 제주대학교 산학협력단 CEO ADD TEL FAX E-MAIL URL I N T R O D U C E Lee Nam-Ho 이남호 1 02 Jejudeahakno, Jeju-si, Jeju Special SelfGoverning Province, 690-756, Korea 82-64-754-2474 82-64-702-2461 [email protected] http://iucf.jejunu.ac.kr/ T I O N As one of the central focuses of the Korean government’s ‘Northeast Asia Economic Centralization strategy’, the Incheon Free Economic Zone (IFEZ) was first nationally designated in August, 2003, and includes Songdo, Yeongjeong and Cheongna, for a total area of 169.5km2. IFEZ is an international city for global business to become the driving engine for the best economic activity. Songdo Bio Front in Songdo, IFEZ is attracting research, manufacturing and service businesses in the fields of bio pharmaceutical and medical industries. Songdo Bio Front already attracted many global companies as Samsung Biologics, Dong-A Pharm, Celltrion, Ajinomoto, etc. Songdo Bio Front has many strengths as below. 1)C onvenience in import and export thanks to the Incheon International Airport and Incheon Sea Port, both located in IFEZ. 2) World-class bio pharmaceutical production capacity. 3) Easy access to the major domestic market including the Seoul, and eco-friendly living environment. 인천경제자유구역은 2003년 8월 송도, 영종, 청라국제도시에 총 169.5㎢ 규모로 우리나라 최초의 경제자유구역으로 지정되었습니 다. 인천경제자유구역은 글로벌 비즈니스 전진기지로 최고의 경제 활 동을 보장하는 국제도시입니다. 인천경제자유구역 송도지구 내 위치한 송도 바이오 프론트는 의료· 바이오 기업 및 바이오 분야 서비스 기업 등 글로벌 앵커 기업 유치 를 추진하고 있습니다. 삼성바이오로직스, 동아제약, 셀트리온, 아지 노모도 등 글로벌 기업이 이미 송도 바이오 프론트를 선택하여 입주 하였습니다. 송도 바이오 프론트는 1)바이오 산업 글로벌화의 필수 인프라인 인천국제공항과 인천항을 보유 2)세계적 수준의 개발 및 생 산규모 확보, 3)수도권에 입지하고, 송도 국제도시의 우수한 거주환 경 등의 강점을 지니고 있어 명실상부한 바이오 클러스터로 국내· 외의 이목이 집중되고 있습니다. 136 X H I B I T S Excellent patent technology exhibition 우수특허 기술 전시 I N T R O D (주)이뮨메드 CEO Introduction of IFEZ and Songdo Bio Front 인천경제자유구역 및 송도 바이오 프론트 소개 ImmuneMed, Inc. U C T I O N Our main role is efficient research funds administration and enforcement, academic support program activities, intellectual property management, business operations include collaboration with foreign institutions. 산학협력단의 역할로는 교수과제연구비 관리 및 집행, 학술활동지원, 지식재산관리, 대외기관과의 협력사업 운영 등이 있습니다 ADD Sun-Mi Kim 김선미 Room #304, Bld.#2 Biotown, 32 Soyanggangro, Chuncheon-si, Gangwon-do, South Korea, 200161 82-33-253-1669 82-33-241-1664 [email protected] http://www.immunemed.net IgM and IgG from species-specific antigens at the same time. Some of items are currently sold in South Korea and exported to southeast Asia from 2013. 본사에서는 인간 자체의 면역력을 활용하는 것이 감염성 질환에 대 한 가장 기본적인 해결책이라는 신념을 가지고, 다년간에 걸쳐 연구 를 진행하고 있다. - Virus Suppressing Factor (VSF) VSF는 interferon과 유사하게 생체에서 만들어지는 물질이지만 FAX 동물실험에서 더 많은 범위의 바이러스에서 interferon보다 훨씬 E-MAIL 더 효과적인 항바이러스능을 보였으며 부작용이 없었다. 만일 VSF URL 가 항바이러스 치료제로서 개발된다면, interferon외에 다른 합성 바이러스 치료제의 한계를 극복할 것이다. 또한, 본사는 VSF에 대 하여 2010년 4월에 미국 특허를 받았으며, 전세계적으로 인간화 I N T R O D U C T I O N 된 VSF에 관한 특허를 제출할 준비가 되어있다. ImmuneMed Inc. promises to become a world-trusted company based on creative high-tech intensive research 현재 VSF의 연구개발은 전임상 단계에 와 있으며, 개발에 필요한 자금은 ①정부연구개발비, ②진단키트 판매와 ③외부투자를 할 계 and sound management. We believe that the human 획이다. 자금의 회수는 상장등을 통한 방법으로 진행될 것 이며, immune system itself is the most effective defense system VSF 개발의 성공은 항바이러스 치료제 시장에서 혁신적인 결과물 of our body in curing various infectious diseases. 이 될 것이다. -Virus Suppressing Factor (VSF) VSF is produced in the body, similar to that of interferon: -급성열성질환 진단키트 급성열성질환 (쯔쯔가무시병, 렙토스피라증, 유행성출혈열, 발 however it shows much greater antiviral activity and over 진열)은 세계적으로 새롭게 확산되는 질병이다. 특히 국내 (연간 the wide ranges of viruses in animal experiments than 100, 000명 내외) 및 중국을 포함한 동남아에서 가을철에 발발하 interferon and no side effects. Therefore, if developed 는 전염병으로, 전 세계적으로 매년 천만명 이상에서 발병하는 질 as an antiviral therapeutic, VSF can overcome many of 환이다. 본사는 급성열성 진단 사업을 회사 설립이전부터 실시해 the limitations of existing synthetic antivirals as well as 오고 있었으며 세계 최고수준의 본사 연구력으로 진단키트는 개발 interferon. Also, The company received a US Patent in 완료단계에 있으며, 2013년부터 일부 품목에 대하여 시판 (동남 April 2010 and is ready to submit a patent regarding 아 수출 포함)에 들어갔다. 본사의 진단키트는 종특이항원을 개발 appropriated human VSF worldwide. 하여 사용하였으며, 이에 대한 IgM과 IgG를 동시에 확인하므로 The current stage for research and development of VSF 민감도와 특이도를 높였으며, 그 결과를 10분내로 판독할수 있다. is ready to enter a preclinical trial. The sources of this 국내외의 일반병원, 임상검사소, 농촌 보건소, 군부대 진료소 등이 project will be ① the government research grant, ② sales 주 사용처가 될 것이다. of diagnostic kit, and ③ investment from the outside. The retrieve of funds will be processed through a listed company and so on. The success of VSF development will be an innovative product in the antiviral therapeutics market. -Acute Febrile Illness (AFI) Diagnostic Kit and Vaccine Acute febrile illnesses (scrub typhus, leptospirosis, pandemic haemorrhagic fever with renal syndrome, murine typhus) are newly spreading infectious diseases in the world. These infections occur in Korea, Southeast Asia, and China, causing epidemics particularly in autumn. More than 10 million people are estimated to be infected worldwide annually. We have focused on developing a rapid, accurate, and reproducible AFI diagnostic kit with high sensitivity and specificity using TEL 137 A13 C10 Industry-academic Cooperation Foundation, Keimyung University 계명대학교 산학협력단 CEO ADD TEL FAX E-MAIL URL E H I B I T S Bio-patent 바이오 분야 특허 I N T R O D U C T I O N The IACF was established in September 2004 with the intent of contributing to local economic growth and school development by internally promoting research and academics and externally reinforcing industrial cooperation. -「산업교육진흥및산학협력촉진에관한법률」의 규정에 따라 우수연 구 진흥 및 산학협력을 강화함으로서 학교의 발전과 지역산업에 이바지함을 목적으로 2004년 4월에 설립 되었음. - 고부가 식품/식료품, IT융복합 의료기기, 자동차부품, 스마트IT기기 등 전 분야에 걸쳐 우수기술 및 연구인력을 보유하고 있으며, 특허 청 발표에 따르면 2006년~10년 국내 216개 대학 중 식품/식료 품 분야에서 서울의 주요대학을 제치고 상위권 (전국 4위)를 차지 하는 등 특허 명문대학 임. -중소기업청 주관 2011년도 산학연공동기술개발사업 수행기관 평가에서 최우수기관으로 선정되어 대통령표창을 수상하였으며, LINC사업단, 창업지원단, 중소기업산학협력센터 등과 연계하여 산학공동기술개발, 기술사업화 및 기술창업 등을 지원하고 있음. 138 Institute for Refractory Cancer Reseach E10 International Pharmaceutical Federation (FIP) 삼성서울병원 난치암연구 사업단 CEO Nam Jae-yeol 남재열 1095 Dalgubeoldaero, Dalseo-Gu, Daegu, 704701 Korea 82-53-580-6742 82-53-580-6947 [email protected] http://sanhak.kmu.ac.kr X M24 ADD TEL FAX E-MAIL URL International Scientific Standards 인터내셔널 사이언티픽 스탠다드 Do-Huun Nam 남도현 81 Irwon-ro, Gangnam-gu, Seoul 135-710, Korea 82-2-2148-9775 82-2-2148-9829 [email protected] http://www.Smcircr.re.kr CEO ADD TEL FAX E-MAIL URL Mr. Luc Besancon Andries Bickerweg 5, 2517 JP The Hague, Netherlands 31-302-1971 31-70-302-1999 [email protected] http://www.fip.org CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O N IRCR seeks to build a global hospital-based platform for the development of new biologics by strengthening its human and technology networks. We are cooperating with leading domestic and overseas institutions and are scounting technology for the discovery of new potential drugs. Based on these, we are expanding the institution’s pipeline and are establishing an open innovating system. This system is built on a strong infrastructure of preclinical translational research organizations that can accurately evaluate the efficacy of new drug candidates and can serve as a foundation for developing and industrializing novel treatments that can treat refractory cancer. We believe we have what it takes to make significant and impactful contribution to the medical industry and assist in humanity’s conquest of diseases. 난치암연구 사업단은 세계수준의 병원기반 바이오신약개발 플랫폼 구축을 통한 국내의 우수기관과 연구협력으로 인적/기술적 네트워크 를 강화하고, 유망과제 발굴을 위한 기술 스카우팅을 통해 오픈이노 베이션 기반 개방형 사업단 파이프라인 구축이 가능한 모델을 개발 하고 있습니다. 이러한 전문화된 인프라를 바탕으로 난치암을 치료할 수 있는 개인 맞춤형 바이오 신약을 지속적으로 발굴하고 산업화하 여 의료산업 발전 및 인구 질병극복에 이바지하고 자 합니다. E X H I B I T Pharmaceutical Sciences World Congress (PSWC) Bradley Ashbrook 32, Soyanggang-ro, Chuncheon-si, Gangwon-do, 200-161, Korea 82-33-258-6300 82-33-258-6299 [email protected] http://www.isslab.co.kr S E X H I B I T S -Full range of analytical services in state-of-the-art GLP facilities I N T R O D U C T I O N - Bio analysis - Bioassay service 5th FIP Pharmaceutical Sciences World Congress (PSWC) Join leading pharmaceutical scientists from around the - Clinical monitoring service world to discuss cutting edge research and up-and-coming - Regulatory consulting and strategic intelligence services - Global GxP regulatory Services developments in Melbourne, Australia 13-16 April 2014. www.fip.org/pswc2014/ I N T R O D U C T I O N ISS delivers comprehensive high value solutions for international pharmaceutical industry clients through innovation, unmatched quality and excellence. As a Battelle company, ISS plays an important role among a global network of integrated science and technology services delivered by one of the world most advanced research and development organizations. ISS는 세계 최대 규모의 독립적 R&D 기관인 바텔연구소의 자회사로 서, 바텔이 제공하는 통합과학기술서비스 네트워크를 기반으로 성장 하고 있습니다. 과학적 전문 지식과 기술 능력을 토대로 통합서비스 를 통해 고객 맞춤형 서비스를 제공할 것이며, 더 나아가 ISS는 민간 독립 연구소로 성장하여 업계 연구개발의 어려움에 대한 해결책을 제공하는 역할을 하고자 합니다. 139 K30 C43 R21 B20 IntroMedic Co., Ltd. IWOO scientific coporation JBK Natural medicine Institute (주)인트로메딕 (주)이우 과학교역 제이비케이자연의학연구소 CEO ADD TEL FAX E-MAIL URL Andrew Shim 심한보 Suite 1104, E&C Venture Dream Tower 6-Cha, 197-29, Guro-Dong, Guro-Gu, Seoul, 152-719, Korea 82-2-801-9300 82-2-801-9330 [email protected] http://www.intromedic.com CEO ADD TEL FAX E-MAIL URL X H I B I T S CEO ADD TEL FAX E-MAIL URL Kyung mee Leem 임경미 441-853 1-203 89 SeahoRo GwonseonGu, suwon City KyungkiDo korea 82-31-278-5772 82-31-278-5773 [email protected] http://aronia.co.kr X H I B I T S E X H I B I Liquid Handler for Protein Crystallization, Liquid Handler JBK Aronia, Bio-Clean, NOUFA 369 단백질 결정화 실험용 장비, PCR mix 셋업용 장비 장봉근 아로니아, 바이오클린, 노유파 369 T R O TEL FAX E-MAIL Kee, Young Hwan 기영환 Wanam-dong 660, Jecheon-City, Chungcheongbuk -Do, 390-250 Republic of Korea 82-43-647-1011 82-43-647-1022 [email protected] http://www.jcbio.or.kr X H I B I T S Korean Medicine Food etc. 한방식품, 한방제약, 기타 I T ADD E MicroCam® (캡슐내시경) N CEO S MicroCam® (Capsule Endoscope) I 제천한방바이오재단 URL E E Hyuncheol, Kang 강현철 5 F, Yangwoo Bldg., 1503-15, Seocho-dong, Seocho-gu, Seoul 82-2-3473-2332 82-2-579-8873 [email protected] http://www.iwoo.co.kr Jecheon Korean Medicine Bio Promotion Foundation D U C T I O N IntroMedic is a medical device manufacturer, specializing in development of innovative technologies to advance the field of a Capsule Endoscopy. MicroCam® is the capsule endoscope with size of 11x24mm and is intended for visualization of the small bowel mucosa as an adjunctive tool in the detection of abnormalities of the small bowel with a wireless camera contained in a capsule. N T R O D U C T I O N N T R O D U C T I O N This company sells JBK Aronia and Bio-Clean, contain I Aronia anthocyanins (C3G), patented material and NOUFA Jecheon herbal medicine through biotechnology 369, contains five kinds of non-oxidative oils. These biotechnology industry infrastructure based on a network Products may maintain or improve the health of the cells. of organizations are supporting the growth of local businesses. 특허물질 아로니아 안토시아닌(C3G)를 함유한 장봉근아로니아와 바 이오클린, 무산화방식으로 착유한 5종 혼합유제품인 노유파 369 관 제천한방바이오 인프라 구축을 통한 한방바이오산업 네트워크의 거 련 제품을 개발 판매하는 회사입니다. 이들 제품은 세포의 건강을 유 점기관으로 지역기업의 성장을 지원하고 있습니다. 지 또는 개선합니다. (주)인트로메딕은 세계 최초 수준의 고화질 영상을 가진 최첨단 캠슐 내시경 시스템인 MicroCam® 을 개발하여 국내와 세계 80 여개 국가에 공급하고 있는 의료기기 전문 벤처기업입니다. 캡슐내시경은 기존의 내시경과 달리 검사에 따른 피검사자의 고통 없이 알약 모양과 크기의 캡슐을 삼키어 소화기 질환 진단에 필요한 영상을 회득하고, 회득한 영상을 가지고 피검사자의 질환 등을 분석, 진단할 수 있는 효과적이며 안전한 의료기기 입니다. 140 141 F20 N20 Jeonnam BioPharmaceutical Research Center (JBRC) 전남생물산업진흥원 생물의약연구원 CEO ADD TEL FAX E-MAIL URL E H I B I T S -Research Products of 7 centers of JBF -Main Business Area of 7 centers of JBF -전남생물산업진흥원은 산하에 7개 특화센터를 보유하고 기업을 위 한 연구와 생산지원을 하고 있습니다. 7개 특화센터는 식품산업연 JID Corporation Co., Ltd. Johns Hopkins University 제이지 비지니스 링크 인터네셔널 (주)제이아이디코퍼레이션 존스 합킨스 대학교 TEL FAX E-MAIL URL 0410 Observation Dr. Suite 105, Germantown, 2 MD 20876 USA 1-301-916-7210 1-301-916-7212 [email protected] www.jgbli.com E X H I B I T T R O D U C T I O N Jeonnam Bioindustry Foundation (JBF) has been established to boost and develop the bioindustry of Jeollanamdo (South Jeolla Province) since 2002. JBF has 1 HQ and 7 research centers, which are Bio Food Technology Center, Biopharmaceutical Research Center, Nano Bio Research Center, Institute for Natural Resources Research, Marine Bioindustry Center, Development Institute of Korean Traditional Medicine, and Bio Control Center. 전남생물산업진흥원은 생물산업에 관한 연구개발 역량을 높이고, 전 남의 지역 경제 활성화와 지역산업 발전에 기여하고자 2002년 출범 한 기관입니다. 재단 산하에는 7개 바이오산업 관련 센터가 있어, 식품산업 연구 및 기업 지원을 위한 나주의 식품산업연구원, 신약개발 및 의약품 산업 지원을 위한 화순의 생물의약연구원, 나노기술연구 및 산업지원을 위 한 장성의 나노바이오연구원과 천연자원 및 환경을 이용하여 소재개 발 및 연구를 추진하는 장흥의 천연자원연구원, 한방산업 구축 및 우 수한약재 인증을 위한 장흥의 한방산업진흥원, 해양바이오전문기업 육성과 연구개발을 위한 완도의 해양바이오산업원, 생물방제연구를 위한 곡성의 생물방제연구원이 활발한 연구활동과 기업지원을 진행 하고 있습니다. 142 ADD TEL FAX E-MAIL 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, Johns Hopkins University, University of Maryland School of Medicine, Montgomery County, University of Maryland BioPark, BioHealth Innovation 총 7개 업체 함께 참여 E T R O D U C T I O N JG Business Link International (JGBLI) specializes in business networking and relationship management. JGBLI is committed to research and development for the vitalization of Bio Technology, Information Technology, and Green Energy projects. JG Business Link International has partnerships and agreements with Amarex, Cangene BioPharma, Duane Morris, Calibre Systems, University of Maryland at Baltimore, Johns Hopkins University, Bio Health Innovation, BioCentury, and the University of Maryland BioPark. This year we are providing a number of programs to provide services to partner U.S. and Korean companies. Our programming will create opportunities for FDA approval, patent applications, investment and research funding, and sales and marketing for products in both markets. 제이지 비지니스 링크 인터네셔널 (JG BLI)은 마케팅을 전문으로 하 는 컨설팅 회사입니다. JG BLI는 바이오 산업, 정보 통신 기술 산업, 에너지 산업과 관련하여 활발한 사업을 펼치고 있으며, 한국 중.소 기 업들이 미국 시장에 진출 할 수 있는 발판을 마련해 주고 있습니다. 한.미간 바이오 기업들의 정확한 정보 및 지식교류, FDA 승인 및 특 허, 투자연구비 및 판매에 이르기까지 최선의 서비스를 제공해 드리 며, 대형 CRO, CMO 회사와의 임상시험 대행과 위탁 생산 컨설팅 을 제공합니다. 또한, 매년 ‘Korea-Maryland, USA Bio Expo’를 개최함으로써 한 국과 미국 사이의 사업연계, 계약 및 양해각서 체결을 도와줍니다. X H I B I T S N T R O D U C 400 North Charles St., Baltimore, Maryland 21218, 3 U.S.A. 1-410-516-4600 http://www.jhu.edu/ ADD TEL URL E X H I B I T S ‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland 2020’ Strategic Plan Introduction 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, Johns Hopkins University, University of Maryland School of Medicine, Montgomery County, University of Maryland BioPark, BioHealth Innovation 총 7개 업체 함께 참여 쎄니터리 다이아프램 밸브, 산업용 밸브 플라스틱 다이아프램 밸브, 글로브&컨트롤밸브 솔레노이드밸브, 하이퓨리티 밸브 센서&디스플레이 장치 멜라닌폼 (보온재), 체크밸브, 플렉시블호수 I N Yim Kyung Jae 임경재 Honglk Jeil B/D, 478-12, Seokyo-Dong, Mapo-Gu, Seoul, 121-839, Korea 82-2-326-5545 82-2-326-5549 [email protected] http://www.jidcorp.com S ‘Korea-Maryland , USA Bio Expo 2013’ & ‘BioMaryland 2020’ Strategic Plan Introduction I N CEO URL 구원, 생물의약연구원, 나노바이오연구원, 천연자원연구원, 한방산 업진흥원, 해양바이오연구원, 생물방제연구원입니다. I N20 JG Business Link International ADD Shin Hyun Kyoung 신현경 San15-12 Dongsudong Naju, Jeollanamdo, South Korea 82-61-339-1324 82-61-333-8076 [email protected] http://www.jbf.kr X C23 T I O N I N T R O D U C T I O N GEMU-JID Corporation은 GEMU고객의 한국내 유일한 공식 공 The Johns Hopkins University is a private research university based in Baltimore, Maryland, United States. Johns Hopkins 고객의 Need에 부응하여 만족할 만한 높은 기술력과 품질을 갖춘 pioneered the concept of the modern research university 독일 GEMU사의 밸브를 제공해 드리고 있습니다. 제약 및 생명바이 in the United States and has ranked among the world's 오산업, 식품산업, 전기도금, 제철산업, 화학 및 석유화학산업 등 널 top such universities throughout its history. The National 리 적용되고 있습니다. 또한 그밖에 제품으로 멜라닌폼 (보온재), 체 Science Foundation has ranked Johns Hopkins #1 among 크밸브, 플렉시블 호수가 있습니다. 고객 여러분께 전문적인 제품정 U.S. academic institutions in total science, medical and 보, 정확학 제품, 정직한 가격, 보다 빠른 납기 그리고 철저한 사후 서 engineering research and development spending for 31 비스를 제공해 드리는 신뢰 할 수 있는 기업입니다. consecutive years. As of 2011, thirty-five Nobel Prize winners have been affiliated with Johns Hopkins, and the university's research is among the most cited in the world. 급업체입니다. 존스합킨스 대학교는 미국 메릴랜드 주 볼티모어에 위치한 명문 사 립대학교이며, 특히 의학, 공공보건, 국제학 분야의 명성이 높이 알려 져 있습니다. National Science Foundation은 존스합킨스 대학교 를 과학, 의학, 공학 연구 분야 최고의 학교로 선정했으며, 세계 상위 10~20위권 대학에 포함될 정도로 명성이 높습니다. 존스합킨스 대 학교 출신 중 37명의 노벨상 수상자가 배출되었으며, 2011년에는 아담 리스 (Adam Riess)가 노벨 물리학상을 수상한 바 있습니다. 존 스합킨스 대학교 안에는 바이오기술 연구소, 정보보안연구소, 생명윤 리연구소, 알츠하이머 연구소 등 160개 이상의 연구소가 위치해 있 습니다. 143 G42 E10 E33 K30 JUNGJIN INT'L IP LAW FIRM JW CreaGene Inc. JW PHARMACEUTICAL JW PHARMACEUTICAL 정진국제특허법률사무소 JW크레아젠 JW중외제약 JW중외제약 CEO ADD TEL FAX E-MAIL URL Soon Woong Kim 김순웅 6F Ace Techno Tower 5th, 197-22, Guro-dong, Seoul, 152-766, Korea 82-2-6677-7600 82-2-2109-6901 [email protected] http://www.jjpat.com/ CEO ADD TEL FAX E-MAIL URL E X H I B I T S Patent/Utility Model, Design, Trademark, Korean IP Law & Consulting 국내외 특허출원 및 소송, 기술이전, 특허 및 기술 컨설팅 I N T R O D U C T I O N We sincerely believe that JungJin Intellectuall Property Law Firm is able to grow and develop continuously thanks to continuous trust of our clients. And, to meet our clients' various needs, we will make every effort to maintain commitment to excellence incessantly. 정진국제특허법률사무소는 지식재산권 분야의 전문지식을 가진 직 원들이 고객 여러분께서 맡겨주신 지식재산권 분야의 국내 업무와 PCT출원 등의 국제출원업무, 특허심판, 감정, 기술평가 및 특허침해 소송 등 지식재산권에 관한 전반적인 서비스 업무를 신의에 따라 성 실하고, 신속 정확하게 처리해 드리고 있습니다. 저희 정진국제특허법률사무소는 언제나 고객의 눈높이에서 고객이 원하는 바를 찾아 고객이 필요로 하는 특허법률서비스를 제공하겠습 니다. Kim, Jin Hwan 김진환 462-120. 2F Jungang Induspia V, 138-6 Sangdaewon -dong, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea 82-31-737-3300 82-31-737-3301 [email protected] http://www.creagene.com CEO ADD TEL FAX E-MAIL URL E LEE KYUNG HA 이경하 (137-864) 2477 Nambusunhwan-ro, Seocho-gu, Seoul, Korea 82-02-840-6777 82-02-841-1213 [email protected] http://www.jw-pharma.co.kr X H I B I T S CEO ADD TEL FAX E-MAIL URL E LEE KYUNG HA 이경하 (137-864) 2477 Nambusunhwan-ro, Seocho-gu, Seoul, Korea 82-02-840-6777 82-02-841-1213 [email protected] http://www.jw-pharma.co.kr X H I B I Research & Clinical Development Pipeline Global Business Portfolio I.V. Solutions Research & Clinical Development Pipeline Global Business Portfolio I.V. Solutions 연구개발 및 임상개발 현황 글로벌 사업 현황 수액 전문생산 연구개발 및 임상개발 현황 글로벌 사업 현황 수액 전문생산 I N T R O D U C T I O N JW Pharmaceutical has been striving to produce and provide innovative new technologies and services heading for healthy lives of human beings. Based on leading competitiveness in the prescription drug market, JW Pharmaceutical has built up strong sales network across the country and superior pipelines in I.V- solutions, antibiotic, cardiovascular, gastrointestinal, nephrology/ antianaemic, anticancer and neuropsychiatry. Moreover, JW Pharmaceutical is making efforts to provide medical equipments, various self-modification products and OTC products satisfying the requirements for prevention and diagnosis of diseases. Also, JW Pharmaceutical has diligently opened up itself to the overseas market with competitive APIs and finished products developed on a basis of our creative technologies. JW Pharmaceutical will go together for the life and the nature. I N T R O D U C T T I S O N JW Pharmaceutical has been striving to produce and provide innovative new technologies and services heading for healthy lives of human beings. Based on leading competitiveness in the prescription drug market, JW Pharmaceutical has built up strong sales network across the country and superior pipelines in I.V- solutions, antibiotic, cardiovascular, gastrointestinal, nephrology/ antianaemic, anticancer and neuropsychiatry. Moreover, JW Pharmaceutical is making efforts to provide medical equipments, various self-modification products and OTC products satisfying the requirements for prevention and diagnosis of diseases. Also, JW Pharmaceutical has diligently opened up itself to the overseas market with competitive APIs and finished products developed on a basis of our creative technologies. JW Pharmaceutical will go together for the life and the nature. JW중외제약은 글로벌 기준에 부합하는 혁신신약 개발기술과 강력한 JW중외제약은 글로벌 기준에 부합하는 혁신신약 개발기술과 강력한 144 오리지널 파이프라인, 이미페넴 퍼스트 제네릭 세계 최초 개발 등 오 랜 경험과 기술력을 바탕으로 ‘생명존중, 개척정신’의 창업이념을 실 현하며 국내 전문의약품 시장 선도하고 있는 대표적인 제약기업이자 오리지널 파이프라인, 이미페넴 퍼스트 제네릭 세계 최초 개발 등 오 랜 경험과 기술력을 바탕으로 ‘생명존중, 개척정신’의 창업이념을 실 현하며 국내 전문의약품 시장 선도하고 있는 대표적인 제약기업이자 세계 5대 수액제 전문 생산기업으로 글로벌 헬스케어 그룹으로 거듭 나고 있습니다. JW중외제약은 글로벌 시장에서 경쟁력 있는 신기술 및 제품 개발과 동시에 사회적 책임을 실천하며, '사람&환경&미래' 라는 브랜드 슬로건 아래 인류의 건강과 함께 환경까지 생각하는 초 일류 기업으로 도약해 나갈 것입니다. 세계 5대 수액제 전문 생산기업으로 글로벌 헬스케어 그룹으로 거듭 나고 있습니다. JW중외제약은 글로벌 시장에서 경쟁력 있는 신기술 및 제품 개발과 동시에 사회적 책임을 실천하며, '사람&환경&미래' 라는 브랜드 슬로건 아래 인류의 건강과 함께 환경까지 생각하는 초 일류 기업으로 도약해 나갈 것입니다. 145 M22 M25 KBI BIOPHARMA L10 KCRN Research, LLC N35 Kem-En-Tec Diagnostics KEOSYS Medical Imaging 캠엔택 다이그노스틱스 CEO ADD TEL FAX E-MAIL URL Joe Mcmahon 1101 hamlin Road, durham, nc 27704 USA 1-630-518-2172 1-630-983-6017 [email protected] http://www.kbibiopharma.com CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O Hugh Lee 이형주 20271 Goldenrod Lane Suite 2014, Germantown, MD 20876 USA 1-301-540-2600 1-877-310-9158 [email protected] http://www.kcrnresearch.com CEO ADD TEL FAX E-MAIL URL N I X H I B I T S Contract services for biologic drugs such as monoclonal E antibodies including analytical method development, Clinical and regulatory service on early phase drug formulation development, process development , cGMP development in US manufacturing of recombinant proteins by fermentation and cell culture, lot release, ICH stability studies. 초기 미국 임상시험과 관련 RA 서비스 I N T R O D U C T I O T R O D U C T I CEO ADD TEL FAX E-MAIL O N 효소면역측정법(substrates)과 면역측정법(immunoassays)을 위 한 완충용액 (buffer)들을 생산하는 유럽의 선두적인 생산업체입니 다. 본사와 제조시설들은 덴마크 코펜하겐의 외각지역에 위치해 있으 URL E Mr. Jerome FORTINEAU 1, impasse Augustin Fresnel, ZA du Moulin Neuf, BP 60227 44815 SAINT HERBLAIN Cedex, FRANCE 33 2 40 92 26 13 33 2 40 92 26 14 [email protected] [email protected] http://www.keosys.com X H I B I T S Medical Imaging Services for Clinical Trials 며, 미국지사를 두고 프리미엄 ELISA, 면역 블로팅법(단백질 분석 기 법)과 면역조직화학을 위한 성분들을 제공해오고 있습니다 I N T R O D U C T I O N KEOSYS is a global provider of medical imaging data management solutions and full central reading services for clinical trials. N KCRN Research is the first Korean CRO in US with handson clinical and regulatory experiences in US clinical studies and regulatory affairs and provides hands-on services with ‘low cost high efficiency’ through practical strategies for the early phase drug development in US of Korean pharmaceutical/biopharmaceutical companies N Henrik Christensen Kuldyssen 10 DK-2630 Taastrup Denmark 45-3927-1771 45-3920-0178 [email protected] www.kem-en-tec.com ' KCRN Research은 미국 임상시험과 관련 RA 실무 경험을 갖춘 최 초의 한국 CRO로서, 한국 제약/바이오 회사들의 글로벌 신약 개발 초기 단계에 ‘low cost high efficiency’ 의 실무서비스를 제공하고 있습니다. 146 147 A30 E37 으로 하여 교육, 연구, 산업분야는 물론 바이오, 의료진단 분야의 제 품들로 글로벌 시장에 진출하여 세계 일류기업으로 도약하는 기틀을 마련하고자 하며, 특히 고성장이 예상되는 체외진단 분야에 성공적으 K-MAC 케이맥(주) CEO ADD TEL FAX E-MAIL URL 로 진출 하고자 케이맥의 R&D 센터는 시장의 다양한 요구에 부합할 Joong-whan Lee 이중환 수 있는 획기적인 선도기술을 가진 체외진단기기 신제품들을 출시하 554 Yongsan-dong, Yuseong-gu, Daejeon, 305기 위하여 오늘도 끊임없이 연구 개발에 매진하고 있습니다. 500 Korea 82-42-930-3800 82-42-930-3979 [email protected] http://www.kmac.com/eng 한국콜마(주) CEO ADD TEL FAX E-MAIL URL E E X H I B I T S Real-time PCR Automatic Diagnostic System I N T R O D U C T I O N Since1996, K-MAC (Korea Materials & Analysis Corp.) has developed and supplied the unique and advanced analytical solution for Semiconductor, Flat Panel Display, Electronic Materials, Chemical Analysis and Life Sciences. K-MAC, a technology leader and driving force of the measurement and diagnostics markets, has accomplished a remarkable growth from its establishment and achieved worldwide recognition for its exceptional performance. To face new challenges and opportunities, K-MAC has made endless commitments for research and development. K-MAC has been developing diverse IVD products for human-kinds. We improved quality of our products persistently by knowhow of professionals and our own core technology. In addition, R&D Center is preparing for grand launching of new and innovative IVD products according to customer’s needs. 케이맥은 1996년 설립 이래 반도체, 평판디스플레이, 정보소재, 생 명공학 및 화학분석 분야에서 세계 일류의 기술력으로 시장을 선도 하기 위해 최선을 다하고 있습니다. 더불어 급변하는 산업의 요구에 부응하면서 끊임없는 도전과 지속된 연구로 성장에 성장을 거듭한 결과, 오늘의 케이맥은 명실상부한 측정•분석기기 산업의 대표주자 가 되었으며, 평판 디스플레이 공정용 박막두께 측정기를 비롯한 계 측검사 장비는 글로벌 시장에서도 그 기술력을 인정받아 현재 세계 유수의 기업들과 파트너십을 맺고 있습니다. 하지만 오늘의 성공에 그치지 않고 지속 가능한 성장 잠재력을 가진 시장으로 사업을 다각화하며 끊임없는 기술 개발을 통해 어디에도 비교될 수 없는 단단한 내일을 준비하고 있습니다. 평판 디스플레이 산업용 장비에서 구축된 브랜드 파워와 기술력에 대한 신뢰를 근간 148 품, 건강기능식품의 연구, 개발에서부터 생산에 이르는 토털 서비스 를 제공하고 있습니다. 한국콜마는 의약품의 제조와 품질관리 등에 대한 엄격하고 철저한 생산시설과 품질관리 기능을 갖추고 의약품의 내용액제, 외용액제, KOLMAR KOREA Co., Ltd. Cho, Hong-Koo 조홍구 18 Saimdang-ro, Seocho-gu, Seoul, Korea 82-2-3485-0398 82-2-515-1532 [email protected] http://www.kolmar.co.kr X H I B I 고형제, 연고, 크림제를 생산할 수 있는 KGMP (우수의약품제조 및 품질관리기준) 시스템을 구축하고 있습니다. T S Bondan Tab (Ibandronate Sodium 150mg) Talniflumate Tab (Talniflumate 370mg) Pelium Syrup (Pelargonium Sidoides Ext.) Hiforge Tab (Valsartan Amlodipine besylate) Kolmar Desmopressin Tab (Desmopressin acetate 0.2mg) Mitra Cap (Itaconazole 100mg) Tablets, Soft Capsules, Hard Capsules, Liquid Capsules, Dry Syrups, Granulates, Powders, Ointments/Creams 본단정 (Ibandronate Sodium 150mg) 탈니플루메이트정 (Talniflumate 370mg) 펠리움 시럽 (Pelargonium Sidoides Ext) 하이포지정 (Valsartan Amlodipine besylate) 콜마 데스모프레신정 (Desmopressin acetate 0.2mg) 마이트라캡슐 (Itaconazole 100mg) 내용고형제 (정제, 캡슐, 파우더), 내용액제, 외용액제, 연고, 크림제 I N T R O D U C T I O N No 1. Pharmaceutical CMO Company in Korea We, Kolmar Korea, have been specialized in Contract Manufacturing Service of Pharmaceutical Products in Korea. One-stop solution of Pharmaceuticals based on fast supply, highly strict Q/C system and low-cost competitiveness is provided to our customers Kolmar Korea operates two production sites which provide a technology that covers oral dosage forms and external dosage forms such as liquid, solution, ointment, creams. With extensive know-how and years of experience in approving marketing authorization of 300 products from KFDA, we have the skills you need in a partner. 한국콜마는 1990 년 화장품 OEM 기업으로 시작하여 국내에서 ODM Network라는 새로운 비즈니스 모델을 업계최초로 도입하여 정착시켰습니다. 우수한 품질력과 제조기술을 기반으로 화장품, 의약 149 B45 H22 센터를 두고 있으며, 그 중 오창센터에서는 고자기장 자기공명장치 Korea Basic Science Institute 한국기초과학지원연구원 CEO ADD TEL FAX E-MAIL URL E Kwang Hwa Chung 정광화 169-148 Gwahak-ro, Yuseong-gu, Daejeon 305806, Korea 82-42-865-3663 82-42-865-3645 [email protected] http://kbsi.re.kr X H I B I T S (900 MHz NMR)·초고분해능 질량분석기 (15 T FT-ICR MS)·고 분해능 이차이온 질량분석기 (HR-SIMS) 등 세계적 수준의 대형 연 구장비를 구축.운영하고 있습니다. ‘기초과학 진흥을 위한 연구지원 및 공동연구 수행’을 미션으로 하고 있는 기초 (연)은 이러한 대형 연 구장비와 탁월한 장비 운용 및 분석 지원 능력을 토대로 전국적인 네 트워크를 활용한 연구지원 및 공동연구를 수행하고 있습니다. A33 KITECH (Korea Institute of Industrial Technology) KOMA BIOTECH 한국생산기술연구원 고마바이오텍(주) CEO 나경환 CEO TEL 82-41-5898-114 http://kitech.re.kr ADD URL E X H I 줄기세포 배양용 재조합성장인자 재생의학용 3D printer 홍보동영상, 리플렛, 연보, 등 I N T R O D U C T I O N Korea Basic Science Institute is a government funded institute estalished in 1988 with the goal of promoting basic science research. The institute has been developing analytical technology, performing research support activities and operating large-scale research facilities as a sole research support institute for basic science in Korea. KBSI is composed of Daedeok Headquarters, Ochang Center and nine regional centers across the country and provides distinctive support for national R&D through these regional bases. We have installed and have been operating world-class research equipments such as the second largest High Voltage Electron Microscope (HVEM) in the world installed in Daedeok HQs, High Field-Nuclear Magnetic Resonance (HF-NMR), Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FT-ICR MS) and High Resolution-Secondary Ion Mass Spectrometer (HRSIMS), which are installed in Ochang Center. As our mission statement proclaims, KBSI contributes to 'research support and collaboration to advance national basic science' on the basis of our large-scale research equipment, its effective operation and high quality of analytical services through our vast national network. I T 3D cell culture scaffold Recombinant growth factors for stem cell culture 3D printer for regenerative medicine 3차원 세포배양 지지체 Promotional Video, Leaflet, Annual Report, etc. B S TEL FAX E-MAIL URL E Sang Hoon Moon 문상훈 19F, IS BIZ Tower, Sunyudo Station 1cha, Yangpyeongdong, 5ga 1-1, Yeongdeungpo-gu, Seoul 150-105, Korea 82-02-579-8787 82-02-578-7042 [email protected] http://www.komabiotech.co.kr/ X H I B I T S Luminex system & Multiplex assay kit, Drug discovery service, Cytokine ELISA Kits, Assay kits, Electrophoresis system & Pre-Cast Gels, PCR reagents, Cell culture media, 7X Cleaning solutions, Muse cell analyzer, Antibodies, Inhibitors, Enzymes, stem cell Biochemicals 루미넥스 & 멀티플렉스 분석 키트, 신약개발분석서비스, 엘라이자, 다양한 종류의 분석 키트, 전기영동 관련 제품 및 프리케스트 젤, PCR 관련 제품, 세포배양 배지, 7X 실험전용 세척액, 세포 카운팅 & 분석기기, 항체, 인히비터, 엔자임, 바이오케미칼 I N T R O D U C T I O N KOMA BIOTECH manufactures and provides reagents and tools for life science research, including molecular biology, immunology, cell biology, proteomics and genomics research. Key products include protein electrophoresis systems & pre-cast gels, PCR amplification reagents, Transfection reagent, Direct PCR, nucleic acid purification kits and ELISA kits for cytokines, immunoglobulins. 고마바이오텍(주)는 생명과학 연구를 위한 다양하고 품질 좋은 시약 및 소모품, 장비 등을 공급해오고 있으며, 좀 더 편리하고 사용하기 쉬운 연구용 실험시약의 자체개발과 생산에 힘쓰고 있는 바이오 벤 처 기업입니다. 항체, 인히비터, 바이오케미칼, 다양한 종류의 분석 키트, 멀티플렉스 키트와 루미넥스를 이용한 분석서비스 제공에 이르 기까지 생명공학 연구에 필요한 모든 시약 제품을 제공해드립니다. 한국기초과학지원연구원은 기초과학 진흥을 목적으로 1988년 설립 된 정부출연연구원입니다. 기초 (연)은 대한민국 기초과학발전을 위 한 연구지원 및 분석과학, 대형 연구장비 운용 등 기초과학 연구지원 을 수행하는 기관입니다. 또한, 초고전압투과전자현미경이 설치.운용 되고 있는 대덕 본원과 오창센터를 중심으로 전국 9개 지역에 지역 150 151 I10 E45 뜻을 모아 2011년 9월 출범했습니다. 후보물질에서 비임상·임상시험까지 신약개발 전주기에 걸쳐 혁신적 Korea Drug Development Fund 범부처신약개발사업단 CEO ADD TEL FAX E-MAIL URL E Dongho Lee 이동호 14th Fl, KT&G Seodaemun Tower, 21-1, Migeundong, Seodaemun-gu, Seoul, 120-020, Korea 82-2-361-3600 82-2-361-3609 [email protected] http://www.kddf.org X H I B I T S Posters 포스터 I N T R O D U C T I O N The Korea Drug Development Fund (KDDF) is a government -initiated drug development program established in 2011 and is government-initiated drug development program that manages a total budget of US $1 billion. The program is backed by a collaborative effort of healthcare related Korean ministries. Signaling a new change in gover nment funded strategy, KDDF operates through close management of development projects, linking grant support to the achievement of milestone-based research objectives. This investment in the country’s future is aimed at nurturing success that is initially driven by government and then transformed into a sustainable growth engine through valued researchers and industry partners. We openly welcome foreign investment and partnerships with international organizations who seek to gain a competitive edge in the next ten years. Since our establishment we have reviewed over 132 proposals and now have 37 projects were funded under our management. We actively focus on supporting business development and partnering activities for licensing out and also aim to establish international expertnetworking to move Korea into a global position of leadership in new drug R&D. 범부처신약개발사업단은 세계 시장에 진출할 신약을 개발하고 신약 개발 분야 글로벌 경쟁력을 확보하고자 교육과학기술부 (현 미래창조 과학부)와 지식경제부 (현 산업통상자원부), 보건복지부 3개 부처가 152 인 투자•관리 체계를 갖추기 위해 부처 간 R&D 경계를 초월한 협력 을 바탕으로 출범한 사업단은 국내 최고의 전문가들이 역량을 발휘 할 수 있도록 2020년까지 9년간 1조600억원 (정부 5300억원, 민 간 5300억원)을 지원, 국내에서 글로벌 신약을 개발하는 결실을 맺 고자 합니다. 사업단은 2013년 현재까지 접수된 총 132개의 연구과제 중 37개 를 선정, 신약개발 연구를 지원하고 있습니다. 체계적인 시스템의 선 정과정과 과제 경쟁력을 높이는 관리로 지원 과제가 잘 성숙해 갈 수 있도록 돕고 있으며, 국내 신약개발 연구 역량을 강화할 수 있는 사 업개발 및 라이센싱-아웃을 위한 파트너링 활동 등에도 적극 나서고 있습니다. 훌륭한 연구자들 및 기업들과 국내외 전문가 네트워크를 통하여 글 로벌 신약개발 사업 추진체계를 구축하여 한국이 글로벌 신약개발 국가로 도약하는데 기여할 것입니다. Korea Health Industry Development Institute (Medical Korea) 한국보건산업진흥원 (메디컬코리아) CEO ADD TEL FAX E-MAIL URL E Ko Kyung-hwa 고경화 K orea Health Industry Development Institute, Osong Health Tethnology Administration Complex., 187 Osongsaengmyeon 2 (i)-ro, Chungcheongbukdo South Korea (Zip 363-700) 82-43-713-8234 82-43-713-8906 [email protected] http://medical-korea.org/home/en/main/main.asp X H I B I T -홍보부스 운영 : 국내외 관련 기관 약 60여 테마별 부스 전시 예 정 *국가별 환자식 전시 및 시식회, 해외환자 선도업체 등 다양한 테마 별 부스 운영 -병원체험행사 : 중국, 중동 및 동남아, CIS 등 주요 전략국가 정 부기관 및 의료기관, 해외 환자유치 에이전시, 글로벌 보험사 관 계자 등 11개국 40여명 참가 예정 S Medical Korea 2014 : Global Healthcare & Medical Tourism Conference 메디컬 코리아 2014: 제5회 글로벌헬스케어 & 의료관광 컨퍼런스 I N T R O D U C T I O N The annual Global Healthcare & Medical Tourism Conference has now secured its position as the largest platform for information exchange in Asia. And Medical Korea 2014 - the 5th Global Healthcare & Medical Tourism Conference will bring a central issue in the field of medical tourism in the form of seminar, panel discussion etc. Moreover, promotional exhibitions and business meetings will enrich your international networks and provide you a quality healthcare information. Especially, BIO KOREA 2014, which is the biggest Biorelated exhibition in Asia, will simultaneously be held at the same location so that it makes your insight widen. 메디컬 코리아 2014: 제5회 글로벌헬스케어 & 의료관광 컨퍼런스 목적 -아시아 최대 글로벌 헬스케어 비즈니스의 장을 마련하여 한국의 료 브랜드 인지도 강화 및 의료관광 선도국으로서 위상 제고 -국내 의료기관과 유치업체의 글로벌 네트워크 확대를 지원하여 주요 타켓 국가별 유치채널 확보 및 관련 상품 개발 촉진 내용 컨퍼런스 : 글로벌헬스케어 최신 트렌드 관련 발표 및 토론 -비즈니스 미팅 : 사전 온라인매칭을 통한 운영 (해외 바이어 50 여명) 153 P10 J20 G20 R25 Korea Biomedicine Industry Association Korea Institute of Oriental Medicine Korea Institute of Toxicology 한국바이오의약품협회 한국한의학연구원 안전성평가연구소 Kim Myung-Hyun 김명현 5 F, Mokchon B/D Sajikno 119 5th Nejadong, Jongno-Gu, Seoul, Korea 82-2-725-8432 82-2-725-8439 www.kobia.kr CEO ADD TEL FAX URL CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O Choi Seung-hoon 최승훈 1672 Yuseong-daero, Yuseong-gu, Daejeon 305811, Republic of Korea 82-42-8689580 82-42-8689616 [email protected] http://www.kiom.re.kr CEO ADD TEL FAX E-MAIL URL Korea Licorice Farming Association Corporation LEE Sang-Joon 이상준 1 41 Gajeongro, Yuseong-gu, Daejeon 305-600, KOREA 82-42-610-8250 82-42-610-8085 [email protected] http://www.kitox.re.kr N 한국감초영농조합법인 CEO ADD TEL FAX E-MAIL E X H I B I T S KOBIA was established on May 17th of 2011. Under E business initiative by Main founder like Samsung, SK, Institution Overview & Research Achievements CJ, Celltrion and etc, we have been conducting product commercialization service in field of R&D and RA of 기관 소개 및 연구성과 biopharmaceuticals and globalization of those products Also, wa have been doing international business for I N T R O D U C T I O N facilitative in and out licensing for member companies. KIOM is the only government-funded research institute 한국바이오의약품협회는 2012년 5월 17일 창립되었다. 삼성, CJ, for traditional Korean medicine. Since its establishment in SK, 셀트리온, 세원셀론텍, 메디포스트, 드림씨아이에스등의 발기하 1994, KIOM has strived to develop future-oriented original 에 바이오의약품의 연구개발, 임상, 인허가 등 제품화를 지원하고 글 technology for Korean medical treatments, develop core 로벌 진출을 가속화하기 위한 사업을 추진 중이다. 바이오의약품 전 technology of Korean medicine-based herbal drugs to 문가 양성을 추진하고 바이오의약품 기업 간 제품/기술 등 교류를 추 support the National Agenda, and establish Korean medical 진하는 가교역할을 수행 중이다. 정부와 기업간의 원활한 소통과 협 knowledge and the informatics infrastructure based on 력을 위한 공동, 위탁 사업 등도 적극 수행 중이다. Korean medical knowledge accumulated over centuries. Through these efforts, the institute is taking the lead in scientific advancement, standardization, industrialization and globalization of Korean medicine. 한국한의학연구원은 1994년 설립된 한의학 분야 유일의 정부출연연 구기관입니다. 우리 연구원은 수천 년 동안 축적된 한의학 지식을 바 탕으로 미래 선도형 한의치료원천기술개발, 국가 아젠다 해결형 한약 제제 개발, 한의기술인프라 구축 추진을 위해 최선을 다하고 있으며, 이러한 노력을 통해 한의학의 과학화와 표준화, 산업화, 세계화를 선 도하고 있습니다. E X H I B I T S Nonclinical Services KIT가 제공하는 다양한 비임상분야 연구ㆍ시험 서비스 Yong-sang jang 장용상 390-810 충북 제천 송학면 무도길 65 82-43-651-1015 82-43-648-1015 [email protected] X H I B I T S 감초원물 (500g, 300g, 100g, 50g) I N T R O D U C T I O N 감초영농조합법인은 대부분 수입에 의존하고 있던 감초 대량재배에 I N T R O D U C T I O N Korea Institute of Toxicology (KIT) is a world-class prestigious nonclinical contract research organization located in South Korea. KIT’s GLP system has been certified by Korean and international regulatory authorities based on OECD and US FDA GLP criteria. Also, KIT is the first organization in Asia accredited by AAALAC International for human laboratory animal treatment. KIT offers a full range of nonclinical research with high scientific standards and competitive prices. 성공하였으며, 우리지역 제천에서는 국산감초 생산량의 약 80%에 해당하는 47톤이 생산되고 있습니다. 대량으로 재배되는 감초를 대 량으로 더 안전하게 가공하고, 나아가 지역농가의 소득증대에 기여하 는 기업이 되고자 노력하고 있습니다 안전성평가연구소 (KIT)는 안전성평가 기술에 관한 연구 개발을 주도 하고 관련 분야 전문시험 서비스를 제공함으로써, 국민 보건 향상과 인 류 복지 증대에 이바지함을 목적으로 2002년 1월에 설립되었습니다. 국가 안전성평가 체계구축과 관련 기술 축적에 20여 년의 역사를 가 지고 있는 KIT는 국내의 보건복지부 (1988), 환경부 (1998), 농림 부 (2002) GLP인증에 이어 일본 농림수산성 GLP인증 (1990)과 2000년 OECD GLP 상호방문평가에 이어 2005년과 2012년 미국 FDA의 실태조사 결과 적격 (VAI)기관 인증을 받은 바 있습니다. 신약 및 각종 화학물질에 대한 안전성평가 (독성평가)를 다양한 실험 동물 (쥐, 토끼, 개, 영장류)을 통해 진행하고 있는 KIT는 대전연구소 에 이어 최근 전북영장류시험본부 (2010)와 경남환경독성본부 (2012)를 새로이 마련, 국제적 수준의 GLP 시설과 전문인력, 과학적 시스템을 재정비함으로써 ‘세계 TOP10 안전성평가기관’ 도약의 비 전을 실현하고 있습니다. 154 155 E46 D10 을 위해 2010년 3월 보건복지부 인가의 사단법인 한국국제의료협회 로 출범하였습니다. Korea International Medical Association 사단법인 한국국제의료협회 CEO ADD TEL FAX E-MAIL URL E Byung-Hee Oh 오병희 363-700 Secretariat 4th Froor, Korea Health Industry Development Institute Osong Health Technology Administration Complex 187 Osongsaengmyeong2ro, Gangoe-Myeon Cheongwon-Gun, ChungcheongbukDo, Republic of Korea 82-43-713-8353 82-43-713-8906 [email protected] http://www.koreahealthtour.co.kr X H I B I T S 홍보 동영상 및 홍보 책자 등 I N T R O D U C T I O N KIMA was found in 2007 as a public-private joint conference group to promote the excellent services of the Korean medical institutions to changed to a corporation aggregate authorized by the Ministry of Health and Welfare in 2010. Over the past 5 years, KIMA has undertaken a variety of activities including holding a road show and FAM tour with pride and belief that Korean provides a world- class medical service, besides, it has played a pivotal role in Global healthcare business through supporting to foster human resources in the field of global healthcare, producing promotional booklets in 4 languages (English, Chinese, Russian, Arabic), and managing the KIMA websites. Now a total of 36 renowned teaching hospitals, general hospitals, and special clinics have joined and actively engaged as a member, and as for an government institutions, the Ministry of Health and Welfare, the Korea Healthcare Industry Development Institute (KHIDI) and Korea tourism Organization (KTO) participate as a special member. Hence forward, KIMA will play a leading role to contribute to international society and globalization of Korean medical technology & services by providing medical education and charity to underdeveloped countries. 한국국제의료협회는 한국의 우수한 의료서비스를 해외환자들에게 홍 보하기 위해 2007년 설립된 민관 공동의 협의체로 원활한 사업수행 156 협회는 지난 5년간 한국의 의료서비스는 곧 세계적 수준이라는 자부 심과 신념으로 의료기관 해외로드쇼, 한국병원 체험행사 등 다양한 활동을 전개함과 동시에, 국제의료 관련 인적 인프라 구축지원, 4개 국어 (영•중•러•아랍어) 홍보책자 제작, 홈페이지 운영사업 등을 통해 해외환자유치에 중추적인 역할을 해왔습니다. 현재 국내 유수의 36개 대학병원, 종합병원, 전문클리닉이 회원으로 가입되어 활동 중이며, 정부기관으로는 보건복지부, 한국보건산업진 흥원, 한국관광공사가 특별회원으로 함께 참여하고 있습니다. 향후 협회는 저개발국가에 대한 의료교육 및 의료봉사를 통해 국제 사회에 기여함과 동시에 한국의 의료기술 및 서비스가 세계화될 수 있도록 선도적인 역할을 하겠습니다. 또한 다양한 사업과 홍보를 통 해 세계에 대한민국의 의료브랜드를 높이는 데 중추적인 역할을 하 겠습니다. I42 Korea National Enterprise for Clinical Trials KOREA PHARM 2014 국가임상시험사업단 제4회 국제의약품전 CEO ADD TEL FAX E-MAIL URL I N Sang-Goo SHIN 신상구 1F. BioMedical BLDG. 101 Daehangno, Jongno-gu, Seoul 110-744, Korea 82-2-3668-7609 82-2-3675-4777 [email protected] http://www.konect.or.kr T R O D U C T I O N As a government funded organization responsible for expanding the infrastructure of clinical trials in Korea, Korea National Enterprise for Clinical Trials(KoNECT) manages regional clinical trial centers, operates clinical trials training academies and provides clinical trial technology development programs. KoNECT is leading the way in promoting Korea as the global hub of clinical trials. 국가임상시험사업단은 의료산업의 지역 균형 발전과 임상연구 인력 개발 및 핵심기술 개발을 위해 정부, 학계, 제약산업계가 뜻을 모아 보건복지부 지정 사업단으로 2007년 12월 출범했다. 국가임상시험사업단은 대한민국의 임상시험 인프라 구축을 위해 지 역임상시험센터 지정 및 시설 장비 확충, 임상시험 전문인력 양성, 임 상시험 신기술개발을 지원하고 있다. 또한, 국내외 관련 기관 및 연 구자 간의 네트워크를 활성화해 ‘대한민국을 세계적인 임상시험 허브 로’ 도약하기 위한 구심점 역할을 수행하고 있다. 이번 바이오코리아에는 CTC(가톨릭대, 건국대, 경북대, 고려대구로, 고려대안암, 동아대, 서울대, 이대목동, 인제제대부산, 인하대, 전남 대), CRO(드림CIS, C&R리서치, LSK Global, GDFI, 메디칼엑셀런 스, ICON, 에이플러스, Novotec, Quintiles, Paraxel, PPD)가 공동 으로 부스를 운영한다. CEO ADD TEL FAX E-MAIL URL E Kim Young Soo 김영수 Rm. 501, Geumsan Bldg., 750, Gukhoe-daero, Yeongdeungpo-gu, Seoul, 150-727, Korea 82-2-785-4771 82-2-785-6117 [email protected] http://www.koreapharm.org X H I B I T S KOREA PHARM 2014 (The 4th International Pharmaceutical Ingredient Exhibition) June 10 (Tue.) ~ 13 (Fri.), 2014 KINTEX 1, KOREA I N T R O D U C T I O N As KOREA PHARM 2014 is hosted by MFDS (Ministry of Food and Drug Safety), organized by KPMA (Korea Pharmaceutical Manufacturers Association), Kyungyon Exhibition Corp., KOREA PHARM 2014 becomes the most important industrial event of pharmaceutical field in Korea. On behalf of Organizer, we cordially invite you to KOREA PHARM 2014 to be held on June 10~13, 2014, KINTEX, KOREA. The government in South Korea has announced capital and institutional support to boost pharmaceutical manufacturing, with the aim of becoming one of the world's Top seven global pharmaceutical producing countries by 2020. At the same time, the Korea Drug Development Fund was set up in 2011 with $1.6 billion to develop at least 10 new drugs by 2020 for the global market. Under the theme above, KOREA PHARM 2014 will be the best platform to initiate or expand your market share in Korea as well as Asia-Pacific region. 국산의약품의 홍보 및 세계화를 추진하고, 해외시장진출 지원을 목적 으로 개최하는 KOREA PHARM 전시회는 식품의약품안전처가 주 최하고 한국제약협회, 경연전람이 주관하는 국내 유일의 국제의약품 전시회입니다. KOREA PHARM은 유력 해외바이어 초청은 물론 식약처 주최 의약 품 정책설명회, GMP 정책설명회, 해외바이어 초청 수출상담회, 각 종 의약품 관련 세미나 등 다채로운 행사가 동시 개최되어 제약업계 에 새로운 비즈니스의 장을 마련합니다. 157 C13 F20 Korea Research Institute of Bioscience and Biotechnology 한국생명공학연구원 ADD TEL FAX URL O10 Korea Testing & Research Institute KOREA UNITED PHARM. INC. Korea University Medical Center 한국화학융합시험연구원 한국유나이티드제약(주) 고려대학교 의료원 CEO Tae Kwang Oh 오태광 125 Gwahak-ro, Yuseong-gu, Daejeon 306-809, Korea 82-42-860-4114 82-42-861-1759 http://www.kribb.re.kr/eng CEO K30 ADD TEL FAX E-MAIL URL Choi Hyeongki 최형기 155, Beodeunaru, Yeongdeungpo-gu, Seoul, 150038, Korea 82-02-2164-0011 82-02-2164-0011 [email protected] http://www.ktr.or.kr CEO ADD TEL FAX E-MAIL URL Gang Deok Young 강덕영 2 5-23, Nojanggongdan-gil, Jeondong-myeon, Sejong-si, Republic of Korea 82-2-558-8612 82-2-558-8613 [email protected] http://www.kup.co.kr CEO ADD TEL FAX E-MAIL URL E E X H I B I T S E X H I B I T S Introduction to business organizations (testing, certification, consulting) - Main Achievements with products -To protect patent right and facilitate technology transfer of research outcomes 기관 업무 소개 (시험, 인증, 컨설팅) -Introducing National Biosafety Framework and KBCH(KoreaBiosafety Clearing House) activity I - 연구원 대표성공사례 -연구성과의 확산 및 기술사업화 촉진을 위한 특허관리 및 전략적 기술 마케팅 -바이오안전성 국가관리체계 소개 및 한국바이오안전성정보센터 (KBCH) 활동 홍보 I N T R O D U C T I O N KRIBB is the only government research institute dedicated to biotechnology research in Korea across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as new drug discovery, novel biomaterials, integrated biotechnology, and bioinformation. 한국생명공학연구원은 생명현상의 근본적 이해를 위한 기초연구를 비롯하여 보건의료, 식량증산, 바이오신소재, 환경정화, 신 에너지개 발 등 첨단 생명공학연구를 수행하고 있는 국내 유일의 바이오전문 정부출연 연구기관입니다. N T R O D U C T I O N Korea's representative testing, certifying, consulting institute, KTR. KTR (Korea Testing and Research institute), established on National Standards Law, is an international testing certifying institute and conducts tests, inspections and product certifications for bio-industry including the areas of chemistry, the environment, agrichemicals and new medicine areas as well as, engineering and construction, material parts, electronics and electrics, EMI, and IT. 23 countries, 92 organizations network worldwide, KTR is a partner for national companies for global market. KTR is a laboratory for Korean product development and quality improvement, helping save money and time in acquiring such international certifications as CE, GOST-R, JIS, NSF, REACH, IECEE, EnergyStar and FCC. required for exports overseas. 한국을 대표하는 시험·인증·기술컨설팅 기관 KTR. 국가표준기본법에 의해 설립된 KTR은 화학을 비롯한 전기전자, 자동 차·조선, 토목·건축, 금속, 환경, 의료기기, 헬스케어 신재생에너지 및 녹색산업 등 산업 전분야에 대한 종합 시험·인증·기술컨설팅 업무를 실시하고 있는 국제공인 시험•인증기관입니다. 전세계 23개국 및 국제기구 92개 기관과 네트워크, KTR은 세계속으 로 뻗어나가는 국내기업의 파트너입니다. E X H I B I T S Clanza CRⓇ tab. Cilostan CRⓇtab. Clavixin DuoⓇ cap. Leen Kim 김 린 73, Inchon-ro, Seongbuk-gu, Seoul 136-705 82-2-2286-1535 82-2-2286-1120 [email protected] http://www.kumc.or.kr/main/index.do X H I B I T S Medical Device etc. 의료기기 외 클란자CRⓇ정 실로스탄CRⓇ정 클라빅신듀오Ⓡ캡슐 I N T R O D U C T I O N We, Korea United Pharm. Inc., have been manufacturing, marketing, and selling over 500 pharmaceutical products, since 1987. At present, We have branch offices in the Philippines, the USA, Myanmar and Vietnam and have been exporting to 30 countries around the world. We have exellent researchers and increased investment in our Research & Development program, which allows us to manufacture products at the highest quality. We are expending our presence globally by out-licensing of Incrementally Modified Drugs to Eastern Europe and China. 한국유나이티드제약은 1987년 설립되었으며, 미국, 베트남, 필리핀 지사를 통해 국내는 물론 세계 30여개국에 수출하는 한국인이 주인 인 다국적 제약기업입니다. 지속적인 R&D투자로 고품질의 의약품과 신개품 개발에 힘쓰고 있으며 현재 3개의 개량신약을 출시하여 업계 내 개량신약 선두주자로 거듭났습니다. 현재 개량신약 제품은 동유럽 과 중국과의 라이센스 아웃계약으로 세계적으로 한국의 제약기술을 널리 알리고 있습니다. KTR은 KC, KS 등 국내인증은 물론, 해외 23개국, 2개 국제기구의 92개 기관과 사업 파트너십을 구축, 유럽 러시아 일본 미국 등 해외 주요수출국에서 발행하고 있는 CE, GOST-R, JIS, IECEE-CB, FCC, NSF, 에너지스타 등의 해외인증을 짧은 기간에 저비용으로 받을 수 있도록 지원하고 있습니다. 158 159 E35 B20 B38 & 37 O10 Kwangdong Pharmaceutical Co., Ltd. Kyeong Bang Co., Ltd. Kyongshin Scientific Co. Ltd 광동제약 (주)경방 경신과학(주) CEO ADD TEL FAX E-MAIL URL CHOI, SUNG WON 최성원 1577-4 Seocho-dong, Seocho-gu, Seoul, Korea 82-2-6006-7258 82-2-6006-7024 [email protected] http://www.ekdp.com CEO ADD TEL FAX E-MAIL Eu Su oK 어수옥 112 Business incubator, Daewon university college, 316 DaeHak-ro, Jecheon City, Chungbuk, Korea 82-43-648-3777 82-43-648-3776 [email protected] CEO ADD TEL FAX E-MAIL E X H I B I T S E X H I B Pharmaceutical, Cosmetic, Health functional Food PropolisSuYeonPeer-JinToothpaste 의약품, 화장품, 건강기능식품 프로폴리스수연피어진치약 I N T R O D U C T I O N Kwang Dong first started serving the people 50 years ago with the goal of providing scientific benefits of the Oriental medicine. Keeping the goal in mind, all Kwang Dong employees have endeavored to improve the health and quality of life of people around the world. Our feature products have commanded the patronage of numerous consumers, including, for example, herbal cold syrup “Kwang Dong Tang” and chewable Woo Whang Chong Shim Won, which is casually deemed some form of the Oriental panacea. Furthermore, we have made continuous R&D investments to develop various cancer drugs, which in turn have laid sound foundations for creation of diverse products covering everything from over-the-counter drugs to prescription drugs to health. 저희 광동제약은 한방과학화를 창업이념으로 50년동안 독창적인 약품 개발과 우수한 기술도입을 통해 국민보관과 삶의 질 향상에 력을 다해왔습니다. 특히 한방감기약 "광동탕"과 동의보감 처방의 "우황청심원"은 수십 간 국민들의 사랑을 받고 있으며, 아울러 전문치료제 시장에서도 암제를 위한 우수 의약품 개발을 중앙연구소를 통해 지속적으로 진함으로써 일반의약품, 전문의약품, 건강드링크, 건강식품이라는 별화된 산업기반을 구축해 가고 있습니다. 160 의 전 년 항 추 차 I N T R O D U I T S URL T I O N Teeth whitening and plaque removal and periodontal disease is to suppress the toothpaste. In order to minimize the stimulation of toothpaste propolis (honey) extract, Peer-Jin (Cnidium, Angelica, Angelica dahurica root, Artemisia capillaris, licorice, herbs extracted from pine extract) was added to toothpaste. By improving the effectiveness and usability of medicinal plants in the oral cavity for the prevention of bacterial and inflammatory improve sterilizing dental and oral cleanliness can be maintained. The prevention and treatment of dental caries and periodontal disease have the ability to added herbal extracts herbal toothpaste. 치아미백과 프라그 제거 및 치주질환을 억제하기 위한 통상적인 치 약에 프로폴리스 (벌꿀)추출물, 피어진 (천궁, 당귀, 백지, 사철쑥, 감 초, 솔잎으로부터 추출한 한약재추출물)을 첨가하여 충치 및 치주염 을 예방하며 치료하는 기능을 가지는 한방추출물이 첨가된 한방치약 입니다. -특허출원제품 (10-2012-0021647) -규 격 : 170g*3ea 자연주의를 추구하며, 제천지역에서 생산, 판매되는 친환경 한약재를 사용하여, 우리가 일상 생활에서 매일 접하는 샴푸, 바디클린져, 치약 등을 생산, 판매하는 업체입니다. Sangpyo Yook 육상표 (6th Fl. Namseoul BD., Yangjae-dong) Dongsanro 13gil 48, Seocho-gu Seoul, Republic of Korea, 137-896 82-2-576-6303 82-2-576-6309 [email protected] http://www.kyongshin.co.kr 경북대학교병원 모발이식센터 CEO ADD TEL FAX E-MAIL URL URL E C KYUNGPOOK NATIONAL UNIVERSITY HOSPITAL HAIR TRANSPLANTATION CENTER X H I B I T JUNGCHUL KIM 김정철 6F, Daegu City Center, #611, Gukchaebosang-ro, Jung-gu, Daegu, Korea 82-53-200-4100 82-53-200-4123 [email protected] http://knuh.kr http://hair.knu.ac.kr S X H I Hudson Robotics (PlateCrane, Solo Robotic pipettor, E Micro10X Dispenser) / Bertin Technologies (Precellys24, Hair Transplantation, Shampoo Precellys24-Dual, Minilys) / Zymo Research (DNA/RNA kit) / Axis-Shield (Density Gradient media) 모발이식, 샴푸 I N T R O D U C T I O N I N T R O D B U I C T T I S O N Kyongshin Scientific Co., Ltd. have strived to identify most exciting new technology companies and to supply high quality research products focused on cell biology, pharmaceutics, proteomics, genomics and diagnostics to the life science community in Korea. KNUH Hair Transplantation Center is Korea’s first hair transplantation center established at a university hospital in 1996. The follicular unit hair transplantation technique, developed by Professor Jung-Chul Kim, makes it possible to transplant 1, 000-1, 500 hairs per hour. With this 경신과학 (주)에서는 해외 선진 기업들의 우수한 품질의 제품을 발굴 technique, the survival rate of transplanted hairs exceeds 하여 국내에 공급하고 있습니다. 전시제품은 실험 자동화 장비 및 실 92%, thus guaranteeing the most natural looking result. 험결과를 빠르게 도출할 수 있는 시약키트 입니다. The Center and its nationwide network of hospitals, with Center-trained doctors, provide high-quality service for hair-loss patients. KNUH Hair Transplantation Center opens a new chapter in male-pattern baldness through continuing research and development. 경북대학교병원 모발이식센터는 1996년 국내 최초로 대학병원 내 설립되었으며 20년 이상의 임상경험과 높은 기술력을 보유하고 있습 니다. 본 센터에서는 김정철 교수가 개발한 모낭군 이식술과 KNU 식모기 를 이용하여 시간당 1, 500-2, 000여개 모발을 이식할 수 있으며, 이식된 모발의 생존율이 92%를 상회하므로 가장 자연스러우면서도 최상의 결과를 보장합니다. 경북대학교병원 모발이식센터는 끊임없는 연구와 개발을 통해 남성 형 탈모 치료의 새로운 지평을 열고 있습니다. 161 I20, F33 K30 이미 세계적인 기술과 제품력을 확보해오고 있으며, 이러한 연구개발 LG Life Sciences 력과 노하우를 바탕으로 의약, 동물의약, 정밀화학 등 3개 분야를 집 중 육성하고 있습니다. LG생명과학 CEO ADD TEL FAX E-MAIL URL E 인체의약 분야에서는 국내 최초로 미국 FDA 승인을 획득한 차세 Iljae Jung 정일재 대 퀴놀론계 항균제 '팩티브' (03)를 비롯해 인터페론 '인터맥스 감마' L G Gwanghwamun Bldg., 58, Saemunan-ro, (89)와 '인터맥스 알파' (92), B형 간염백신 '유박스B' (92), 인성장호 Jongno-gu, Seoul, Korea 110-783 르몬 '유트로핀' (93), 퇴행성 관절염치료제 '히루안플러스' (05), 배란 82-2-6924-3366 유도제 '폴리트롭' (06), 서방형 성인성장호르몬 '디클라제' (07) 등을 82-2-6924-3051 독자기술로 개발, 상품화했습니다. [email protected] 동물의약 분야에서는 세계 두번째로 젖소산유촉진제 'BST' (94)를 개 http://www.lgls.com 발해 미국을 제외한 세계 각국에서 시장점유율 1위를 기록하고 있으 며, 치료개념이 도입된 젖소 유방염 백신 '마스터백' (06)을 개발, 상 X H I B I T S 정밀화학 분야에서는 독자기술로 국산 신물질 1, 2호인 벼제초제 '피 안커' (97)와 살균제 '가디안' (99) 그리고 토양과 경엽 동시 적용이 가능한 신규제초제 '플럭소' (04)을 개발, 상품화한 바 있습니다. LG 생명과학은 '세계적 신약을 보유한 초우량 생명과학회사'라는 Vision 달성을 위해, 개발후보 발굴 능력과 전략적 제휴를 확대하여 세계적인 신약 개발을 가속화하고 있으며, 선진시장에 대한 Global Marketing 역량 확보에도 주력하고 있습니다. LG생명과학은 대표적 고부가가치 두뇌산업으로 부각되고 있는 생명 과학, BT 산업분야의 국내 리더기업으로서 거듭나겠습니다. Korea’s first diabetes treatment- Zemiglo Sustain-released growth hormone – Eutropin Plus Korea’s first multi vaccine – Euforvac-Hib 국내최초 당뇨치료제- 제미글로 소아용 서방형 성장호르몬 – 유트로핀플러스 국내최초 5가백신 – 유포박-히브 I N T R O D U C T I 품화했습니다. O N In August 2002, LG Life Sciences was upgraded from a business division to a full-fledged LG affiliate in order to grow as a life sciences specialist and maximize shareholder value. LG Life Sciences began research in genetic engineering in 1981 and has invested steadily in the life sciences ever since. This effort has already resulted in world-class technology and product capabilities. The company has focused R&D resources and know-how on three areaspharmaceuticals, animal health and specialty chemicals. LG Life Sciences has developed and commercialized an array of pharmaceuticals over the years. These include interferon in 1989 (Intermax-gamma) and 1992 (Intermaxalpha), hepatitis B vaccine in 1992 (EUVAX B™), human growth hormone in 1993 (EUTROPIN™), degenerative arthritis treatment in 2005 (HYRUAN Plus™), rhFSH (recombinant human follicle stimulating hormone) in 2006 (Follitrope™), and SR-hGH (Sustained Release-human Growth Hormone) in 2007 (Declage™). A company milestone was reached in 2003, when its next-generation quinolone antibiotic (FACTIVEⓇ) was approved by the FDA in the United States. N25 Legochem Biosciences, Inc. Marken Ltd (주)레고켐 바이오사이언스 마켄 CEO ADD TEL FAX E-MAIL URL Yong Zu Kim 김용주 8 -26 Munpyeongseo-ro Daedeok-gu Daejeon, 306-220, Korea 82-42-861-0688 82-42-861-0689 [email protected] http://www.legochembio.com CEO ADD TEL FAX E-MAIL URL E X 포스터판넬 H I B I T Wes Wheeler 150-737, 10F Kyobo Securities Bldg, Yoido-dong, 97, Euisadang-daero, Youngdungpo-gu, Seoul, Korea 82-2-6336-6776 82-2-6336-6886 [email protected] http://www.marken.com S E X H I B I T S Domestic and Int’l Services Depot Services I N T R O D U C T I O N Cold Chain Management (Packagings for Ambient, L egoChem Biosciences(“LCB”)is a leading chemistry- Refrigerated, Frozen, Cryogenic, Temperature Monitor) based venture company working on the discovery and IATA DG (Infectious substances, Toxic) packaging solutions Pre-clinical Services (Live Animal Transportation) development of new small molecule drugs. LCB’s current therapeutic areas include antibiotics, IP Drug Destruction, Kit production etc anticoagulants, anticancer and ADC(Antibody-Drug국내 및 해외 운송 Conjugates). LCB is listed up KOSDAQ(May.2013) Team : CEO has 30 years’ of experience in drug discovery 의약품 보관 Depot 서비스 and development including LG Life sciences as a research 콜드체인매니지먼트 (온도조건별/사이즈별 포장재 제공, 온도모니터 director. CTO and Key scientists also have 10~20 years’ 서비스 제공) experiences in various research areas. Currently LCB have 감염성, 독성 등 위험물 포장 및 운송 서비스 38 research scientists(including 7 Ph.Ds), of which are 23 전임상 서비스 (생동물 운송 등) organic chemistry part and 15 biology and development 임상의약품 폐기, Kit production 등 part. ∙ Technology : “LegoChemistry” N T R O D U C T I O N → Scaffold-based and fragment-based approaches I based on strong medicinal chemistry. LCB also has drug- In existence since 1980, Marken prides itself on discerning like screening technology, such as in vitro early ADME/T and satisfying the premium logistical needs of the ∙ Pipeline : Currently 11 ongoing projects pharmaceutical, biotechnology and clinical research ∙ Phase I : OXa.Antibiotics, FXa Inhibitor(coagulant) industries Marken is the leading global clinical supply chain ∙Preclinical : next generation OXa.Antibiotics service provider dedicated 100% to the pharmaceutical Gram (-) Antibiotics ->licensed-out to Astrazeneca in and life sciences industries, supporting over 49, 000 Dec., 2012 investigator sites in more than 150 countries, though strategically-placed offices in 24countries worldwide. 1980년에 설립된 마켄은 의약품, 바이오테크놀러지, 임상시험에 대 한 글로벌 물류기업으로서 라이프사이언스에 100% 특화된 전문물 류회사입니다. 전세계 24개국 전략적 요지에 마켄 지사를 운영하고 있으며, 150여 개국 49, 000개 이상의 임상시험 사이트를 서포트하 고 있습니다. 지난 1981년 유전공학 연구를 처음 시작한 이래 지속적인 투자로 162 163 F40 N20 M20 Markpro co. Maryland Bio Park MedClaris Inc. (주)마크프로 메릴랜드 바이오 파크 (주)메드클래리스 CEO ADD TEL FAX E-MAIL URL E Cha Sang Jin 차상진 3F, Ace High Tech City Bldg.2, Mullae-dong 3-ga, Yeongdeungpo-gu Seoul, Korea 82-2-785-3040 82-2-78-3043 [email protected] http://www.markpro.com X H I B I T S ADD TEL E-MAIL URL 01 West Baltimore Street Baltimore, MD 21201, 8 U.S.A. 1 410- 706-5592 [email protected] http://www.umbiopark.com/ N T R O D U C T I O N ADD TEL E-MAIL URL E X H I B I T S ‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland 2020’ Strategic Plan Introduction Trademark Searching Database services, technology commercialization, technology research/analysis, 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, technology evaluation, SMK Johns Hopkins University, University of Maryland School 마크서치 (MarkSearch), 기술거래서비스, 기술평가, 특허조사 서비 of Medicine, Montgomery County, University of Maryland 스, 기술소개서 BioPark, BioHealth Innovation 총 7개 업체 함께 참여 I CEO I N T R O D U C T I O N Markpro is one of the leading global intellectual Property service companies in the world. We provide professional patent annuity payment services, Technology Transfer & Commercialization services, and Trademark Searching Database services. The BioPark is a biomedical research park on the vibrant academic medical center campus of the University of Maryland, Baltimore (UMB). Its community of life science companies and academic research centers are commercializing new drugs, diagnostics and devices and advancing biomedical research. (주)마크프로 (2012년 지식경제부 “기술사업화전문회사” 지정)는 국 BioPark building designs maximize flexibility to 내 최고의 IP (Intellectual Property)관리 전문 회사로 특허연차료 accommodate a range of occupancies from small-scale pre관리, 상표검색 서비스, 기술거래 사업화 컨설팅 등의 서비스를 제공 built lab and office space in the BioInnovation Center to full 한다. floor users. Infrastructure meets the requirements of the most demanding science environments while permitting optimum internal planning flexibility with minimum intrusions. 미국 내 바이오 클러스터는 그 지역의 대학들이 중심이 되어 정부와 기업의 협력으로 세계적인 집적지로 성장 및 발전 되어 왔습니다. 메 릴랜드 대학 바이오 파크는 메릴랜드주립대학과 메릴랜드주 몽고메 리 카운티의 '바이오 인큐베이터'가 2003년부터 공동으로 추진한 바 이오 클러스터입니다. 이곳에서는 암, 게놈, 백신, 혈관 생물학 및 재 생의료 등 각 분야 1, 200명의 교수진을 갖춘 메릴랜드메디컬 스쿨 을 기반으로 초기단계 바이오 기업이 성장할 수 있도록 높은 수준의 실험실 환경과 사무실을 제공합니다. I Julie Yi 이주연 #1203-Yongbiuchonga, Jongo-gu, Naesu-dong, Seoul 110-070 Republic of Korea 82-2-6351-3652 [email protected] http://www.biologicsconsultinggroup.com http://www.biovian.com N T R O D U C T I O 북유럽에 소재한 Biovian사는 바이오의약품 생산 전문 CMO로서, 2003년 설립 이후 다수의 commercial product (DP)와 임상 물질 (DS) 을 생산하고 있음 유럽 EMA인증 cGMP 기관으로서, 미국 FDA의 inspection을 받은 후 Drug Firm Registration으로 등록되어 있음 N 1. Biologics Consulting Group Biologics Consulting Group, Inc. is the leading regulatory consulting firm in product development and regulatory strategy for Biologics, Drugs, and Medical Devices. For almost 20 years, Biologics Consulting Group has supported clients in the preparation and review of CBER, CDER and CDRH regulatory applications, product development strategies, Quality (or CMC) requirements, pre-clinical and clinical study designs, GLP/GCP/GMP audits, and strategic business planning. 2. Biovian Biovian is a one-stop-shop CMO for cGMP manufacture and development of biopharmaceuticals. Biovian’s offers cell line development, mammalian cultivation, microbial fermentation, protein purification, viral vector production, formulation, aseptic filling, labeling and QP release. Biovian's 2300 m2 facilities are located in Turku, Finland. Biovian is EMA and FDA certified for cGMP production of investigational and commercial products (including biopharmaceuticals, gene therapy and sterile products). Biovian, founded in 2003, is privately-owned, independent company entirely focused on customer projects. (주) 메드클래리스는 2012년 설립된 바이오의약품 개발 및 해외 허 가 컨설팅 회사로 해외 유명 CRO와 CMO와 연계하여 국내 제약사 의 제약 연구 개발을 지원합니다. 1. Biologics Consulting Group 미국 버지니아 주에 소재한 Biologics Consulting Group 사 (BCG)는 바이오제재를 포함한 의약품과 의료기기의 임상, 허가 컨설 팅을 전문으로 하는 전문 컨설팅그룹임 US FDA reviewer들로 구성된 BCG는 의약품 및 의료기기의 개발 단계부터 허가까지 고객 맞춤 컨설팅 서비스를 제공하고 있음 2. Biovian 164 165 L10 E10 B46 B20 MEABCO A/S MEDIAN Diagnostics Inc. Medical Writing Mediogen Co., Ltd. 미압코 (주)메디안 디노스틱 메디컬라이팅 주식회사 메디오젠 CEO ADD TEL E-MAIL URL Stig Loefberg Richard Mortensens Vej 61, 1 DK-2300 Copenhagen Denmark 45-3246-0370 [email protected] www.meabco.com CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O Myung-Jin, Cha 차명진 Geodudanji 1-gil 41, Chuncheon, Gangwon-do, 200-883 Republic of Korea 82-33-244-0100 82-33-244-4634 [email protected] http://www.mediandiagnostics.com N 암과 anti-방사선치료에 초점을 두고 있는 제약회사로 질병과 컨디 션을 타깃으로 하는 혁신적인 상품들의 포트폴리오를 개발하기 위 해 BP-Cx-1기술 플랫폼을 사용하며, Anti-Cancer BP-C1, AntiRadiation BP-C2등을 생산합니다 CEO ADD TEL E-MAIL URL X H I B I T S X H I B I T I R O D U C T I O N MEDIAN Diagnostics Inc. have more than 1, 300 hybridoma cell lines for human and animal diagnostic. This is the largest holding amount in south korea. (주)메디안 디노스틱은 2001년 동물진단용의약품 제조업을 허가받 은 국내 최초 기업으로 “돼지열병바이러스 항체검사 ELISA”를 시초 로 지금까지 10 여종의 동물용 체외진단 의약품의 품목 허가를 취득 하고 동물진단 기술의 사업화를 꾸준히 추진하고 있는 기업입니다. 뿐만 아니라 진단 시약 제조에 필요한 동물용 및 인체용 항체, 항원 원료 등을 공급하는 분야로 사업영역을 확대하여 체외진단 제품 및 원료 공급 전문선도기업으로 성장하였습니다. FAX E-MAIL N T Nam-Soo Paek 백남수 #981, Wangam-dong, Jechon-city, Chungcheongbuk -do, 390-250, Korea 82-43-644-4216~7 82-43-644-4215 [email protected] http://www.mediogen.co.kr/index-e.html X H I B I T S Probiotics (Lacticacid bacteria, materials), Probiotics (Finished products), Fermented natural materials (Food, Cosmetics) 항체, 항원, FBS, BSA 등 원료 제품 T TEL E Service Information Leaflet 서비스 소개 자료 N ADD S Antibodies, Antigens, FBS, BSA I CEO URL E E Hye-Ryon Kim 김혜련 #409 Nam Yang Building, 49-5, Samjeon-dong, Songpa-gu, Seoul 138-838, Korea 82-70-7687-7210 [email protected] http://medicalwriting.co.kr R O D U C T I O N 프로바이오틱스 (유산균, 원료), 프로바이오틱스 (완제품), 발효천연문 Clinical QA and medical writing services by specialized 농축액 (식품, 화장품용 원료) professionals 전문 auditor와 medical writer의 특화된 서비스 (임상시험QA, 계 획서/보고서 작성 및 번역) I N T R O D U C T I O N MEDIOGEN Co is a growing bioventure corporation based on the life science. We are promoting the research and development steadily so that it can provide the probiotic products of the highest quality that can be applied health functional foods, dairy products, fermented herbal products, cosmetics, and animal medicine and having mass production of 20 kinds of lactic acid bacteria. Particularly MEDIOGEN produces probiotics with the characteristics for gastric juice and bile acid resistance and probiotics finished products is very advantageous because of having high survival rate in long-term storage. In addition we provide fermented herb products that enhance more the physiological activity and absorption rate than original herb by bioconversion. 주식회사 메디오젠은 생명과학을 기반으로 성장하는 바이오 벤처기 업입니다. 당사는 건강기능식품, 유제품, 생약 발효물, 화장품 및 동 물 의약품등에 응용할 수 있는 최상급 품질의 probiotics 제품을 제 공할 수 있는 꾸준한 연구개발과 20여종의 유산균을 대량생산을 하 고 있습니다. 특히 메디오젠의 probiotics 제품은 내산성과 내담즙 성의 특징을 보유하여 장관내의 생존율이 높고 장기 보존시 낮은 사 멸율로 완제품 유통시 매우 유리 합니다. 또한 생약을 발효하여 유효 성분을 생물전환 시키므로서 보다 생리활성이 높고 흡수율이 증강된 생약 발효물을 제공하고 있습니다. 또한 그간 축적된 기술을 근간으 로 다양한 제형의 완제품을 개발, 생산, 납품하고 있습니다. 166 167 N10 A24 J42 C48 Merck Ltd. Korea META BIOMED MetaBio, Inc. MicroDigital Co., Ltd. 머크 주식회사 메타바이오메드 메타바이오 주식회사 마이크로디지탈 Michael Grund 15th, Floor, Haesung-2-Bldg., 942-10, Daechi-2dong, Gangnam-Gu, Seoul, 135-725, Korea 82-2-2185-3800 82-2-2185-3900 http://www.merckmillipore.com CEO ADD TEL FAX URL CEO ADD TEL FAX E-MAIL E X H I B I T S Total Solutions for Bioindustry through USP to DSP URL E Seok Song Oh 오석송 O song Bio-Health Science Technopolis, 270, Osongsaengmyeong1ro, Osong-eup, cheongwongun, Chungbuk, South Korea, 363-951 82-43-218-1981 82-43-217-1988 [email protected] http://www.meta-biomed.com X H I B I T S -Synthetic Absorbable Suture -Bone Restoration Materials Merck Millipore (Protein research assays and reagents, -Non-absorbable Surgical Mesh cell culture solutions and drug discovery services for biopharmaceutical companies as well as laboratory -흡수성 봉합사 chemicals for research, analytical and hospital laboratories) -골 대체제 -요실금 메쉬 I N T R O D U C T I O N I N T R O D U ADD TEL FAX E-MAIL URL C T I O N (주)메타바이오메드는 보건의료산업발전을 위해 의료용구 제조업체 로 1990년 설립 된 이후 지속적인 연구개발을 통하여 치과용 제품 뿐만아니라 외과용 새운해성 수술용봉합사 등 우수한 신제품을 개발, 생산하여 미국, 유럽을 포함한 80여 개국에 수출하고 있습니다. 또한 정형외과용 골수복재에 대한 연구를 차세대 신기술과제로 진행하고 있습니다. 이러한 끊임없는 연구개발로 메타바이오메드는 생명공학 분야의 창조적인 기업으로 성장해 나갈것이며 이를 위해 전 임직원 은 새로운 가치창조를 추구하고 있습니다. KIM MOON BO 김문보 358-10 Cheonho-Dong, Gangdong-Gu, Seoul, KOREA 82-2-482-5690 82-2-482-8670 [email protected] http://www.metabio.co.kr CEO ADD TEL FAX E-MAIL E X H I B I T S URL Kim KyungNam 김경남 #A-101, Korea Bio Park B/D, 694-1, SamPyungDong, Bundang-Gu, Sungnam-Si, GyungGi-Do, 463-400, KOREA 82-31-628-2207 82-31-628-2222 [email protected] http://www.md-best.com Tumorgraft (orthotopic cancer model mouse) X H I B 3-D Histoculture Drug Response Assay (in vitro chemosensitivity E test) 1. Integrated Sample Banking System 2. MicroPlate Luminometer 3. Quantitative Real-time PCR I Since its foundation in 1990 as a manufacture of medical devices to contribute to the development of health & medical industry. META-BIOMED Co., Ltd has manufactured excellent products such as not only biodegradable surgical sutures but also dental products through sustained R&D and are exporting such products to over 80 countries including the USA and Europe. Creativity and challenge. As a result of positively focusing on R&D investment as a technology-intensive small/medium enterprise since its foundation, the company could be positioned as an enterprise that is capable of manufacturing superior products being acknowledged at home and abroad including world best products and localized products being selected as the products of new technology. 168 CEO N T R O D U C T I O I T S N Metabio, Inc. is a venture company specializing in cancer research and biomedicine, established in 2000. We have close working links with cancer centers in general hospitals where we are fulfilling our medical purpose of individually customized cancer programs. First goal is to build “Anticancer susceptibility test system” from which personal anti susceptibility can be forecasted by using patient’s cancer tissue. Second goal is to make it realized the followings: 1.To predict individual medical treatment through “ Mini cancer patient (Avarta mouse) model” that has the same cancer as that of patients. 2.To improve cancer patients’ life quality based on patients’ individual information regarding the cancer. Also, Metabio, Inc. as “ Medicine and medical supplies quality control institution”, performs various tasks such as study of biomedicines and quality control and we are making our ways to realization of individual customized medical treatment and as well as development of new medicines by using in variety of disease-model animals and DNA chips. 1. 통합검체보관시스템 2. 유전자발현 발광측정기 3. 실시간유전자증폭기기 I N T R O D U C T I O N MicroDigital is a manufacturer and developer of biomedical instruments for laboratories in hospitals and institutes. Based on Optical Detection and Lab Automation System, we produce Microplate Luminometer, Quantitative RealTime PCR and Sample Banking Total Solution. And Multi-mode Microplate Reader, Disposable Bioreactor, and Toxicity Monitoring Instrument are currently in development. Countless general hospitals and institutes are currently taking advantage of MicroDigital's cuttingedge technology. MicroDigital is firmly holding its place as a leading company in the field of biomedical through constant research and development. (주)마이크로디지탈은 바이오메디칼 장비 제조/판매 회사로서, 광학 측정 및 자동화 분야의 독보적인 기술을 기반으로 iSBS (통합검체보 관 솔루션), LuBi (발광측정장치), AmVer (Real-Time PCR)를 생 산/판매하고 있으며, 많은 병원, 대학교, 연구기관에서 마이크로디지 탈의 제품을 사용하고 있습니다. 또한 멀티모드 마이크로플레이트 리더, 일회용 배지 혼합 시스템, 생 태독성 모니터링 장치 등의 제품을 정부연구과제와 연계하여 개발 중에 있습니다. (주)마이크로디지탈은 혁신적인 기술을 바탕으로 바이오메디칼 장비 분야의 선도기업으로 발돋움 하고 있습니다. 169 N23 P22 Missouri Trade & Investment Office - South Korea 미국 미주리 주정부 한국사무소 CEO ADD TEL E-MAIL URL Montgomery County MPI Research (주)모든스킨 몽고메리 카운티 엠피아이 리서치 ADD TEL FAX E-MAIL URL E X H I B I T Woong–ho Cha 차웅호 # 2203 Saengsankwan, CTP, 43-5 Sameun-Ri, Jiksan-Eup, Cheonan-Si, ChungNam, S.Korea 330858 070-7819-1002 0303-3442-1002 [email protected] www.drjina.com S Injectable dermal fillers - RPC (Rapidly polimerizing collagen) - NanoMatrix (gold nanoparticle-collagen matrix) E X H I B I T S Cosmetics 화장품 I N T R O D U C T I O B35 MODNSKIN Inc. CEO Luis Jimenez 1610 S Providence Rd. Columbia, MO, 65211, USA 1-573-319-9020 [email protected] http:// www.eternogen.com N20 N EternoGen is a medical Bio-Tech company with a focus on I N T R O D U C T I O N designing and manufacturing a novel collagen scaffolds for Dr.JinaCha is health & beauty venture enterprise based on soft tissue therapeutic applications. pharmacy Doctor & cosmetic researcher. Dr.JinaCha will try to make an effort to creat beauty and keep healthy using bio mechanism within cosmetics, healthy foods, and new functional ingredients. 기능성 화장품 브랜드Dr.JinaCha는 미국 약학박사인 Jina Cha와 화장품 개발자이자 오빠인 Woong-ho Cha가 뜻을 모아 만든 것에 서 시작되었습니다. “From Natural" 이라는 모토로 효능이 있는 화장품을 만들기 시작 합니다. S tella B. Werner Council Office Building 100, Maryland Avenue Rockville, MD 20850, U.S.A. 1-240-777-7900 http://www.montgomerycountymd.gov/ ADD TEL URL CEO ADD TEL FAX E X H I B I T S ‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland 2020’ Strategic Plan Introduction 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, Johns Hopkins University, University of Maryland School of Medicine, Montgomery County, University of Maryland BioPark, BioHealth Innovation 총 7개 업체 함께 참여 I N T R O D U C T I O N Montgomery County is a county in the U.S. state of Maryland situated just north of Washington, D.C., and southwest of Baltimore. It is one of the most affluent counties in the USA, and has the highest percentage (29.2%) of residents over 25 years of age who hold postgraduate degrees. Montgomery County is the epicenter for biotechnology in the Mid-Atlantic region. It is the third largest biotechnology cluster in the USA, holding the principal cluster and companies of large corporate size in the state. E-MAIL URL E William U. Parfet 54943 North Main Street, Mattawan, MI 490719399, USA 1-269-668-3336 1-269-668-4151 [email protected] http://www.mpiresearch.com X H I B I T S We will introduce MPI Research's services to visitors 엠피아이 리서치에서 수행하는 연구/시험 서비스를 소개 합니다. I N T R O D U C T I O N 엠피아이 리서치는 의약품, 생물의약품, 의료기기, 동물의약품, 그리 고 농약개발을 위해 필요한 전임상 및 초기 임상 연구/시험 대행서비 스를 제공합니다. 1995년 미국 미시간 주에 설립되어 현재 전 세계 시장을 대상으로 그 영역을 넓히고 있으며 (주)다인토탈솔루션을 통 하여 국내에 소개되고 있습니다. MPI Research is a privately held Midwestern company that focuses on the preclinical and early clinical research needs of the biotech, pharmaceutical, medical device, animal health, and agrichemical industries. Our success is attributed to the mastery of effective teamwork and to being the very best in our field. 몽고메리 카운티는 미국 메릴랜드 주 동부 해안에 위치한 카운티로 미국 내에서 인구가 가장 많은 도시 중의 하나이며 자원이 풍요로운 행정중심지입니다. 또한 25세 이상 인구 중 가장 많은 박사학위 보유 자 (29.2%)가 거주하고 있는 도시이기도 합니다. 몽고메리 카운티는 미국 동부 지역의 바이오 산업 발전의 진앙지이 며, 미국에서 세번째로 큰 바이오 클러스터가 위치해 많은 기업이 밀 집해 있습니다. 170 171 Q18 O13 A15 H10 NANOSCOPE SYSTEMS, INC. National Cancer Center Natural Bio-Materials Inc. 나노스코프시스템즈(주) 국립암센터 (주)엔비엠 CEO ADD TEL FAX E-MAIL URL CHUN BYUNG SEON 전병선 Unit 333 Hanshin S-MECA Gwanpyeong-dong Yuseong-gu Daejeon 305-509 Republic of Korea 82-42-862-0772 82-42-336-4774 [email protected] http://www.nanoscope.co.kr/ CEO ADD TEL FAX E-MAIL URL X H I B I T S K1-Fluo, NS-3500 I N T R O D U C T I O N NANOSCOPE SYSTEMS, INC. the nation's first highresolution three-dimensional laser scanning confocal microscope developed with its own technology was first commercialized in Korea brand. K1-Fluo biochemical studies in the field of the high sensitivity of fluorescence confocal microscopy for imaging observations, currently holds a regular microscope can be mounted in a frame which is practical and economical product is configurable. A world-class NS-3500 laser scanning confocal microscopy techniques have been implemented as a product, threedimensional observation of micro-meter level in a variety of fields that require measurement only is used as a module or universal instrument. 나노스코프시스템즈 (주)는 국내 최초로 고해상도 3차원 레이저 스캐 닝 공초점 현미경을 자체 기술로 개발하여 최초의 한국 브랜드로 제 품화 하였습니다. K1-Fluo 는 생화학 연구 분야에서의 고감도 영상 관측을 위한 형 광 공초점 현미경으로, 현재 보유하고 있는 일반 현미경 프레임에 장 착할 수 있어 실용적이고 경제적인 구성이 가능한 제품입니다.NS- 3500 은 세계 수준의 레이저 스캐닝 공초점 현미경 기술이 구현된 제품으로서, 마이크로미터 수준의 3차원 관측이 필요한 다양한 분야 CEO ADD TEL FAX E-MAIL URL I E Jin-Soo Lee 이진수 410-769 경기도 고양시 일산동구 일산로 323 82-31-920-2148 82-31-920-2139 [email protected] http://www.ncc.re.kr N T R O D U C T I O NET/GH CERTIFICATION (Korea Health Industry Development Institute) Tae-Ho Kwon 권태호 8 09-2, yongam-ri, Bondong-eup, Wanju-gun, Jellabuk-do, Korea 82-63-223-4555 82-63-223-4550 [email protected] http://www.nbms.co.kr 국립암센터는 2000년도 설립 이후 암 연구 수행 및 지원, 암환자 진 료, 국가암관리사업 지원, 암전문가 교육훈련 등을 통해 우리나라 국 민의 암부담을 줄이기 위해 지속적으로 노력하고 있습니다. 특히 암 관리정책 개발, 국내 암연구 진흥, 국내 암전문 의료기관 및 국제기 구와의 협력 네트워크 강화 등을 통해 2006년도부터 시작된 정부의 제2기 ‘암정복10개년계획’의 추진을 적극 뒷받침하고 있습니다. CEO ADD TEL FAX E-MAIL N Ever since its inception in 2000, the National Cancer Center has persevered to lessen the burden of cancer for Koreans by conducting and offering assistance to cancer research, diagnosing and treating cancer patients, assisting in the National Cancer Control Initiatives, and finally, educating and training cancer specialists. Moreover, the NCC is aggressively backing the government's 2nd "10-year Cancer Control Plan (2006)" by devising cancer control policies, promoting cancer research in Korea, and by strengthening the cooperative network forged between Korean cancer-specialized medical institutions and international organizations. NET.GH 인증관 (한국보건산업진흥원 E X H I B I T S URL KO Kyung-hwa 고경화 1 87 Osongsaengmyeong2 (i)-ro, Osong-Eup, Cheongwon-gun, Chungcheongbukdo 363-951, KOREA 82-43-713-8280, 8343 82-43-713-8908 [email protected], [email protected] http://ghmark.or.kr -재조합단백질 (animal free, biotoxin free) E X H I B I T -Enterokinase, Trypsin, hGM-CSF, hG-CSF외 -Plant derived recombinant proteins (animal free, biorisk- NET (New Excellent Technology) Certification free) -Enterokinase, Trypsin, hGM-CSF, hG-CSF etc. NET, GH 인증마크 제품 (의약품, 의료기기, 식품, 화장품 등) I N T R O D U C T I O S N NBM Inc. is a privately owned company established in 2007. NBM is an innovative company that is committed to economically viable and enabling solutions for the production of recombinant proteins, such as growth factors, cytokines and proteases, using transformed plants. The company is approaching the medical scientific research community and the cell culture media and diagnostics market with its products. Our product portfolio has expanded steadily to meet the needs of our customers with biorisk-free growth factors and cytokines. (주)엔비엠은 식물을 이용하여 난발현성 단백질인 단백질 분해효소 (Trypsin, chymotrypsin, Enterokinase, TEV endopeptidase 등)와, 사이토카인 (GM-CSF, G-CSF, INF 등)의 대량생산과 함께 분자농업 기술을 활용하여 희귀병 (고셔병, 헌터증후군, 고뇨산혈증 등) 치료제를 중심으로 한 바이오시밀러 의약품의 생산을 진행하고 I N T R O D U C T I O N GH (Goods of Health) Certification (Medicines, Medical devices, Foods, Cosmetic, etc) 한국보건산업진흥원은 국내유일의 보건산업 육성기관으로 보건신기 술 (NET)와 우수 보건제품 (GH) 품질인증 사업을 수행하고 있습니다. 보건신기술과 우수 보건제품의 우수성을 알리고 글로벌 경쟁력을 강 화하기 위하여 통합홍보를 합니다. Korea Health Industry Development Institute (KHIDI) is an organization that helps improve the national healthcare service which service New Excellent Technology (NET) and Goods of Health (GH) Certification. To inform the excellence and enhancement the global competitiveness of New Excellent Technology (NET) and Goods of Health (GH), Korea Health Industry Development Institute is planning every effort via integrated marketing communication 있으며, GM작물을 이용한 분자농업의 산업화를 위하여 LED를 기반 으로 한 폐쇄형 식물공장 (크린룸)을 구축하여 국내에서 최초로 분자 농업의 산업화를 이루었습니다. 에서 전용 측정 모듈 또는 범용 측정기로 활용되고 있습니다. 172 173 K30 A11 NEOFECT NFEC (National Research Facilities & Equipment Center) 네오펙트 CEO ADD TEL FAX E-MAIL URL Hoyoung Ban 반호영 Jongjadong 158-6 Mosun building 5th floor, bundanggu, Seongnam, Kyunggi 82-70-4235-0215 82-31-711-7057 [email protected] http://www.neofect.com 국가연구시설장비진흥센터 CEO ADD TEL FAX E-MAIL URL E E47 X H I B I T S T R O D U C T I O S (주)노아닉스 누스코 ADD TEL FAX E-MAIL URL Brad Choi 최형준 7 11 Sejung Techno Valley, 134 Gongdanro, Heongdeokgu, Cheongju, Chungbuk, 361290 82-43 905 0972 82-43 715 9202 [email protected] http://www.noanix.com CEO ADD TEL E-MAIL URL Changwoo Baek 백창우 137-061 201ho, 833-27, Bangbae 1-dong, Seocho -gu, Seoul, Korea 82-70-8292-7708 [email protected] http://www.nousco.com E X H I B I T X H I B I T S S EHR Platform, Case Management Tool, Template Editor Spray Coater, Automated Liquid Dispensing System, Precision Pump, Spray Nozzle EHR 플랫폼, Case관리툴, 템플릿 에디터 스프레이코터, 자동분주기, 정량펌프, 스프레이노즐 I N 네오펙트는 디지털 뇌졸중 재활 솔루션을 만들고 있는 회사입니다. 디 지털 뇌졸중 재활 솔루션은 센서가 부착된 재활 기구와 게임화된 재 활 컨텐츠를 통해서 환자의 재활 효과를 극대화 시키는 제품입니다. NOUSCO E -NTIS 국가연구시설장비관리서비스 (http://nfec.ntis.go.kr) -ZEUS 장비이용자서비스 (http://zeus.nfec.go.kr) NEOFECT is developing a digital rehabilitation system for -FEEL 시설장비전자도서관 (http://feel.nfec.go.kr) stroke patients. A digital rehabilitation system motivates patients with rehabilitation game and sensor devices and I N T R O D U C T I O helps them to improve their motor performance. N Noanix Corporation CEO Kyung Man You, Director, 유경만 센터장 169-148 Gwahangno, Yusung-gu, Daejeon, 305806, Korea 82-42-865-3579 82-42-865-3559 [email protected] http://www.nfec.go.kr X H I B I T Electronic glove with motion sensor for stroke rehabilitation E and rehabilitation game -National Science & Technology Information, NTIS -Zone for Equipment User Service, ZEUS 뇌졸중 재활 장갑 및 재활 게임 -Facilities & Equipment Electronic Library, FEEL I K30 The National Research Facilities and Equipment Center (NFEC) performs overall management for the advance of research facilities and equipment through ‘strategic investment’, ‘promotion of share-use’, ‘equipment Engineer’, and ‘enhancement of development capabilities’ of national research facilities and equipment. NFEC support policy-making and legislating of research facilities and equipment, to construct and operate the Deliberative Council of Research Equipment Budget for the efficiency of national R&D investment. 국가연구시설장비진흥센터 (NFEC)는 범부처 연구시설·장비 총괄 전담기관으로 국가 연구시설·장비의 고도화 추진 및 효율적 운영관 리를 위해 ‘전략적 투자', '공동활용 촉진', '전문인력 양성', ’총괄 운영 T R O D U C T I O N NOUSCO is developing EHR platfrom and medical information system and softwares since establishment in Noanix Corporation designs and provides several products 2008 for leading technology and contribute our country. for microfluidics. Main products are Spray Coater, Automated Liquid 누스코는 2008년 설립이래 최고의 기술로써 국가 발전에 이바지한 다는 일념으로 EHR 플랫폼 및 의료정보 시스템, 각종 시스템 소프트 Dispensing System, Precision Pump and Spray Nozzle. For example, Spray coater is used for thin film coatings for 웨어 기술을 개발해오고 있습니다. mainly BioMedical applications. I N N N T R O D U C T I O N 의료 분야 (주)노아닉스는 미세유체 분야의 숨은 강자입니다. 주 제작품은 스프 레이코터, 자동분주기, 스프레이노즐, 정량펌프입니다. 대표적인 스프레이코터는 박막코팅이 필요할 때 쓰이는 정밀한 유체 기기입니다.주 타켓은 바이오메디칼입니다. -국제표준 EHR 플랫폼 개발 (ISO/HL7, ISO/CEN 13606 동시지 원) -국제표준 응용 프로그램 저작용 IDE 개발 -DICOM 뷰어 & 클라이언트 개발 -모바일 PHR 개발 시스템 분야 -국방 & 의료용 RTOS 커널 개발 -보안 운영체제 개발 -하이퍼바이저 개발 -C/C++ 지원 가상머신 개발 관리‘의 4대 전략목표 수립하고, 과학기술하부구조의 고도화를 위하 여 최선의 노력을 다 하고 있습니다. NFEC는 국가연구시설장비 정 책 수립 및 법·제도 개선지원, 국가연구개발 예산편성을 위한 연구 장비예산심의위원회 구성·운영 등의 역할을 수행하고 있습니다. 174 175 C20 L10 L10 A23 NOVAPRO., Ltd NOVO Nordisk Novozymes Biopharma DK A/S NTS Co., Ltd. (주)노바프로 노보노디스트 노보자임 바이오파마 엔티에스 주식회사 CEO ADD TEL FAX E-MAIL URL Yim Min Jae 임민재 Honglk Jeil B/D, 478-12, Seokyo-Dong, Mapo-Gu, Seoul, 121-839, Korea 82-2-338-0059 82-2-338-0079 [email protected] http://www.cryste.co.kr CEO ADD TEL FAX E-MAIL URL X H I B I T S *INFORS Minifors - 소형바이오리엑터 Multitron & Minitron - 교반형 인큐베이터, CO2-습도-온도 컨트 롤 *CRYSTE PURICUBE-Clean Bench PURISUC-Suction Master PURIFUME-Fume Hood PURISTER-Autoclave PURICELL-Incubator PURICELL CO2-CO2 Incubator PURI LOW-Low Temp. Incubator PURIFROZ-Refrigerator PURIVEN-Drying Oven PURIVEN VACUUM-Vacuum Oven PURIKER-Shaker PURIBATH-Water Bath I N T R O D U CEO ADD TEL FAX E-MAIL URL Peder Holk Nielsen Krogshoejvej 36 DK-2880 Bagsvaerd Denmark 45-4446-2896 45-4446-1080 [email protected] www.biopharma.novozymes.com CEO ADD TEL FAX E-MAIL URL I E Lars Rebien Sørensen Novo Allé 2 DK-2880 Bagsvaerd Denmark 45-4444-8888 45-4449-0555 [email protected] www.novonordisk.com N T R O D U C T I O N 당뇨 치료에 있어 90년간의 지속된 글로벌 의료 기업으로, 스칸디나 비아에 인슐린이 제품으로 처음 소개된 1923년 덴마크에 설립되었 습니다. 본사는 덴마크에 있으며 현재 75개국에서 약 35,000명의 직원을 두고 180개국 이상에서 제품을 판매하고 있습니다. 당뇨병 외에도 혈우병 치료, 성장 호르몬 치료, 그리고 호르몬 대체 요법을 개발 및 생산하고 있습니다. I N T R O D U C T I O JeongCheol Jae 제정철 410, Yongsu-ri, Chowol-eup, Gwangju-si, Gyeonggido, Korea 464-865 82-31-765-5620 82-31-767-7260 [email protected] http://www.nts2002.com N 바이오 이노베이션에서 세계적인 선두주자로서 내일의 산업적인 바 이오 솔루션을 창조해 내는 기업입니다. 약 25년간 바이오 제약 산업 에서 특화된 기술과 재 조합된 알부민(albumin), 약물 투여의 필요 성과 의료장비 산업에 맞게 만들어진 히알루론산과 같은 재 조합된 상품들을 생산 및 제공하고 있습니다. E X H I B I T S TSI: BioTrak, 7510, 9500 Rap ID: SPE RamanID+Metal ID, Layer Explorer SISTEMA : FOGGER Particle Generator Thermo Scientific: Prima pro, Standard Particle I N T R O D U C T I O N NTS Co., Ltd. is conduction business of importing for the various analyzers, measuring equipments and process monitors those are related to pharmaceutical, chemical, semiconductor and electronics production line as well as atmospheric environment. 당사는 환경에 관한 토탈 솔루션 제공을 목표로 설립되어, 주로 반도 체 / FPD 생산라인 환경과 관련한 분석 장비의 수출입 업무 및 관련 SYSTEM 의 제작과 일반환경, 제약, 화학 식품공정 라인상의 측정 장비 등을 취급하고 있으며 이와 관련된 각종 서비스 (설치, 유·무상 서비스, 장비 임대 서비스)및 컨설팅 업무를 제공하고 있습니다. C T I O N 저희 CRYSTE는 세계 일류 이화화학기기 제조업체로 도약하기 위 해 생산전문가, 영업전문 인력, 서비스 기술자 그리고 제품디자이너 에 이르기까지 목표를 향해 최선의 노력을 다하고 있는 저희 회사는 향후에도 증대되는 시장의 요구사항에 부합하는 제품생산을 위해 최 상의 성능을 유지하는 제품을 지속적으로 공급하고자 합니다. 아울 러 최상의 품질 기준 을 충족 시키고 있는 최첨단 공장에서 생산되는 CRYSTE는 저희 회사만의 고유의 열정과 책임감 그리고 신념을 가 지고 시장을 선도해 나갈것입니다. 176 177 R25 O22 식품제조사업은 국/탕/찌개, 면, 육가공, 냉동밥, 반찬, 베이커리 등 우리 식탁을 풍성하게 채워주는 다양한 카테고리의 제품을 생산하고 있습니다. OUR HOME (주)아워홈 CEO ADD TEL FAX E-MAIL URL Seung-woo Lee 이승우 5F Meritz Tower, 382, Gangnamdae-ro, Gangnamgu, Seoul, Korea 82-70-8685-2806 82-2-6713-6531~3 [email protected] http://www.ourhome.co.kr/ 특히 2007년부터 HMR을 대표하는 200여가지 다양한 상품군을 선 보이며 소비자의 맛과 품질에 대한 신뢰를 바탕으로 비약적인 성장 을 거듭하고 있습니다. 이번 박람회에 소개드리는 오곡감초 삼계탕은 몸에 좋은 5가지 곡물 (찹쌀, 흑미, 현미, 보리, 율무)에 GAP인증 제천산 감초를 더한 영양 강화형 삼계탕으로 불필요한 첨가물을 사용하지 않고 몸에 좋은 재 료와 건강한 레시피로 만들었습니다. B30 OLYMPUS KOREA Co., Ltd. Orient Bio Inc. 올림푸스한국(주) 주식회사 오리엔트바이오 CEO ADD TEL FAX E-MAIL URL KATSUHIKO INADOMI Olympus-Tower B-dong 4th floor, 114-9 SamseongDong, Gangnam-Gu, Seoul, Korea. 82-2-6255-3200 82-2-6255-3377 [email protected] http://www.olympus-scope.com ADD TEL FAX URL I E X H I B I T S Five Grains & Licorice Ginseng Chicken Soup 오곡감초삼계탕 I N T R O D U C T I O N OURHOME is a food specialty brand that seeks to contain the love and care of mothers. OURHOME continues to grow with customers from a leader in food service into a super excellent general food company covering food supplies, restaurants, and food manufacturing. Among the many businesses, Food business produce a broad array of products encompassing almost the entire range of culinary culture and tradition in korea, including the many soups, stews, noodles, processed meat, frozen rice dishes and food, side dishes, bakery, and so forth. Especially we launched an HMR brand in 2007, deploying 200 or so products and has continued with its explosive growth based on customer trust in the taste and quality. At the fair, we introduce the five grains & Licorice Ginseng chicken soup (samgyetang). Five kinds of salubrious grains (gluinous rice, black rice, brown rice, barlay, and adlay) and added the GAP certified Jecheon licorice to fortified chicken soup. We make our products with healthy and fresh ingredients, minimizing the use of additives. *HMR: Home Meal Replacement *GAP: Good Agricultural Practices E X H I B I T Jae-Jin Jang 장재진 3 22, Galmachi-ro, Jungwon-gu, Sungnam-si, Gyeonggi-do, Korea 82-31-730-6100 82-31-730-6715 http://www.orientbio.co.kr CEO N T R O D U C T I O N S Orient Bio Inc. has contributed to the development of Biological Microscopes, Metallurgical Microscopes, new drug and biotech research industry in Korea by introducing, producing and supplying highest quality of Industrial Videoscopes, Endoscopes, Video Equipment research animals, which is core composition of biotech. 금속현미경, 생물현미경, 산업내시경, 의료내시경, 영상기기 With the help of technical cooperation with the World’s best research animal providers, we supply IGS (International Genetic Standard) research models from rodents to nonI N T R O D U C T I O N rodents and a variety of research equipments and facilities. The first product produced by Olympus was a microscope, Also, through our affiliated CRO company - Genia Inc., we introduced in 1920. Since then, Olympus has become the carry out studies on new drug development, safety and leading provider of precision microscopes and microscope efficacy test, xenograft and disease models. systems to clinical laboratories, science, engineering, education and research industries. Olympus bioimaging (주)오리엔트바이오는 바이오산업의 근간이 되는 국제표준의 고품질 technologies are assisting a variety of the latest scientific 실험동물 도입·생산·공급함으로써 한국의 신약 및 바이오 연구개 researches in biology and medicine, which will help define 발에 기여하고 있습니다. 이를 위해 세계최고의 실험동물 기업과 기 the next generation of healthcare, including mechanisms 술 제휴를 통해 설치류부터 중대형동물까지 국제표준 실험동물과 다 양한 실험장비 및 실험설비를 공급하고, 비임상시험 기관인 자회사 for drug action and immunity mechanisms. 올림푸스한국은 현미경 및 산업용내시경으로 국내 반도체를 비롯한 정밀산업 전반, 생물학 및 의학발전에 이바지하고 있습니다. 금속현 미경은 기계 및 금속의 표면 검사 및 측정장비로 사용되고 있으며 생 물현미경의 경우 각종 병원, 학교, 국가기관, 기업연구소에서 기초과 학부터 임상연구까지 광범위하게 사용되며 암치료제 개발, 각종 세포 제니아를 통해 신물질 탐색, 안전성 및 유효성 시험, 이종장기 이식연 구와 질환모델 연구 등을 진행하고 있습니다. 치료제 개발 등 의학 발전의 핵심 역할을 하고 있습니다. 아워홈은 어머니의 정성과 요리 전문가의 손맛을 가득 담은 브랜드 입니다. 아워홈은 Food service 분야 리더에서 식재, 외식, 식품제조에 이르 는 초일류 종합요리식품기업으로 고객과 함께 성장해 갑니다. 그중, 178 179 K30 J47 A14 N31 PANAGENE, Inc. PCL, Inc. Pharma Line Inc 주식회사 파나진 피씨엘(주) 파마라인(주) CEO ADD TEL FAX E-MAIL URL Sung Kee Kim 김성기 305-510, 54, Techno 10-ro, Yuseong-gu, Daejeon, Korea 82-42-861-9295 82-42-861-9297 [email protected] http://www.panagene.com CEO ADD TEL FAX E-MAIL URL In-kyu Kim 김인규 (153-777) #701, 99, Digital-ro 9-gil, Geumcheongu, Seoul 153-777 REPUBLIC OF KOREA 82-70-4673-3455 +82-70-4673-3443 [email protected] http://www.pclchip.com CEO ADD TEL FAX E-MAIL URL Pharma Stores LLC Lee du yong 이두용 IF, 24Dangjin-ro32beon-gil, Gwonseon-gu Suwoncity, Gyeonggi-do, korea 82-31-505-5207 82-31-505-5209 [email protected] http://www.pharmaline.co.kr CEO ADD TEL FAX E-MAIL E E X H I B I T S Molecular Diagnostic Kit, PNA Oligomer E X H I B I T S SolB Complete Kit, sciFLEXARRAYER, Sensovation fluorescence /colorimetric scanner, Hi3 multiplex diagnostics 유전자 진단시약, PNA Oligomer N T R O D X H I B I T S U C T I O N Panagene is a worldwide custom PNA (peptide nucleic acid) oligomer provider, and has focused on developing various molecular diagnostic products based on PNA oligomers. With strong patent portfolio for manufacturing PNA products, Panagene succeed to commercialize diagnostic kits for somatic mutation and infectious disease. N T R O D U C T I O H I B I T S Medicine, Foods I N T R O D U C T I O N Pharmaceutical & Medical Devices N 피씨엘 (주)는 한국, 보스톤 (USA) 에 사무실을 두고 있는 바이오 벤 처 회사로써 SG CapTM 이라는 원천 기술을 바탕으로 연구용 시 약인 SolBTM complete kit 과 혈액 선별용 진단칩 개발과 신약 타겟 물질 동정 서비스를 진행하고 있음. 또한 독일의 Scienion 사 의 국내 독점 대리점으로 microarrayer 를 판매하고 있으며, 독일 의 Sensovation 사의 대리점으로 fluorescence/colorimetric scanner 의 판매를 진행하고 있음. X Nova Matrix R-3d.Bead Generator 세포배양키트, 비드생성기 I I E Dr. Mohammed Sadiq Hussain Alias Khalid P.O. Box : 39803. Dubai, U.A.E. Creek Tower, Site no. 22-B, 22nd Floor. 97-14-229-6655 97-14-229-6363 [email protected] I N T R O D U C T I O N Kit for 3D cell culture in alginate scaffolds Encapsulation system for immobilization of materials 알지네이트 지지체의 3차원 세포 배양을 위한 키트 비드 생성기 파나진은 2001년 창업하여 인공 DNA인 PNA의 세계 유일한 대량 생산법을 개발하고 PNA의 전세계 독점 판매권을 취득하여 판매하 고 있다. 유전자 진단 PNA 칩을 개발하여 세계 최초로 상용화에 성 공하였으며, 맞춤형 암치료에 필수인 암 유전자 변이 진단 키트, 결 핵 진단 키트 등 다양한 유전자 진단 제품을 출시하여 판매하고 있는 International biotec co. PCL, Inc has offices in Seoul, S. Korea and Boston, USA. PCL offers three categories of products based on its proprietary SG Cap™ technology and SolB™ reagents: 1) Blood-based diagnostic tests, 2) Research reagents and tools and 3) Drug discovery R&D 유전자 진단 전문 회사이다. 자궁경부암 진단 PNA 칩으로 2010년 services. PCL is local distributor of Scienion, non-contact Frost & Sullivan 사로부터 제품혁신상을 수상하였고, 암 유전자변 type microarrayer supplier and Sensovation, fluorescence / 이 진단 키트는 기술력과 경쟁력을 인정받아 2012년 지식경제부장 colorimetric scanner supplier in Germany 관으로부터 세계일류상품 인증을 받았다. 180 181 K30 L38 P15 N36 Pharmabcine Pharmaphenix S.L. PIPC (Patent Information Promotion Center) (주)파멥신 파마페닉스 한국특허정보원 특허정보진흥센터 CEO ADD TEL FAX E-MAIL URL Jin-San Yoo 유진산 305-811 Daejeon BioVentureTown, 461-8, JeonminDong, Yuseong-Gu, Daejeon, Republic of Korea 82-42-863-2017 82-42-863-2080 [email protected] http://pharmabcine.com CEO ADD TEL E-MAIL URL N T R O D U C T I O N PharmAbcine is a specialized biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases. We build competitive pipelines & drug discovery platform (Tanibirumab & Bi-Specific Antibody) by in-house approach. 파멥신은 암치료를 위한 항체 신약개발을 목표로하는 바이오벤처 기업으로 2008년 설립이후 Novartis, OrbiMed, (주)녹십자 등 국내외 유수의 벤처 캐피탈의 투자를 유치하였으며, 세계적 수준 의 완전인간화 치료용항체 및 이를 기반으로 한 이중표적항체 연 구를 진행하고 있다. 특히, 당사의 파이프라인 가운데 선도물질인 Tanibirumab은 현재 임상1상이 진행중에 있으며, 2014년 IPO 성 공을 통해 세계적 기업으로의 성장을 목표로 하고 있다. 182 CEO ADD TEL FAX E-MAIL URL E I Pascal Nizet Parc Cientìfic de Barcelona, Carrer Baldiri Reixac 4-8, 08028 Barcelona, Spain 34-93-449-7649 [email protected] http://www. pharmaphenix.com X H I B I T N T R O D U T I O N Pharmaphenix is a boutique international pharmaceutical consulting company established in 2008 that has specialized in all aspects of the Business Development chain. Our clients include a broad range of investors, biotechs, start-up ventures, and pharmaceutical companies located in Europe, North America and Asia. We focus on the rapidly emerging markets of Latin America, MENA and Korea. Our in-depth corporate experience gives us a global reach with a contact base that includes key players (companies and people) in our target markets, but also allows us to reach the rest of the world thanks to our unique platform. Our objective is to make our customers grow through the development of new businesses (new markets, new products or new structures) and assess them in that process. For BioKorea, we look for biotechs and pharmaceutical companies interested in looking for marketing partners for their products, either in development or even already marketed in Korea. X H I B I T Mr Vijay Shah 247 Business Park, A - Wing, 6th Floor LBS Marg, Vikhroli (West) Mumbai 400083, India 91-22-3096-6666 91-22-3096-6665 http://piramalpharmasolutions.com CEO ADD TEL FAX URL I E C Park Jeong Ryeol 박정렬 146-8 Donggyo-dong, Mapo-gu, Seoul, Korea 121-816 82-2-6915-6250 82-2-6915-6497 [email protected] http://www.pipc.or.kr S Consulting, license in, out-licensing I Piramal Healthcare Ltd. N T R O D U C T I O N S Pharma Solutions is the contract development and manufacturing (CDMO) division of Piramal | Healthcare, a part of the Piramal Enterprise. We are one of the largest custom manufacturing companies in the world 민간에 제공하는 특허정보서비스 (KIWEE), KIWEE 검색, IP리서치, that provides flexibility and scalability of operations. We have created a vast network of contract development IP컨설팅, 특허평가·통계 서비스 등 and manufacturing facilities located in North America, Europe and Asia that offers a multitude of services that I N T R O D U C T I O N cover the entire drug-cycle, from development and PIPC (Patent Information Promotion Center), a public commercial manufacturing to off-patent supplies of Active institution affiliated with KIPO (Korean Intellectual Property Pharmaceutical Ingredients (APIs) and formulations. Office), supports the KIPO’s policies and offers various patent information services such as IP research, analysis, evalution and consulting. etc. IP information services (KIWEE) IP research, IP consulting, Patent evalution (K-PEG). etc 특허청 산하의 공공기관으로서, 특허청의 정책업무를 지원하는 동시 에 특허정보 조사·분석·평가·컨설팅 등 다양한 특허정보서비스를 민간에 제공하고 있습니다. 183 M23 L31 PRA International CEO ADD TEL FAX E-MAIL URL K30 Propharma Medical Supplies Colin Shannon 4130 ParkLake Avenue, Raleigh, North Carolina, 27612 1 (919) 786-8200 1 (919) 786-8201 [email protected] http://www.praintl.com CEO ADD TEL FAX E-MAIL URL Dr. Mohammed Abuelkhair Plot-C2 Meena Store Abu Dhabi, U.A.E. 971-2-673-4781 971-2-673-4768 [email protected] www. propharma.ae R20 ProteomeTech Inc. Puretech P&T Co., Ltd. (주)프로테옴텍 (주)퓨어테크피앤티 CEO ADD TEL FAX E-MAIL URL Lim, Kook Jin 임국진 B 202 Yonsei Dairy Building, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-110 Korea 82-2-323-8325 82-2-323-8379 [email protected] http://www.proteometech.com CEO ADD TEL FAX E-MAIL URL E X H I B I T S E X H I B I T S E Human IgG Rapid CRO N T R O D U C T I O X H I B I T S Viral Clearance studies, Viral Safety Testing, The Immunoprofiling LAB, Viral Safety and Immunology Services 휴먼 이뮤노글로불린G 래피드 I Kim, Tae Bong 김태봉 Western Tower II, A-dong 704ho, 24, Jeongbalsanro, Ilsandong-gu, Goyang-city, Gyeonggi-Province, 410-838, KOREA 82-31-908-6870 82-31-908-6873 [email protected] http://www.ipuretech.com N As a leading CRO, PRA is transforming clinical trials through our people, innovation and operational transparency. With 5,000+ employees in 80+ countries, PRA provides a full suite of services across all phases. We have conducted the pivotal or supportive trials that led to FDA and/or international regulatory approval of 40+ drugs marketed across several therapeutic areas. Since our inception in 1976, we have amassed a level of expertise that enables us to work on a variety of compounds, ranging from niche treatments and therapies to blockbuster drugs. PRA clients benefit from our strategic investment in key therapeutic programs and research areas, including neurology/psychiatry, oncology/hematology, infectious diseases, biosimilar products, cardio-metabolic diseases, and rare diseases. PRA’s advanced technological tools and finely tuned systems ensure seamless delivery and transparency throughout our organization. Our dynamic services and forward-thinking approach to drug development programs are making a difference to healthcare patients worldwide. I N T R O D U C T I O N Human IgG Rapid of Proteometech is research reagents monitoring Human IgG content in real time by immune chromatographic techniques 프로테옴텍은 “나를, 회사를, 사회를 행복하게” 라는 경영이념을 가 지고, Biomarker분석연구 및 rapid 정량기술 등을 통하여 고객의 unmet need 충족을 위해 항상 노력하며 성장하는 기업입니다. 프 로테옴텍의 Human IgG Rapid는 면역 크로마토그래피기술을 이용 하여 인간 유래 면역글로불린 G (Human IgG, hIgG)의 함량을 실 시간으로 모니터링 할 수 있는 연구용 시약입니다. 바이러스 제거 연구, 바이러스 안전 테스트, Immunoprofiling 연구 소, 바이러스 안전 및 면역학 서비스 I N T R O D U C T I O N Puretech P&T is a service provider providing cutting- edge technologies, tools and services for Biopharmaceuticals, Pharmaceuticals, Food &Beverage, Semiconductor, Chemicalmanufacturing. Our company have three strategic business unit. Filtration Unit related with Filter and Resin. This unit is working with MERCK MILLIPORE, ENTEGRIS (MYKROLIS), DOW (RHOM & HASS), TAMI, KOCH, MEGA, VSEP. Engineering unit provide custom purification system. Service unit is working with TEXCELL, INTERTEK, LONZA HUSTON as a strategic partner, we collaborate with customers to confront the world’s challenging industry issues. (주)퓨어테크피앤티는 바이오, 제약, 식품 및 반도체 업계에 공정용 필터 및 수지, 정제 장비 제조, 대행생산 및 대행실험을 제공하는 전 문 기업입니다. MERCK MILLIPORE, ENTEGRIS (MYKROLIS), DOW (RHOM&HASS), TAMI, KOCH, MEGA, VSEP사의 제품 판매 분야와 제품을 기반으로한 고객 맞춤 설비 ENGINEERING분 야, TEXCELL, INTERTEK, LONZA HOUSTON의 CRO & CMO 서비스 분야에서 고객과 함께 일하고 있습니다. 현재 여러 기업에 대 한 컨설팅 및 엔지니어링 그리고 판매 서비스를 담당하고 있으며, 차 별화된 전문성을 기반으로 고객 친화 서비스를 실현해 가고 있습니다. 184 185 K30 E10 I40 REGENPRIME Co., Ltd. Regeron, Inc. REP. OF NEW BRUNSWICK SCIENTIFIC CO., INC 리젠프라임(주) (주)리제론 (주)한국 엔비에스 CEO ADD TEL FAX E-MAIL URL E J.H. Yoon 윤정호 5F Seoyeong plaza, 518-3, Uman-dong, Paldal-gu, Suwon, Gyeonggi-do, S.Korea 82-31-217- 4011 ~ 4 82-31-217-4015 [email protected] http://regenprime.com/ X H I B I T S ArtiFilm, CorneFilm, SIS sheet, SIS Powder, PCP, PCP-WS N T R O D U C T I O ADD TEL FAX E-MAIL URL E Dahlkyun Oh 오달균 103 Bio-2, Hi-Tech Venture Town, 40 SoyanggangRo, Chuncheon, Kangwon-Do, South Korea 82-33-258-6263 82-33-258-6264 [email protected] http://www.regeron.com X H I B I N 리젠프라임 (주)은 생체소재 (의료기기)와 세포치료제 개발을 하는 재 생의료 전문기업입니다. ‘05년에 설립하여, ‘10년에 생체소재 제품을 국내 최초로 인허가를 받았으며, ‘12년에는 ISO9001 인증을 받았습니다. 이후 2종의 소재 제품과 2종의 세포치료제를 개발하고 있습니다. 허가 받은 제품 ‘아 티필름’은 무릎 연골손상 환자에게 치료를 하는 수술보조기기로, ‘13 년 3분기에 국내판매 개시, ‘14년 CE 인증을 통한 유럽판매 예정입 니다. 두 번째 소재제품인 안과 수술용 보조재 (코니필름)도 ’14년 임상, ‘15년 허가승인을 통해 판매 예정입니다. 세포치료제는 개발진행 중 이고 주로 무릎연골손상 치료제로 개발하고 있습니다. 또한 경기 바이오 센터에 KGMP인증 제조시설을 구축하여 세포치료 제, 의료기기 생산시설을 완비해 명실상부한 글로벌 조직 및 장기 재 생 전문기업의 초석을 마련했습니다. 당사는 이미 확보된 원천 기술과 새로운 기술을 시장에 맞게 상용화 하여 국내 조직재생 시장을 선점함은 물론 해외 시장에서도 인정받 는 선두업체가 되겠습니다. S N T R O D U C T I O N Regeron, Inc. was born as a research institute at 2000. 6 year of hard work from the beginning of Regeron, we developed human growth hormone into cosmetic ingredient as world first. Step by step and one by one we have developed highly functional cosmetic ingredients in this ground breaking bio-ingredient field. To share the passion for re-youth with everyone, we are providing from core-tech-made-ingredients to cosmetics (OEM services and own brand). 리제론은 연구기관으로서 탄생한 이래 6년에 걸친 독자개발과정을 걸쳐 세계최초로 인간성장호르몬을 화장품원료로써 개발하였습니다. 그 후 기능성 화장품원료 개발의 최전선에서 성장인자단백질을 통한 화장품과 그 원료개발에 매진해왔습니다. 그리고 지금은 리제론 탄생 의 원동력이였던 젊음에 대한 열정을 고객과 함께 실현코자 최고의 서비스를 제공하고 있습니다. ADD TEL FAX E-MAIL URL E Kim Han Ip 김한입 #201 SungGwang BLDG, 351-8, Yangjae-Dong, M2P社로부터 Mini-Bioreactor를 국내에 도입하였습니다. 장비 외 Seocho-Gu, Seoul, Korea 에도, Single Use Bag (ASI社), Tubing 제품 (Walton-Mallow社 82-2-587-8558 , Flowsmart社)등을 공급하며, 우리나라 의약산업의 발전에 헌신 할 82-2-583-5874 수 있도록 최신기술의 장비와 서비스를 제공해 드리도록 항상 노력 [email protected] 하고 있습니다. http://WWW.knbs.co.kr X H I B I T S 발효기 백 -주름개선 특효, 미백 특효, 여드름 특효 I CEO 저희 한국엔비에스는 여기에 그치지 않고 미국 Refine社와 독점계약 을 맺어, 차세대 Perfusion System인 ATF system를 국내 처음으 로 성공적으로 도입 및 지속적으로 공급하고 있으며, 최근에는 독일 BIOREACTOR ASI BAG 화장품 : 엔씨지와이/오피나인/프리스틴클레어–리버스에이징, 주름 개선, 미백 화장품원료 : 성장인자단백질 화장품 원료 1. 핵심기술로부터 탄생한 기능성 원료의 제공 2. 자사브랜드화장품 3. OEM 화장품 제조 (최고급 기능성) 등 186 T Cosmetics Skincare - NCGY / OP9 / Pristeen Claire Hair care - Pristeen Cosmeceuticals - BioLetDAge CS line 아티필름, 코니필름, SIS sheet, SIS Powder, PCP, PCP-WS I CEO 및 CO2 Incubator 등 내구성 강한 연구 기자재를 최고의 조건으로 제공 및 서비스하고 있습니다. I N T R O D U C T I O N Our company, K.NBS started business 13 years ago in 1999 with New Brunswick an eppendorf Company Brand product which company is very well known for in manufacturing the Fermentor as well as the Bioreactor over the world. At the early of our business stage, we could successfully introduce the Fermentor and Bioreactor to our Korean biotechnology field. And until now, NBS product became one of our mother based business to growing up and extending our business areas. Also, we successfully introduced the ATF System (Newgeneration perfusion system) in Korea for the first time by getting exclusive supplier contact with Refine company in U.S. And, recently, we bring the Mini-Bioreactor from M2P company in Germany. Besides these Biotech devices, we are taking care of disposal products such as Single Use Bag (ASI), Tubing Products (Walton-Mallow, Flowsmart). we always trying our best to finding our valuable items to meet the customer’s detailed and sophisticated requirement and to contribute to our Korean Biotechnologies. (주)한국엔비에스 ( K . NBS Inc .)는 60 년 전통의 세계최고성능 을 자랑하는 미생물 발효 및 생명공학 연구장비 생산업체인 New Brunswick an eppendorf Company 社의 한국대리점으로서 지 난 20년간 Fermentor 와 Cell Culture Bioreactor 장비를 수 많 은 제약 회사 및 연구소에 제공해오고 있습니다. 그 외에도 Shakers 187 R25 C10 A34 REXGENE BIOTECH Co., Ltd. Samsung Medical Center (Clinical Trial Center) Rev-Med, Inc (주)렉스진바이오텍 삼성서울병원 (임상시험센터) (주)레보메드 CEO ADD TEL FAX E-MAIL URL Kwon, Suk Hyung 권석형 94, Gangni 1-gil, Ochang-eup, Cheongwon-gun, Chungbheongbuk-do Korea 82-43-218-0510 82-43-218-0517 [email protected] http://www.rexgenebio.co.kr CEO ADD TEL FAX E-MAIL URL N T R O D U C T I O N CEO ADD TEL FAX E-MAIL URL I I Young Suk Park 박영석 81 Irwonro, Gangnam-gu, Seoul 135-710, Korea 82-2-3410-0916 82-2-3410-0958 [email protected] http://ctc.samsunghospital.com N T R O D U C T I O N Samsung Medical CTC was established to promote the RexGene Biotech opened in 1996 by the Onnuri Chain international standards in clinical trials, to support the Drugstores, the first and the biggest pharmacy franchise development of clinical research and to provide optium in Korea. The philosophy of our company is to make life research environment for investigators in 1999. happier and healthier for people by providing health food of good quality. We are committed to producing the 저희 삼성서울병원 임상시험센터는 지난 1999년 세계 최고 수준의 highest quality supplements using the latest in technology 임상연구 수행을 위하여 설립되었고, 우리나라가 세계적인 임상시험 and state-of-the-art manufacturing facilities in Ochang, 허브로 성장하는데 기여하는 임상시험센터가 되도록 노력하고 있습 ChungBuk, Korea. Our plant meets or exceeds all Korea 니다. Food and Drug Administration and other health and nutrition standards. Our facilities also operate using current GMP established by the Korea FDA. Our scientists in Life Science Institute meet with professors, medical doctors, nutritionists and other healthcare experts on a regular basis to ensure we are providing products and services that meet the demand of our consumers. By collaborating with many experts in research institutes, we are developing new products and delivering accurate information to our customers. As we have grown over the years, so has our commitment. We have set the standard in the health and nutrition industry by demanding truth in labeling, ingredient safety and potency, while remaining on the cutting edge of nutritional science. We keep helping our customers improve their quality of life through better nutrition and healthier living. E I N T R O D U C T I O N • Foundation : 2009.Jan • Staff : 20 • Sales/Year : usd15M Shin Bong Guen 신봉근 462-806 513-22 Sangdaewon-dong Joongwon-gu • Product line 1.Cell including stemcell concentration or separation Sungnam-city, kyungki-do Joongil EinsPlatz #301 products 82-31-741-0996 PRP kit/Bone marrow stemcell kit/ Adipose stemcell 82-31-741-0976 harvest kit [email protected] 2.Minimally invasive Herniated disc treatment http://www.revmedinc.com equipments Plasma D30 Spine system (PDCT) X H I B I T S 1. TriCeLL PRP kit · Perfect separation : Interlocking bar · You can see the PRP line : bottle neck shape · PRP density is adjustable from 1cc to 5cc · 100% closed system : Most safety and clean ·4~10 times more platelet than whole blood (1,000,000 platelet/uL is guaranteed) CE / USA FDA approval • 설립일자: 2009년 1월30일 • 직원수 : 20명 • 제조품목 : 1. TriCeLL PRP Kit (자가혈 줄기세포 및 혈소 판농축기) 2. TriCeLL BMC kit (골수줄기세포농축기) 3. 자가지방이식용 지방세포 분리기 2. TriCeLL BMC kit (Bone Marrow StemCell) · 100% closed system : The most safety and clean · First in the world, Built in bone marrow filter system · Powerful concentration of CD34+ & MSC · You can see stemcell line with its bottle neck shape. · Perfect separation with interlocking bar system CE / USA FDA 510-K pending 1. TriCeLL prp kit ·인터락킹바를 통한 완벽한 혈액 분리 ·병목구간을 이용하여 혈소판층을 육안으로 확인가능 ·Prp의 농축도를 조절가능 ·완벽한 밀봉구조로 안전성 극대화 ·전혈대비 약 4배에서 10배의 혈소판 농축가능 (1ul당 1,000,000 개이상의 혈소판 보장) CE/FDA 승인 2. TriCeLL BMC (골수줄기세포농축) 기 ·적혈구층의 완벽한 격리가능 ·완벽한 밀봉구조를 구현하여 안전성 극대화 ·골수의 불순물제거용 필터를 키트내부에 내장하여 안전성 및 편 의성 극대화 ·CD34+ 및 MSC 의 농축력이 우수함 ·병목구간을 통해 줄기세포 층을 육안으로 확인가능 CE/FDA 510-Kpending 188 189 M10 P13 conservation The purpose to participate Bio Korea 2013 are as below:1.Tropical herbs and functional agricultural products as 경제개발 투자청 dried super powder (up to 500nano size) 2.Biomass from Palm Oil Mill Datuk Dr. Mohd. Yaakub Hj. Johari. JP 3.Investment supporting program to Sabah state lot 1 wisma SEDIA, Off Jalan Pintas Penampang, government, Malaysia P.O.Box 17251 60-88-450-650 사바 경제개발 투자청은 사바주 개발 코리도의 기초계획, 조정, 홍보 60-88-450-699 를 촉진하기위한 원스톱 기관으로서 생활, 업무 및 투자 최적지로서 [email protected] 의 선도적인 경제발전 지역으로 말레이지아 사바주개발 코리도의 성 http://www.sedia.com.my 공을 촉진하며 이를위한 사회적이고 성장 지속적인 개발을 최우선으 SEDIA (Sabah Economic Development and Investment Authority 사바 CEO ADD TEL FAX E-MAIL URL E X H I B I T S 1.Nano process machinery 2.Tropical herbs and functional agricultural products as dred super powder (up to 500nano size) 3.Biomass from Palm Oil Mill 4.Investment supporting program to Sabah government, Malaysia 1. 나노기계 2.열대 허브및 기능성 농작물을 500나노사이즈의 초미세 분말로 가 공한 제품과 기술 3. 팜공장에서 발생하는 유기물 4. 말레이지아 사바주 정부의 투자지원 프로그램. I N T R O D U C T I O N SEDIA has been entrusted as the One-Stop Authority to drive Sabah Development Corridor (SDC), with the primary responsibility to plan, coordinate, promote and accelerate the development of the SDC. The Objectives of SEDIA are as follows: To Promote and accelerate the development of the SDC into a leading economic region and a choice investment destination for investment, work and living; and To ensure that social development and sustainable development are kept as priorities whilst driving economic growth in the SDC. The SDC programs are underpinned by the three key principles that will guide development in Sabah, namely the need to: - Capture higher value economic activities - Promote balance economic growth with distribution -Ensure sustainable growth via environmental 190 로함을 목적으로 한다. 사바주 개발코리도의 프로그램은 다음과같은 사바주 개발의 세 가지 핵심 원칙에 의해 뒷받침된다 : - 고부가가치의 경제활동 영위 - 성장과 나눔의 균형 - 환경보존을통한 지속적인 성장 이번 Bio Korea 2013의 참가목적은 다음과같다. 1.열대 허브및 기능성 농작물을 500나노사이즈의 초미세 분말로 가 공한 제품과 기술 2. 팜공장에서 발생하는 유기물 3. 말레이지아 사바주 정부의 투자지원 프로그램. A20 Samwoo S&T SCAS-BTT Bioanalysis 삼우에스앤티 (주)스카스비티티바이오애널리시스 CEO ADD TEL FAX E-MAIL URL E Lee Sang Hoon 이상훈 10F MarkCity-Yellow BDG, 963 WoonJoon-Dong Bundang-Gu, Gyeonggi-Do Korea 82-31-755-0350 82-31-754-9645 [email protected] http://www.samwoosnt.com X H I B I T S Amicon, Amicon-Pro, IT4, Lab Scale, Quik Scale, NovA mixer, NovA Valve, NovA Septum, Equinox pump, Milliflex quantum, EZ-stream pump, Microfil, MAS100, Milli-Q integral, Q-Pod, Milli-Q Direct system, Tank, Water purification system CEO ADD TEL FAX E-MAIL URL E N T R O D U C T I O N Samwoo is one of the best distributor of Merck Millipore Korea, we started business with them already over 20 years. The main line of business is all of the filter for Bio industry. our organization growing constantly and very hopeful company. (주)삼우에스앤티는 생명공항, 제약업계, 병원 및 이화학계열 업 체에 실험기자재를 비롯한 생산장비를 공급하는 전문기업으로 Merck Millipore사의 Amicon, 초순수제조장치, bio process 필터 및 시스템, 미생물 측정장치, Column 및 관련 Media를 제 공하며 그 밖에 MP-BIO의 바이오케미칼 등을 취급, JNC 제품의 Chromatography media를 취급하고 있습니다. X H I B I T S Development of Bioanalytical Method Validation, Validation of Analysis Methods, Concentration test of PK & TK, Measure drug concentration of clinical Trial (I, II, III, IV), Measure drug concentration of Bioequivalence Test I I Kang Jong-gu 강종구, Sakaue Shigeyuki 4 43-270 Gyeonggi Bio-center, Iui-dong, Yeongtong-gu, Suwon-si, Gyeonggi-do 82-31-888-6454 82-31-888-6460 [email protected] http://www.scas-btt.com N T R O D U C T I O N SCAS-BTT Bioanalysis, the largest comprehensive analysis company in Japan called Sumika Chemical Analysis Service (SCAS) and the first leading of nonclinical CRO company in Korea which is BIOTOXTECH, based on the highest level of analysis techniques. SBB is Biological Method Validation CRO which established to contribute for development of new drugs. SBB has a variety of experience, the best analytical techniques, the latest equipment and facilities, using the internationally respected CRO of Biological Method Validation, as a high-quality analysis, testing the shortest time and competitive price for developing as early as possible new drugs on the market. SBB wants to contribute for promoting the welfare of all mankind and health. (주)SCAS-BTT Bioanalysis는 일본 최대규모의 종합분석회사인 (주) 스미카분석센터와 한국 민간 최초 및 최대 규모의 비임상시험CRO 인 (주)바이오톡스텍이 최고 수준의 분석기술을 바탕으로 신약 개발 에 공헌하기 위해 설립한 생체 시료 분석 CRO입니다. (주)SCASBTT Bioanalysis는 다양한 경험, 최고의 분석 기술, 최신 기기 및 설 비를 이용하여 국제적으로 신뢰받는 생체시료분석CRO로서, 고품질 의 분석시험을 최단 기간 및 최적 가격으로 수행하여 하루라도 빨리 신약이 시장에 출시되어 인류의 복지 및 건강에 기여할 수 있도록 노 력하고 있습니다. 191 Q13 D30 B13 D20 sellus Co., Ltd. SEOUL METROPOLITAN GOVERNMENT Seoulin Bioscience Severance Hospital Gene Bank 주식회사 셀루스 서울특별시 마곡사업추진단 (주)서린바이오사이언스 연세의료원 (세브란스유전자은행) CEO ADD TEL FAX E-MAIL URL E Kim Ji Woon 김지운 6 2 0 - 2 7 , Yo n g t a n - d o n g , C h u n g j u - s i , Chungcheongbuk-do, Korea 82-43-856-7588 82-43-856-7591 [email protected] http://www.sellus.co.kr X H I B Creant Mise Toothpaste, Boan Cream I T S PARK WON – SOON 박원순 110, Sejong-daero, Jung-gu, Seoul, 100-744 Korea 82-2-2133-1528 82-2-2133-1015 http://english. seoul.go.kr CEO ADD TEL FAX URL ADD TEL FAX E X H I B I T S E-MAIL URL Eul Moon Hwang 황을문 4F. #A, KOREA BIO PARK, 694-1, Sampyeong, Bundang-gu, Seongnam-si, Gyeonggi-do 463400, Korea 82-1670-5911 82-31-628-3006 [email protected] http://www.seoulin.co.kr CEO ADD TEL FAX E-MAIL URL Hogeun Kim 김호근 Yonsei University Health System (YUHS), 134 Sinchon-dong, Seodaemun-gu, Seoul, Korea 82-02-2228-7810 82-02-312-9792 [email protected] http://sev.iseverance.com/dept_clinic/center/gene/ Etc (Yonsei University Health System) SEOUL MAGOK R&D INDUSTRIAL DISTRICT E I N T R O D U C T I O N Seoul city is developing Magok, "last massive land development project of Seoul" to make it the cradle of cutting edge industries. Magok is a urban type of R&D cluster which can use abundant workforce and convenient transportation of Seoul, capital city of dynamic korea and at the same time, eco-friendly new city of high quality equipped with large scale park and green area. And also Magok has the advantage of supplying the industrial districts at production costs. Magok will be the best choice for the bio-tech company dreaming of taking a leap. 서울시는 ‘서울의 마지막 남은 땅‘ 마곡을 첨단산업의 요람으로 만들 고자 '서울 마곡 R&D 산업단지’를 개발하고 있습니다. 마곡은 서울의 풍부한 연구인력과 교통을 활용할 수 있는 ‘도시형 연구단지’인 동시 에, 대규모 공원과 녹지를 갖춘 ‘친환경 명품 신도시’입니다. 또한 산 업용지를 조성원가로 공급하는 이점도 있어 도약을 꿈꾸는 바이오기 업에게 최고의 선택이 될 것입니다. 192 CEO X H I B I T S I N T R O D U C T I O N Thermo Scientific HyClone Animal culture serum free The purpose of the Gene Bank is to provide samples medium, Disposable bags. collected from Severance Hospital to support biomedical Applikon Bioreactor, Purfusion system, Fermentor. research for the prevention and treatment of human disease. We always collect samples with consent of the donors and by complying with the bioethics and safety I N T R O D U C T I O N regulations without harming the donors. We perform As leading total solutions in life sciences, Seoulin Bioscience efficient collection, storage, and fair supply of samples is providing animal culture serum free medium, Bioreactor, for the development of biotechnology, thereby striving to contribute to health and quality of life of the public. Disposable bags. Currently, the Gene Bank has collected a large amount of (주)서린바이오사이언스는 생명공학 선도기업으로 바이오 의약품 제 materials that are essential for development of diagnostic 조 시에 필요한 동물세포 배지, 시약, 배양기, 일회용 bag을 제공하 and therapeutic biomarkers for malignant tumors and 고 있습니다. other incurable diseases. 세브란스병원 유전자은행은 연세대학교 세브란스병원에서 사람으로 부터 유래한 검체를 이용하여 수행하는 연구가 생명윤리 및 안전기준 에 따라 인간의 존엄과 가치를 침해하거나 인체에 위해를 주는 것을 방지하고, 생명과학기술이 인간의 질병 예방 및 치료 등을 위하여 개 발.이용 될 수 있도록 유전자 검사용 검체 수집 및 보관, 유전자 연구 를 위한 검체 공급, 정확한 유전자 검사 등에 대한 여건을 조성함으로 써 국민의 건강과 삶의 질 향상에 이바지함을 목적으로 한다. 현재 세 브란스 유전자은행은 악성 암이나 난치성 질환의 진단과 치료에 대한 바이오마커 발굴에 필수적인 많은 양의 검체를 보유하고 있다. 193 D20 E32, F47 Severance Integrative Research Institute for Cerebral & Cardiovascular Diseases (SIRIC) 연세의료원 (세브란스 뇌심혈관질환융합연구사업단) CEO ADD TEL FAX E-MAIL URL I N Dong Ik-Kim 김동익 Yonsei University Health System, 50 Yonsei-ro, Seodaemoon-gu, Seoul, Korea 82-2-2228-0381 ~ 0385 82-2-2227-7906 [email protected] http://www.siric.re.kr/ T R O D U C T I O E38 R13 SHIN POONG PHARM SK Chemicals SNC-Lavalin Korea 신풍제약(주) 에스케이케미칼 에스엔씨라발린코리아 CEO ADD TEL FAX E-MAIL URL Kim Chang Kyun 김창균 Yoksam-Ro, Kangnam-Ku Seoul korea 135-925 82-2-2189-3400 82-2-558-0565 [email protected] http://www.shinpoong.co.kr Lee In Serk 이인석 3 10 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 Korea 82-2-2008-2008 82-2-2008-2959 http://www.skchemicals.com CEO ADD TEL FAX URL 세브란스 뇌심혈관질환 융합연구사업단은 2008년 12월 보건복지부 선정 선도형 연구중심병원사업으로 발족되었다. 병원의 우수한 인력 을 중추로 한 총 3개 단위, 12개의 산·학·연 세부 팀들이 뇌심혈관 질환의 극복을 위해 예방, 진단, 치료의 전 과정에서 공동으로 연구를 수행하며 체계적이고 효율적인 융합연구의 새로운 패러다임을 만들 고 있다. ADD TEL FAX E-MAIL URL E X H I B I T S E X H I B I Medicurtain Inj. 1.2 ml, 2ml, 5ml etc Medicines, Vaccine, Blood Derivatives 메디커튼 주 1.2ml, 2ml, 5ml 등 의약품, 백신, 혈액제 등 T Todd Farrell 4F, Joongpyeong Building, 748-15, Yeoksam-dong, Gangnam-gu, Seoul, Korea 82-2-566-1400 82-2-566-5633 [email protected] http://www.snclavalin.com S E X H I B I T S Engineering & Construction N Severance Integrative research Institute for Cerebral & Cardiovascular Diseases (SIRIC) was initiated in December 2008 as The project of Leading research-centered hospital under the support of Korean Ministry of Health and Welfare. The SIRIC aims to present a new paradigm for systematic and effective integrated research. This is to enable clinical doctors, basic researchers and experts from industry to conduct joint studies for prevention, diagnosis and treatment of cerebrovascular and cardiovascular disease. CEO 엔지니어링 & 건설 I N T R O D U C T I O N SHIN POONG has contributed to human community with company mission of “For the health of the people” since its foundation in 1962, and now is the one of best pharmaceutical company in Korea with its remarkable growth. We are headquarted in Korea with 5 oversea subsidiaries, getting the spotlight as the best pharmaceutical company in terms of ETC prescription of domestic market in Korea and keeping its global presence in more than 40 countries. Medicurtain Inj. to exhibit at this time is optimal combination of sodium hyaluronate has effect of a physical barrier in preventing adhesion formation and hydroxyethylstarch has effect of inhibiting blood clot as risk factors for the occurrence of adhesion. I N T R O D U C T I O N SK Chemicals is recording continuous sales expansion such as Sunpla the domestic new drug No.1 anti-cancer medicine, Joins the domestic natural new drug No.1, Mvix the domestic new drug No.13, blood derivatives, and medical devices etc. Also our company has set to build a new type of cell culture-based vaccine manufacturing facility as a next step for the global vaccine manufacture. I N T R O D U C T I O N Founded in 1911, SNC-Lavalin (SNC-Lavalin Inc., its subsidiaries and affiliates) is one of the leading groups of engineering and construction companies in the world and a key player in the ownership and management of infrastructure and facilities. The company provides engineering, procurement, construction, project management and project financing services to a variety of SK케미칼은 국내신약 1호 선플라 (항암제), 국내천연물신약 1호 조 sectors. 인스, 국내신약 13호 엠빅스, 혈액제, 의료기기 등을 바탕으로 지속 적으로 사업 영역을 확장하고 있다. 또한 세포배양기술의 백신을 개 1911년에 설립된 SNC-Lavalin (SNC-Lavalin (주)와 그 계열회사 발하여 글로벌 백신회사로의 발전을 진행하고 있다. 들)은 설계 및 건설 분야를 선도하는 세계적인 기업들 중 하나이며, 다양한 인프라와 시설들을 소유 및 관리하는 대표적인 기업입니다. SNC-Lavalin은 여러분야에 대한 설계, 조달, 건설, 프로젝트 관리 및 프로젝트 파이낸싱 서비스를 제공합니다. 신풍제약은 1962년 창립 초기부터 국산화를 위해 원료합성기술을 개발하고 원료합성 및 완제품 생산 공장을 모두 갖추어 원료의약품 및 완제의약품을 생산하여 국내 판매와 해외 수출을 지속적으로 추 구하고 있다. 이러한 노력으로 글로벌 국산 신약 피라맥스정 개발에 성공하였으며, 세계화를 위한 새로운 도약으로 충북 오송생명과학단 지 내에 세파계 항생제 전용공장을 완공하여 우수한 의약품을 생산 중에 있다. 이번에 전시할 메디커튼주는 HA 와HES 성분의 새로운 조합으로 개발된 유착방지제로 혈전 형성을 억제해 유착을 방지하는 제품이다. 또한, 중앙연구소와 제제개발 연구소를 분리 이원화하여 선택과 집중을 통한 연구 역량을 극대화하고 있다. 194 195 Q23 B24 R10 F38 Song Am Trading Corp. Soon Chun Hyang Lab-based Industry Cooperation SPIRAXSARCO KOREA ST Pharm. Co., Ltd. 송암교역 순천향대학교 LINC사업단 한국스파이렉스사코(주) 에스티팜(주) CEO ADD TEL FAX E-MAIL URL Seo Jeong Moon 서정문 #1005 Daeyoung Golden Valley 290-2, GocheonDong, Uiwang-City, Gyeonggi-Do 82-31-450-6681 82-31-450-6684 [email protected] http://www.songamnano.com CEO ADD TEL FAX E-MAIL URL E X H I B I T KIM HAK MIN 김학민 5F Entrepreneur ship Soon Shun Hyung University, Shinchang-myun, Chungcheongnam-do, Sonth Korea 82-41-530-4851 82-41-530-4783 [email protected] http://linc.sch.ac.kr I T S 순천향대학교 산학협력 N T R O D U C T I ADD TEL FAX E-MAIL URL Jang chang woo 장창우 71B-14L Namdong 2nd Industrial Complex 64013, Gojan-dong, Namdong-gu, Incheon 405-817, Korea 82-32-820-3970 ~ 5 82-32-811-0321 [email protected] http://www.watson-marlow.com/kr CEO ADD TEL FAX E-MAIL URL Lim Geun Jo 임근조 S hihwa Industrial Complex 1Na-802. 1241-2, Jungwang-dong, Siheung-si, Gyeonggi-do 429912, Korea 82-2-527-6393 82-2-561-6006 [email protected] http://www.stpharm.co.kr S X H I B Tumbler Mixer, Microcapsule equipment, High pressure E homogenizer Soon Chun Hyang Lab-based Industry Cooperation public relations Tumbler Mixer, Microcapsule 설비, 고압 분산기/균질기 I CEO O N SongAm Trading Corp is a importing company about bio / nano facilities. We are trying to develop national industries to introduce unique equipments to Korea Companies. In this time, we are introducing some instruments here bellow. We can lend you some equipment and test. 1. Accelerate your Protein Formulation Development (complete in 45 days) 2. Microcapsule Equipment 3. High Pressure Homogenizer 4. Tumbler Mixer (Three Dimensional Mixer) 5. Bio Centrifuge 6. Jet Mill 당사는 해외 기술을 국내에 소개함으로써 국가 산업 발전에 이바지 하고자 노력하고 있습니다. 이번 전시를 통하여 당사가 새로운 혁명적인 여러 설비를 아래와 같이 소개 드립니다. 선도대학 (LINC) 육성사업단 홍보 I N T R O D U C T I O N SCH LINC for Medi-Bio & New IT Convergence Industry public relations “교육과학기술부 지원” 순천향대학교 산학협력 선도대학 (LINC) 육 성사업단 의약바이오-New IT 컨버전스 산학협력 선도대학 육성사업 홍보 E X H I B I T S I N T R O D U C T I O N Watson-Marlow Pump, Medical OEM Pump, Flexicon Filling ST Pharm [a member of Dong-A Socio group] has been & capping machine offering excellent custom manufacturing services of APIs and their intermediates to meet global pharmaceutical c o m p a n y ’s h i g h e x p e c t a t i o n o f c o m p l i a n c e t o I N T R O D U C T I O N cGMP requirements for their uses in pharmaceutical Watson-Marlow Pumps is acknowledged as the world's development. leading manufacturer of positive displacement pumps. Our facilities are inspected and approved by US-FDA, EMA, Founded on over 50 years of supplying engineering, our ANVISA, TGA, PMDA, KFDA etc. pumps are tried, tested and proven to deliver. ST Pharm is also globally recognized as top-tier manufacturer of nucleoside APIs and RNA/DNA oligonucleotides APIs in 왓슨말로우 펌프는 50년 이상 엔지니어링 및 프로세스 전문기술을 various drug applications. 제공하고 있으며, 전 세계에 100만대 이상의 펌프가 설치되었고, 다 양한 현장에 적용/검증되었습니다. 1983년 설립 후 생명과학분야의 원료의약품 전문회사로 발전해온 에스티팜은 뉴클레오시드 항바이러스제 약물의 원료 및 중간체 개발 에 집중해 왔으며 그 결과 세계 초일류 제약사들과 장기적인 공급 계 약을 체결하여 안정적인 원료 공급을 해오고 있습니다. 미국 FDA를 비롯하여 유럽, 일본, WHO등의 유관 기관들로부터 cGMP 인증을 받은 국제적인 생산시스템을 운영 중에 있습니다. 한편, 에스티팜은 2010년 6월 동아쏘시오그룹의 일원이 되었으며, 사명 (社名)을 ST (Science & Technology) Pharm으로 하고, 보다 커다란 비젼을 추구하는 Global 선진기업이 되고자 합니다. 그룹 시너지 효과를 극대화하여 현재의 위치에 만족하지 않고 미래 의 생명과학분야를 선도하는 세계적인 기업으로 도약하기 위해 최선 을 다하겠습니다. 일부 설비에 관하여는 국내보유하고 있으며 임대 및 당사에서 Test 가능합니다. 1. Protein Formulation 설비 (45일 완성) 2. Microcapsule 설비 3. 고압 균질기 4. 3차원 Mixer 5. Bio Centrifuge 6. Jet Mill 196 197 N23 L39 State of Missouri N20 Strex, Inc. 미국 미주리 주정부 사무소 CEO ADD TEL E-MAIL URL Luis Jimenez 1610 S Providence Rd. Columbia, MO, 65211, USA 1-573-319-9020 [email protected] http:// www.eternogen.com X H I B I T S Injectable dermal fillers - RPC (Rapidly polimerizing collagen) - NanoMatrix (gold nanoparticle-collagen matrix) I N T R O D U 기업이 탄생되는 곳이며 현재 500개 이상의 바이오 관련 기업이 입 주해 있습니다. 이에 메릴랜드 주 한국무역통상부는 한국기업이 미국 시장에 진출할 수 있도록 기초 창업단계에서부터 공동연구, 임상실 메릴랜드주 한국무역통상부 CEO ADD TEL FAX E-MAIL E 주립대학을 중심으로 생명공학단지를 조성하여 수많은 바이오 벤처 State of Maryland Business Office-Korea C T I URL E Norio Ishida Shashin-kaikan 4F, 2-7-14, Minami-Semba, Chuoku, Osaka, Japan, 542-0081 81-6-6271-9373 81-6-6271-9372 [email protected] http://www strex.co.jp/ X H I B I T S Process/Machinery O N I N T R CEO ADD TEL E-MAIL URL E Gun-Seon, Lee 이근선 험, FDA 승인에 이르기까지의 모든 컨설팅 업무를 지원합니다. 20410 Observation Dr. Suite 105 Germantown, MD 20876, U.S.A. +1 301-528-2200 [email protected] www.sombok.org www.kmbioexpo.com X H I B I T S ‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland 2020’ Strategic Plan Introduction O D U C T I O N EternoGen is a medical Bio-Tech company with a focus on STREX instruments apply various stretched or compressed designing and manufacturing a novel collagen scaffolds for stress to culturing cells, and can simulate in vivo soft tissue therapeutic applications. environment. 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, Johns Hopkins University, University of Maryland School of Medicine, Montgomery County, University of Maryland BioPark, BioHealth Innovation 총 7개 업체 함께 참여 I N T R O D U C T I O N State of Maryland Business Office-Korea is officially designated, from Maryland, to connect and develop businesses between Korea and the U.S. Maryland is located in the Mid-Atlantic Region; bordering Washington, D.C. and 19 federal regulatory agencies such as NIH, FDA, and NIST which are located in Maryland. There are over 500 bioscience companies such as Human Genome Sciences and MedImmune which are also headquartered in Maryland, and this creates the most innovative biotechnology cluster in the entire United States. State of Maryland Office-Korea is here to provide consulting services from the basic, clinical trials, joint research, and FDA approval process. The 2ndannual ‘Korea-Maryland, USA Bio Expo’will be held in Oct.9th-12th, 2012 in Maryland. Business partnering sessions, Health and Life Science Forums and Medical Robotics Forums are prepared. Please visit us to find the right partner to develop innovative technologies. 메릴랜드 주 한국무역통상부는 한.미간 산업 교류 및 발전을 위해 메 릴랜드주로부터 공식 지정된 정부기관입니다. 미국의 수도 워싱톤 DC 바로 옆에 위치한 메릴랜드 주는 NIH, FDA, NIST를 포함한 19 개의 연방 규제기관이 위치해 있고, 존스합킨스 대학교와 메릴랜드 198 199 Q19 C40 E34 L23 Synex Consulting Ltd. TAEJIN ENG Co., Ltd. Taejoon Pharmaceutical Co., Ltd. 사이넥스 (주)태진이엔지 태준제약 CEO ADD TEL FAX E-MAIL URL E Young Kim 김 영 1 0th Floor Daejong Building 435, Teheran-ro, Gangnam-Gu, Seoul 135-527, Korea 82-2-6202-3300 82-2-2040-6250 [email protected] http://www.synex.co.kr X H I B I T S International Healthcare Market Access Regulatory Affairs, Clinical Research Reimbursement Approval, Market Research CEO ADD TEL FAX E-MAIL URL E Kang Hee Cheol 강희철 138BL-9LT Namdong Industrial Complex 709-8 Gojan-dong, Namdong Gu, Incheon 405-821 Korea 82-32-899-1842 82-32-818-8477 [email protected] http://www.taejineng.co.kr X H I B I T S Center Table, Corner Table, Sink Table, Reagent Cabinet, Safty Cabinet CEO ADD TEL FAX E-MAIL URL E Taiwan Bio Industry Organization (BioTaiwan 2014) Mr. Tae Young Lee 이태영 8, Daesagwan-ro 31-gil, Yongsan-gu, Seoul, Korea 82-2-798-6601~7 82-2-798-6610 [email protected] [email protected] http://www.taejoon.co.kr X H I B I T S T R O D U C T I O N N T R O D U C T I O N (주)태진이엔지는 산업용철제가구, 클램핑툴 및 물류운반기기를 전 We are multifunctional because it is important to your 문적으로 생산하는 회사로 국내시장을 선도하는 동종업계 최대의 기 업으로 인체공학적 설계에 의해 제작된 실험실가구는 제품의 내구성 success. 사이넥스는 헬스케어 시장진입에서 중요한 영역의 과제를 통합적으 로 서비스하는 전문 컨설팅 회사 입니다. TEL FAX E-MAIL URL E I I I N ADD 증대, 효용성 증대 및 실험실환경과 연구원의 안전을 최대한 고려한 제품입니다. Johnsee Lee 7F-1, No.3-2, YuanQu St., Nankang Dist., Taipei City 115, Taiwan 886-2-2655-8692 886-2-26557419 [email protected] http://www.biotaiwan.com.tw X H I B I T S Xalost, Xalost Plus, Infresh Plus, Hyaluni, Iobrix Inj., Government /Organization / Institution Radisense Inj., Qretin tab, CoolPrep powder 중앙실험대, 코너실험대, 싱크테이블, 시약장, 위험물보관함 보건의료사업 진입전략 및 수행 허가, 임상시험, 보험, 시장조사 I CEO N T R O D U C T I O N Established in 1978 under the slogan, “to create a healthy world, ” Taejoon Pharmaceutical Co., Ltd. (“Taejoon”) is one of the leading specialty pharmaceutical companies in ophthalmology and contrast media with a global presence in Europe, Africa, Asia Pacific Region and the United States of America. Taejoon began to look beyond its national boundary in early 2000s. As the first step of its globalization, Taejoon built a state-of-the art factory to the standard of cGMP certification in 2005. The next step of its globalization was to obtain the GMP certification from the European Union (the “EU”). In 2008, Taejoon became the first ophthalmic product manufacturer in Korea to obtain GMP certification from the EU and started exporting its first product to the EU in 2009 and to the United States in 2013, respectively. In recent years, Taejoon has expanded into a number of new markets and increased its presence in existing key markets. Currently, Taejoon’s products are marketed in 39 countries worldwide N T R O D U C T I O N With the synergy of exhibition, one-on-one partnering, BioBusiness Asia conference, plenary luncheon and conference on Greater China opportunity, BioTaiwan 2013 attracts more than 60, 000 visitors. BioTaiwan 2014 will be held on July 24-27 in Taipei. Join BioTaiwan 2014; come meet your Taiwan and Asian partners! 35년간 인류의 생명과 건강을 위해 최선을 다해 온 태준제약은 국내 최초로 혈관조영제의 국산화를 이룩하였으며, EU로부터 GMP인증 을 받아 국내 최초로 녹내장 치료제인 잘로스트 점안액을 유럽에 수 출하였습니다. 안구건조증 치료제인 인프레쉬플러스점안액을 미국에 수출하는 등 현재 태준제약의 제품은 세계 39개국에 수출되고 있습 니다. 태준제약은 2012년 혁신형제약기업에 선정되었으며 쿨프렙 등 10 개 품목이 한국보건산업진흥원으로부터 GH품질인증을 받는 등 실질 적인 품질 우수 제약기업입니다. 200 201 C33 L10 <INNOVATIVE RESEARCH> -Title: The function of tetherin (BST-2) in viral release and control of the tetherin effect -Institute/Organization: Korea University TEPIK (Transgovernmental Enterprise for Pandemic Influenza in Korea) 신종인플루엔자 범 부처 사업단 CEO ADD TEL FAX E-MAIL URL E Woo Joo Kim 김우주 <R&D INFRASTRUCTURE> 3F Koryo-guro Bldg. #226 Gugo-dong, Guro-gu -T itle: Influenza research information and national Seoul.Korea reference material repository 82-2-2626-2434 -Institute/Organization: Centers for Disease Control and 82-2-2626-2466 Prevention/National institute of health [email protected] http://www.tepik.or.kr • TEPIK전시부스 참여기관 X H I B I T S Agencies that participate in TEPIK exhibition 과제명: 세포배양 기술을 활용한 인플루엔자 백신 제품화 (SK케미칼) 사업단 전시부스 참여 연구기관 및 과제명 소개 I N T R O D U C <백신개발 분야> 과제명: 인플루엔자 백신효능증가 원천기술 개발 (세종대학교) 과제명: 재조합아데노바이러스 기반 차세대 신종인플루엔자 백신 개 발 (이화여자대학교) T I O N • Agencies that participate in TEPIK exhibition <VACCINES> -Title: Development of an adjuvant for influenza vaccine -Institute/Organization: Sejong University -T itle: Developing recombinant adenovirus-based next generation flu vaccines -Institute/Organization: Ewha Womans University -T itle: Influenza vaccine commercialization using cell culture technique -Institute/Organization: SK chemicals <치료제 개발 분야> 과제명: 계절성 및 유행성 인플루엔자 예방 및 치료용 항체 개발 (셀 트리온) 과제명: 유기저분자 화합물 유래의 항인플루엔자 바이러스제 후보물 질 발굴 및 효능 평가 (한국화학연구원) <진단기술개발 분야> 과제명: 인플루엔자 주요 아형 감별이 가능한 고민감도 및 고특이도 를 보이는 인플루엔자 현장용 신속진단법 개발 (고려대학교) <창의 분야> 과제명: 인플루엔자 바이러스 방출 억제에 미치는 테더린 (BST-2)의 기능과 이의 조절 (고려대학교) <연구 인프라 분야> <THERAPEUTICS> 과제명: 인플루엔자 연구정보 및 국가 표준품 뱅크 확충 (질병관리본 -T itle: Development of Prophylactic and Therapeutic 부) Antibody for Seasonal and Pandemic Influenza -Institute/Organization: Celltrion -T itle: Discovery and validation of anti-influenza drug candidates via chemical synthesis of small organic compounds -Institute/Organization: Korea Research Institute of Chemical Technology H23 Technical University of Denmark testo Korea Ltd. 덴마크공과대학 테스토코리아 CEO ADD TEL FAX E-MAIL URL I N Anders Bjarklev Anker Engelunds Vej 1 Bygning 101A DK-2800 Kgs. Lyngby Denmark 45-4525-2525 45-4588-1799 [email protected] www.dtu.dk T R O D U C T I O N 사회에 유익하게 하기 위한 자연과학과 기술과학을 이용하여 가치 를 창조하고 개발하기 위해 1829년 설립된 덴마크 내 최고의 공 과 대학입니다. 토목공학, 건축, 우주공학, 바이오 지속가능성(biosustainability), 음식(food), 그린기술(green-tech), 기후연구, 재 생에너지, 에너지혁신 분야 에서 연구중심의 교육뿐만 아니라 고급 의 공공 컨설팅 사업, 기술혁신, 기술이전과 전략적 국제협력 능력으 로도 알려져 있으며 북유럽국가들과 유럽뿐만 아니라 한국의 KAIST, 및 세계의 여러 대학들과 교류를 하고 있습니다. CEO ADD TEL FAX E-MAIL URL E Martin Winkle 4 -1 KT & G Building 5F, Mullae-dong 5-ga, Yeongdeungpo-gu, Seoul, Korea 82-2-2672-7200 82-2-2679-9853 [email protected] www.testo.co.kr X H I B I T S Wireless Data Logger system Saveris, Temperature & Humidity Data Logger, Multi Function of Temperature/ Humidity/Velocity, etc 무선 온습도 측정 시스템, 온습도 데이터로거, 다기능 환경 측정기 외 I N T R O D U C T I O N testo (Korea) Ltd is German Company supplying Thermometer, thermal Imager, Hygrometer, Anemometer, Flue Gas Analyzer, Pressure, Data Logger Water Analysis, Tachometer, Sound level meter, Light/Sound etc by completing best quality of products with more than 50 years’ Experiences. We Test (Korea) Ltd are doing endless research and development to show upgrade model. Furthermore we are developing dew point measurement, installed Temperature & Humidity exchanger, Flue gas leak detection etc to satisfy customer’s variety of needs for comfortable, accurate and suitable instruments at variable working condition. 테스토 코리아 (유)는 온도계, 열화상 카메라, 습도계, 풍속계, 연소가 스분석기, 압력계, pH미터, RPM 측정기, 소음측정기, 조도계 등 다 양한 산업용 환경 휴대형 측정 장비를 50여 년의 역사와 함께 세계 최고의 품질로 완성시켰으며 끊임없는 연구와 개발로 현재까지 지속 적인 업그레이드 모델을 선보이고 있는 독일계 자회사입니다. 추가로 공조기용 노점 측정기, 설치용 온습도 변환기, 연소가스 누출감지기 등도 개발하여 고객의 다양한 작업환경에 맞는 편리하고 정확한 첨 단장비를 만들어내기 위해 최선을 다하고 있습니다. <DIAGNOSTICS> -T itle: Development of Rapid and multiple influenza diagnostic kit for field assay -Institute/Organization: Korea University 202 203 L10 O10 The Embassy of Denmark The National Project for Personalized Genomic Medicine 주한 덴마크 대사관 CEO ADD TEL FAX E-MAIL URL H20 차세대 맞춤의료 유전체사업단 Peter Lysholt Hansen 서 울시 용산구 이태원동 260-199 남송빌딩 501호 82-2-795-4187 82-2-796-0986 [email protected] http://sydkorea.um.dk/ko CEO ADD TEL FAX I N T R O D U C T I O N 주한 덴마크 대사관은 한국과의 정치, 경제적인 관계뿐만 아니라 문 화, 영사를 비롯한 다양한 영역에서 덴마크의 이해관계를 대표합니 다. 또한 한국에서 활동하고 있거나 진출을 희망하는 덴마크 회사, 연 구기관 및 단체들에게 맞춤 서비스도 제공하고 있습니다. 우리는 한 국 내 덴마크 비즈니스와 연구 커뮤니티를 위한 최고의 업무 컨디션 을 제공하며 한국과 덴마크 사이의 상업, 과학, 기술, 및 혁신을 기초 로 이노베이션 센터의 확장을 포함한 협력을 제공합니다. E-MAIL URL I N R O D U C TNT Express Tracer Pharma 티엔티 익스프레스 트레이서 파마 CEO Hyung-Lae Kim 김형래 BLDG A#408, School of medicine, Ewha Medical Center, 911-1, Mok-dong, Yangcheon-gu, Seoul, 158-710, Korea 82-2-2654-8734 82-2-2652-2555 [email protected] http://pgm21.or.kr T L10 T I O N •Established in April 2011 •P GM21 is comprised of five different centers for Translational Genomic research, Pharmacogenomics center, Clinical Proteomics center, BI center, ELSI center •Brings out a new era in clinical diagnostics and medical treatments through the translation of genomic research and implementation of personalized medicine •Mission -Scientific: Global hub for implementing genomicsbased personalized medicine -M edical: Practical application of theragnosis & genomics-base disease prediction -Wellbeing: Decrease disease burden & increase quality of life -Socioeconomic: Decrease healthcare expenditure & Promote healthcare industry by leading personalized medicine •2011년 4월에 발족 •PGM21 중개임상, 약물유전체센터, 단백체 연구센터, BI센터, ELSI 센터로 구성 •맞춤의학의 구현과 중개임상연구를 통한 임상진단 및 의료치료의 새로운 시대를 도모 • 미션 -과학 기술적: 유전체기반 맞춤의료기술 지식을 사업화하는 글로 벌 거점 육성 -의료기술적: Theragnosis와 유전체기반 예측기술의 실용화 -보건의학적: 질병의 경감과 삶의 질 향상 -경제사회적: 보건의료비용절감과 맞춤의학신사업의 활성화 ADD TEL FAX E-MAIL URL Jongchul Kim 김종철 TNT Building 687-8, Gonghang-dong, Gangseogu, Seoul 82-2-2669-0566 82-2-6678-6633 [email protected] http://www.tnt.com/express/en_kr CEO ADD TEL E-MAIL URL I E X H I B I T S 1.Domestic & International Transportation Service for Healthcare pharmaceutical and biological products 2.Storage & Distribution Service for Healthcare pharmaceutical and biological products 3.P a c k i n g s o l u t i o n s f o r t e m p e r a t u re s e n s i t i v e pharmaceutical and biological products I N T R O D U C T I O N John Bo Jacobsen F rederiksborgvej 399, bldg. 124N DK-4000 Roskilde Denmark 45-2939-5200 [email protected] www.tracer-pharma.com T R O D U C T I O N 의약용 활성 성분의 품질 계약 제조회사이며 핵 의학의 방사선 의약 품에서는 중간 제조업체입니다. 우수의약품제조관리기준(GMP)기준 에 따라 운영되며 소규모 제조공장 설립 등 특정한 고객들의 필요나 주문제작을 해결하며, 고객의 요구에 빠르고 만족스러운 결과를 제공 하는 것에 가장 큰 가치를 두고 있는 기업입니다. N TNT Express is one of the world's largest express delivery companies. TNT Express delivers to more than 200 countries and operate road and air transportation networks in Europe, the Middle East and Africa, Asia-Pacific and the Americas. TNT Express has a strong position in Europe market and provides value-added services for specific industry sectors (e.g. automotive, healthcare, high tech, life-style). Door-to-door customized delivery service of clinical demonstration samples and related good from hospitals and pharmaceutical companies with TNT Clinical Packing Solution and dedicated team’s support. · Stable data transfer though web interface ·Locate controlled agencies in Chuncheon, Choongju, and Gwangju aside existing TNT depots ·Packing materials for clinical demonstrations (Dry ice packing on requests) ·Thorough management from designated CS and clinical express with proactive POD and etc. · Operate dedicated clinical express vehicles TNT Express는 제약, 바이오 분야 운송 서비스 No.1 회사로써, 전 세계 네트워크, 온도 솔루션, 전문 인력을 바탕으로 시간과 온도에 민 감한 의약품, 바이오 물품을 신속하고 안전하게 배송하여 귀사의 성 공적인 비즈니스를 위한 경쟁력을 보장해 드립니다. 현재 TNT Express는 시간과 온도에 민감한 의약품 및 바이오 물품 을 위한 해외/국내 배송, 보관, 통관, 온도 관리, 포장 솔루션 등을 제 공하는 통합 물류 서비스를 제공하고 있습니다. 204 205 N33 K30 Translational Health Science and Technology Insitute (THSTI) CEO ADD TEL E-MAIL URL Dr. G. Balakrish Nair 496, UDYOGVIHAR PHASE 3, GURGAON 122016 INDIA 91 124 2876300 [email protected] http://www.thsti.res.in K30 U&I CORPORATION Unhwa Co., Ltd. University of Maryland School of Medicine 유앤아이(주) (주)운화 메릴랜드 약학 대학 CEO TEL FAX E-MAIL URL E E X H I B I T S N20 Ja-Kyo Koo 구자교 82-31-852-0102 (ext713) 82-31-852-0128 [email protected] http://www.ldisq.com X H I ADD TEL FAX E-MAIL URL B I T S L’DISQ, L’DISQ C, L’DISQ C.7 E 61-360 전라북도 전주시 덕진구 장동 452-79 5 82-63-240-9818 82-63-240-9566 [email protected] http://unhwa.com X H I B I TEL URL E T S 식품, 화장품 I N T R O D U COMPANY: WWW.YOUIC.COM THSTI is an autonomous institute founded by Department PRODUCTS : WWW.LDISQ.COM of Biotechnology, Ministry of Science & Technology, Government of India. It is part of an emerging health 회사소개: WWW.YOUIC.COM 참조 biotech science cluster with an ambitious initiative to create 제품소개: WWW.LDISQ.COM 참조 the unique institutional environment for the conduct of truly multidisciplinary research that translates scientific and technological advancements into medical innovations that will improve public health. It also seeks to establish collaborations with research institutions and hospitals around the World, making this a national undertaking through its centers. 206 N T R O D U C T I O X H I B I T S ‘Korea-Maryland, USA Bio Expo 2013’ & ‘BioMaryland 2020’ Strategic Plan Introduction food, cosmetic Academic Research Institute I 20 W. Lexington St., Baltimore, Maryland, U.S.A. 6 1-410-706-3100 http://www.umaryland.edu/ ADD C T I O N N I N T R O D U C T I O N Unhwa Corporation is making an aggressive progress in R&D and commercialization under its corporate mission of contributing to prolongation of human life, promotion of health and improvement in quality of life. Departing from conventional cell culture method, Unhwa has succeeded in isolation and mass culture of plant stem cell (also called “immortal cell”), which is known as the origin of plant vitality. This technology, which received scholastic recognition through its publication on the cover page of Nature Biotechnology (November 2010), is a core platform technology that can be applied to various industrial sectors including high value-added biomaterial and botanical drug development. In addition to conducting joint research with a number of prominent institutions at home and abroad, Unhwa promotes commercialization in drug, nutrition, and cosmetic business by forming strategic alliance with global leading companies in respective industries. Unhwa will make an utmost effort to become the world’s best food and cosmetic ingredient company by 2017 and to achieve its corporate value of respecting human life. 한.미 바이오 엑스포 2013 소개 및 메릴랜드 주 바이오 정책 소개 메릴랜드 주 한국무역통상부, JG Business Link International, Johns Hopkins University, University of Maryland School of Medicine, Montgomery County, University of Maryland BioPark, BioHealth Innovation 총 7개 업체 함께 참여 I N T R O D U C T I O N University of Maryland, Baltimore comprises some of the oldest professional schools in the nation and world and it is part of the University System of Maryland. The campus is composed of 58 buildings located near Camden Yards and Baltimore's famous Lexington Market. UMB comprises 7 professional schools; School of Medicine, School of Law, Dental School, School of Pharmacy, School of Nursing, Graduate School, School of Social Work, and School of Public Health. 메릴랜드 약학 대학은 미국에서 가장 오래된 전문 대학교이며, 메릴 랜드 대학 시스템에 속해 있습니다. 메릴랜드 약학 대학은 총 7개의 전문 분야를 가르치고 있는데, 이에는 약학대학, 법학대학, 치과대학, 의학대학, 간호대학, 대학원, 사회복지 및 공공정책 학과가 속합니다. 207 B23 G22 H47 VGX International, Inc. Vivagen Co., Ltd. 브이지엑스인터내셔널(주) (주)비바젠 CEO ADD TEL FAX E-MAIL URL Young K. Park. 박영근 #1903 Keungil Tower, 677-25 Yeoksam-dong, Gangnam-gu, Seoul, Korea 82-2-527-0600 82-2-557-6784 [email protected] http://www.vgxi.com/en CEO ADD TEL FAX E-MAIL URL E X H I B I T N T R O D E E U C X H I B I T S Water purification system, pipette, tips, pH meter, Balance, test paper, filter paper, syringe filter 플라스미드 DNA백신, 바이오의약품 위탁생산 I Park Joon Sang 박준상 Suite 618, Woolim Lion’s valley I, 311-3 SangdaewonDong, ungwon-Gu, Seongnam-Si, Gyeonggi-Do, South Korea 462-806 82-31-737-2080 82-31-737-2083 [email protected] http://www.vivagen.co.kr S Plasmid DNA Vaccine, CMO T I O N Bio/Chemistry/Medicals as well as Semiconductor, Display. Wonwoo has been doing our best to set up one-stop (주)원우시스템즈 system for sales, repair, maintenance and application counseling for customers also developing optimized Woo, Won Kyun 우원균 CEO S antevill 106-209, #719, Shindaebang-dong, software for custom application. ADD Dongjak-gu, Seoul, Korea Optical sensing part 및 광 계측, 성분분석용 장비 전문 공급업체 82-2-533-6720 TEL (주)원우시스템즈는 2000년 회사설립 이래로, 반도체 및 디스플레 82-2-3289-1293 FAX 이 분야뿐 아닌 바이오/화학/의약학 분야 장비 개발 업체를 위한 다 E-MAIL [email protected] 양한 optical part, OEM spectrometer, sub modules, 각종 광 http://www.wonwoosystem.co.kr URL 원 및 optical accessories 에서부터 분석장비에 이르기까지 total solution을 제공합니다. 저희는 제품 판매뿐 아니라 유지, 보수, 관 WONWOO SYSTEMS Co., Ltd. 초순수 제조 장치, 피펫, 팁, pH 미터, 미세저울, 테스트 페이퍼, 필터 페이퍼, 시린지 필터 VGX International, with its proprietary technology, manufacturing ability, and strong IP position, will continue N T R O D U C T I O N to move forward with its DNA vaccine clinical studies for I a number of different indications and will continue to Founded in 2003, Vivagen Co., Ltd. is the company increase its dominant position in the DNA vaccine market. which consists of experts who have more than 10 years experience in sales, marketing and R&D. VGX인터내셔널은 DNA백신 분야에서 앞선 연구성과와 저명한 전 Vivagen Co., Ltd. provides differentiated services to 문가 집단을 보유한 선도기업으로 감염성 질환을 타깃으로 DNA백 customers in various experiments such as filtration, 신 개발을 진행하고 있으며, 플라스미드 DNA 생산분야의 오리지널 purification, concentration, incubation and analysis. We are 기술력과 특허를 바탕으로 바이오의약품 위탁생산 (CMO) 사업을 sure our expertise and technical know-how help customers 수행하고 있습니다. solve their complex problems and achieve their goals. (주)비바젠은 여과. 분리, 정제, 농축, 배양, 분석 등 다양한 실험 분야 에서 영업, 마케팅, 연구개발업무로 10년 이상 경험을 쌓아온 전문가 들로 구성된 회사입니다. 저희 비바젠은 필드에서의 폭넓은 경험과 풍부한 지식으로, 고객 여 러분께 최적의 제품과 차별화된 서비스를 제공해 드릴 것을 약속 드 립니다. X H I B I T S 리까지 원스톱 시스템을 구축하는데 최선을 다하고 있습니다. Optical parts, sub module and analyzing equipments for Bio, Medical application •Optical sensing part/OEM spectrometers - EMBED 2000+ spectrometer - STS spectrometer •Sub-system modules - Absorbance measurement module (pulsed Xe lamp, Custom cuvette holder, USB2000+ spectrometer) •Analyzing Equipment -Stand-alone analyzer: This is a stand-alone desk-top integrated system with a small on-board computer -ACUMAN Raman system: desk-top Raman system 바이오, 의약 분야를 위한 성분 분석 장비 개발을 위한 sensing 파 트, sub module 및 분석장비 (Absorbance, Raman 측정장비) •광학 센싱 파트/OEM spectrometer -EMBED2000+ -STS spectrometer •서브시스템 모듈 -Absorbance measurement module (pulsed Xe lamp, Custom cuvette holder, USB2000+ spectrometer) •Analyzing Equipments -Stand-alone analyzer (desk-top integrated system with a small on-board computer -ACCUMAN 라만시스템 I N T R O D U C T I O N Since 2000, WonWoo systems Co., Ltd. has supplied the advanced optical sensing parts such as OEM spectrometers, optical part, sub modules, light sources and optical accessories, optical measuring and analyzing equipments to equipments’ manufacturers in the business fields of 208 209 G24 F40 -의약품 및 바이오 국제/국내 프리미엄 운송 서비스 (Door to Door) -Cold Chain Management Service (상온/냉장/냉동/극저온 WORLD COURIER KOREA., LTD. 월드쿠리어 코리아 CEO ADD TEL FAX E-MAIL URL John Butler #1205, Woori Venture Town II, 82-29 Mullae-dong 3-ga, Yeongdeungpo-gu, Seoul, Korea 82-2-6335-8538 82-2-6335-8539 [email protected] http://www.worldcourier.co.kr 외) -바이오 의약품 원료, 완제 및 연구 시료에 대한 운송 솔루션 제공 -수출입 관련 인허가 및 서류 검토 및 절차 가이드 제공 -Qualified / Validated 특수 포장재 제공 -운송중 온도 기록 및 모니터링 서비스 -냉매 (Dry Ice 및 Gel Pack, 액화질소) 제공 및 보충 서비스 -실험용 생동물 및 Animal Product 운송 (검역, 통관, 운송 일괄 서비스) -관련 교육 (IATA 전염성품목 운송규정/콜드체인) -임상용 의약품 보관 및 배송 서비스 (인도, 중국, 남미, 러시아 외) -Clinical Logistics Service: Customized Logistics solutions, -24hours x 7days, 365일 휴일 및 야간 운송 서비스 24-hour collection and delivery of biological specimens -위험물, 전염성 물질 운송 / UN / IATA 인증 Package 제공 (including infectious samples), bulk investigational drugs, kits and other study materials and supplies I N T R O D U C T I O N -Cold Chain Services including temperature controlled packaging, supplies and expertise in-transit dry ice/gel Established in 1969, World Courier is the global leader in the transportation of clinical samples, investigational drugs pack replenishment and temperature monitoring -Temperature-controlled Packing Solutions: We offer a and clinical trial supplies, Infectious substances for the full range of temperature controlled packaging solutions pharmaceutical industry, with over 38 years of experience to fit any volume, budget or temperature need from a in the handling of time – critical and temperature bulk consignment of investigational drugs at 2˚C to 8˚C controlled shipments. We have handled the logistics for or minute quantities of an irreplaceable pharmaceutical thousands of clinical trials world wide, we understand compound at -70˚C, the in-house temperature control intimately your timeline and demanding supply chain and Quality Assurance experts in each World Courier requirements. World Courier has wholly owned global office can recommend packaging options to protect your network over 140 offices, 2500 employees throughout the world. sensitive shipments. -Individual monitoring of each shipment from p ick-up to delivery – including real-time online tracking via our web- 1969년 설립이래, 월드쿠리어는 바이오 제약 물류 분야의 선도 기 업으로 국내의 유수의 제약사와 병원, 연구소, 국가기관의 물류파트 based Customer Resource Center, automatic e-mail alert 너로서 포괄적이고 전문화된 운송서비스를 제공해 오고 있습니다. and confirmation -Specialized brokerage assistance, customs clearance 오랜 경험과 노하우, 글로벌 네트웍을 통하여, 임상, 전임상, R&D 검 and delivery of consignments in over 220 territories and 체 및 의약품, API, 감염성 물질 및 연구용 생동물에 이르기까지 고객 의 Needs에 가장 적합하고 안전한 운송 솔루션을 제공해 드릴 것을 nations 약속 드립니다. -Assistance with permit applications including import permits, Ministry of Health authorizations, etc. -GMP compliant Clinical Trial Material Storage Facility & Distribution in Latin America, India, China, Australia, Russia, South Africa -Laboratory Live animal transportation (Rat, Mice) -Training Courses (Cold Chain Management, IATA shipping guidelines for infectious Substances) -Strict adherence to global SOPs for all temperature ranges E 210 X H I B I T S I47 WIPS Co., Ltd. WON INTERNATIONAL PATENT & LAW FIRM 주식회사 윕스 원 국제특허법률사무소 CEO ADD TEL FAX E-MAIL URL E LEE HYUNG CHIL 이형칠 DMC Tower 18-19th Floor, 189 Sungam-ro, Mapogu, Seoul, South Korea 121-904 82-2-726-1100 82-2-777-7334 [email protected] http://wipscorp.com X H I B I T S TEL FAX E-MAIL URL E LEE, Won-Hee 이원희 8th Floor, Sung-ji Heights II, 642-16, Yoksam-dong, Gangnam-gu, Seoul 135-080, Republic of Korea 82-2-3453-0507, 82-2-3453-0508 82-2-3453-8155, 82-2-3453-8156 [email protected] http://www.wonpat.com X H I B I T S 회사 및 기술이전대상 소개/특허상담 윈텔립스 N ADD Firm and Technology Introduction/Patent Consulting WINTELIPS I CEO T R O D U C T I O N WIPS is a designated search institute by the Korean Intellectual Property Office, and it provides qualified prior art, PCT, trademark & design services and customized IP consulting services with fully evaluating and analyzing each client's IP workflows and processes. Since its founding in 1999, WIPS Keeps holding the number one on-line IP (Intellectual Property) market share position in South Korea. And with its accumulated IP knowledge and skills, WIPS finally released WINTELIPS. WINTELIPS is an integrated Patent Search and Analysis Online Service with fully functional In-depth analysis, Statistical Analysis, and Report Services for Patent Attorneys, IP Legal Experts, IP Consultants, or IP Researchers to easily establish a successful IP Strategy. (주)윕스는 특허, 상표, 디자인에 이르는 지식재산 Total Service 분 야의 국내1위 기업으로, 각 산업별로 R&D에서 특허, 그리고 사업화 로 이어지는 독보적인 서비스 제공 전문기업입니다. 윕스의 스마트 특허정보 솔루션 윈텔립스는 업무목적 별로 활용 가 능한 다양한 검색과, 특허전략 수립을 보다 용이하게 할 수 있는 특 허동향분석 및 심층분석 기능, 업무결과를 원클릭으로 해결하는 리포 트 기능을 제공합니다. I N T R O D U C T I O N Since the foundation in 1995, WON International Patent & Law Firm focused on the goal of increasing the value of the clients’ intellectual property. By the turn of 21 century, the IP environment has dynamically changed, and WON International is equipped with in-depth understanding on the technologies to provide one-stop solution integrating from preparing an application until registration thereof, assessment on the patentability of technologies and transfer and license. The Life Science Dept. and Chemical Dept. are the two major forces of our firm, which work independently from each other based on their own expertise specialized to respective technical fields. Further, Patent Attorneys and staff at WON International are mostly with master’s degrees or doctor’s degrees, who continue in their efforts to come up with the best option to satisfy client’s demands. WON International will continue to provide customized service based on its experiences, expertise and ability it accumulated in the IP field. 원국제특허법률사무소는 1995년 설립이래 고객의 무형자산인 지식 재산권의 가치를 높이기 위해 최선을 다해왔으며, 출원 및 등록절차 물론 기술의 특허가치평가 및 이전, 라이센싱까지 통합솔루션을 제공 해드리고 있습니다. 특히 당소는 바이오분야와 화학분야가 독자적인 팀으로 구성이 되어있어 각 분야의 전문성을 바탕으로 한 최적의 서 비스 제공이 가능하다는 것이 장점이며, 당소의 석박사급의 변리사 및 구성원들은 지식재산권에 대한 고객의 기대에 부응하고자 매순간 최선의 방안을 강구하고 있습니다. 당소는 IP분야에서 쌓아온 경험과 전문성, 능력을 주요한 자산으로 앞으로도 고객맞춤형 서비스를 지속 하여 제공해드리겠습니다. 211 B20 D33 Yakchoin Yonsei Medical Device Development & Promotion Center 약초인 연세대학교 의료기기개발촉진센터 CEO 박경배 ADD 90-890 충북 제천시 탐안로 28길 22 3 82-70-4119-9485 82-70-4369-9488 http://약초인.kr TEL FAX URL D20 CEO ADD TEL E X H I B I 도라지청, 도라지생강청, 칡청, 도라지가루, 하수오가루 T S FAX E-MAIL URL E H I B I T S Government·Organization I N T R O D U C Yonsei University Health System Yonsei University Wonju Severance Hospital 연세의료원 (특허출원 및 기술사업화/연구중심병원) 연세대학교 원주세브란스병원 CEO Kim Young Ho 김영호 Medical Industry Venture Center 408, 1272, Maeji, Heungup-myun, Wonju-si, Gangwin-do, 220-842, Korea 82-33-760-2848 82-33-763-1953 [email protected] http://www.ymdpc.com X D38 T I O N Public Health Department and Yonsei University Medical Device Development and Promotion Center supervise health medical technology quickly industry domestic put into practical use for the benefit of from May 2010 until March 2015 plan 105, 000, 000 estimated training Idea realization a variety a kind of restriction it can be. Expert technology, knowledge, and through expense, a group of people risk, marketability, preceding design, many patent infringement we center sponsor replacement performance. ADD TEL FAX E-MAIL URL Lee chul 이 철 50 Yonsei-ro, Seodaemoon-gu, Seoul, Korea 82-2-2228--1214~5, 1218, 1211 82-2-2227-8000 [email protected] http://www.iseverance.com CEO ADD TEL FAX E-MAIL URL I N T R O D U C T I O Yeoseung Yun 윤여승 20 in Gangwon province Dobaru Ilsan (220-701) Yonsei University Wonju Severance Hospital 82-33-741-1704 82-33-746-1704 [email protected] http://ctc.yonsei.ac.kr N 연세의료원은 의료산업화를 선도하는 기관으로 지난 4월 연구중심병 원에 선정됨과 아울러 의료사업화에 매진하고 있습니다. 1996년부 터 2013년 7월말 기준으로 연세의료원에서 출원한 전체 특허수는 745건으로 국내 출원이 569건, 국제 출원이 176건 입니다. 도출된 특허가 HT 산업화를 위해 적극 활용될 수 있도록 연세의료원 의과학 연구처는 관련 산업체와 언제든지 논의할 준비가 되어 있습니다. I N T R O D U C T I O N This center was designated as a Medical Device Clinical Trial Center by the Ministry of Health and Welfare in 2010 May. The aim of this center is to establish the infrastructure for medical device clinical trials and to obtain the highly developed technology for the clinical trials. Finally we expect that our domestic medical devices could be more reliable and competitive in the global market. 본 센터는 2010년 5월 보건복지부로부터 의료기기임상시험센터로 지정되어 선진국 수준의 맞춤형 의료기기임상시험센터 조성 및 인프 라 구축과 첨단 의료공학과 연계하는 의료기기임상시험 기술 확립을 목적으로 의료기기의 제품 경쟁력 강화와 이를 통한 지역 및 국가경 제 발전에 이바지하기 위해 최선을 다하고 있습니다. 본 사업은 보건복지부와 연세대학교 의료공학연구원 의료기기개발촉 진센터가 주관하여 보건의료신기술 (Health Technology, HT)을 신 속하게 산업화 내지는 실용화 하기 위하여 2010년 5월부터 2015년 3월까지 총 사업비 102.78억의 예산으로 수행 중에 있습니다. 본 사업은 기존 R&D 사업과는 달리 이 사업은 개방형 시스템을 바탕 으로 의료기기에 대한 창의적인 아이디어를 실현화할 수 있는 기반 을 구축하는 사업입니다. 전문적인 기술과 지식, 시간과 비용으로 인 한 리스크, 시장성, 선행기술과 특허침해 등 많은 문제점을 저희 센터 가 제안자를 대신해서 실행하는 사업입니다. 212 213 K20 O23 B33 J40 Young Sciences, Inc. YUJIN HITECH Co., Ltd. ZETACORPORATION (주)FMS-KOREA (주)영사이언스 유진하이텍(주) 주식회사 제타 (주)에프엠에스코리아 CEO ADD TEL FAX E-MAIL URL Chung Kwang Duk 정광덕 301-1304, Bucheon TechnoPark Ssangyong 3rd, No.36-1, Samjeong-dong, Ojeong-gu, Bucheon-si, Gyeonggi-do 82-32-624-4500 82-32-624-4505 [email protected] http://www.youngscience.com CEO ADD TEL FAX E-MAIL URL BK SEO 서병권 # 917, WOOLIM LION’S VALLEY 1B/D, 311-3 Sangdaewon-Dong, Jungwon-Gu, Seongnam-Si, Gyeonggi-Do, 462-806, Korea 82-31 737 2315 82-31 737 2318 [email protected] http://www.yujinhitech.com CEO ADD TEL FAX E-MAIL URL E E X H I B I T S E X H I B I T S Single-use Bioreactor, Filtration, Purification & Separation YSI 당분석기, GEA Niro-Soavi high pressure homogenizer, Solutions, Virus Safety Testing Service, Sealer & Welder, Kuhner incubator Autoclave, BSC, Isolator, VHP Generator, Filling system, Culture media, Microbiological media I N T R O D U C T I O N Young Sciences specializes in providing products related to human, animal µbiological "CELL CULTURE" and is conducting joint research with its Celltec Bio-Research Center. For pharmaceutical customers, Young Sciences does not only supply sterilizers, BSC, freeze dryers, dry ovens, and isolators but also provides thorough follow-up maintenance and validation service. (주)영사이언스는 1992년 창립이래 국내 바이오산업의 발전과 더불 어 꾸준하게 성장해 왔습니다. 특히 제약관련 분야에서 필수적인 관 련 장비로서 Single-use Bioreactor, VHP Generator, Isolator, Sterilizer, BSC, Freeze Dryer, Dry oven, Welder 등의 장비들도 공급하고, 철저한 사후관리와 Validation service를 전문적으로 제 공하고 있습니다. Shin sang min 신상민 SK Ventium, 166 Gosan-ro, Gunpo-si Gyeonggido, Korea 82-31-451-2415 82-31-451-2408 [email protected] http://zetacorporation.com X H I B I T S CEO ADD TEL FAX E-MAIL URL E CHOI DONG HO 최동호 1 52-2 Dongcheon-dong, sooji-gu, Yongin-si, Gyeonggi-do, Korea 82-31-266-1586-7 82-31-266-1801 [email protected] http://www.gfms.co.kr X H I B Dispenser, laminator, slitter, cutter2대, mixer Gio-box, Inmark-box, GU-box, GVP 디스펜서, 라미네이터, 슬리터, 커터2대, 믹서 보냉, 보온. 바이오/의약품 팩키징 I N T R O D U C T I O N Zeta is the leading supplier of equipment for the research, development and production of diagnostic test strips, biosensors and biochips. Using its core technologies in laminators, dispensers, cutters, slitting/bottling & automatic assembler, we are expanding market worldwide. Moreover, we take the lead in the research and development of dispensing technology applicable for biochips/biosensors and microarray in collaboration with government institutes and universities. I N T R O D U I C T T I S O N Korea’s first and best specialized packaging solution enterprise in the field of distribution’s fresh temperature management and the safe temperature management for the bio pharma field. 국내최초, 최고의물류, 유통분야에 대한 신선 온도관리 바이오, 제약분야의 안전온도 관리 팩키징 전문솔루션 기업입니다. 당사는 진단용 테스트키트 (diagnostic test strips and device) 생산장비를 개발 및 제작하는 전문업체로서 Laminator장비, 정밀 Dispenser장비, 각종 Cutter류 및 Auto Assembler, Bottling 장 비 등의 국산화 개발 성공으로 그 기술력을 인정받아 왔으며, 이를 바탕으로 국내는 물론 해외시장을 확대해 나가고 있습니다. 아울러 미래형 융합기술인 바이오칩/바이오센서 산업의 성장에 이바지 할수 있는 dispensing 기술개발에 앞장서고 있습니다. 또한, 한층 업그레 이드된 Microarray 및 나노리터단위의 정밀 디스펜싱 기술개발로 바이오산업의 발전에 이바지하고 있습니다. 214 215 D42 R25 (주)K-Greenbio (재)충북테크노파크 바이오센터 제천감초산업육 성사업단 (주)케이그린바이오 CEO ADD TEL FAX E-MAIL E Enkhva Kim 김용화 314, ETRI CTRCC, Gajeong-Dong, Yuseong-Gu, Daejeon, Korea 82-42-389-0058 82-42-389-0060 [email protected] X H K30 I B I T S Bio fertilizer (주)바이오인프라 CEO 남창현 CEO ADD 90-250 충북 제천시 왕암동 932 3 82-43-270-2614 82-43-270-2699 [email protected] http://www.cbtp.or.kr ADD TEL FAX E-MAIL URL E X H I B K30 TEL FAX E-MAIL URL I T S 감초, 맑은감초음료, 발효감초, 홍삼차, 오곡감초삼계탕, 발효감초 디 톡스차, 발라먹는 조청, 男다른차, she 비밀스러운차 등 E 보령제약(주) Chul-Woo Kim 김철우 Seoul National University Cancer Research Institute 8F 101, Daehak-ro, Jongno-gu, Seoul Korea 82-2-3668-7941 82-2-3673-0609 [email protected] http://www.bio-infra.com X H I B I T S CEO ADD TEL FAX E-MAIL URL E Tae Hong Choi 최태홍 (110-750) Boryung Bldg, #66-21, Wonnam-dong, Chongro-Ku, Seoul, Korea 82-2-708-8168 82-2-708-8439 [email protected] http://www.boryung.co.kr X H I B I T S Kanarb (Anti-hypertensive drug) 판넬, 팜플렛, 리플렛 천연유기질비료 카나브, 원료의약품 I I N T R O D U C T I O N •Our technology, which involves combing germanium with fulvic acid and humic acid via coordinate bonding, assists in the growth and development of the crop, thus significantly improving the crop’s quality. •S ince fulvic acids and humic acids assist in plants’ absorption of minerals, our technology is capable of increasing the concentration of organic germanium contained in the crop by combining germanium and humic acid on a molecular level. •카이스트의 기술력과 환경의 만남 •천연물질로부터 추출한 환경 친화적 물질인 풀빅산, 부식산과 천 연물질로부터 추출한 미네랄 및 아미노산, 비타민등의 시너지 효 과로 식물생장, 생육에 도움을 줘 작물의 품질향상에 도움을 줌 •또한, 풀빅산, 부식산은 미네랄이 식물에 잘 흡수되도록 하는 기능 을 가지므로 이러한 원리에 기초하여 본 사업화 기술은 분자수준 에서 부식산에 게르마늄을 결합시켜 게르마늄 유기복합체를 비료 로 만들어 식물의 유효 유기 게르마늄의 농도를 높이도록 함 N T R O D U C T I O N 농림축산식품부 향토산업육성사업의 일환으로 운영되는 제천감초산 업육성사업단은 제천의 향토자원인 감초에 대한 가공설비를 구축하 여 감초재배 확산과 농가소득 증대에 기여하고 감초를 이용한 원료 의 고부가가치를 확립하고자 설립되었음. I N T R O D U C T I O N Multiplex Cancer Early Diagnostics (In Vitro Diagnostic Multivariate Index Assays) 바이오인프라는 설립 이후 단백질분석 알고 리듬을 개발, 기존 암검 사의 단점을 극복, 암 조기진단의 원천핵심기술을 확보하였고 국민들 에게 의료보편성, 의료공정성, 건강주권부여를 구현하기 위해 노력합 니다. I N T R O D U C T I O N Boryung Pharmaceutical Company (here after Boryung) founded in 1963 based on company's ideology, "coexistance and co-prosperity" has led Korean pharmaceutical industry concentrating its utmost efforts on the development of new drugs. Boryung makes an effort to strengthen the product pipelines in the specialty areas such as cardiovascular drugs, antineoplastics drugs and antibiotics/antiviral. Boryung devote itself to achieving aspiration of the company which is "Dedicating to the health of Mankind" and becoming a global innovative pharmaceutical company. Boryung Pharmaceutical has developed Kanarb, an antihypertensive drug that has been approved by the KFDA as the 15th new drug, and also it is 8th new ARB drug in the world. Boryung is in the process of exporting Kanarb to 13 countries in South America, BRICs, southeast Asia, the U.S., and Europe. 1963년 창립된 보령제약은 ‘삶의 질’을 높이는 우수한 의약품을 계 속적으로 발매해왔으며 지속적인 혁신을 통해 궁극의 목적인 ‘인류 건강에 공헌’을 영속적으로 실천하는 기업이다. 특히, 심혈관계 질환 과 항암 분야에 파이프라인을 집중하고 있다. 카나브 정은 세계 8번 째 ARB 신약이자, KFDA로부터 15번째로 승인 받은ARB 계열 항 고혈압제 신약으로 중남미 13개국과의 수출 계약을 비롯해 BRICs 및 중동아시아, 미국, 유럽 등 전세계적으로 수출을 진행하고 있다. 216 217 MEMO Job Fair Overview Job Fair Overview Floor Plan for Job Fair 218 Job Fair Overview The ‘Job Fair 2013’ will be held to carry out corporate social responsibility to promote Bio industry and to create more jobs. The Job Fair will bring a corporate and its job seekers one step closer allowaccessing thousands of employment and career opportunities in healthcare and Bio industry. The fair also provides an on-site job interview, a job consulting, and special lectures. We welcome individuals who are interested in leading future Bio industry and look forward to meet you at the fair. Information D A T E 2013. 9.11 (Wed) ~ 12 (Thur) 10:00 ~ 17:00 V E N U E Hall 8A, KINTEX Exhibition Center II T arget Job seekers in Healthcare, Bio industry companies MAY 28 ~ 30, 2014 / KINTEX Participants Over 40 Healthcare and Bio industry companies Brand New Start in MAY! H O S T Managed by Sponsored by Ministry of Health and Welfare Ministry of Employment and Labor Center for Women In Science, Engineering and Technology 221 Floor Plan for Job Fair Program • Employment Section 1:1 job interview with recruiting companies • Job Support Section Support communication between corporate recruiters and job seekers • Consulting Section Resume, Interview, Image Making consulting for Job seekers • Exhibition Event Section Finger Print Personality & Aptitude Test, Job Tarot Card, Photo Shooting for Resume • Seminar Section ∙ Special Lecture Jae Chun Choe, Professor, Ewha Womans University - Consilience: The Unity of Knowledge Young Sook Park, Chair, Millennium Project Korea Job Fair - Future Social Mega-Trends and Future Jobs ∙ Healthcare Industry Job Presentation Topic: Type of a talented candidateand must have abilities that needed in Pharmaceutical, Medical, Cosmetic, food corporates ∙ Pharmaceutical Specialized Graduate School Conference Topic: Pharmaceutical Education & Career Development 222 223 MEMO Special Event Overview The Entrepreneurship Boot Camp 2013 Welcome Reception Bio-microphotography Exhibition BIO KOREA 2014 Poster Contest 224 225 Special Event "The Entrepreneurship Boot Camp 2013" From the early stage of novel drug development to a successful licensing preparation, BIO KOREA 2013 provides a crucial education program to advance your business to the global world. De Risking Your Globalisation Strategies-for Korean Life Science Companies. D A T E September 10 (Tue), 2013, 10:00~18:00 V E N U E Conference Rm. 303, KINTEX Exhibition Center II Organized by KHIDI, ERA Consulting Group Program Time MAY 28 ~ 30, 2014 / KINTEX Brand New Start in MAY! Program Speaker 09:30-10:00 Registration 10:00-10:15 Opening Remarks 10:15-11:15 Session 1 Preparing for international regulatory requirements during early stage biopharmaceutical product development Gillian Lennard 11:15-11:30 Coffee Break 11:30-12:30 Session 2 Globalizing your business - How to bring your business to the next level Sebastian Fernandez 12:30 -13:30 Lunch 13:30-14:30 Session 3 GMP Compliance - How to align your business with Christiane international GMP Requirements Furstenberg 14:30-14:45 Coffee Break 14:45-15:45 Session 4 Intercultural challenges for Asian companies in partnering with European companies - How to come to an agreement Christian Hofer 15:45-16:00 Coffee Break 16:00-16:20 Panel Discussion 16:20-17:30 Closing Remarks 17:30-18:00 Time allowed for short private consultations and questions 227 Welcome Reception The valuable opportunity to make cultural exchange and build a strong global network. D A T E September 11 (Wed), 2013, 18:00~20:30 V E N U E Outdoor Fountain Square, KINTEX Exhibition Center II E V E N T S Opening Performance, Welcoming remarks and Toast BIO KOREA 2013 Official Sponsors BIO KOREA Shuttle Bus Service Bio-microphotography Exhibition The great opportunity to comprehend the life science industry as a pop-culture and make an enjoyable time for all the participants. BIO KOREA 2014 Poster Contest Get involved and vote for the new face of BIO KOREA 2014. Meet 15 candidates for BIO KOREA 2014 poster. D A T E September 11 (Wed) ~ 13(Fri) 2013, 3days V E N U E Hall 7, 8A, KINTEX Exhibition Center II 228 BIO KOREA 2013 Official Sponsors Gold Sponsors Silver Sponsors Bronze Sponsor MAY 28 ~ 30, 2014 / KINTEX Brand New Start in MAY! Speacil Sponsor Promotion Partner 231 BIO KOREA Shuttle Bus Service Seoul Stn. (Subway Exit No. 14) KINTEX II Service Recurrence 123456 Departure Time 08:0008:3009:0010:0011:0013:00 KINTEX II Seoul Stn. Service Recurrence 123456 Departure Time 13:0014:0015:0016:0017:0018:00 Hak-dong Stn (Subway Exit No. 9) KINTEX II Service Recurrence 123456 Departure Time 08:0008:3009:0010:0011:0013:00 KINTEX II Hak-dong Stn Service Recurrence 123456 Departure Time 13:0014:0015:0016:0017:0018:00 232 BASF Plant Science BASF Plant Science – a BASF group company – is one of the world’s leading companies providing innovative plant biotechnology solutions for agriculture. INNOVATION YIELDS RESULTS As “Trait Technology Partner”, BASF Plant Science accesses markets through partnerships with leading seed and food chain companies, focusing on yield and quality traits for major crops such as higher yielding corn, soy, hybrid rice, sugarcane, sugarbeet; drought tolerant corn; herbicide tolerant soy; healthy fatty acids from canola; soy and corn with enhanced fungal resistance. For more information, please visit www.basf.com/plantscience Critical Samples. On time. In perfect condition. The shipment of infectious or diagnostic biological samples and clinical trial supplies requires expert handling. World Courier is a pioneer in the transport of sensitive medical and pharmaceutical shipments, delivering the first human heart tissue for transplant in 1984. Specialising in the transport of temperature controlled and time critical samples; World Courier is committed to handling every consignment on an individual, priority basis. This translates into a premium service where our experienced staff ensure that your shipment arrives on time and in perfect condition. With in-house scientists to understand your needs, World Courier can recommend and provide appropriate packaging and refrigerants to ensure the integrity of your temperature controlled shipment. Refrigerants are routinely checked and replenished during transit as required. BASF Company Limited 15F, KCCI Bldg., 45, 4-ga, Namdaemunro, Jung-gu, 100-743 Seoul, Korea Tel: 82-2-3707-7873 Fax: 82-2-3707-3239 For contact information visit www.worldcourier.com Documentation and regulatory requirements are managed by World Courier to ensure your shipment complies with country requirements. Each World Courier office employs a team trained in Dangerous Goods. Your shipment is dispatched on the first available flight and actively monitored throughout its journey. Confirmation of the delivery is provided immediately upon arrival. • All shipments placed on the first available flight and monitored until delivery • Specialists in temperature controlled, UN/IATA approved packaging • Expertise in handling complex documentation and regulatory requirements • Over 140 company owned offices worldwide, operating 24 hours a day, 365 days a year • Worldwide logistical support for clinical trials • Specialists in live mice transportation • IATA accredited Dangerous Goods training for site personnel • Development of Investigator Manuals www.kiwee.or.kr 서울시 마포구 동교동146-8 TEL. 02) 6915-6114 FAX. 02) 6915-6630 E-mail. [email protected] BIO KOREA Organizing Committee Tel +82-2-1661-0810 E-mail [email protected] www.biokorea.org
Similar documents
DAESUNG MACHINERY CO., LTD
designed specially for automatic process of dry/cooling, transportation and sorting of powder / solid recycle of food chemical stuff & raw material Our Company is has continued to invest in R&D to ...
More information에이비온 주식회사 - Abion Inc.
Flu-like Reactions; Depression; Headache; Fatigue Liver Test Abnormalities
More information110327-111029 화물내지
Seoul/SEL(ICN) (+9) --- Los Angeles/LAX (--7/--8) KE203 KE213 KE001 KE001 KE017 KE011 KE061 KE061 KE015 KE005-KE006
More information(shenzhen)co., ltd.
* Contact. MPC general manager N. Kang 82-51-510-3027 [email protected]
More information